0001144204-14-073974.txt : 20141215 0001144204-14-073974.hdr.sgml : 20141215 20141215165448 ACCESSION NUMBER: 0001144204-14-073974 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20141031 FILED AS OF DATE: 20141215 DATE AS OF CHANGE: 20141215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NON INVASIVE MONITORING SYSTEMS INC /FL/ CENTRAL INDEX KEY: 0000720762 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 592007840 STATE OF INCORPORATION: FL FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-13176 FILM NUMBER: 141287064 BUSINESS ADDRESS: STREET 1: 1840 W AVE CITY: MIAMI BEACH STATE: FL ZIP: 33139 BUSINESS PHONE: 3055343694 MAIL ADDRESS: STREET 1: 1840 WEST AVE CITY: MIAMI BEACH STATE: FL ZIP: 33140 FORMER COMPANY: FORMER CONFORMED NAME: BIRDFINDER CORP DATE OF NAME CHANGE: 19891116 10-Q 1 v395845_10q.htm FORM 10-Q

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC. 20549

 

FORM 10-Q

 

(Mark One)

 

xQuarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the Quarterly Period ended October 31, 2014

 

or

 

¨Transition Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 for the Transition Period from _______________ to ____________________

 

Commission File Number 000-13176
       
NON-INVASIVE MONITORING SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

 

Florida   59-2007840
(State or other jurisdiction of incorporation or organization)    (I.R.S. employer identification no.)  

 

4400 Biscayne Blvd., Suite 180, Miami, Florida 33137

(Address of principal executive offices) (Zip code)

 

Registrant’s telephone number, including area code: (305) 575-4200

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes x   No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

79,007,423 shares of the Company’s common stock, par value $0.01 per share, were outstanding as of December 14, 2014.

 

 
 

  

NON-INVASIVE MONITORING SYSTEMS, INC.

 

TABLE OF CONTENTS FOR FORM 10-Q

 

PART I. FINANCIAL INFORMATION  
    
ITEM 1. FINANCIAL STATEMENTS  
       
  Condensed Consolidated Balance Sheets as of October 31, 2014 (unaudited) and July 31, 2014 3
     
  Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended October 31, 2014 and 2013 (unaudited) 4
     
  Condensed Consolidated Statement of Changes in Shareholders’ Deficit for the three months ended October 31, 2014 (unaudited) 5
     
  Condensed Consolidated Statements of Cash Flows for the three months ended October 31, 2014 and 2013 (unaudited) 6
     
  Notes to Condensed Consolidated Financial Statements (unaudited) 7
     
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 16
     
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 20
     
ITEM 4. CONTROLS AND PROCEDURES 20
     
PART II. OTHER INFORMATION  
       
ITEM 1. LEGAL PROCEEDINGS 21
     
ITEM 1A.    RISK FACTORS 21
     
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 21
     
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 21
     
ITEM 4. MINE SAFETY DISCLOSURES 21
     
ITEM 5. OTHER INFORMATION 21
     
ITEM 6. EXHIBITS 21
     
  SIGNATURES 22

 

2
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

   October 31, 2014   July 31, 2014 
  (Unaudited)      
ASSETS          
Current assets          
           
Cash  $42   $21 
Inventories, net   455    455 
Prepaid expenses, deposits, and other current assets   37    49 
Total current assets   534    525 
           
Tooling and equipment, net   1    1 
           
Total assets  $535   $526 
           
LIABILITIES AND SHAREHOLDERS' DEFICIT          
Current liabilities          
Notes payable – Related party  $1,200   $1,150 
Notes payable – other   50    50 
Accounts payable and accrued expenses   973    909 
Customer deposits   4    4 
Total current liabilities   2,227    2,113 
           
Total liabilities  $2,227   $2,113 
           
Shareholders' deficit          
Series B Preferred Stock, par value $1.00 per share;
100 shares authorized, issued and outstanding, as of October 31, 2014 and July 31, 2014; liquidation preference $10		   –    – 
Series C Convertible Preferred Stock, par value $1.00 per share;
62,048 shares authorized, issued and outstanding, as of October 31, 2014 and July 31, 2014; liquidation preference $62		   62    62 
Series D Convertible Preferred Stock, par value $1.00 per share; 5,500 shares authorized;
2,782 and 2,795 shares issued and outstanding as of October 31, 2014 and July 31, 2014, respectively; liquidation preference $4,174		   3    3 
Common Stock, par value $0.01 per share; 400,000,000 shares authorized;
79,007,423 and 78,942,423 shares issued and outstanding as of October 31, 2014 and July 31, 2014, respectively		   790    789 
Additional paid in capital   21,930    21,931 
Accumulated deficit   (24,428)   (24,323)
Accumulated other comprehensive loss   (49)   (49)
Total shareholders' deficit   (1,692)   (1,587)
Total liabilities and shareholders' deficit  $535   $526 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3
 

  

NON-INVASIVE MONITORING SYSTEMS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Unaudited

(In thousands, except per share amounts)

  

   Three months ended October 31, 
   2014   2013 
Revenues          
Product sales, net  $–   $– 
Royalties   –    1 
           
Total revenues   –    1 
           
Operating costs and expenses          
           
Cost of sales   –    – 
Selling, general and administrative   71    85 
Research and development   –    1 
           
Total operating costs and expenses   71    86 
           
Operating loss   (71)   (85)
           
Other expense          
Interest expense, net   (34)   (33)
Total other expense   (34)   (33)
Net loss  $(105)  $(118)
           
Comprehensive net loss  $(105)  $(118)
           
Net loss attributable to common shareholders  $(105)  $(118)
           
Weighted average number of common          
shares outstanding - basic and diluted   78,943    78,942 
           
Basic and diluted loss per common share  $(0.00)  $(0.00)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT - Unaudited

For the three months ended October 31, 2014

(Dollars in Thousands)

 

   Preferred Stock       Additional   Accum-   Accumu-
lated Other
Compre-		     
   Series B   Series C   Series D   Common Stock   Paid in   ulated   hensive     
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Loss   Total 
                                                 
Balance at July 31, 2014   100    $–    62,048   $62    2,795   $3    78,942,423   $789   $21,931   $(24,323)  $(49)  $(1,587)
                                                             
Conversion of Preferred Stock to Common Stock   –    –    –    –    (13)   –    65,000    1    (1)   –    –    – 
Net loss   –    –    –    –    –    –    –    –    –    (105)   –    (105)
Balance at October 31, 2014   100   $–    62,048   $62    2,782   $3    79,007,423   $790   $21,930   $(24,428)  $(49)  $(1,692)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Unaudited

(Dollars in thousands)

 

Three months ended October 31, 2014 and 2013

 

   2014   2013 
Operating activities          
Net loss  $(105)  $(118)
Adjustments to reconcile net loss to net cash used in operating activities          
Depreciation and amortization   –    2 
Stock-based compensation expense   –    1 
           
Changes in operating assets and liabilities          
Accounts and royalties receivable, net   –    – 
Inventories, net   –    1 
Prepaid expenses, deposits and other current assets   12    13 
Accounts payable and accrued expenses   64    (8)
Net cash used in operating activities   (29)   (109)
           
Financing activities          
Proceeds from notes payable – related party   50    – 
Net cash provided by financing activities   50    – 
           
Net increase (decrease) in cash   21    (109)
Cash, beginning of period   21    296 
Cash, end of period  $42   $187 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

October 31, 2014

 

The following (a) condensed consolidated balance sheet as of July 31, 2014, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements included herein have been prepared by Non-Invasive Monitoring Systems, Inc. (together with its consolidated subsidiaries, the “Company” or “NIMS”) in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to the quarterly report on Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These statements reflect adjustments, all of which are of a normal, recurring nature, and which are, in the opinion of management, necessary to present fairly the Company’s financial position as of October 31, 2014, and results of operations and cash flows for the interim periods ended October 31, 2014 and 2013. The results of operations for the three months ended October 31, 2014, are not necessarily indicative of the results for a full year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The Company’s accounting policies continue unchanged from July 31, 2014. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended July 31, 2014.

 

1.ORGANIZATION AND BUSINESS

 

Organization. Non-Invasive Monitoring Systems, Inc., a Florida corporation (together with its consolidated subsidiaries, the “Company” or “NIMS”), began business as a medical diagnostic monitoring company to develop computer-aided continuous monitoring devices to detect abnormal respiratory and cardiac events using sensors on the human body’s surface. It has ceased to operate in this market and has licensed the rights to its technology. The Company now focuses on developing and marketing its Exer-Rest® line of acceleration therapeutic platforms based upon unique, patented whole body periodic acceleration (“WBPA”) technology. The Exer-Rest line of acceleration therapeutic platforms currently includes the Exer-Rest AT3800 and AT4700 models.

 

Business. The Company is developing and marketing its Exer-Rest® line of acceleration therapeutic platforms based upon unique, patented whole body periodic acceleration (“WBPA”) technology. The Exer-Rest line of acceleration therapeutic platforms currently includes the Exer-Rest AT3800 and AT4700 models.

 

The Company received revenue from royalties on sales of diagnostic monitoring hardware and software by SensorMedics and from VivoMetrics in prior years. SensorMedics indicated they will discontinue licensed product sales after current inventory is depleted and, therefore, the royalty revenue from SensorMedics is expected to be minimal to none. VivoMetrics ceased operations in July 2009 and filed for Chapter 11 bankruptcy protection in October 2009. Pursuant to VivoMetrics’ approved bankruptcy plan of reorganization, our license with VivoMetrics was assigned to another company; however, there can be no assurance as to the future amount of royalty revenue, if any, that we may derive from this license or from our existing license with SensorMedics. In fiscal year 2009, NIMS began commercial sales of its third generation Exer-Rest therapeutic platforms.

 

During the calendar years 2005 to 2007, the Company designed, developed and manufactured the first Exer-Rest platform (now the Exer-Rest AT), a second generation acceleration therapeutics platform, and updated its operations to promote the Exer-Rest AT overseas as an aid to improve circulation and joint mobility and to relieve minor aches and pains.

 

The Company has developed a third generation of Exer-Rest acceleration therapeutic platforms (designated the Exer-Rest AT3800 and the Exer-Rest AT4700) that had been manufactured by Sing Lin Technologies Co. Ltd. (“Sing Lin”) based in Taichung, Taiwan (see Note 10).

 

The Company’s condensed consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying unaudited condensed consolidated financial statements, the Company had net losses of $105,000 and $118,000 for the three month periods ended October 31, 2014 and 2013, respectively, and has experienced cash outflows from operating activities. The Company also has an accumulated deficit of $24.4 million as of October 31, 2014, and has potential purchase obligations at October 31, 2014 (see note 10). The Company had $42,000 of cash at October 31, 2014 and negative working capital of approximately $1,693,000.

 

Absent any significant revenues from product sales, the Company will likely need to incur additional debt, equity financing or a strategic collaboration for the Company to continue its business activities. Management intends to obtain any additional capital needed to continue its business activities through new debt or equity financing, but there can be no assurance that it will be successful in this regard. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.

 

7
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

October 31, 2014

 

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Consolidation. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Non-Invasive Monitoring Systems of Florida, Inc., which has no current operations, and NIMS of Canada, Inc., a Canadian corporation, which has no current operations. All material inter-company accounts and transactions have been eliminated in consolidation.

 

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions, such as accounts receivable, stock based compensation, warranty accrual and deferred taxes as estimates, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Such items include input variables for stock based compensation, accounts receivable, warranty accrual and deferred taxes. Actual results could differ materially from these estimates.

 

Cash and Cash Equivalents. The Company considers all highly liquid short-term investments purchased with an original maturity date of three months or less to be cash equivalents. The Company had approximately $42,000 and $21,000 on deposit in bank operating accounts at October 31, 2014 and July 31, 2014, respectively.

 

Allowances for Doubtful Accounts. Royalties and other receivables are recorded at the stated amount of the transactions. The Company provides an allowance for royalties and other receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance at the end of each period are determined using a combination of the Company’s historical loss experience, customer-by-customer analysis of the Company’s accounts receivable each period and subjective assessments of the Company’s future bad debt exposure.

 

Inventories. Inventories are stated at lower of cost or market using the first-in, first-out method, and are evaluated at least annually for impairment. Inventories at October 31, 2014 and July 31, 2014 primarily consisted of finished Exer-Rest units and accessories. Provisions for potentially obsolete or slow-moving inventory are made based on management’s analysis of inventory levels, historical obsolescence and future sales forecasts.

 

Tooling and Equipment. These assets are stated at cost and depreciated or amortized using the straight-line method, over their estimated useful lives.

 

Long-lived Assets. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In performing the review for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized as the difference between the fair value and the carrying amount of the asset.

 

Taxes Assessed on Revenue-Producing Transactions. The Company presents sales taxes assessed on revenue-producing transactions between a seller and customer using the net presentation; thus, sales and cost of revenues are not affected by such taxes.

 

Income Taxes. The Company provides for income taxes using an asset and liability based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382. Tax years ranging from 2011 to 2014 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision.

 

Revenue Recognition. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured. The Company recognizes royalties as they are earned, based on reports from licensees. Research and consulting revenue and revenue from sales of extended warranties on therapeutic platforms are recognized over the term of the respective agreements.

 

8
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

October 31, 2014

 

Advertising Costs. The Company expenses all costs of advertising and promotions as incurred. There were no advertising and promotional costs incurred for the three months ended October 31, 2014 and 2013.

 

Research and Development Costs. Research and development costs are expensed as incurred, and primarily consist of payments to third parties for research and development of the Exer-Rest device and regulatory testing and other costs to obtain FDA approval.

 

Warranties. The Company’s warranties are two years on all Exer-Rest products sold domestically and one year for products sold outside of the U.S. and are accrued based on management’s estimates and the history of warranty costs incurred. There were no material warranty costs incurred during the three months ended October 31, 2014 and 2013, and management estimates that the Company’s accrued warranty expense at October 31, 2014 will be sufficient to offset claims made for units under warranty.

 

Stock-based compensation. The Company recognizes all share-based payments, including grants of stock options, as operating expenses, based on their grant date fair values. Stock-based compensation expense is recognized over the vesting life of the underlying stock options and is included in selling, general and administrative costs and expenses in the condensed consolidated comprehensive statements of operations for all periods presented.

 

Fair Value of Financial Instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2014 and July 31, 2014. The respective carrying value of certain on-balance-sheet financial instruments such as cash, royalties and other receivables, accounts payable and accrued expenses approximate fair values because they are short term in nature or they bear current market interest rates.

 

As of October 31, 2014, the respective carrying value of the notes payable – related party and notes payable – other approximate our current borrowing rate for similar debt instruments of comparable maturity and are considered Level 3 measurements within the fair value hierarchy. Level 3 Inputs to the valuation methodology are those that are unobservable and significant to the fair value measurement.

 

Foreign Currency Translation. The functional currency for the Company’s foreign subsidiary is the local currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date while income and expense amounts are translated at average exchange rates during the period. The resulting foreign currency translation adjustments are disclosed as a separate component of stockholders’ deficit and other comprehensive loss. There was no foreign currency translation adjustments for the three months ended October 31, 2014 and 2013.

 

Comprehensive Income (Loss). Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources, including foreign currency translations.

 

Loss Contingencies. We recognize contingent losses that are both probable and estimable. In this context, we define probability as circumstances under which events are likely to occur. In regards to legal costs, we record such costs as incurred.

 

Recent Accounting Pronouncements.  In May 2014, the FASB issued an accounting standard update which affects the revenue recognition of entities that enter into either (1) certain contracts to transfer goods or services to customers or (2) certain contracts for the transfer of nonfinancial assets. The update indicates an entity should recognize revenue in an amount that reflects the consideration the entity expects to be entitled to in exchange for the goods or services transferred by the entity. The update is to be applied to the beginning of the year of implementation or retrospectively and is effective for annual periods beginning after December 15, 2016 and in interim periods in that reporting period. Early application is not permitted. The Company is currently evaluating the effect the update will have on its financial statement.

 

9
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

October 31, 2014

 

3.INVENTORIES

 

The Company’s inventory consisted of the following at October 31, 2014 and July 31, 2014 (in thousands):

 

   October 31, 2014   July 31, 2014 
Work-in-progress, spare parts and accessories  $9   $9 
Finished goods   446    446 
 Total inventories  $455   $455 

 

4.STOCK-BASED COMPENSATION

 

The Company measures the cost of employee, officer and director services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. The Company recorded stock-based compensation of $0 and $1,000, respectively, for the three months ended October 31, 2014 and 2013, respectively. All stock-based compensation is included in the Company’s selling, general and administrative costs and expenses.

 

The Company’s 2000 Stock Option Plan, as amended (the “2000 Plan”), provides for the issuance of up to 2,000,000 shares of the Company’s common stock. The 2000 Plan allows the issuance of incentive stock options, stock appreciation rights and restricted stock awards. The exercise price of the options is determined by the compensation committee of the Company’s Board of Directors, but incentive stock options, if any, must be granted at an exercise price not less than the fair market value of the Company’s common stock as of the grant date or an exercise price of not less than 110% of the fair value for a 10% shareholder. Options expire up to ten years from the date of the grant and are exercisable according to the terms of the individual option agreements. The 2000 Plan expired on March 1, 2012. No additional grants may be made under the 2000 Plan; however, previously granted options will remain in force pursuant to the terms of the individual grants.

 

In November 2010, the Company’s Board and Compensation Committee approved the Non-Invasive Monitoring Systems, Inc. 2011 Stock Incentive Plan (the “2011 Plan”). Awards granted under the 2011 Plan may consist of incentive stock options, stock appreciation rights (SAR), restricted stock grants, restricted stock units (RSU) performance shares, performance units or cash awards. Subject to adjustment in certain circumstances, the 2011 Plan authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2011 Plan. The 2011 Plan was approved by our shareholders in March 2012 and no awards have been granted under the 2011 Plan as of October 31, 2014.

 

The Company did not grant any stock options during the three months ended October 31, 2014 or 2013.

 

A summary of the Company’s stock option activity for the three months ended October 31, 2014 is as follows:

 

   Shares   Weighted
Average
Exercise
Price		   Weighted
average
remaining
contractual
term (years)		   Aggregate
intrinsic
Value		 
Options outstanding, July 31, 2014   378,750   $0.380           
Options granted   -    n/a            
Options exercised   -        n/a            
Options forfeited or expired   -    n/a           
Options outstanding, October 31, 2014   378,750   $0.380    1.88   $0 
Options expected to vest, October 31, 2014   378,750   $0.380    1.88   $0 
Options exercisable, October 31, 2014   378,750   $0.380    1.88   $0 

 

Of the 378,750 options outstanding at October 31, 2014, 378,750 were issued under the 2000 Plan and none were issued outside of shareholder approved plans. There were no options exercised during the three month periods ended October 31, 2014 and 2013. There were no options forfeited or expired during the three month periods ending October 31, 2014 and there were 75,000 options forfeited or expired during the three month periods ending October 31, 2013.

 

As of October 31, 2014, there was no unrecognized costs related to outstanding stock options.

 

10
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

October 31, 2014

 

5.ROYALTIES

 

The Company is a party to two licensing agreements with SensorMedics and VivoMetrics. The Company previously received royalty income from the sale of its diagnostic monitoring hardware and software from SensorMedics and previously received royalties from VivoMetrics prior to its bankruptcy.

 

Royalty income from the SensorMedics license amounted to $0 and $1,000 for the three months ended October 31, 2014 and 2013, respectively. SensorMedics indicated they will discontinue licensed product sales after inventory is depleted and, therefore, the royalty revenue from SensorMedics is expected to be minimal to none. There were no royalties recognized from VivoMeterics for the three months ended October 31, 2014 and 2013. VivoMetrics ceased operations in July 2009 and filed for Chapter 11 bankruptcy protection in October 2009. Under VivoMetrics’ approved bankruptcy plan of reorganization, our license with VivoMetrics was assigned to another company; however, there can be no assurance as to the future amount of royalty income, if any, that may result from this license or from our existing license with SensorMedics.

 

6.NOTES PAYABLE

 

2010 Credit Facility. On March 31, 2010, the Company entered into a new Note and Security Agreement with Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock (“Frost Gamma”), and Hsu Gamma Investments, LP, an entity controlled by the Company’s Chairman and Interim CEO (“Hsu Gamma” and together with Frost Gamma, the “Lenders”), pursuant to which the Lenders have provided a revolving credit line (the “Credit Facility”) in the aggregate principal amount of up to $1.0 million, secured by all of the Company’s personal property. The Company is permitted to borrow and reborrow from time to time under the Credit Facility until July 31, 2015 (the “Credit Facility Maturity Date”). The interest rate payable on amounts outstanding under the Credit Facility is 11% per annum, and increases to 16% per annum after the Credit Facility Maturity Date or after an event of default. All amounts owing under the Credit Facility are required to be repaid by the Credit Facility Maturity Date, and amounts outstanding are prepayable at any time without premium or penalty. As of October 31, 2014, the Company had drawn an aggregate of $1,000,000 under the Credit Facility and there is no available balance remaining.

 

2011 Promissory Notes. On September 12, 2011, the Company entered into two promissory notes in the principal amount of $50,000 each with Frost Gamma, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock, and with an unrelated third party for a total of $100,000. The interest rate payable by NIMS on both the Frost Gamma Note and the unrelated third party note is 11% per annum, payable on the maturity date of July 31, 2015 (the “Promissory Notes Maturity Date”). The Company may prepay either or both notes in advance of the Promissory Notes Maturity Date without premium or penalty.

 

2012 Promissory Note. On May 30, 2012, the Company entered into a promissory note in the principal amount of $50,000 with Hsu Gamma, an entity controlled by NIMS’ Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao, (the “Hsu Gamma Note”). The interest rate payable by NIMS on the Hsu Gamma Note is 11% per annum, payable on the maturity date of July 31, 2015. The Hsu Gamma Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.

 

2013 Promissory Note. On February 22, 2013, the Company entered into a promissory note in the amount of $50,000 with Jane Hsiao, the Company’s Chairman of the Board and Interim Chief Executive Officer (the “2013 Hsiao Note”). The interest rate payable by the Company on the 2013 Hsiao Note is 11% per annum, payable on the maturity date of July 31, 2015. The 2013 Hsiao Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.

 

2014 Promissory Note. On September 24, 2014, the Company entered into a promissory note (the “2014 Hsiao Note”) in the principal amount of $50,000 with Jane Hsiao, NIMS' Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by NIMS on the 2014 Hsiao Note is 11% per annum, payable on the maturity date of July 31, 2015. The 2014 Hsiao Note may be prepaid in advance of the Maturity Date without penalty.

 

11
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

October 31, 2014

 

At October 31, 2014, the Company was obligated under the above described Credit Facility and promissory notes to make future principal payments (excluding interest) as follows:

 

Year Ending October 31,    
     
2015   1,250,000 
   $1,250,000 

 

7.SHAREHOLDERS' EQUITY

 

The Company has three classes of Preferred Stock. Holders of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters.

 

Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared.

 

Series C Preferred Stock is redeemable by the Company at a price of $0.10 per share upon 30 days prior written notice. This series has a liquidation value of $1.00 per share plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $0.10 per share, if declared. Each share of Series C Preferred Stock is convertible into 25 shares of the Company’s common stock upon payment of a conversion premium of $4.20 per share of common stock. The conversion rate and the conversion premium are subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events.

 

Series D Preferred Stock is not redeemable by the Company. This series has a liquidation value of $1,500 per share, plus declared and unpaid dividends, if any. Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company’s common stock. The conversion rate is subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In October 2014, a holder of the Company’s Series D Preferred Stock converted 13 shares into 65,000 shares of the Company’s common stock.

 

On April 8, 2013, the Company entered into a stock purchase agreement (the “Stock Purchase Agreement”) with 12 investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 10,020,000 shares of the Company’s common stock, par value $0.01 (the “Shares”), at a price of $0.05 per share, for aggregate consideration of $501,000. The $0.05 per share price was less than the market price, which was approximately $0.12 as of the date of the agreement. Among the Investors purchasing Shares pursuant to the agreement were Dr. Jane Hsiao, the Company’s Chairman of the Board and Interim Chief Executive Officer and Frost Gamma, an entity controlled by Dr. Phillip Frost, one of the largest beneficial owners of the Company’s common stock. Dr. Hsiao purchased 2.0 million Shares and Frost Gamma purchased 2.0 million Shares.

 

The Company issued 65,000 shares of the Company’s common stock for the conversion of 13 shares Series D Preferred Stock during the three months ended October 31, 2014 and did not issue any shares of the Company’s common stock for the three months ended October 31, 2013. No preferred stock dividends were declared for the three months ended October 31, 2014 and 2013.

 

12
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

October 31, 2014

 

8.BASIC AND DILUTED LOSS PER SHARE

 

Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three months ended October 31, 2014 and 2013, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed exercise of outstanding options and warrants and the conversion of preferred stock would be anti-dilutive.

 

Potential common shares not included in calculating diluted net loss per share are as follows:

 

   October 31, 2014   October 31, 2013 
Stock options   378,750    538,750 
Series C Preferred Stock   1,551,200    1,551,200 
Series D Preferred Stock   13,910,000    13,975,000 
Total   15,839,950    16,064,950 

 

9.RELATED PARTY TRANSACTIONS

 

The Company signed a five year lease for office space in Miami, Florida with a company owned by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s Common Stock. The current rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, are approximately $1,250 per month and are currently on a month-to-month basis. The Company recorded rent expense related to the Miami lease of approximately $4,000 and $4,000, respectively, for the three months ended October 31, 2014 and 2013.

 

The Company signed a three year lease for warehouse space in Hialeah, Florida with a company jointly controlled by Dr. Frost and Dr. Jane Hsiao, the Company’s Chairman and Interim CEO. The rental payments under the Hialeah warehouse lease, which commenced February 1, 2009 and expired on January 31, 2012, then continued on a month-to-month basis. As further described in Note 10, the Company vacated the Hialeah warehouse in September 2014 and entered into a new lease. The Company recorded rent expense related to the Hialeah warehouse of approximately $6,000 and $11,000, respectively, for the three months ended October 31, 2014 and 2013.

 

As more fully described in Note 6, the Company entered into a $1.0 million Credit Facility in March 2010 with both an entity controlled by Dr. Frost and an entity controlled by Dr. Hsiao. There were no advances under the Credit Facility during the three months ended October 31, 2014. There was $1.0 million outstanding balance due, plus interest, on the Credit Facility as of October 31, 2014 and July 31, 2014 and there is no available balance remaining. The Credit Facility expires in July 31, 2015.

 

On September 12, 2011, the Company entered into a promissory note in the principal amount of $50,000 with Frost Gamma, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of our common stock. The interest rate payable by NIMS on the Frost Gamma note is 11% per annum, payable on July 31, 2015. The Frost Gamma note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.

 

On May 30, 2012, the Company entered into a promissory note in the principal amount of $50,000 with Hsu Gamma, an entity controlled by our Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao. The interest rate payable by NIMS on the Hsu Gamma note is 11% per annum, payable on the Promissory Notes Maturity Date. The Hsu Gamma note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.

 

On February 22, 2013, the Company entered into a promissory note in the amount of $50,000 with Jane Hsiao, the Company’s Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by the Company on the 2013 Hsiao Note is 11% per annum, payable on the Promissory Notes Maturity Date. The 2013 Hsiao Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.

 

On September 24, 2014, the Company entered into a promissory note in the principal amount of $50,000 with Jane Hsiao, NIMS' Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by NIMS on the 2014 Hsiao Note is 11% per annum, payable on the maturity date of July 31, 2015. The 2014 Hsiao Note may be prepaid in advance of the Maturity Date without penalty.

 

13
 

 

NON-INVASIVE MONITORING SYSTEMS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

October 31, 2014

 

The Company incurred interest expense related to the Credit Facility of approximately $28,000 for the three months ended October 31, 2014 and 2013. The Company also incurred interest expense related to the promissory notes of approximately $6,000 and $5,000 for the three months ended October 31, 2014 and 2013, respectively. Approximately $532,000 and $498,000 of accrued interest remained outstanding on the Credit Facility and promissory notes at October 31, 2014 and July 31, 2014, respectively.

 

Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each significant stockholders, officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (“TransEnterix”), a publicly-traded, medical device manufacturer, Tiger X Medical, Inc. (“Tiger X”) (formerly known as Cardo Medical, Inc.), a publicly traded former medical device company, and Tiger Media, Inc. (“Tiger Media”) (formerly known as SearchMedia Holdings Limited), a publicly-traded media company operating primarily in China. The Company’s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until October 2, 2013. The Company’s Chief Financial Officer continued as an employee of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staffs of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staffs of NIMS and TransEnterix were shared.  Since December 2009, the Company’s Chief Legal Officer has served under a similar cost sharing arrangement as Corporate Counsel of Tiger Media and as the Chief Legal Officer of each of TransEnterix and Tiger X. The Company recorded to selling, general and administrative costs and expenses to account for the sharing of costs under these arrangements of $7,800 and $9,000, respectively, for the three months ended October 31, 2014, and 2013. Accounts payable to TransEnterix related to these arrangements totaled approximately $5,000 and $3,000 respectively, at October 31, 2014 and July 31, 2014.

 

10.COMMITMENTS

 

Leases.

 

The Company is under an operating lease agreement for office space that expired in 2012 and continues on a month to month basis. The Company is also under an operating lease agreement for warehouse space that runs through September 2015 and requires for the payment of taxes, insurance and utilities.

 

Generally, the lease agreements require the payment of base rent plus escalations for increases in building operating costs and real estate taxes. Rental expense for operating leases amounted to $17,000 and $15,000 for the three months ended October 31, 2014 and 2013, respectively.

 

Product Development and Supply Agreement.

 

On September 4, 2007, the Company entered into a Product Development and Supply Agreement (the “Agreement”) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan ("Sing Lin"). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices. The Agreement commenced as of September 3, 2007 and had a term that extended three years from the acceptance by NIMS of the first run of production units. Thereafter, the Agreement automatically renewed for successive one year terms unless either party sent the other a notice of non-renewal. Either party was permitted to terminate the Agreement with ninety days prior written notice. Upon termination, each party’s obligations under the Agreement were to be limited to obligations related to confirmed orders placed prior to the termination date.

 

Pursuant to the Agreement, Sing Lin designed, developed and manufactured the tooling required to manufacture the acceleration therapeutic platforms for a total cost to the Company of $471,000. Sing Lin utilized the tooling in the performance of its production obligations under the Agreement. The Company paid Sing Lin $150,000 of the tooling cost upon execution of the Agreement and $150,000 upon the Company’s approval of the product prototype concepts and designs. The balance of the final tooling cost became due and payable in September 2008 upon acceptance of the first units produced using the tooling, and was paid in full during the year ended July 31, 2009.

 

Under the now-terminated Agreement, the Company also granted Sing Lin the exclusive distribution rights for the products in certain countries in the Far East, including Taiwan, China, Japan, South Korea, Malaysia, Indonesia and certain other countries. Sing Lin agreed not to sell the Products outside its geographic areas in the Far East.

 

14
 

  

NON-INVASIVE MONITORING SYSTEMS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

 

October 31, 2014

 

The Agreement provided for the Company to purchase approximately $2.6 million of Exer-Rest units within one year of the September 2008 acceptance of the final product. The Agreement further provided for the Company to purchase $4.1 million and $8.8 million of Exer-Rest products in the second and third years following such acceptance, respectively. These minimum purchase amounts were based upon 2007 product costs multiplied by volume commitments. Through October 31, 2014, the Company had paid Sing Lin $1.7 million in connection with orders placed through that date. As of October 31, 2014, the Company has approximately $41,000 of payables due to Sing Lin. As of October 31, 2014, aggregate minimum future purchases under the Agreement totaled approximately $13.9 million.

 

As of October 31, 2014, the Company had not placed orders sufficient to meet the first-year or second-year minimum purchase obligations under the Agreement. The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. As of the date of the issuance of these financial statements Sing Lin has not followed up on its July 2010 demand. There can be no assurance that Sing Lin will not attempt to enforce its remedies under the Agreement, or pursue other potential remedies.

 

11.LONG-LIVED ASSETS

 

The Company’s long-lived assets include furniture and equipment, tooling, websites and software, leasehold improvements, patents and trademarks. Tooling and equipment, net of accumulated depreciation, consists of the following at October 31 and July 31, 2014 (in thousands):

 

   Estimated
Useful Life		  October 31,
2014		   July 31,
2014		 
Furniture and fixtures, leasehold improvements, office equipment and computers  3 – 5 years  $85   $85 
Website and software  3 years   26    26 
       111    111 
Less accumulated depreciation      (110)   (110)
Tooling and equipment, net     $1   $1 

 

Depreciation expense was $0 and $2,000 during the three months ended October 31, 2014 and 2013, respectively. Nine Exer-Rest AT3800 and AT4700 demonstration units are included in furniture and fixtures at an aggregate cost of $25,000. These units were placed in service in fiscal 2009 and 2010, and are being depreciated based upon five-year estimated useful lives. In June 2014, the Company transferred an Exer-Rest unit with a net book value of $0 from long-lived assets to inventory.

 

15
 

 

NON-INVASIVE MONITORING SYSTEMS, INC

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Cautionary Statement Regarding Forward-looking Statements.

 

This Interim Report on Form 10-Q contains, in addition to historical information, certain forward-looking statements regarding Non-Invasive Monitoring Systems, Inc. (the “Company” or “NIMS,” also referred to as “us”, “we” or “our”). These forward-looking statements represent our expectations or beliefs concerning the Company’s operations, performance, financial condition, business strategies, and other information and that involve substantial risks and uncertainties. For this purpose, any statements contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. The Company’s actual results of operations, some of which are beyond the Company’s control, could differ materially from the activities and results implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the Company’s: history of operating losses and accumulated deficit; immediate need for additional financing; the Company’s inability to repay the Credit Facility currently due on July 31, 2015 or promissory notes due on July 31, 2015, dependence on future sales of the Exer-Rest® motion platforms; current and future purchase commitments; competition; dependence on management; changes in healthcare rules and regulations; risks related to proprietary rights; government regulation, including regulatory approvals; other factors described herein as well as the factors contained in “Item 1A - Risk Factors” of our Annual Report on Form 10-K for the year ended July 31, 2014. We do not undertake any obligation to update forward-looking statements, except as required by applicable law. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance.

 

Overview

 

We are primarily engaged in the development, manufacture and marketing of non-invasive, whole body periodic acceleration (“WBPA”) therapeutic platforms, which are motorized platforms that move a subject repetitively head to foot. Our acceleration therapeutic platforms are the inventions of Marvin A. Sackner, M.D., our founder, former Chief Executive Officer and a current member of our Board of Directors. Over thirty peer reviewed scientific publications attest to the benefits of whole body periodic acceleration in animal and human research investigations. According to those studies, the application of this technology causes increased release of beneficial substances such as nitric oxide from the inner lining of blood vessels throughout the vasculature for improved circulation and the reduction of inflammation. These findings are not being claimed as an intended use of the device for marketing purposes, but demonstrate a potential mechanism for its benefits.

 

The development and commercialization of the Exer-Rest has necessitated substantial expenditures and commitments of capital, and we anticipate expenses and associated losses to continue for the foreseeable future. We will be required to raise additional capital to fulfill our business plan, but no commitment to raise such additional capital exists or can be assured. We are also examining strategic alternatives. If we are unsuccessful in our efforts to expand sales and/or raise capital, or some other strategic alternative, we will not be able to continue operations.

 

Products

 

Whole Body Periodic Acceleration (“WBPA”) Therapeutic Devices

 

The original AT-101 was a comfortable gurney-styled device that provided movement of a platform repetitively in a head-to-foot motion at a rapid pace. Sales of the AT-101 commenced in October 2002 in Japan and in February 2003 in the United States. QTM Incorporated (“QTM”), an FDA registered manufacturer located in Oldsmar, Florida, manufactured the device, which was built in accordance with ISO and current Good Manufacturing Practices. As discussed above, we ceased manufacturing and selling the AT-101 in the United States in January 2005 as we began development of the Exer-Rest AT. We continued selling our existing inventory of AT-101 devices overseas until the Exer-Rest AT became available in October 2007, at which time we discontinued marketing of the AT-101.

 

16
 

 

NON-INVASIVE MONITORING SYSTEMS, INC

 

The Exer-Rest AT is based upon the design and concept of the AT-101, but has the dimensions and appearance of a commercial extra long twin bed. The Exer-Rest AT, which was also manufactured by QTM until we stopped production in July 2009, weighs about half as much as the AT-101, has a much more efficient and less costly drive mechanism, has a much lower selling price than did the AT-101 and is designed such that the user can utilize and operate it without assistance. The wired hand held controller provides digital values for speed, travel and time, rather than analog values for speed and arbitrary force values as in the AT-101. Sales of the Exer-Rest AT began outside the United States in October 2007 and in the United States in February 2009. We discontinued manufacturing of the Exer-Rest AT in July 2009, and we no longer have any of these units available.

 

The Exer-Rest AT3800 and Exer-Rest AT4700, which were manufactured for us by Sing Lin prior to the termination of our agreement with them, are next generation versions of the Exer-Rest AT and further advance the acceleration therapeutic platform technology. The AT3800 (38” wide) and AT4700 (47” wide) models combine improved drive technology for quieter operation, a more comfortable “memory-foam” mattress, more convenient operation with a multi-function wireless remote and a more streamlined look to improve the WBPA experience. Sales of the Exer-Rest AT3800 and Exer-Rest AT4700 platforms began outside the United States in October 2008, and U.S. sales commenced in February 2009.

 

LifeShirt®

 

The LifeShirt is a patented Wearable Physiological Computer that incorporates transducers, electrodes and sensors into a sleeveless garment. These sensors transmit vital and physiological signs to a miniaturized, battery-powered, electronic module which saves the raw waveforms and digital data to the compact flash memory of a Personal Digital Assistant (“PDA”) attached to the LifeShirt. Users of the LifeShirt can enter symptoms (with intensity), mood and medication information directly into the PDA for integration with the physiologic information collected by the LifeShirt garment. The flash memory can then be removed from the LifeShirt and the data uploaded and converted into minute-by-minute median trends of more than 30 physical and emotional signs of health and disease. Vital and physiological signs can therefore be obtained non-invasively, continuously, cheaply and reliably with the comfortably worn LifeShirt garment system while resting, exercising, working or sleeping. The LifeShirt was sold exclusively by VivoMetrics, but has not been marketed since VivoMetrics ceased operations in July 2009. Under VivoMetrics’ approved bankruptcy plan of reorganization, our license with VivoMetrics was assigned to another company; however, there can be no assurance as to the future amount of LifeShirt sales, if any, that may result from this license.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations set forth below under “Results of Operations” and “Liquidity and Capital Resources” should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this Form 10-Q. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to royalties, inventory, tooling and equipment and contingencies. The Company’s accounting policy for loss contingencies complies with ASC 450-20-25-2. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. A more detailed discussion on the application of these and other accounting policies can be found in Note 2 in the Notes to the Consolidated Financial Statements set forth in Item 8 of our Annual Report on Form 10-K for the year ended July 31, 2014. Actual results may differ from these estimates.

 

Results of Operations

 

In January 2005, we began developing the Exer-Rest line of acceleration therapeutic platforms, which were designed to be more efficient and less expensive than the original AT-101 platform. The Exer-Rest AT platform was first available for delivery to certain locations outside of the United States in October 2007. Our newest platforms, the Exer-Rest AT3800 and AT4700, which we developed under our former agreement with Sing Lin, became available for sale in October 2008. In January 2009, the Exer-Rest line of therapeutic platforms was registered by the FDA in the United States as Class I (Exempt) Medical Devices. We began our US and international sales activity with aggressive marketing and promotional pricing beginning in February 2009. We opened our first demonstration and therapy center in Toronto, Canada in April 2009; however we closed that facility in January 2010 to focus our marketing and sales efforts on healthcare providers as well as individuals. We currently market the Exer-Rest to hospitals, cardiac rehabilitation clinics, chiropractic and physical therapy centers, senior living communities and other healthcare providers, as well as to their patients, professional athletes and other individuals.

 

17
 

 

NON-INVASIVE MONITORING SYSTEMS, INC

 

Three months ended October 31, 2014 compared to three months ended October 31, 2013

 

Revenues. Total revenues decreased from $1,000 for the three months ended October 31, 2013, to $0 for the three months ended October 31, 2014. This $1,000 decrease resulted from no longer receiving royalty revenues and no product sales. There were no Exer-Rest platform product sales during the three months ended October 31, 2014 and 2013, primarily due to not having a sales team.

 

Cost of Sales. There were no cost of sales for the three months ended October 31, 2014 and 2013.

 

Selling, general and administrative costs and expenses. Selling, general and administrative (“SG&A”) costs and expenses decreased to $71,000 for the three months ended October 31, 2014 from $85,000 for the three months ended October 31, 2013. This $14,000 decrease was primarily attributable to decreases in depreciation expense, professional fees and lower stock-based compensation costs.

 

Research and development costs and expenses. Research and development (“R&D”) costs and expenses decreased to $0 for the three months ended October 31, 2014 from $1,000 for the three months ended October 31, 2013, a decrease of $1,000. This was primarily due to R&D cost reductions associated with our Exer-Rest product.

 

Total operating costs and expenses. Total operating costs and expenses decreased $15,000 to $71,000 from $86,000 for the three months ended October 31, 2014 and 2013, respectively. This decrease was primarily attributable to the lower SG&A and R&D costs and expenses discussed above.

 

Other expense. Other expense was $34,000 and $33,000 for the three months ended October 31, 2014 and 2013, respectively. The $1,000 increase was primarily related to an increase in interest expense resulting from the addition of interest bearing promissory notes entered into by the Company (see Note 6).

 

Liquidity and Capital Resources

 

The Company’s operations have been primarily financed through private sales of its equity securities and advances under Credit Facility and promissory notes. At October 31, 2014, we had approximately $42,000 of cash and negative working capital of approximately $1,693,000. We believe that the cash on hand at October 31, 2014 will not be sufficient to meet our anticipated cash requirements for operations over the next 12 months.

 

We expect to incur losses from operations for the foreseeable future. It is likely that we will not able to generate significant additional revenue and we will be required to obtain additional external financing through public or private equity offerings, debt financings or collaborative agreements to continue operations. No assurance can be given that such additional financing will be available on acceptable terms or at all. We are also examining strategic alternatives. Our ability to sell additional shares of our stock and/or borrow cash could be materially adversely affected by the current climate in the global equity and credit markets. Current economic conditions have been, and continue to be, volatile and continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business and to replace, in a timely manner, maturing liabilities or to successfully examine strategic alternatives. Additionally, the sales of equity or convertible debt securities may result in dilution to our stockholders.

 

Net cash used in operating activities was $29,000 and $109,000 for three months ended October 31, 2014 and 2013, respectively. This $80,000 decrease is primarily due to increases in accounts payable and accrued liabilities in 2014.

 

No cash was used or provided by investing activities for three months ended October 31, 2014 and 2013.

 

Net cash provided by financing activities was $50,000 and $0 for the three months ended October 31, 2014 and 2013, respectively. The $50,000 increase was a result of the $50,000 related party promissory note entered into in September 2014 (see Note 9).

 

Under our now-terminated agreement with Sing Lin, we were committed to purchase approximately $2.6 million of Exer-Rest units within one year of acceptance of the final product, which acceptance occurred in September 2008, and an additional $4.1 million and $8.8 million of products in the second and third years following acceptance of the final product, respectively. Under the agreement, we were required to pay a portion of the product purchase price at the time production orders were placed, with the balance due upon delivery. Through October 31, 2014, we paid Sing Lin $1.7 million in connection with orders placed through that date. As of October 31, 2014, we had not placed orders sufficient to satisfy the first-year or second-year purchase obligations under the agreement. We notified Sing Lin in June 2010 that we were terminating the agreement effective September 2010, and Sing Lin in July 2010 demanded that we place orders sufficient to fulfill the three year minimum purchase obligations in the agreement. There can be no assurance that Sing Lin will not attempt to enforce its remedies against us, or pursue other potential remedies. If Sing Lin seeks to enforce remedies against us, any such remedies could have a material adverse effect on our business, liquidity and results of operations. As of October 31, 2014, the Company had payables due to Sing Lin of approximately $41,000.

 

18
 

 

NON-INVASIVE MONITORING SYSTEMS, INC

 

On April 8, 2013, the Company entered into the Stock Purchase Agreement with the Investors pursuant to which the Investors agreed to purchase in a private placement an aggregate of 10,020,000 shares of the Company’s common stock, par value $0.01 (the “Shares”), at a price of $0.05 per share, for aggregate consideration of $501,000. The $0.05 per share price was less than the market price, which was approximately $0.12 as of the date of the agreement. Among the Investors purchasing Shares pursuant to the agreement were Dr. Jane Hsiao, the Company’s Chairman of the Board and Interim Chief Executive Officer and Frost Gamma, an entity controlled by Dr. Phillip Frost, one of the largest beneficial owners of the Company’s common stock. Dr. Hsiao purchased 2.0 million Shares and Frost Gamma purchased 2.0 million Shares.

 

2010 Credit Facility. On March 31, 2010, the Company entered into a new Note and Security Agreement with Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock (“Frost Gamma”), and Hsu Gamma Investments, LP, an entity controlled by the Company’s Chairman and Interim Chief Executive Officer, Jane H. Hsiao (“Hsu Gamma” and together with Frost Gamma, the “Lenders”), pursuant to which the Lenders have provided a revolving credit line (the “Credit Facility”) in the aggregate principal amount of up to $1.0 million, secured by all of the Company’s personal property. The Company is permitted to borrow and reborrow from time to time under the Credit Facility until July 31, 2015 (the “Credit Facility Maturity Date”). The interest rate payable on amounts outstanding under the Credit Facility is 11% per annum, and increases to 16% per annum after the Credit Facility Maturity Date or after an event of default. All amounts owing under the Credit Facility are required to be repaid by the Credit Facility Maturity Date, and amounts outstanding are prepayable at any time. As of October 31, 2014, the Company had drawn an aggregate of $1,000,000 under the Credit Facility and there is no available balance remaining.

 

2011 Promissory Notes. On September 12, 2011, the Company entered into two promissory notes in the principal amount of $50,000 each with Frost Gamma and with an unrelated third party for a total of $100,000. The interest rate payable by NIMS on both the Frost Gamma note and the unrelated third party note is 11% per annum, payable on the maturity date of July 31, 2015 (the “Promissory Notes Maturity Date”). The Company may prepay either or both notes in advance of the Promissory Notes Maturity Date without premium or penalty.

 

2012 Promissory Note. On May 30, 2012, the Company entered into a promissory note in the principal amount of $50,000 with Hsu Gamma, an entity controlled by NIMS’ Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao, (the “Hsu Gamma Note”). The interest rate payable by NIMS on the Hsu Gamma Note is 11% per annum, payable on the maturity date of July 31, 2015. The Hsu Gamma Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.

 

2013 Promissory Note. On February 22, 2013, the Company entered into a promissory note in the amount of $50,000 with Jane Hsiao, the Company’s Chairman of the Board and Interim Chief Executive Officer (the “2013 Hsiao Note”). The interest rate payable by the Company on the 2013 Hsiao Note is 11% per annum, payable on the maturity date of July 31, 2015. The 2013 Hsiao Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.

 

2014 Promissory Note. On September 24, 2014, the Company entered into a promissory note (the “2014 Hsiao Note”) in the principal amount of $50,000 with Jane Hsiao, NIMS' Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by NIMS on the 2014 Hsiao Note is 11% per annum, payable on the maturity date of July 31, 2015. The 2014 Hsiao Note may be prepaid in advance of the Maturity Date without penalty.

 

As of December 9, 2014, the Company had cash and cash equivalents of approximately $10,000, and did not have any further funding available under the Credit Facility. Further, the Maturity Date of the Credit Facility is July 31, 2014 and the Company currently does not have sufficient funds to repay the Credit Facility. If we are unable to generate significant revenues from sales of Exer-Rest platforms, we will have insufficient funds to repay our existing debt and continue operations without raising additional capital. We are also examining strategic alternatives. There can be no assurance that we will be able to raise such additional capital on terms acceptable to us or at all or that we will be successful in our examination of strategic alternatives. This uncertainty, along with the Company’s limited remaining cash balances, raises substantial doubt about the Company’s ability to continue as a going concern.

 

19
 

 

NON-INVASIVE MONITORING SYSTEMS, INC

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not required for smaller reporting companies as defined in Rule 12b-2 of the Exchange Act.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of October 31, 2014 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

 

Changes in Internal Control over Financial Reporting

 

There were no material changes in our internal controls over financial reporting or in other factors that could materially affect, or are reasonably likely to affect, our internal controls over financial reporting during the quarter ended October 31, 2014. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

20
 

 

NON-INVASIVE MONITORING SYSTEMS, INC

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None.

 

Item 1A. Risk Factors

 

None.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosure

 

None.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits Index

 

31.1   Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).*
     
31.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).*
     
32.1   Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
     
32.2   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
     
101.INS   XBRL Instance Document.*
     
101.SCH   XBRL Taxonomy Extension Schema Document.*
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document.*
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document.*
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document.*
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document.*

 

* Filed herewith.

 

21
 

 

NON-INVASIVE MONITORING SYSTEMS, INC

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: December 15, 2014 By: /s/ Jane H. Hsiao  
    Jane H. Hsiao, Interim Chief Executive Officer
     
Dated: December 15, 2014 By: /s/ James J. Martin  
    James J. Martin, Chief Financial Officer

 

22

 EX-31.1 2 v395845_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, Jane H. Hsiao, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Non-Invasive Monitoring Systems, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: December 15, 2014 By: /s/ Jane H. Hsiao  
    Jane H. Hsiao, Interim Chief Executive Officer

 

 
 EX-31.2 3 v395845_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

CERTIFICATIONS

 

I, James J. Martin, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Non-Invasive Monitoring Systems, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: December 15, 2014 By: /s/ James J. Martin  
    James J. Martin, Chief Financial Officer

 

 
 EX-32.1 4 v395845_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION PURSUANT

TO 18 U.S.C. Section 1350, as Adopted Pursuant to

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Non Invasive Monitoring Systems, Inc. (the "Company") on Form 10-Q for the quarterly period ended October 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jane H. Hsiao, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)         The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)         The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Dated: December 15, 2014 By: /s/ Jane H. Hsiao  
    Jane H. Hsiao, Interim Chief Executive Officer

 

 
 EX-32.2 5 v395845_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

 

CERTIFICATION PURSUANT

TO 18 U.S.C. Section 1350, as Adopted Pursuant to

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Non Invasive Monitoring Systems, Inc. (the "Company") on Form 10-Q for the quarterly period ended October 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James J. Martin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)         The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2)         The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Dated: December 15, 2014 By: /s/ James J. Martin  
    James J. Martin, Chief Financial Officer

 

 
 EX-101.INS 6 nimu-20141031.xml XBRL INSTANCE DOCUMENT 0000720762 2014-07-31 0000720762 2013-08-01 2013-10-31 0000720762 2014-08-01 2014-10-31 0000720762 2007-09-01 2007-09-04 0000720762 2014-10-31 0000720762 2014-12-14 0000720762 2013-07-31 0000720762 2013-10-31 0000720762 us-gaap:SeriesBPreferredStockMember 2014-07-31 0000720762 us-gaap:SeriesCPreferredStockMember 2014-07-31 0000720762 us-gaap:SeriesDPreferredStockMember 2014-07-31 0000720762 us-gaap:SeriesBPreferredStockMember 2014-10-31 0000720762 us-gaap:SeriesCPreferredStockMember 2014-10-31 0000720762 us-gaap:SeriesDPreferredStockMember 2014-10-31 0000720762 nimu:TwoThousandPlanMember 2014-10-31 0000720762 nimu:TwoThousandElevenPlanMember 2010-11-30 0000720762 nimu:SensormedicsMember 2013-08-01 2013-10-31 0000720762 nimu:SensormedicsMember 2014-08-01 2014-10-31 0000720762 nimu:TwoThousandAndThirteenPromissoryNoteMember nimu:JaneHsiaoMember 2013-02-22 0000720762 nimu:TwoThousandAndTenCreditFacilityMember us-gaap:MinimumMember 2010-03-31 0000720762 nimu:TwoThousandAndTenCreditFacilityMember us-gaap:MaximumMember 2010-03-31 0000720762 nimu:TwoThousandAndTwelvePromissoryNoteMember nimu:HsuGammaInvestmentsLPMember 2012-05-30 0000720762 nimu:TwoThousandAndElevenPromissoryNotesMember nimu:FrostGammaInvestmentTrustMember 2011-09-12 0000720762 nimu:TwoThousandAndFourteenPromissoryNoteMember nimu:JaneHsiaoMember 2014-09-24 0000720762 nimu:TwoThousandAndElevenPromissoryNotesMember 2011-09-12 0000720762 nimu:TwoThousandAndTenCreditFacilityMember nimu:FrostGammaInvestmentTrustMember 2010-03-31 0000720762 nimu:TwoThousandAndTenCreditFacilityMember 2014-10-31 0000720762 nimu:TwoThousandAndThirteenPromissoryNoteMember nimu:JaneHsiaoMember 2013-02-01 2013-02-22 0000720762 nimu:FrostGammaInvestmentTrustMember nimu:TwoThousandAndTenCreditFacilityMember 2010-03-01 2010-03-31 0000720762 nimu:TwoThousandAndTwelvePromissoryNoteMember nimu:HsuGammaInvestmentsLPMember 2012-05-01 2012-05-30 0000720762 nimu:JaneHsiaoMember nimu:TwoThousandAndFourteenPromissoryNoteMember 2014-08-25 2014-09-24 0000720762 us-gaap:CommonStockMember 2014-10-31 0000720762 us-gaap:PrivatePlacementMember 2013-04-01 2013-04-08 0000720762 nimu:DrhsiaoMember 2013-04-01 2013-04-08 0000720762 nimu:FrostGammaMember 2013-04-01 2013-04-08 0000720762 us-gaap:PrivatePlacementMember 2013-04-08 0000720762 us-gaap:EmployeeStockOptionMember 2013-08-01 2013-10-31 0000720762 us-gaap:SeriesCPreferredStockMember 2013-08-01 2013-10-31 0000720762 us-gaap:SeriesDPreferredStockMember 2013-08-01 2013-10-31 0000720762 us-gaap:EmployeeStockOptionMember 2014-08-01 2014-10-31 0000720762 us-gaap:SeriesCPreferredStockMember 2014-08-01 2014-10-31 0000720762 us-gaap:SeriesDPreferredStockMember 2014-08-01 2014-10-31 0000720762 nimu:MiamiLeaseMember 2008-01-01 2008-01-31 0000720762 nimu:MiamiLeaseMember 2013-08-01 2013-10-31 0000720762 nimu:MiamiLeaseMember 2014-08-01 2014-10-31 0000720762 nimu:HialeahLeaseMember 2013-08-01 2013-10-31 0000720762 nimu:HialeahLeaseMember 2014-08-01 2014-10-31 0000720762 nimu:PromissoryNotesMember nimu:JaneHsiaoMember 2014-09-24 0000720762 nimu:TwoThousandAndThirteenPromissoryNoteMember 2013-02-22 0000720762 nimu:TwoThousandAndTwelvePromissoryNoteMember 2012-05-30 0000720762 nimu:PromissoryNotesMember 2014-09-24 0000720762 nimu:TwoThousandAndTenCreditFacilityMember nimu:FrostGammaInvestmentTrustMember 2011-09-12 0000720762 nimu:DrPhillipFrostMember 2014-10-31 0000720762 nimu:PromissoryNotesMember 2013-10-31 0000720762 nimu:CreditFacilityMember 2013-10-31 0000720762 nimu:PromissoryNotesMember 2014-10-31 0000720762 nimu:CreditFacilityMember 2014-10-31 0000720762 nimu:ExerRestUnitsMember 2014-10-31 0000720762 nimu:SingLinMember 2014-10-31 0000720762 nimu:FurnitureAndFixturesLeaseholdImprovementsOfficeEquipmentAndComputersMember 2014-07-31 0000720762 nimu:WebsiteAndSoftwareMember 2014-07-31 0000720762 nimu:FurnitureAndFixturesLeaseholdImprovementsOfficeEquipmentAndComputersMember 2014-10-31 0000720762 nimu:WebsiteAndSoftwareMember 2014-10-31 0000720762 us-gaap:MinimumMember nimu:FurnitureAndFixturesLeaseholdImprovementsOfficeEquipmentAndComputersMember 2014-08-01 2014-10-31 0000720762 us-gaap:MaximumMember nimu:FurnitureAndFixturesLeaseholdImprovementsOfficeEquipmentAndComputersMember 2014-08-01 2014-10-31 0000720762 nimu:WebsiteAndSoftwareMember 2014-08-01 2014-10-31 0000720762 us-gaap:FurnitureAndFixturesMember 2014-10-31 0000720762 us-gaap:InventoryExchangesMember 2014-06-30 0000720762 us-gaap:CommonStockMember 2014-07-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2014-07-31 0000720762 us-gaap:RetainedEarningsMember 2014-07-31 0000720762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-07-31 0000720762 us-gaap:SeriesBPreferredStockMember 2014-08-01 2014-10-31 0000720762 us-gaap:CommonStockMember 2014-08-01 2014-10-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2014-08-01 2014-10-31 0000720762 us-gaap:RetainedEarningsMember 2014-08-01 2014-10-31 0000720762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-08-01 2014-10-31 0000720762 us-gaap:AdditionalPaidInCapitalMember 2014-10-31 0000720762 us-gaap:RetainedEarningsMember 2014-10-31 0000720762 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-10-31 0000720762 nimu:TransenterixMember 2014-07-31 0000720762 nimu:TransenterixMember 2014-10-31 0000720762 nimu:TwoThousandPlanMember 2014-08-01 2014-10-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> 3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; INVENTORIES</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s inventory consisted of the following at October 31, 2014 and July 31, 2014 (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 79.35pt; MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>October&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Work-in-progress, spare parts and accessories</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>446</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>446</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Total inventories</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; STOCK-BASED COMPENSATION</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font> <font style="FONT-SIZE: 10pt"><br/> The Company measures the cost of employee, officer and director services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of the Company&#8217;s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. The Company recorded stock-based compensation of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font>, respectively, for the three months ended October 31, 2014 and 2013, respectively. All stock-based compensation is included in the Company&#8217;s selling, general and administrative costs and expenses.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company&#8217;s 2000 Stock Option Plan, as amended (the &#8220;2000 Plan&#8221;), provides for the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares of the Company&#8217;s common stock. The 2000 Plan allows the issuance of incentive stock options, stock appreciation rights and restricted stock awards. The exercise price of the options is determined by the compensation committee of the Company&#8217;s Board of Directors, but incentive stock options, if any, must be granted at an exercise price not less than the fair market value of the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Company&#8217;s common stock as of the grant date or an exercise price of not less than 110% of the fair value for a 10% shareholder.</font> Options expire up to ten years from the date of the grant and are exercisable according to the terms of the individual option agreements. The 2000 Plan expired on March 1, 2012. No additional grants may be made under the 2000 Plan; however, previously granted options will remain in force pursuant to the terms of the individual grants.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In November 2010, the Company&#8217;s Board and Compensation Committee approved the Non-Invasive Monitoring Systems, Inc. 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;). Awards granted under the 2011 Plan may consist of incentive stock options, stock appreciation rights (SAR), restricted stock grants, restricted stock units (RSU) performance shares, performance units or cash awards. Subject to adjustment in certain circumstances, the 2011 Plan authorizes up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000,000</font>&#160;shares of the Company&#8217;s common stock for issuance pursuant to the terms of the 2011 Plan. The 2011 Plan was approved by our shareholders in March 2012 and no awards have been granted under the 2011 Plan as of October 31, 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company did not grant any stock options during the three months ended October 31, 2014 or 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Company&#8217;s stock option activity for the three months ended October 31, 2014 is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.3in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Weighted<br/> &#160;average<br/> &#160;remaining<br/> &#160;contractual<br/> &#160;term&#160;(years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate<br/> intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options outstanding, July 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options forfeited or expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options outstanding, October 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0.380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options expected to vest, October 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0.380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options exercisable, October 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0.380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Of the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 378,750</font> options outstanding at October 31, 2014, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 378,750</font> were issued under the 2000 Plan and none were issued outside of shareholder approved plans. There were no options exercised during the three month periods ended October 31, 2014 and 2013. There were no options forfeited or expired during the three month periods ending October 31, 2014 and there were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 75,000</font> options forfeited or expired during the three month periods ending October 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of October 31, 2014, there was no unrecognized costs related to outstanding stock options.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ROYALTIES</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is a party to two licensing agreements with SensorMedics and VivoMetrics. The Company previously received royalty income from the sale of its diagnostic monitoring hardware and software from SensorMedics and previously received royalties from VivoMetrics prior to its bankruptcy.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Royalty income from the SensorMedics license amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000</font> for the three months ended October 31, 2014 and 2013, respectively. SensorMedics indicated they will discontinue licensed product sales after inventory is depleted and, therefore, the royalty revenue from SensorMedics is expected to be minimal to none. There were no royalties recognized from VivoMeterics for the three months ended October 31, 2014 and 2013. VivoMetrics ceased operations in July 2009 and filed for Chapter 11 bankruptcy protection in October 2009. Under VivoMetrics&#8217; approved bankruptcy plan of reorganization, our license with VivoMetrics was assigned to another company; however, there can be no assurance as to the future amount of royalty income, if any, that may result from this license or from our existing license with SensorMedics.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">6.</font></strong> <font style="FONT-SIZE: 10pt"><strong> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; NOTES PAYABLE</strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 45.8pt; MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">2010 Credit Facility.</font></strong> <font style="FONT-SIZE: 10pt">On March 31, 2010, the Company entered into a new Note and Security Agreement with Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company&#8217;s common stock (&#8220;Frost Gamma&#8221;), and Hsu Gamma Investments, LP, an entity controlled by the Company&#8217;s Chairman and Interim CEO (&#8220;Hsu Gamma&#8221; and together with Frost Gamma, the &#8220;Lenders&#8221;), pursuant to which the Lenders have provided a revolving credit line (the &#8220;Credit Facility&#8221;) in the aggregate principal amount of up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million, secured by all of the Company&#8217;s personal property. The Company is permitted to borrow and reborrow from time to time under the Credit Facility until July 31, 2015 (the &#8220;Credit Facility Maturity Date&#8221;). The interest rate payable on amounts outstanding under the Credit Facility is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% per annum, and increases to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 16</font>% per annum after the Credit Facility Maturity Date or after an event of default. All amounts owing under the Credit Facility are required to be repaid by the Credit Facility Maturity Date, and amounts outstanding are prepayable at any time without premium or penalty. As of October 31, 2014, the Company had drawn an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,000,000</font> under the Credit Facility and there is no available balance remaining.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">2011 Promissory Notes.</font></strong> <font style="FONT-SIZE: 10pt">On September 12, 2011, the Company entered into two promissory notes in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> each with Frost Gamma, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company&#8217;s common stock, and with an unrelated third party for a total of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font>. The interest rate payable by NIMS on both the Frost Gamma Note and the unrelated third party note is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% per annum, payable on the maturity date of July 31, 2015 (the &#8220;Promissory Notes Maturity Date&#8221;). The Company may prepay either or both notes in advance of the Promissory Notes Maturity Date without premium or penalty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">2012 Promissory Note.</font></strong> <font style="FONT-SIZE: 10pt">On May 30, 2012, the Company entered into a promissory note in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> with Hsu Gamma, an entity controlled by NIMS&#8217; Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao, (the &#8220;Hsu Gamma Note&#8221;). The interest rate payable by NIMS on the Hsu Gamma Note is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% per annum, payable on the maturity date of July 31, 2015. The Hsu Gamma Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">2013 Promissory Note.</font></strong> <font style="FONT-SIZE: 10pt">On February 22, 2013, the Company entered into a promissory note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> with Jane Hsiao, the Company&#8217;s Chairman of the Board and Interim Chief Executive Officer (the &#8220;2013 Hsiao Note&#8221;). The interest rate payable by the Company on the 2013 Hsiao Note is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% per annum, payable on the maturity date of July 31, 2015. The 2013 Hsiao Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">2014 Promissory Note.</font></strong> <font style="FONT-SIZE: 10pt">On September 24, 2014, the Company entered into a promissory note (the &#8220;2014 Hsiao Note&#8221;) in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> with Jane Hsiao, NIMS' Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by NIMS on the 2014 Hsiao Note is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% per annum, payable on the maturity date of July 31, 2015. The 2014 Hsiao Note may be prepaid in advance of the Maturity Date without penalty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.7in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>At October 31,</font><font style="FONT-SIZE: 10pt">&#160;2014, the Company was obligated under the above described Credit Facility and promissory notes to make future principal payments (excluding interest) as follows:</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div>Year&#160;Ending&#160;October&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> 7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; SHAREHOLDERS' EQUITY</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">The Company has three classes of Preferred Stock. Holders of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100</font> per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> per share, if declared.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">Series C Preferred Stock is redeemable by the Company at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> per share upon 30 days prior written notice. This series has a liquidation value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> per share, if declared. Each share of Series C Preferred Stock is convertible into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25</font> shares of the Company&#8217;s common stock upon payment of a conversion premium of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.20</font> per share of common stock. The conversion rate and the conversion premium are subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">Series D Preferred Stock is not redeemable by the Company. This series has a liquidation value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,500</font> per share, plus declared and unpaid dividends, if any. Each share of Series D Preferred Stock is convertible into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000</font> shares of the Company&#8217;s common stock. The conversion rate is subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In October 2014, a holder of the Company&#8217;s Series D Preferred Stock converted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13</font> shares into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 65,000</font> shares of the Company&#8217;s common stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">On April&#160;8, 2013,&#160;the Company entered into a stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with 12 investors (the &#8220;Investors&#8221;) pursuant to which the Investors agreed to purchase in a private placement an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,020,000</font> shares of the Company&#8217;s common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font> (the &#8220;Shares&#8221;), at a price of $0.05 per share, for aggregate consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">501,000</font>. The $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.05</font> per share price was less than the market price, which was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.12</font> as of the date of the agreement. Among the Investors purchasing Shares pursuant to the agreement were Dr.&#160;Jane Hsiao, the Company&#8217;s Chairman of the Board and Interim Chief Executive Officer and Frost Gamma, an entity controlled by Dr.&#160;Phillip Frost, one of the largest beneficial owners of the Company&#8217;s common stock. Dr.&#160;Hsiao purchased <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.0</font>&#160;million Shares and Frost Gamma purchased <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.0</font>&#160;million Shares.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company issued 65,000 shares of the Company&#8217;s common stock for the conversion of 13 shares Series D Preferred Stock during the three months ended October 31, 2014 and did not issue any shares of the Company&#8217;s common stock for the three months ended October 31, 2013. No preferred stock dividends were declared for the three months ended October 31, 2014 and 2013.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> 8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; BASIC AND DILUTED LOSS PER SHARE</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three months ended October 31, 2014 and 2013, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed exercise of outstanding options and warrants and the conversion of preferred stock would be anti-dilutive.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Potential common shares not included in calculating diluted net loss per share are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.3in; MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>October&#160;31,&#160;2014</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>October&#160;31,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>538,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Series C Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,551,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,551,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Series D Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>13,910,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>13,975,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>15,839,950</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>16,064,950</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> 9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; RELATED PARTY TRANSACTIONS</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company signed a five year lease for office space in Miami, Florida with a company owned by Dr. Phillip Frost, who is the beneficial owner of more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company&#8217;s Common Stock. The current rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, are approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,250</font> per month and are currently on a month-to-month basis. The Company recorded rent expense related to the Miami lease of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,000</font>, respectively, for the three months ended October 31, 2014 and 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company signed a three year lease for warehouse space in Hialeah, Florida with a company jointly controlled by Dr. Frost and Dr. Jane Hsiao, the Company&#8217;s Chairman and Interim CEO. The rental payments under the Hialeah warehouse lease, which commenced February 1, 2009 and expired on January 31, 2012, then continued on a month-to-month basis. As further described in Note 10, the Company vacated the Hialeah warehouse in September 2014 and entered into a new lease. The Company recorded rent expense related to the Hialeah warehouse of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,000</font>, respectively, for the three months ended October 31, 2014 and 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As more fully described in Note 6, the Company entered into a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million Credit Facility in March 2010 with both an entity controlled by Dr. Frost and an entity controlled by Dr. Hsiao. There were no advances under the Credit Facility during the three months ended October 31, 2014. There was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million outstanding balance due, plus interest, on the Credit Facility as of October 31, 2014 and July 31, 2014 and there is no available balance remaining. The Credit Facility expires in July 31, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On September 12, 2011, the Company entered into a promissory note in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> with Frost Gamma, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of our common stock. The interest rate payable by NIMS on the Frost Gamma note is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% per annum, payable on July 31, 2015. The Frost Gamma note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On May 30, 2012, the Company entered into a promissory note in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> with Hsu Gamma, an entity controlled by our Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao. The interest rate payable by NIMS on the Hsu Gamma note is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% per annum, payable on the Promissory Notes Maturity Date. The Hsu Gamma note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On February 22, 2013, the Company entered into a promissory note in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> with Jane Hsiao, the Company&#8217;s Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by the Company on the 2013 Hsiao Note is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% per annum, payable on the Promissory Notes Maturity Date. The 2013 Hsiao Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On September 24, 2014, the Company entered into a promissory note in the principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> with Jane Hsiao, NIMS' Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by NIMS on the 2014 Hsiao Note is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>% per annum, payable on the maturity date of July 31, 2015. The 2014 Hsiao Note may be prepaid in advance of the Maturity Date without penalty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company incurred interest expense related to the Credit Facility of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28,000</font></font> for the three months ended October 31, 2014 and 2013. The Company also incurred interest expense related to the promissory notes of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font> for the three months ended October 31, 2014 and 2013, respectively. Approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">532,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">498,000</font> of accrued interest remained outstanding on the Credit Facility and promissory notes at October 31, 2014 and July 31, 2014, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each significant stockholders, officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (&#8220;TransEnterix&#8221;), a publicly-traded, medical device manufacturer, Tiger X Medical, Inc. (&#8220;Tiger X&#8221;) (formerly known as Cardo Medical, Inc.), a publicly traded former medical device company, and Tiger Media, Inc. (&#8220;Tiger Media&#8221;) (formerly known as SearchMedia Holdings Limited), a publicly-traded media company operating primarily in China. The Company&#8217;s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until October 2, 2013. The Company&#8217;s Chief Financial Officer continued as an employee of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staffs of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staffs of NIMS and TransEnterix were shared.&#160;&#160;Since December 2009, the Company&#8217;s Chief Legal Officer has served under a similar cost sharing arrangement as Corporate Counsel of Tiger Media and as the Chief Legal Officer of each of TransEnterix and Tiger X. The Company recorded to selling, general and administrative costs and expenses to account for the sharing of costs under these arrangements of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,800</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,000</font>, respectively, for the three months ended October 31, 2014, and 2013. Accounts payable to TransEnterix related to these arrangements totaled approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000</font> respectively, at October 31, 2014 and July 31, 2014.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> 10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; COMMITMENTS</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Leases</font></b><font style="FONT-SIZE: 10pt">.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company is under an operating lease agreement for office space that expired in 2012 and continues on a month to month basis. The Company is also under an operating lease agreement for warehouse space that runs through September 2015 and requires for the payment of taxes, insurance and utilities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Generally, the lease agreements require the payment of base rent plus escalations for increases in building operating costs and real estate taxes. Rental expense for operating leases amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,000</font> for the three months ended October 31, 2014 and 2013, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Product Development and Supply Agreement.</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On September 4, 2007, the Company entered into a Product Development and Supply Agreement (the &#8220;Agreement&#8221;) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan ("Sing Lin"). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices. The Agreement commenced as of September 3, 2007 and had a term that extended three years from the acceptance by NIMS of the first run of production units. Thereafter, the Agreement automatically renewed for successive one year terms unless either party sent the other a notice of non-renewal. Either party was permitted to terminate the Agreement with ninety days prior written notice. Upon termination, each party&#8217;s obligations under the Agreement were to be limited to obligations related to confirmed orders placed prior to the termination date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Pursuant to the Agreement, Sing Lin designed, developed and manufactured the tooling required to manufacture the acceleration therapeutic platforms for a total cost to the Company of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">471,000</font>. Sing Lin utilized the tooling in the performance of its production obligations under the Agreement. The Company paid Sing Lin $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> of the tooling cost upon execution of the Agreement and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> upon the Company&#8217;s approval of the product prototype concepts and designs. The balance of the final tooling cost became due and payable in September 2008 upon acceptance of the first units produced using the tooling, and was paid in full during the year ended July 31, 2009.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Under the now-terminated Agreement, the Company also granted Sing Lin the exclusive distribution rights for the products in certain countries in the Far East, including Taiwan, China, Japan, South Korea, Malaysia, Indonesia and certain other countries. Sing Lin agreed not to sell the Products outside its geographic areas in the Far East.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Agreement provided for the Company to purchase approximately $2.6 million of Exer-Rest units within one year of the September 2008 acceptance of the final product. The Agreement further provided for the Company to purchase $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.1</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.8</font> million of Exer-Rest products in the second and third years following such acceptance, respectively. These minimum purchase amounts were based upon 2007 product costs multiplied by volume commitments. Through October 31, 2014, the Company had paid Sing Lin $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.7</font> million in connection with orders placed through that date. As of October 31, 2014, the Company has approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41,000</font> of payables due to Sing Lin. As of October 31, 2014, aggregate minimum future purchases under the Agreement totaled approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.9</font> million.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of October 31, 2014, the Company had not placed orders sufficient to meet the first-year or second-year minimum purchase obligations under the Agreement. The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. As of the date of the issuance of these financial statements Sing Lin has not followed up on its July 2010 demand. There can be no assurance that Sing Lin will not attempt to enforce its remedies under the Agreement, or pursue other potential remedies.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"> 11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; LONG-LIVED ASSETS</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company&#8217;s long-lived assets include furniture and equipment, tooling, websites and software, leasehold improvements, patents and trademarks. Tooling and equipment, net of accumulated depreciation, consists of the following at October 31 and July 31, 2014 (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Estimated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>October&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Useful&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Furniture and fixtures, leasehold improvements, office equipment and computers</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3 &#150; 5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Website and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Less accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(110)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(110)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Tooling and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Depreciation expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font> during the three months ended October 31, 2014 and 2013, respectively. Nine Exer-Rest AT3800 and AT4700 demonstration units are included in furniture and fixtures at an aggregate cost of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font>. These units were placed in service in fiscal 2009 and 2010, and are being depreciated based upon five-year estimated useful lives. In June 2014, the Company transferred an Exer-Rest unit with a net book value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> from long-lived assets to inventory.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 21000 42000 455000 455000 49000 37000 525000 534000 1000 1000 526000 535000 1150000 1200000 50000 50000 909000 973000 4000 4000 2113000 2227000 2113000 2227000 0 62000 3000 0 62000 3000 789000 790000 21931000 21930000 -24323000 -24428000 -49000 -49000 -1587000 -1692000 526000 535000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Consolidation.</font></i></b><b><font style="FONT-SIZE: 10pt"></font></b><font style="FONT-SIZE: 10pt">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Non-Invasive Monitoring Systems of Florida, Inc., which has no current operations, and NIMS of Canada, Inc., a Canadian corporation, which has no current operations. All material inter-company accounts and transactions have been eliminated in consolidation</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt">Use of Estimates.</font></i></b> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions, such as accounts receivable, stock based compensation, warranty accrual and deferred taxes as estimates, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Such items include input variables for stock based compensation, accounts receivable, warranty accrual and deferred taxes. Actual results could differ materially from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt">Cash and Cash Equivalents.</font></i></b> <font style="FONT-SIZE: 10pt">The Company considers all highly liquid short-term investments purchased with an original maturity date of three months or less to be cash equivalents. The Company had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">21,000</font> on deposit in bank operating accounts at October 31, 2014 and July 31, 2014, respectively.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt">Allowances for Doubtful Accounts.</font></i></b> <font style="FONT-SIZE: 10pt">Royalties and other receivables are recorded at the stated amount of the transactions. The Company provides an allowance for royalties and other receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance at the end of each period are determined using a combination of the Company&#8217;s historical loss experience, customer-by-customer analysis of the Company&#8217;s accounts receivable each period and subjective assessments of the Company&#8217;s future bad debt exposure.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt">Inventories.</font></i></b> <font style="FONT-SIZE: 10pt">Inventories are stated at lower of cost or market using the first-in, first-out method, and are evaluated at least annually for impairment. Inventories at October 31, 2014 and July 31, 2014 primarily consisted of finished Exer-Rest units and accessories. Provisions for potentially obsolete or slow-moving inventory are made based on management&#8217;s analysis of inventory levels, historical obsolescence and future sales forecasts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt">Tooling and Equipment.</font></i></b> <font style="FONT-SIZE: 10pt">These assets are stated at cost and depreciated or amortized using the straight-line method, over their estimated useful lives.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Long-lived Assets.</font></i></b> <font style="FONT-SIZE: 10pt">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In performing the review for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized as the difference between the fair value and the carrying amount of the asset.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Taxes Assessed on Revenue-Producing Transactions.</font></i></b> <font style="FONT-SIZE: 10pt">The Company presents sales taxes assessed on revenue-producing transactions between a seller and customer using the net presentation; thus, sales and cost of revenues are not affected by such taxes.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font></i></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i><b><i>Income Taxes.</i></b> The Company provides for income taxes using an asset and liability based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382. Tax years ranging from 2011 to 2014 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company&#8217;s policy to include income tax interest and penalty expense in its tax provision.</i></b></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Revenue Recognition.</font></i></b> <font style="FONT-SIZE: 10pt">Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured. The Company recognizes royalties as they are earned, based on reports from licensees. Research and consulting revenue and revenue from sales of extended warranties on therapeutic platforms are recognized over the term of the respective agreements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Advertising Costs.</font></i></b> <font style="FONT-SIZE: 10pt">The Company expenses all costs of advertising and promotions as incurred. There were no advertising and promotional costs incurred for the three months ended October 31, 2014 and 2013.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Research and Development Costs.</font></i></b> <font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred, and primarily consist of payments to third parties for research and development of the Exer-Rest device and regulatory testing and other costs to obtain FDA approval.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Warranties.</font></i></b> <font style="FONT-SIZE: 10pt">The Company&#8217;s warranties are two years on all Exer-Rest products sold domestically and one year for products sold outside of the U.S. and are accrued based on management&#8217;s estimates and the history of warranty costs incurred. There were no material warranty costs incurred during the three months ended October 31, 2014 and 2013, and management estimates that the Company&#8217;s accrued warranty expense at October 31, 2014 will be sufficient to offset claims made for units under warranty.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Stock-based compensation.</font></i></b> <font style="FONT-SIZE: 10pt">The Company recognizes all share-based payments, including grants of stock options, as operating expenses, based on their grant date fair values. Stock-based compensation expense is recognized over the vesting life of the underlying stock options and is included in selling, general and administrative costs and expenses in the condensed consolidated comprehensive statements of operations for all periods presented.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Fair Value of Financial Instruments.</font></i></b> <font style="FONT-SIZE: 10pt">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2014 and July 31, 2014. The respective carrying value of certain on-balance-sheet financial instruments such as cash, royalties and other receivables, accounts payable and accrued expenses approximate fair values because they are short term in nature or they bear current market interest rates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of October 31, 2014, the respective carrying value of the notes payable &#150; related party and notes payable &#150; other approximate our current borrowing rate for similar debt instruments of comparable maturity and are considered Level 3 measurements within the fair value hierarchy. Level 3 Inputs to the valuation methodology are those that are unobservable and significant to the fair value measurement.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Foreign Currency Translation.</font></i></b> <font style="FONT-SIZE: 10pt">The functional currency for the Company&#8217;s foreign subsidiary is the local currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date while income and expense amounts are translated at average exchange rates during the period. The resulting foreign currency translation adjustments are disclosed as a separate component of stockholders&#8217; deficit and other comprehensive loss. There was no foreign currency translation adjustments for the three months ended October 31, 2014 and 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Comprehensive Income (Loss).</font></i></b> <font style="FONT-SIZE: 10pt">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources, including foreign currency translations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Loss Contingencies.</font></i></b> <font style="FONT-SIZE: 10pt">We recognize contingent losses that are both probable and estimable. In this context, we define probability as circumstances under which events are likely to occur. In regards to legal costs, we record such costs as incurred.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Recent Accounting Pronouncements.</font></i></b><i><font style="FONT-SIZE: 10pt">&#160;</font></i> <font style="FONT-SIZE: 10pt"> In May 2014, the FASB issued an accounting standard update which affects the revenue recognition of entities that enter into either (1) certain contracts to transfer goods or services to customers or (2) certain contracts for the transfer of nonfinancial assets. The update indicates an entity should recognize revenue in an amount that reflects the consideration the entity expects to be entitled to in exchange for the goods or services transferred by the entity. The update is to be applied to the beginning of the year of implementation or retrospectively and is effective for annual periods beginning after December 15, 2016 and in interim periods in that reporting period. Early application is not permitted. The Company is currently evaluating the effect the update will have on its financial statement.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company&#8217;s inventory consisted of the following at October 31, 2014 and July 31, 2014 (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 79.35pt; MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>October&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Work-in-progress, spare parts and accessories</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>446</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>446</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 52px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Total inventories</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">A summary of the Company&#8217;s stock option activity for the three months ended October 31, 2014 is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.3in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average<br/> Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Weighted<br/> &#160;average<br/> &#160;remaining<br/> &#160;contractual<br/> &#160;term&#160;(years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate<br/> intrinsic<br/> Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options outstanding, July 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options forfeited or expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>n/a</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options outstanding, October 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0.380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options expected to vest, October 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0.380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="38%"> <div>Options exercisable, October 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0.380</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">At October 31,</font><font style="FONT-SIZE: 10pt">&#160;2014, the Company was obligated under the above described Credit Facility and promissory notes to make future principal payments (excluding interest) as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%"> <div>Year&#160;Ending&#160;October&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,250,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Potential common shares not included in calculating diluted net loss per share are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.3in; MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>October&#160;31,&#160;2014</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>October&#160;31,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>378,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>538,750</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Series C Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,551,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>1,551,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Series D Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>13,910,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>13,975,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>15,839,950</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="15%"> <div>16,064,950</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company&#8217;s long-lived assets include furniture and equipment, tooling, websites and software, leasehold improvements, patents and trademarks. Tooling and equipment, net of accumulated depreciation, consists of the following at October 31 and July 31, 2014 (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Estimated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>October&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>Useful&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Furniture and fixtures, leasehold improvements, office equipment and computers</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3 &#150; 5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Website and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>111</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Less accumulated depreciation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(110)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(110)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div>Tooling and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1.00 1.00 1.00 1.00 1.00 1.00 100 62048 5500 100 62048 5500 100 62048 2795 100 62048 2782 100 62048 2795 100 62048 2782 10000 62000 4174000 10000 62000 4174000 0.01 0.01 400000000 400000000 78942423 79007423 78942423 79007423 9000 9000 446000 446000 378750 0 0 0 378750 378750 378750 0.380 0.380 0.380 0.380 P1Y10M17D P1Y10M17D P1Y10M17D 0 0 0 1000 0 2000000 4000000 Companys common stock as of the grant date or an exercise price of not less than 110% of the fair value for a 10% shareholder. 1000 0 1250000 1250000 0.11 0.11 0.16 0.11 0.11 0.11 50000 50000 50000 100000 50000 1000000 1000000 2015-07-31 2015-07-31 2015-07-31 2015-07-31 0.1 0.1 25 5000 65000 100 1.00 1500 10 0.10 0.10 4.20 10020000 2000000 2000000 501000 0.01 0.12 0.05 0 0 1000 0 1000 0 0 0 85000 71000 1000 0 86000 71000 -85000 -71000 -33000 -34000 -33000 -34000 -118000 -105000 78942 78943 -0.00 -0.00 16064950 538750 1551200 13975000 15839950 378750 1551200 13910000 1250 4000 4000 11000 6000 0.11 50000 50000 50000 0.1 0.1 1000000 1000000 498000 5000 28000 6000 28000 532000 9000 7800 15000 17000 471000 150000 2600000 4100000 8800000 1700000 150000 41000 13900000 111000 85000 26000 111000 85000 26000 110000 110000 P3Y P5Y P3Y 2000 0 25000 0 100 62048 2795 78942423 0 62000 3000 789000 21931000 -24323000 -49000 0 0 0 0 0 -105000 0 100 62048 2782 79007423 0 62000 3000 790000 21930000 -24428000 -49000 2000 0 1000 0 0 0 -1000 0 -13000 -12000 -8000 64000 -109000 -29000 0 50000 0 50000 -109000 21000 296000 21000 187000 42000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ORGANIZATION AND BUSINESS</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt">Organization.</font></i></b> <font style="FONT-SIZE: 10pt">Non-Invasive Monitoring Systems, Inc., a Florida corporation (together with its consolidated subsidiaries, the &#8220;Company&#8221; or &#8220;NIMS&#8221;), began business as a medical diagnostic monitoring company to develop computer-aided continuous monitoring devices to detect abnormal respiratory and cardiac events using sensors on the human body&#8217;s surface. It has ceased to operate in this market and has licensed the rights to its technology. The Company now focuses on developing and marketing its Exer-Rest<sup style="font-style:normal">&#174;</sup> line of acceleration therapeutic platforms based upon unique, patented whole body periodic acceleration (&#8220;WBPA&#8221;) technology. The Exer-Rest line of acceleration therapeutic platforms currently includes the Exer-Rest AT3800 and AT4700 models.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt">Business.</font></i></b> <font style="FONT-SIZE: 10pt">The Company is developing and marketing its Exer-Rest<sup style="font-style:normal">&#174;</sup> line of acceleration therapeutic platforms based upon unique, patented whole body periodic acceleration (&#8220;WBPA&#8221;) technology. The Exer-Rest line of acceleration therapeutic platforms currently includes the Exer-Rest AT3800 and AT4700 models.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">The Company received revenue from royalties on sales of diagnostic monitoring hardware and software by SensorMedics and from VivoMetrics in prior years. SensorMedics indicated they will discontinue licensed product sales after current inventory is depleted and, therefore, the royalty revenue from SensorMedics is expected to be minimal to none. VivoMetrics ceased operations in July 2009 and filed for Chapter 11 bankruptcy protection in October 2009. Pursuant to VivoMetrics&#8217; approved bankruptcy plan of reorganization, our license with VivoMetrics was assigned to another company; however, there can be no assurance as to the future amount of royalty revenue, if any, that we may derive from this license or from our existing license with SensorMedics. In fiscal year 2009, NIMS began commercial sales of its third generation Exer-Rest therapeutic platforms.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">During the calendar years 2005 to 2007, the Company designed, developed and manufactured the first Exer-Rest platform (now the Exer-Rest AT), a second generation acceleration therapeutics platform, and updated its operations to promote the Exer-Rest <sup style="font-style:normal"></sup>AT overseas as an aid to improve circulation and joint mobility and to relieve minor aches and pains.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">The Company has developed a third generation of Exer-Rest <sup style="font-style:normal"> </sup>acceleration therapeutic platforms (designated the Exer-Rest <sup style="font-style:normal"></sup>AT3800 and the Exer-Rest <sup style="font-style:normal"></sup>AT4700) that had been manufactured by Sing Lin Technologies Co. Ltd. (&#8220;Sing Lin&#8221;) based in Taichung, Taiwan (see Note 10).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">The Company&#8217;s condensed consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying unaudited condensed consolidated financial statements, the Company had net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">105,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">118,000</font> for the three month periods ended October 31, 2014 and 2013, respectively, and has experienced cash outflows from operating activities. The Company also has an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24.4</font> million as of October 31, 2014, and has potential purchase obligations at October 31, 2014 (see note 10). The Company had $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,000</font> of cash at October 31, 2014 and negative working capital of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,693,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">Absent any significant revenues from product sales, the Company will likely need to incur additional debt, equity financing or a strategic collaboration for the Company to continue its business activities. Management intends to obtain any additional capital needed to continue its business activities through new debt or equity financing, but there can be no assurance that it will be successful in this regard. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Consolidation.</font></i></b><b><font style="FONT-SIZE: 10pt"></font></b><font style="FONT-SIZE: 10pt">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Non-Invasive Monitoring Systems of Florida, Inc., which has no current operations, and NIMS of Canada, Inc., a Canadian corporation, which has no current operations. All material inter-company accounts and transactions have been eliminated in consolidation<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates.</font></i></b> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions, such as accounts receivable, stock based compensation, warranty accrual and deferred taxes as estimates, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Such items include input variables for stock based compensation, accounts receivable, warranty accrual and deferred taxes. Actual results could differ materially from these estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash and Cash Equivalents.</font></i></b> <font style="FONT-SIZE: 10pt">The Company considers all highly liquid short-term investments purchased with an original maturity date of three months or less to be cash equivalents. The Company had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">21,000</font> on deposit in bank operating accounts at October 31, 2014 and July 31, 2014, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Allowances for Doubtful Accounts.</font></i></b> <font style="FONT-SIZE: 10pt">Royalties and other receivables are recorded at the stated amount of the transactions. The Company provides an allowance for royalties and other receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance at the end of each period are determined using a combination of the Company&#8217;s historical loss experience, customer-by-customer analysis of the Company&#8217;s accounts receivable each period and subjective assessments of the Company&#8217;s future bad debt exposure.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories.</font></i></b> <font style="FONT-SIZE: 10pt"> Inventories are stated at lower of cost or market using the first-in, first-out method, and are evaluated at least annually for impairment. Inventories at October 31, 2014 and July 31, 2014 primarily consisted of finished Exer-Rest units and accessories. Provisions for potentially obsolete or slow-moving inventory are made based on management&#8217;s analysis of inventory levels, historical obsolescence and future sales forecasts.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Tooling and Equipment.</font></i></b> <font style="FONT-SIZE: 10pt">These assets are stated at cost and depreciated or amortized using the straight-line method, over their estimated useful lives.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Long-lived Assets.</font></i></b> <font style="FONT-SIZE: 10pt">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In performing the review for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized as the difference between the fair value and the carrying amount of the asset.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Taxes Assessed on Revenue-Producing Transactions.</font></i></b> <font style="FONT-SIZE: 10pt">The Company presents sales taxes assessed on revenue-producing transactions between a seller and customer using the net presentation; thus, sales and cost of revenues are not affected by such taxes.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Income Taxes.</i></b> The Company provides for income taxes using an asset and liability based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382. Tax years ranging from 2011 to 2014 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company&#8217;s policy to include income tax interest and penalty expense in its tax provision.</div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Revenue Recognition.</font></i></b> <font style="FONT-SIZE: 10pt">Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured. The Company recognizes royalties as they are earned, based on reports from licensees. Research and consulting revenue and revenue from sales of extended warranties on therapeutic platforms are recognized over the term of the respective agreements.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Advertising Costs.</font></i></b> <font style="FONT-SIZE: 10pt">The Company expenses all costs of advertising and promotions as incurred. There were no advertising and promotional costs incurred for the three months ended October 31, 2014 and 2013.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Research and Development Costs.</font></i></b> <font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred, and primarily consist of payments to third parties for research and development of the Exer-Rest device and regulatory testing and other costs to obtain FDA approval.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Warranties.</font></i></b> <font style="FONT-SIZE: 10pt">The Company&#8217;s warranties are two years on all Exer-Rest products sold domestically and one year for products sold outside of the U.S. and are accrued based on management&#8217;s estimates and the history of warranty costs incurred. There were no material warranty costs incurred during the three months ended October 31, 2014 and 2013, and management estimates that the Company&#8217;s accrued warranty expense at October 31, 2014 will be sufficient to offset claims made for units under warranty.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock-based compensation.</font></i></b> <font style="FONT-SIZE: 10pt">The Company recognizes all share-based payments, including grants of stock options, as operating expenses, based on their grant date fair values. Stock-based compensation expense is recognized over the vesting life of the underlying stock options and is included in selling, general and administrative costs and expenses in the condensed consolidated comprehensive statements of operations for all periods presented.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fair Value of Financial Instruments.</font></i></b> <font style="FONT-SIZE: 10pt">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2014 and July 31, 2014. The respective carrying value of certain on-balance-sheet financial instruments such as cash, royalties and other receivables, accounts payable and accrued expenses approximate fair values because they are short term in nature or they bear current market interest rates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of October 31, 2014, the respective carrying value of the notes payable &#150; related party and notes payable &#150; other approximate our current borrowing rate for similar debt instruments of comparable maturity and are considered Level 3 measurements within the fair value hierarchy. Level 3 Inputs to the valuation methodology are those that are unobservable and significant to the fair value measurement.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Foreign Currency Translation.</font></i></b> <font style="FONT-SIZE: 10pt"> The functional currency for the Company&#8217;s foreign subsidiary is the local currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date while income and expense amounts are translated at average exchange rates during the period. The resulting foreign currency translation adjustments are disclosed as a separate component of stockholders&#8217; deficit and other comprehensive loss. There was no foreign currency translation adjustments for the three months ended October 31, 2014 and 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Comprehensive Income (Loss).</font></i></b> <font style="FONT-SIZE: 10pt"> Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources, including foreign currency translations.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Loss Contingencies.</font></i></b> <font style="FONT-SIZE: 10pt">We recognize contingent losses that are both probable and estimable. In this context, we define probability as circumstances under which events are likely to occur. In regards to legal costs, we record such costs as incurred.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Recent Accounting Pronouncements.</font></i></b><i><font style="FONT-SIZE: 10pt">&#160;</font></i> <font style="FONT-SIZE: 10pt"> In May 2014, the FASB issued an accounting standard update which affects the revenue recognition of entities that enter into either (1) certain contracts to transfer goods or services to customers or (2) certain contracts for the transfer of nonfinancial assets. The update indicates an entity should recognize revenue in an amount that reflects the consideration the entity expects to be entitled to in exchange for the goods or services transferred by the entity. The update is to be applied to the beginning of the year of implementation or retrospectively and is effective for annual periods beginning after December 15, 2016 and in interim periods in that reporting period. Early application is not permitted. The Company is currently evaluating the effect the update will have on its financial statement.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 10-Q false 2014-10-31 2015 Q1 NON INVASIVE MONITORING SYSTEMS INC /FL/ 0000720762 --07-31 Smaller Reporting Company NIMU 79007423 1693000 -118000 -105000 -118000 -105000 0 0 0 0 1000 -1000 0 0 0 0 -13 65000 3000 5000 378750 75000 13 EX-101.SCH 7 nimu-20141031.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - ORGANIZATION AND BUSINESS link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - INVENTORIES link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - ROYALTIES link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - NOTES PAYABLE link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - BASIC AND DILUTED LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - COMMITMENTS link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - LONG-LIVED ASSETS link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - INVENTORIES (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - LONG-LIVED ASSETS (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - ORGANIZATION AND BUSINESS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - INVENTORIES (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - ROYALTIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - NOTES PAYABLE (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - SHAREHOLDERS' EQUITY (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - COMMITMENTS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - LONG-LIVED ASSETS (Details) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - LONG-LIVED ASSETS (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 nimu-20141031_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 nimu-20141031_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 nimu-20141031_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 nimu-20141031_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ZIP 12 0001144204-14-073974-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-073974-xbrl.zip M4$L#!!0````(`."&CT4ICB/3)7X``$J5!0`1`!P`;FEM=2TR,#$T,3`S,2YX M;6Q55`D``[18CU2T6(]4=7@+``$$)0X```0Y`0``[%UY<]LXEO^_J_H[8#P] M?519MQT[?N\B'O`^_/.A[Y`[)A47[L>-6KFZ09AK"9N[W8\;7]LGI=T-\L]/ MWW_WX6^E$OG,7":IQVQR.R1'U*-M2:UO*GJ?U,JU\@[!']NE(V:5ZM7:%OGO MZE:S]J[9:/P/^=^K\_\CQZTV*9'[^_NR#35XNH:R)?JD5(K:.:`*VH!Z_CBX M/B/UJC=I& M6-KA[K=4::RI+&072E8;%7Q\"RU'Q?&IS>,7DH7?58*'<=&)JN\;NFSM_?OW M%?TT+JIX5D&HM%;YX_RL9?58G\(0E$==*]47_DC?Q\MS);;JM9W'W@A*1"_8 M;""9A7,[]9WW%2HM*1Q6Z5#+*[&'@4-=Z@DY/('KJ")+^*XGAVFR*6:5N^*N M$C[$F6F4JK72:&XL7TH`WK3WPJ=Z2M,OVHQGOP,/,HJS!ZN771Z?9+S`W3NF MO.Q7@F<9HW$IMU3V._H1OE)+OZ*XE?T"/,@J[@WDE/+P).,%7Y6ZE`[B=SI4 MW>J9#1]D#/W!>00_?YPE0.U[\A'8P-,-8%]"/B`C-)6&^#7K$,T836\X8!\W M%.\/',2OOM>3K/-Q`]F[%'%Q^4'9&Z0"%052XE"X'GOP2(M9'@@?+2&@B4!& M6.%##G"^VE>7;G7GIE&[P;J"KL0EF>MQ;QC>B^]R&^]W.)-$=Y>EAA>1^O#T MUXU/5?BS4Z_NO*M_J(R_'#55&6LKU8,!DUS8$SW0'.U]"J9E!Z8EKCY\DJX[ M44MT*R1"V%X69:J[-U5-E49;U*HAA1H%H1!007J@A=BG@`%W`;U1/:-G456) MX=BCEVK5!&&C)_,D[%:"L$6!7HJP6R\A[-;B"/L^(&QUIRWP]Y;^74#"`DM7 MW\]*V/"EK040%H5DX9":$I(IR,U12&K*U&]J6\6E3+U4VUH096+%6A2UD:!, M8V&*-<5-A:3,Z[D)C;0CWF>N]@UG-=-N6E`[4P=78`DRL/[MEB>L;^>L?\ND MK]!B;8'W"&1RO4.'*G79T07V'[A:,KG'A3SK8J?B]L('-G0$/"9N<2\8!+$C MVGS<"&WPYB-#BHM,)\N'2F9#HY%7LGJ86^,T$P^'!@]9>,@DRUO`PY'!0Q8> M,LFRAG@86:Q&7Q1%7RS43A_'@]$7N=<72\6#T1>YUQ=+PD/[7K1[PE?4M:\< MZB:1L']/I=T>#EBQ9W]L&/@UO9DYZG6\J(?O,YI9*SOFI:[,.=[G'SO@=LT]=Z$>7WSIL7RGF MJ8/A.?U+2"TVBXV*F0>J<3-)MN7!I7CK.@9E!4=9SA:Y])>.^DV]'LBP?U&7 M?5&V[=KO'I<=`UDO1YPHH/+P0'DOBLBV%#Y-C M'[%;[YHI3_J6YTON=O$&S),.M_"N=-^+#`0$*T%_O53=7HR_K]'__J:F;>3:S8D4RAL;>AO0ZSV3`\*O(ZDI4X8% M7LP"C]!ST3SP!!16P@7[&,@,6Z@ME+VP:1KT?D0K7E MHA;!J_71>JA92\B/8GV3:PGC2[KU%RSIII8@YKFDVP@9I0J,8NR`5>K>=1;Z M*1;0EL"L+#!F/LR3!;9#%J@#"Y@ORGG4&F_[BW**>?0WY5F99^Q#]'Q#@NK; M84B0^1"W()7R;,NE8-_]%LHH.JJIOCUK5%/J^]W"=IC?'(I^7[C3H_"/_^W# ML*'40+@H=8H)Z8E(_.QA1<4FB+)N7NE6PBN%W[N!5WHE^1W0Y\JAEB92"A#^ MK>(VIW+8H@Y;CVT9TX<4%&PH@!:A<;-!="1[(PT1ANCJ8)A\4FPPS3)&K;=2=#*(>@11(T?6@.H)4(V3RN`J7ELR M:BZ_:BX=Y)Q$P>*W)AWW!XX8,J;)U[WM!<63F9+?!ZWQ!<"3NE=D$:AY4BAY6Q+X]2-LT:A%4*A%0E.1J'E7J'E M#4ZU\%3AW;:`'XW@]\TYIWU^QJABYOO/$]]_QDFU&EQI4,U\J/)N<.S]\NQN M@ZN"X:H@!KC!5=%PE3<]F"VOOG#J,-HSR'H.LB:)9636(S++8*N(V,J9W)IY M$ZS9*/CRN+>5;.I^`UM;1YMTS!:<'&[!62"P%GR^UBBBW\3HYRQ&?X&@6OC1 M*Y&V-;IT:;JTN,IM?B?UK/W&.K/!/I^'1"2..PP>:"L9M?3+B>))< M*Q)R2TDNT#`Z<2UTXCRRX#T++F]7F.(XE3;BQF==#/BPM5XV1#_F0#TN; M\.,')I$EOKK<"Q&.E$C=+N9DZPG-&,?D_;D`_`%_*;URUQ..?=H?2'&GX_;49:?#+88;PP=:\+DV;@_W/293 MA@'H/>B6-\043E@H?N%@6/RHZF<-+OCP,#>RKNH[VW+RX_[.;A7WD$HMT?'N MJ60&3!-@FD:D-81&0NL8R60DTPJ-'B.9BB>9%G8@3'94V`HDU*/)IXJ+N)>G M;#+"B1/UGHQTO.R2QE&6@-&,D9+(8R6/"/K&5Z8P51R<%'A MZ91:,VM8?\)Y%X9K;MU@9(WK"3D\?K!ZJ'Y2^+@0;E^X#$"=C,(H/C2>&M;=`J,M=\RQJ44X-G5)GW;W;9LC3U#GBG+[U#VD`^Y1Q^`A/J/E M,0*M-S:N07!RE]G'%'2FVU4&%*.PQ2S*K#<:]BW+[_LZ*//2ZS&)M)&LAQ2\ M8Z>N)?K,`"26&L\EUIIAYM'#=`[,83I9A^EDDL6XN8_`R1BN^3)<"P@A8_<6 MP^XM(+2,V9Q7L[F`8#)6=[&M[CQ#;FP1P:C$8JC$5<19&9V65YVV"C08I51L MI;2*+0QZ_0TZ"54]F%WN3^QRGR36FGTG'!,H!AQ%!,>2`WD39Y5@J$<2)^N9 M#V+\A);1J-^L_^*[/`")ZE')QJ>ZSZCR)?L4=D\7B:J+GB6;P-JFU/^U=32E M_'O8(R>7%^TFJ>%U&Z2$(A?LGER+/G4W@QN; M!)>..F3CQZZW1\:J.SP[WK]NW@JO%]14.MD_/SW[LSE6U9Y^UCK]K^.@J3W% M_\.:9+>\S5U2JY6KW)UK]?$HH7K];^"-ZE>>%&X7+_&J`R2-FANK)GBE4?Z1 M]@=[?Z^]J^[E_17UZW,+!57!TT4@KZ8%7@,X+ICFIENO;R:E] MBMB),4WT?O'=G:&?667"ALE/8TW_M/F30@[Z*>S@.,!20VWW&$&OC;K#@!B[ M(&3W%.&16$`9H+@"6XV(#@$GCW2$XXA[[G8)]J>?5+<^&4;A__T2Z=7AP=HZ#9>5]N;,--4C"X!.\1?'(=W MP92RM&$\5\&E:;5_=OKYHGG&.E!OBGA`ISWR^^E1^PL6K_YCU+1';QTV(>,C MTN(_%+7QR[O;_]@C!Y?71\?7I^3RM^/KD[/+WYOD MCBL.56\0BSF.&E`+P3& MU3X]W#^+FH(9\D0_+/A[V,>M*HSGGMM>[^/&NR250TR-P2Z)M(IG%VAPM3F, M[;['/59"9+"F*^XE'<3(.KALMR_/XQZ3VN"!*.%P.X3UJRGR,@KL)"D`)$#< M0_\!O/4)0KY;RC-=SL5#C8/_SU M\_7EUXLC((5E,=;I+$OT_R[DMQ)W2P,INN"%@G,$L)&,P'^>TK86A0[A*6^< MJ1=`8[4DZ7/;=MB"I45^AALA()15[`$1)._VIE#A:O_HZ/3B M<^DZ;#QRV'-/F0S6>5\X?!AV,.Q@V&$9[)`36Z*C_RS+ECCA+E<]9I.N$/;* MC(47CWDITG$V-R+G(%@^018G2Q=(I0Q6V=IZ9_C#\(?A#\,?JS8G(ER<'9]` M7=OU9=N@,YD8;>%1)UX[,I\D9A,:#1`:MC[K?P%BM(ANVHQT>B.>W-;VMF$K MPU:&K0Q;+CE_M%E\IUYA:7HBJ=&5&1>Z%G1@0BW0MI,ZKB`:(T0Q]_$ MH(4]HLN4'#H4OM?L\`=F[ST97Q#7+^-?=MRSY$\Y^AD1Z4/E.<%U4?!?G-8E M+G+9P8@5I%B]5KM MR\-?2P?[K>,CD#3G5\<7K?WVZ>7%).D0[DD=]3Q611OIVLI MZQY//LR*W5-X3@81`Y0>P=N*<`6]0YF"C=[!:/!E3$B*<7P.[\05^BY(4F>( MMY/U*.(KO!?VUH9JHK?[S.L)>Q-4CM?4/S6I"-ZP6=U] MHO5?H#DGJ9X>1`T\N#@>?:04M=XE^$SC"X]V9S(MH4+^T>H0B!U"WF,N&3(J M@2W`0=/5!KU)]D_+0QE#0GL>U$*%I36C"*0X@"$>%W?USA\?A&FDCKL@Y+4% M,([IH#_:)#BG$K1H(//K97(A"(V/9PCZHF#VACCQ?5#%@<[6#<;5[9&>N&>@ MZ)'CV1T7OG*&,4PB^-YST!N2]2G(*?@+Y`-B#WR)+.4]-:*@(T;^SU/^G[HP MVW?!)DJ8_.KF$R(#(9ET%O$B%#5"Y0<5RY@A@3&9@2S)"[#\AJWX9:2%XKL MGUO[U[]L3DKM`(\9#W`['+QVW?KZ"QDPV<$/-*@Q`AVTF;H7E`4Q8E'5BQ5! MR[_]"^0R<@2U_P*9JW?4P>2"7X!'9!"+2\OOXRYA"VM,#YGZ8"!+\&K5(A3L M5J:"'0%^-DVK16BL4Q\5!?$`(TD6C?<>K9((?:`3A2^3\ABMT5#$H7S3&'9% MY*CT*&#AEH$\?@Q%@>H8-X^-+%J0+0I^KZTU<*0(AV/.H:T34C_;C1%:NC7, M?,WUT\BBOL;N$^7WP5H13)[L`NEVCJY_UAZI?#,#6?"/P?K2-W_#CY]O M%@\YVN=?8V=W[:O!@ M8D9S&#.Z7636JI8;NX:Q7B-HBSKS!=YW;XX9>*W0-,RP-N@HZ*[`&4BSN)VA MC_DEX>+MJO"0QUVBRW9"EKLEN&2F.B_^Q:LG/DLW)'N<)XHMSM-8(1DS^,NM M4,-AR[&MEBLX5V\\%6=^\R$>#9P-G(OI"ZQFC2(*YE^9-Y!'[[!P2Q+%\`;R M/=5KL]KP]KR!%9(Q7]Y`OCDLAU]:"V8^%6=^\R$>#9P-G(OI#:QF9:`C9(=Q MO0M51IM>C:MHSA9=N>M02#"8A83\NPYF(:$0'&:^O+Z=^#1P-G`NINN0 M@\T.X_O'C8-ISOHU6R(*ZFGD:I'"[(EXE8-A-D6\`6D\$R)JY=U=`XBUD;6% MDJ7YY@PC)_/GVZQF603/4]9G%GI"'YJ='P1FO[5>G M[!AE54DUG[QX?2-O*MW-Y?PS%I*DX1\G#!23T8>89W':-6YCH=.]N3.4SG/X;59,1:/]FPGYD>;C-"!U4( M0=_%;--=E_]')TS&Q,:2.31<@T]R>RK7V1-3E'FAM:G.O72+Z:VE3H44)3%` MO=7$/$U[1)T^F5(KKE_$O.^Y9\J<<_8R4VX>*KTI=2@?- M(ZXL1V`:],M.,J'D=4"10R2/SGIS@/FEK^A0YS!MLP?OP`'B?/K^N^^_(^2# MR_M^\UH,J>-Q-GJ,&1\]N+AFG8\;5]7=FVKM!F>D+6K5FT;P>X-P&V834X?9 M-XV-3V,XBO&`*BTRNH(I)V-8V@QN;)(67?^Z?M4^/6Y.,=;M$Z;*VAE(RCR/FV",#*KVA M3NEY+XC#+>!U;=/$J8G!E@95U8+[0IXSFUM!GNS?^)TX9YA;-4Q>'-6:R#`, M(I5QM"JD%@)#3/`J^FR45EE1)\C5#,F=A+N=$KS&;-"8D%+KU6^I^D_[`LX9&Z\ZEG]=3ICPU:P'> M8'+[PG=#7?O#/$VU,2,-43+7^FN3AN`L62XC@UCG*<:0/\"L,RRGB819MJW` M$NFQ89"FVP8-#35SUV<1$1'_PO8M3W,5<$3'@Z:X>P=,+.0PR$X_<)C.#._: MH?T#O65!BN*(1X&)&%8[R6,\'9B("<)Y,:)RM#_`KDFF9!="N/6O=K4R8\CS&NQFAR$ MSI2L%.^Z`7VI*W"*,",S"M9$$O?`;YDD-1D(6$ M(C4$:5OSZ]^J`D""%"52$F5);L[9;-N62!0*586Z5XHA]RQ0AN"M^#*P7W$0 M-Y!@Y(::4WG"G8`S^B-"SUXYB&@0S*EMF&3ROE3B&3JL5G%CC9GUPD1K7E[5 M/:Q5W>FK1H2![SV5U7>/<@@P>4.Y.S:UJ+5YM;BT^GQS^WCQ8-UU?^]^N;[( M;'WM^D)J[O!AY^`$?;8[IEQG!D$?%PZ"7HPX@>$;UED`@C*T@.6YR\,\A7-! M>KWUK*]VX`SU-=G8,R=S6S38#^X4[N&M0F[X&[CLZ%I\8$X4X'#NKE;XI42_ M#$`5MWZV1R/;NO*P!D$:`X]!A.4(MA7B#R3?`M_%J[4WLX3GQ MD75V<9L")E[/`$7Z-_TG1BI"]LCD^1NON$9U*A#IO8RC0$0VH!W(0IX3/J6^ M"I;7,T.MZ)FC(F:C7NB[SWCU.Y)^7>XQZV-FH0QMFPOBF>.W;3W*$BTPS^%C M4"`3-24:5VX$P'655M%'2**HCPFD?GE"0)KS*`4T2^%[`"E@!'X&KK4RIC3\ M=<1#K1O[0>"_T"$%3/TB%2N`G%0T_#?QVF?0!I^$W$V-<.P4H1I$0"A9^1S' MA!J(EZ!RD@)`(0&AWIZ0O@74+W&?#FG,A@QV6BV[-C/L.L9PA.=%(\EL0"$! M:O>DV%:[\M&LE97ME+?]%))1,Y9?1;Y'0PM)J,\&-BC2!U;7=1/DOLQ'*WHU M`O:OB,(%TK@*V-CFB?28!XA$5=Y!XGO'^"9YW*#J([D2]:'0@*_BQR,.FX;- MC)F'-@*`/MMG'M/\T.Y;_%E,#4\5[V)/6UFST%E'/GAY-JWGVWN2N/" M=LE*BD&7H/ZF<%BL].*%M-ZPZD+A<"/2"H].29IXMK6P]L'+(1LD:S M1:S1G*-QH6-UG$#A(13Z+LR[`2OEGDX.ZS`;KOIIE>$=ZG12+M)6049AC$^% M](8\Z"O7-[J$8.M^:+O5RZX MT;=AMMG=&[OQ;$&&=[*'EU%!C-098.HLC777,Z([HU*;I)DL3DXV]Q$ M(6+ZJ&,S4_'"%]\.^FF;<\C9P+IX!8,(@Q#6[0!D._J:_VF#E??+`:S*;7]O MBG\36QA/IJS58<@Y?%_Z)=LKO>26,M"B).HI)9OW:\'S?@1/>RV"YY+U@LB& M-[:DZMA>1OJ\M#M354L3*&E/$:GY0MFL?@]ES^19R+QTMH]'[BM MSX03\!Y\DN>UG?*2@8@:V7_%R2R)I!FKG&/K(WMUW(A8(J1*XLYNKZ^[=P\`B0.48(\%^VS=_GIQ?WE] M^]LGZYD+#F\LS!V:"4_I=AHO0QZR?5R"??+\E\`>QR"6'.6C,2>1NTB17?8X MRG78.#;JYPZ/IPOH?F=VD)#J!869DM^56$G^H.7+8G6%RV]Z^^8'/( M(4"@0.:M=[S1#;;1V0`>ENV/G\?P-0WLPMYJ1MYD/RS=".#ZXA+>U3K:FC[3 M>0R-MN$25/!N:_V7';*X'1TTM@@A6]PI8S:6\GK,[+4,GU/-)6L7GPN@9GT- MV2O7?=YM9\EWV+"UU/"H=]!R:'/(VT8YNXW,-:?S4.J9M3B&YWM(M[] M+UNV]X!)@K(%CKCX5\3#"89(JBCDZ]2%?*OTK#C>I9X5#[]T[R]^N;T&N?CP M=^OB?[]=/?X^S54;:%^1EG9A8'O`>`$8\[%C^\](A'PPF1UMVJKN`[/W4SK( M8N:0#K%:FFK.'=<66&+B#ZR[@`U8@!%R$@X'UB]2/.!GR([PK2_9+^WI3\ZR MGZ@:._KP?/K#@,G\/5>-^O%5P)4B9L-DX52=&I:)6]BDPU6`4Q&/ZV(T.(0' M-E+44,'1[#QMS2(/68<26O`'QD9YJ4I()4,Z5Y?#-=2G=@'6L^U&:ZBGR:92 M8'H!]8+;L\9NA%TB@*H"V27"BCS*$@"<\S[S^D+W#3BPSO6?B(P]W]MWHE'D MVIA5H>J1`BHXHN82:ZD,FKT1/HBW4;/#9MEA6B9R,8\50LI*XD[U]-(XF$DQ M5C0&AFLWK+X]T9V!7@(LY_20=0$:3*8!P(7N:XMR8,5WB*CW)W.H8-SNH^XHDW!4(F!<`2LQ M(,8NQ[IX^9M!E-AA*!`L]35:V8'#M.%ELN\-O:[69C8LOJ>UUB)M9D.2S0;8V+HRNVIAUJ"M+)QYVYF)?85Z^+U2 M(FKGXKOZLSU:_7!W5*SLO%R\]:PN*(ANLI$35<>3_&5.PKWDEG$4."`96=)G M,5YO:0[?,^63$$,/5$6A+8X@7; M!]8-=H#1,&<4:2D#8MMDJ6:X[S*&6SHXFXWJ7M@!-G<2=RP@!EH^BGM41W%7 M+70%(#*_@++D6!YH>\#8U$@Q%K6D(I*G932.0JF:D.1$>1\_88=AP'N1%&>@ M8YE/ZRBJ\E&],$RM0A\07#'V$[.\B(JE#>^HN@>,)GK&_2)']J!#W25XRD'] MQ*EQ)AL,M-N%>KB[4CD;@U@#'0QTIS0(U)F;;H>2P,QZ$1D1@GPZU$X154_X MDO9NP!5(F".7M9[QE#B`]&0C:J5E!V`S:S]/ZI[.7'#D\)$((*CS\"41M5S# M?,]7",3@=^S$(G=CCS$/[(<^T_KVU*&;^$RCJL<<.Q),JNF`F!$\9:+$?'(F M8J:5F.SM_^)';A_+L.$9OJ\I8Z(G5C)55KK#[-N04>3*-BB:/?\BU7 M762^'?6$%99,K82-+:XP71I%G6D=XE<:NZHN6/]W-%I[R9WU,79%6L2 M,U*#-T48Z]O]5HK-;2R>?6NYN,8CSQ%\S;U.I[G7VL%ZZ9K":PI_WQ3^_B_W M-W83S$CVV3FM;PO[-+U;-?B[:ER5)S[;>Z?-W>Q<5;-)S29OR2;'G9UDDQU5 M,]+],9N-C2JAQP6JQR/.`MPY!?1-0I4[U>]M&]RSWV?CM^,B`=S9.VF?[IUN MSHE;LUG-9N^?S8[V&D>'.\EF6]!@\3W4T,PLA/OUN/]]V;A^[9X]7MS0.1Z,8Z M(FYEFG1E99>"/WE8WF`-L)YDPNP`Q#<6[6-MA4^UOQ;E%V+:^U=NC_B>=>GZ M`>_;:CHZE6K0U,P7;\[@=Q_+6K"\(5OPBT4.(S]@LH`[%_[EFP"D#F+N\/K!M97JTZMDU-XH8H%JIZ)^WFIO;LT"]66 M'^Z'_K[\5L\67*2GJ@?,P8NL3]C"#3(/B"@>,^\;^)+TA8VMUK?)P^G.#[BU M-:^!G6W$F#E8D>-.]M91D;MIV;'3,DZ>0T;(O5"I'U9NQ7+N%Q!.S![.E'1_ M^IQX8ZKQ@:K]Q[/$WQ;JR)!JPG!Q*]EKMNQ1,!K@SQ!`\=1H*8%.LQ)("ZA$ M`,'K/=H;]R+YG5D2H"NL0110LZ9D/B,@\`;;T38;Z?F.S[8CA4$N]#PU@%9S M1*8%#AH+M,TEA,_TDNL504=O((*:TTU8:AFT-7`"=Y!B,XA<(*YI!CF:.U^Y MZFZ@:5+4?4*RPU11R[,#$"!`!PTI]Q!K\[J]&$)OWK=(#A+?!DS6)GN^'B!L M"K8L1(NUZ(@7L,4;8="LZ^W9+LU#[D>Z+;NG!R]/3:^EQB&YK&B.9#[4 MY<&R/AQ1]VQS5[H0U*H!&]D:H+[QJ>CI_DY6&$3PZS0G3]EVJ'`D9IU+IB#1&7MUL#57]#MYK-_+V+@*YQ1 MNV%HTSLC`'X145%[-^2SI;O([2F3R-0&RO%H#-E&.;28P>26,M#63+O]3!N; MR:V6:LJZ!.>^-;^NM>5C`7>:V%&L@6B3X$@#9\NY-`MNS:;;SZ:&C^AP3[4# MWZ4;UN18O-_^OC;^-&]/,B"W@S%'FF5T7]P'E4Z[]1:1Q=-IXJ/C=IP@,DE%>OPP1F,V%YSA:`0HIVC(#DNX M'C/XW8286J5EW8[(U]A'OI=QJO=Y`+C'_O`/(8Y$L>ZC'I?QPGNX(;^-08^! MVT_.A*0)-/S)XZ`BV+1@T@IY3Z4J!-1K\D?@M.35\`NPWHBE_C:P**'K@O20 MUSU02)P#ZZ/\'M#'@SU@#R$/8++V6_$9J8$4"[U^> M_^*AP_T,-"P_`[,)CB7!T1C)`*6BP'+XF5P17V7/A(<^+8+I@6'8A;Y*@T,Q M]\ZZYB,.5T`>K@@J(_EF3),>@/U!MQW9`7G;IV,;8B:Y25\QZ.$ MG+C9/]Y,(*&>,6PNTW9F?35#)!9HT]Q-YO7L3=][I2!(PL\XN<&SV&CL^A/& M9JPG8U9M+:]4S$AZIH]>4'F8H6`'X=).A@,$7V*C2% MJ`:&Q,:>^%UJVOJD1C%@5$99Q*%/_7%MUZ8B5*V?%BU(RCK1D[DR1';)*BRF$X8ZO]F!/A#)$O7!9CVK"?F`;A\=[)VI6(TRI3 M`_8,%;8KT2ABRPY0FSK&M.*:Q25Q"/+!&K6T-]#1VM-KI+%;2K5ZG_,7%D@) MSV:38QHFEU/ENE[_C&X!8'0'A&D5">4G=4+Y*@GES<8N992?W7[]>O7X]>+F ML4XA7Q=)7&,VGIB#WJ(7U-ZYZKUS6I-!IW)L%\B,UV2`V%2"/PV-T(FAL#Z& MK_6T!M+%A9$*BI?[S&1P`(`LB))09#-P"9``%$O43/SH:9C.#.T04`'[5T3I M3%J+,28FA_8KBFGNP65!;F(:VQJB'X1O_5"L7:&XGZ7ZC:H.S7-+'ZS0!Y0] M&S2"9)XNY<ON?!XB&8('?B! M=2^SI;4#E2@\37E"!7RD=EIM@N#Q6R3\KL=ENMV4MBT<4?I.NPO\?N2$8)D# M=OVQFG;:MQZB\1B4_W@@:P[>:[6DL@`QQ8<;QW/CPV5/:FH\ZYRAN@\H;:X! M]$?F##W?]9^HUZA_8%V'_8,]HXY$.H3PFS9WAA$Z->"G%[@P/W[0;_GPPP&. M\DU-`8T73^^-AC51J0M\+X:"9I!FMM=G^$7MG?+`@E+>%!J*=/'*@OU[IMS/ MVIJ7WD]UTR>(20I-9"9S@O^VQ#^]9&A3_0T+1EK-"*6$2DIR0/X'_DBFT3@. MO(5N[CB0+4$=\$"0;B!'(]'A(XA2B+!S',H+M.92?"OU$C$T7D8)(JNHUP/"E5!R&@J$318%G&JH_CX1*`S%Q6D`)_TU%H' MUC<'IP?TM7,_YF/F7XM6+G+R1I2@D]O MB!"MQ^TYD9[MG1%VU:N=.9`1%+.B#>3=?;9=#9Q"-_X+%#,9TY@[E/+"N)#4 MY:+K66*9[\%[4@C`67LC*K.186WEB,[4$#9.)(S&=9*Z1NC24)!A!$3$=49R MK3TUGT]8.NT(*[G,@B2Z+.1%9KAU&Z>UU*L$SF\Q,WK^RWY\:?9G*4#D='C" M:8JLGU:`V*L#UB;>\7V,$N'(3^0=0E' M?F%CX8N<"(C+2*UM3X9;,$69FW M+1&W*.EXWYC`K>DQ3`;29\-=K8.CI()P8*C<4BBA(HA$H152);*N]N@_2":+QUBN_J4X.3O)72B'99'2*!#.XC?JJQ)('?6V0 MT.!.BM1'H%\GZ,YFG#U2F!-#T*-H9)SY2`9*2K1&D1OR ML7@.!^])"D]CTF-BNR8M)6@ M7;ED_I%E@-T#^PPA1?"1SXZ0-4><*7J&'U;YJ)`27-C_]TX!4N7 M&^#/-+<\N36%O#=E`AH%%&0$(]X-"B$\/GD?D!3'4!A>U-E=ZOX#CNVA5P7K M](6.0M'VXY>^X.[PK78("XYIT\R#*]F1JAP.6^_S?+FQ1[5%Z!/0CJAD@+M^ M[GVFEBR6'Y+-+@&=>0SZ]N0.#,P0GK_X5\3)*UI%;LEIG5LR+3W!V/*]I_() M)LU=2C"YOL7&Y%>_7IQ;W8>'B[PTD_3^M^KBVI4+MDIER$IM=592L@M'MN]R MF?TL&-D):.IC*Y\`[#/4ZRBY5(N/O<1E],)Z@E-I!7Q!^(,0LQOV9/09\_`M M/D+[2UXQ6!T7TEU#I@#XFOH;TQ^N;LXO M4*3#!CY;OUV=/_Z"7S-V\^N[V^[MX]P*(.')P]%NRS=?OK MQ?WE]>UOGZQG+CB\K?"JM6S0B;Q_?,!&S`8D2TUFV*9YV4>'%0\_VZ;-K6L> M_-9,>\^9EW$A0K)Y^_79;??9P091(@%T(%9:4YM5%TNR9[A5ZB/=Z2-%Y:`^ M3\,BK>_0[=_L'72"_T::K#[D^Y/=[ MR.]^N''>57V9E@&AO_N002MGB.;Y4<;#EC/[V"-GB^D7ZHR>;ZXA+?U=X:LR%/9[S& M?DNSBAMJB^)=>ALW?WML]P'7'I5U>52V`R,Y+/&QV6S\4'-#S0TU-]3I--->DNY,U]4R5`Z&3OG<*WN^L<W(NI1Y30(-Z54,A MU54ZKZ8+&_;8GM%8DCI?5]U4O34]4$:W,U6=:+&;G>I;"+#BM%`L*$.P.<[N MH7[7&C^J#2!NL,<0O['_'ON:)@U0!X`^V=*0Z0X@5D15RA:V71('UE72FC#3 M2S'$@8(#1C/3;2_3.5=V'K6I3U+/]_^RGFTW8I5C+3N!!P=73#>-"G&Z^S/8 M67Y0-&)G1[OQ+=)/;VK2HRV&Z1Y[77'K-8YS>^LU80=XOO3%;P_G'X"R'"`< M5_SCPW[[PT\MP$3#Z!(([RZWWHQ>?LWF_/4.6X7K7>FCOV%A^7VV"M;M=%(+ MFXLL!L"LC;>K`^`N8-B*^$)>&T`>M]BJLDO,<18%@1P?4Q(QAP5PG:;`*K%T M)=#.PF)G/K3MXU6A71*+1_/AZK32I[L*"+-0+,0=KHN\"1J2^.I52"#.ZVCG),KN^B,W;<*!'&GG4>QV45O_)") M.]G4VQA.S)DX<^&RIK;(B_)2JT!4-YL(F0':`D!4"O\LS!9(^F:K41G\),_, MYQ=&=H'XSZ!ZUGK+PS4+B06"?DFX](AU]2W@8_A+$+'^-;=[:HSIPB@LD/VG MC?05N@`,E8(_"],%]\;I<;LJ\,\B$?HC%H#QZPN^^"W;*KA0TA?2,%ETY[+?M(J+LRJBJX M?=YB$ZM35<&]M":JFMK(ZE15<)=WHL.`.VV\=MEMI(B]> MO0IX9^&TX+H">`];)RO":WR#S"B,!P1LR#P@<_.9/E)S5U6MLZJFENL+ZG0W%<_U`4OD]A+2<$&;_HQ_C=O;+OGGY; MZ4=Q[@Y.M<-H1Y]&UD@@<21IWB`V/7U'#2:70S75@)MX]J_7I[%I+T!&[F3? M?X'+Q1)13_`^MU'KW+-N?&__RGNV:0[P5Q^HU:)@)7HC9&:OR;Y2B?`CK8Y<`Y&>V^N?KZ@,^>V9Z=/&K+W[F-@S&#L1^H`3T% MKSRPNJYK840\0"1P3-+==_0>]=[5M"!/V(ZTGS'DSCR+N5Q/298S.1," M*!>"WOZH\SQ9D)4;WP2['>@Q(V)Q2='>(4F13@`C^AC;2%\?\O,,-@;%XH+L MFZ`DCO@@BV59J?2F1QKZS0`^F9\#2\P00$@Y`S\8X9THI1Q_CL#(9\<-WN89/DMX=IXG@%QT]S3&<^4PX-F1EZJ#TX'A7]0 MFWRV73S^E;7&P_HNV(:[@!*YD#'H!^.`*[P4M%9)XQ1I.C'PE#7D3T/@+)?# MFJ!<#D$F[..H9$KS$W(J;3R9N*_N";A5`OX$XHC4.I`IP-Z)`#-23T%@Y&;/59^7FS5[W,&440XYX;_9L[R^M&V.9 M7ZS^AOD9NJF!EIE4W?N<4J$N(]OG"X.!\79U)=^@-]! MCP]3+UM:++R"QW M^!W9J*\5-]+%M.JE-3C3D$U+.1QD`M)74!Z\WA5M*BA8'.1'#RQAT.OHYY$] MH5'K.%05555*NG?=`^L^`_`+B.>0H2$P`$N=D>H^H4_Z.'F]KX1SY*DWX3A6 MJ7Z[KGX[&A)JIKLRS!UD.SD:WMA[ST;=KAJ.:1^.O# M=6`#8RJ\)1A1V&6(BD'Z+00YWE'H;+=,ZF7YBB^4QL74>]/*;G)$A!" M7JUSWCJ(J(`BQBF`2G;%NY'[RXCPF1GA*ZO"1[6HWP91KP^45^81,=Y(PD-+ M[!`DP`MP.)GI6(>$MF;P%PN53*%9XSP0X3Z'\Y4_`8]8(Q8._7Y2%L2P("=^ M)=`R%CEYD;18X:4<6)L'R.Y8`V3`4D;E0T\,0,7=B9Z#SOK*I\/%$'Y.%PLI MQXD#-Z60.+3N\,81Y%)%:,8^3F>7]K3?$[[+4&\'LQZ0L3^"K\+.XQ(?VM\( MI+2R]T&V)EZ;M`@TQ&3RN`NWE0M<84A=N:9P&$EY+`Z38D[8RL'`P$S(O=%W M4\C-$E"E$^M7%FS'M6#;!L%F=G:)#[S[+M:`:CGG/X.$@H_YS-+&]\*K97EP2@F))?QM<,X%J&FV M>SNX]KVG:RR>E`4<*_/QR0[Q\9NRZRI<>9V4N,IC6H/'+6#/G+T(BN5.E]2F M500RT1AR'#KP0W*A.4/;>V(R9,,#)QH!=Y,MS+T^W*DADS$+"AW803`A*2-M M,FTE]J3A"N]%JJ=:9*!TBO[$\0`$4EJB^IL8HYBD2Y63"`VI1_+NCCR,>N"" M&!-`+]\`M`EI7#FA-#&ET1>[\%&`Q%8?(B*.=M.^,1K0)TZB/#4`6'Y51"/] M5/QR!82Q+J@ATNT(B,M%B[DPA;S-$R"[D),QYS]Y)")MN5T9D2#-I%IT>'T6?'C'ZTR5KF/5OO7L9LP(IW(\0\D?# MB[*R]#RMI6?UTI,.T-(GB.:!.L/]^!`M\Q37(%Q!J1$D**4!H2.Z"40J$KH_ MCB%*I9EH1K8M`3Q"#I]^[`DR="-LOZ#6(B<3,-XPPK@T+2M'$,MF%DGH%:02 M"E\93,9V$1,9QI91SUT7`RNR\+0G!Q,TX7VKLOI1HV;UZEF]['?2%%W(ZE5N M=-'#G8>.]%\D;5J/"=]F]Y+KXR?53CXJY9)R5GN&RJ-S02;*Q4(A4-L9'ECG M.DDB><7,)!(S,$'*UL#5^2NAS+@6[%\14UJC5IEH)B+I)FR$Z7S!Q%!Q1$K' MR2@T\[)@<-TL5H;?CMQ0[Z9G0D=F7I M_>"S/5"?!YS"%$*F#V)8!",,`WPIB&#;D@X["FK$`0P!%*+F%\&/`2;S MHS9.2^&Q:G^\7,!ZX:XK]6K;1251[B,*`0W_3H4AIO9`^BD?<:49)\"KP($L M'\C+!D5UOL=T+`$?%F@K,/DZF6YI\?1SH)RSX,F7(2?,(0W$D(^548&G("); MIF#A4U>8G8F!?27)X35]!NPB8T#MD]8!T"%^J.8``]4A%1JO:@YK+^ MS)M[1Z[QHOMWNLB&".->6D=5Y*X?->L+N_H+6S.P<5!5A('PQ,U!E@+)7+D(A?0U/OM]7;DR05&.F(L<\ M!.Y!_C?:I\*,V(LDJH[R&P&+(R8RTU*HEFH`*8@7O/;NP9BP`V>HC`=/ M!\65_:!2.PU42V`Q'/X:RJ9^*KD20?#IG@[L,8,KR,'V=B&Z=Q+=0)V)]N9: ME.6ET)"D%5GV4\!D;NG.&RBE)=9T028@*>2HK)V!4;>R\^%H-XMSMES`&:=D MT3&MP;L09T[+9!BA%%]C9=(=@#O]6'L!#0-K8*3F M%ND;BT@6HQM:TD;?9-8]Q9*99`OD]K$]D;E:9")QL-_&LD>8"I;,6$]=K4E^ M!GS('7VM/V&=,J9(A!A141)!FK424%C,[Y$->GG>E5X!,%O?#9.7X-I4J."W M6--9^3+>I9J'G>'MY'RJOX53%KVA\B(OAR^^=F.1-\?@-V69".QQ#ZP)QBUP MFB,KV9#9/.D`DUE1J>\"-V")A&;A;P-7%7QVW=>ULT77%/]'H9`7E^0JLZ,JKI;JG\$ M*7GEX7@CL-`P.679>H:C7:IGV!G91ZT>]J22A)['U#8":09M;)64_:4 MJQ,%PQ.2'IDLLFK3U]6TH/DD14C:R#%\%C+=BQZ7E5U)CH,XL&9M.'&>BER7 MP[/2=5P^B(4K\;Q+H844C#)<$)>BJD[]+J;0[>F:9"F4^R/,A:5Y!,],JWEF MU:LJ5YY15NN876+,TEH`,&EB0%(*42Y3^H6.!8/0WG4QM8(`RLJP2Z`2ZKUU M.[C4$:`KG!41C9*2KL6EUBZEYN^,U,*SLG[5LR3BX[*,\ZI(@%TF^5&)HH$9 M8Q'E:*#*PSTY82.9IZ$C<"HEW^@%H,(U6+R.2@6G)@8JG/=L8C#H*Q/J- M3=Q\9#-S17>R+IGI>2]7S6IY-@4;I6\)`(BB_ MNEV+0G,<$@M*U-9O>I+/KDP*/!!!83$('P$?!;+NS"1GJI4987,17"(N M_M;&D:XM!["NT:JWVM:(V1A%D8]C^3B?2IH<QJAKM%-\UY3-4SZPW'V`F3 MNN"+(4R,S%3X29*GZBS)A4R1,]Y('Q19F,E@!%UF$IG]<\,?=^ M-W8NY3RVW-'MZ9PJ`FMUB6`4MG&*BT9O6-R8#1]JBL% MZ8./K;QWQ.:4?A%``QI,XB^6=32J?D1N2U=V4]$&@3Y!9RZV14V$MMXI.L\] M76E,VU/U/T+'O<@I)PT]V56+7B@KJ'5W1OJC*TM24)O3IJ\&/V?[QMCJWL1X M@%[/':Y?#]9ZNR)>UCIHCV=E(R![6-&8Y>H5571H(L\#/RD\:$.#4K+ M'Y54"LY1SYTX/I>\WA[@69\#9^!0'JO9(=/U2-4C29C?JZJ,2?2I9PAJP?N>QV$/?743/K'G&Q%6Z*7:I%L1H'K0[W-J3++IO! ME;2'2G6T(M^\C_5XQ+2EFF-])&;U(P$?B1\^K5WC>[SXO\?]JYOS"R2`X].# M=@>;!94YF2V*9GU_<[Y_=7E]W[QX` M`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`;5W:!S0MLX!"DVSFL`SA]R4 MGX^#I[-G3A*R7FQA^3V78[OSOA5Y0/;TN=WSGYG59\()>`\^.0M8GX<6'"IW M<;Z0[?6M,0@8+H0?3$`2A;#]T+=&]E_,&D1`2@P^YY[#Q[9KC>W)B'FAL#ZR M5\>-D"FPH3H+F`A_>-/A0[LR:$@^AY?/,)[=([O&5\H#QOVB>]+/GV@T"Y;\ M`4?CUT]V%/KQ*XX:ZYIK-`5/:2?<;L\R.#R>OG9_9W:0D.H%I6TGORM)DOQ! MBY3%M)'W,<)@!_96,*SB_6QT@\[W#>!AV:SZ/(:O:6`7]E8S\O8,IF\=;4UV M:AY#@YY>3_>MH#7#=OC=M@@A6^Q?6\PSO=?J-/9@@9I+MBX)87UIW)7K/N\V M'^4=IGGMZIREK=^-R=AN9:TZ\XGT%&OBCL6Z'@% M=[I>_YR[4[3L_!,N1VRY@?S3R/4O0@&WTYUO<0U<]Z\,/ MEF.[3N3:(3KN^_+T@&5#R_6%L,8LD,]9]-\;>O/3ONJ#-GJK<_`!'[4ZW*L= M_6_FZ#_N;)^C?UO])8=5].#)BV)L2XRBGCC=/)KO^\N-R:2BMC49U&30:+9K MU_!F?1MK=`/GW`*4SF/Y,I]GYSQ=;Q[MV0['W@Z,.]VTJW=I%'7>3\E(S1TU M=ZR?.SKMW>2..DI2L2;!`@[`G%EW`1NP(&!]BY2+G7/K[J;8W$8O]CN:BIPC M^)I[G4YSK[6#@8N:PFL*?]\4_OXO]S=V$\C+_7Q;+O?MMHEV*8-L"U/JMMAP M6DQ\MO=.F[N90E:S2K-QD:5T.,"U>/1#VUWYQ30 M-PE5[E3BY3:X9[_/#,SC(@'XDF]69 MSO)D]$_+9#HOE*F<37@^Y\)Q?1$%3*9)7_-GUN\*P4+Q"W/[EW[P8*^4Z-RI M$YU7371^3'J>2-H_:36//PO+A?/:=_'`+)M.3*<]6X,(2(+ZF&"O$_:OB(^Q MA\F>%?H@7W`0W@OK"8Y]3_`+PA^$+T`Y>R`-;,&&OMNW^&@<^,^,6I_L66,[ MI!XH^.TPL/ML9`=_B0/K4;XONPRF5_L#RW:<:(2IUP!AGXT#YG!J];.'9"2X M@!?"M[!EB\RZIC>9_6+HO?^,W$GTJ*/CI\SZT`WGO"=XZGX$+`0BC%ZK/;[K,K M:%-1MP]Z=T>*RD%]GM7X=;<)#_4=N@33[E`U20FB+CF`U8?]*X? M=('\7G+,1GW(]2'OR"&_^[2NO*OZ,N6`&O!7_%G,]B_Y@P%W6.)"HL<5+:G_R!NH8RF4=`""CC5A=DT)V[[=#39!VI$,IBHYY*1N MM+CEVZWYH>:';0B`O\MBP3S%\S<9UTR%-3=%%-N8%;%6]7&-142Y^N%&5<+M M/MT-I,!O=]7@MJ3`ORV/M(YJ]JC9HV:/FCUV1V%\6T_E#AN7NZHFOFV[_?J` M=V6[:W"6;&FWA:WRFC2;S9TCE9HS:LZH.>,=Z8>9RN'VUI@->3KC-1-B9G%# M;5&\2V_CYF^/[3[@VJ.R+H_*=F`DAR4^-IN-'VINJ+FAYH::&S:I+F[11-0\ M=7%VD6QM7=0NQ^_P@#?1]V2;?"\[-]=QN[PR-5/53%4S5OZ3? M])6->BR(!"Y"+T3-^,RUA;@=T!>ZKURD^PD=?;`BC\LUOCV<_S%FP1^T^@>K MSQP.Y">P!.VGYD&CD>R_W`;6MNVSE;=]O(O;/E]YVR<[L.VD\U5E1'ZZB]M> MF"1&]D1P]J8!");B5;FQURCRMA#+7L+65*?*T4;RUUO%I9]T[JUY> MGC:W@AJKEY.G)=25-Z'&ZN7C:0E%I75\TJIJ9[=1*$+;0\_&6PC(TQ)*2B%) M&C!7O\75B;.$EE*".->ZR=7)M(2F4BPTJ]SC&L1G"57E36EU#8*TA+[RQK2Z M!I%:0G-N=7]-E'L;)J=#?L: M][PR%3<;S?E[!A+>LCVO3-3-1FO^G@^;QX<;WG7U(KG9:&\Y=52/J/O-'(]];.JB2@;IL(*QQT&@FL)>`H1*P9XP#:3;*!K*J!'L1 M%VD&W!)*RV%#_2\7W"(GTD)@SL1J";6C8C"+G29I$)LE7!_')Z>'K<-6>PZ$ M^=9F:>AF(;!9PGUQ?-IH'%<"74D#*@-B"4=$"03.T2T7@W,F*DMX%4J@<@Z< M5]XS"'4_F/SF!W]=@=3U'2S(*H_)@DON-,4D^:LM"]-,K!5<0BO!=,D]+H:L M_[/O]Q?!TU'!Q7AXE`]5:KUEH9J)J>-U0*4G9[$^3EIBGJ`+O1L$MO=$.L27 M2?*5.WN"?^J^V$'_=HQ?-,GU)D(59`$TE[ACVL9H<3LL&:SQ+56(5)R8)Y""PHH*>7/HP"P)[\K119]J-YU\/UI(;R<5?KWC9WL), M`N@"P$]GN(PM&K254N-,//]TU?V\VOC:/SS,H>UO8JT;?PLPP M"[+FXEAM-]:"U>JV5#6R9[-(E5AMK@6K2\"^QHO]"E;BGN!.83`E@YPY\;Y& MI6;83&#?_KKN/CT%[,D.V=)8FQ,OK!9K2V]FC:R:7JBY`-KF>&-ST+86:+-X MZ;JN[V"$*?^D$.V>8#.D3MN0.NW,7N=X>1LRHIQLMQP0E8(^3V#.<0:GCVDY MN)?F"6E>W@X6B9[]\?CB/ZHA\G>N[9E18WKIXV3,IB/%[1)96JULD*WRC6T" M<\T_V@W$7,/$W(7+GIFW"/[*1U-W`7_G3#@!)]FR!#^!LHSKV=X$/>,8_;($ M>FLM6UC^P`J'S'I"A[35!UZR_,"R/8LI&\$:D[4#7_/\T'(QTA0.X?-FL_$W M_?#`YH'U3%?8`)^V\#-".L[?8\%!!2@V,)#%ZKT_L=UP.,(GKRNNS`:A1(:,*9A#C`"('@2YKF;],OMI_^@'E M>TR3W^&<=+4IZ3L3_E4WFJ*)-6UT3HY:6E:7WB46C:.Z>LYZX5<[C`(>#>SZ\86YS^PKH&"X0'#O<+[FV6QUTL)A);#F[7$! MD.>K?7-!SD*`?[OR1!A$"/T5MCX"O>X>!(!,>+D#]H,H.?1HJGCC*"?7IVGD^I1'0J7H:ZOC M;?SQ%?AN%(W,_=^C),S#'//.`F#>$+;*7<"N^5`:G!RT='8++?;KVZ#EJ!`M M1QM'2T@0A)ZES?E64\DD9K8[OC':"OTS^:)+6:?UP& MO@@SJ'P$1(0ED:G4T10R1878/-D);+8.I6*QZ!UPZ4?KO0-.-X$^6)UU1W[D MY5SH6WQA=N9KJAF-8M:65T#-+HBWSGPM=_U(VAG1U9FO5;\EIMYVWP6J>>,- M-KZM\K@SW^VZ)$U<97)5C5M(P._.2;3N:,$R;S=C68EO.]SFN MO('YSMB%X$^OI8SHR3DZG=(.C%;BJ=GFJ_,8?;#-SG[C>+\]4Z,PM[DT0MH* M(0U`R+90]LF;[;ZC=M^"W>^$NG#Z9J@Y^:/54:Z^+;X!CAK+(@3=(Y^^,(\- MN,-M]_;%8X$8\G%)1\)&.>2H.<<.:9(=\M\_%F]P)53LC.)XU*H464FQ#VPV M"-&=/;NCR+>Q[\DOBJD`RYJJ7X_*-$0Q^DPLL8^W0<7J1;%'93J\98H)MPX9 M1E%9+@HN_A4!6V',R_?PILI!0YD&*Y7CH42!\9M4P!^52NEMS&U-D@O]>C9< M@0"HHLWN&^ZX`CXOE0>+1SRG45ZI'9_S9]YG7E_E>JK M2_1LMLZ>!W?ENUR=B(_+MM&%VWOI?::AO&=]-AK+\^?.FS8-;AZ7;9^;WFZI M#:2TO/03B?2&OX]X-'J;S;9*;O;PH-50JED!W`N5.-ZP%_HH6\QY:/@&X.<3 MZ1L`7#[#MNY#!-+ M3\5*&^#(Q/\G!P'Q-#/U5TSEGF]Y_8M=4@H+Y6MCZ M44!9HF]/^_.]?)U&L\R.T[#/Z?EPXP/Z9S65JG9C*S>!26#-S>:;5?I7[2[* M#B>`B\=H^)8`.`5ZLEK!-5KQ1LJ.&X#C,*S?6>#F;4OB>5AX0^>=9[2/FH:.@STL&'6J=!=>?AX*"GBXE%C^#:_1V0/3RX+NSVBK, MPT%!#Y>4XR*UUG*@S$-'0>.6\J`\,!<':O[,/!;8;M?K=_LC;.X28N[J,UNZ M/./D9#Z$)VE/3SDP*@5^'GI/YP-_W*P`^'LFF!TX0_C^.9"LZ],LTZ41?EJB M@:C))',6KP+2.=@]+2_I%P(3*5VH2B[X>`DI=UH@]$^.,N[)]()+`C0/5062 M/T.(10#=ZI1TF:1^/;N3T#PD%5P%^QG6SEET>;CFX:K@BMC/(*L$7#I93GY# M874IE>NTX.[8;[;S8ZY8') M5'FG:LZ,>MPOMN`.7@C=P*E&B"M#'?7@]7P(]`R'YBC2K8N M7ATWZK/^9>"/,"`;A11.NAUDWYZ7:EGJ5$I,D6@>-8X.3\TV6)4`NS$,_'$Q M&KO^A#&C#6"Y4MU6H\SLK':Z9]B.(ZNB&$VK3,_H9J?3;#7>&^Y6#D>WRC2R M;K9/C],W],XA;XX4+M,GN]DY:9_NMIQ*5T$O+Z?*-.[.]C;<<615):?*-!3? M?3F5A[O5Y529)N<@IS(C0M:"/-6/`3O:WK,I-#0E&AHGCS[\T)8___&5VR-^ MS6S!*@C/MN;U4U<5\$;>11KS?P8\D*[ M(:!`LWNSDN)U):*WFMM5ZNR^F2H=0\*?!W=#[KI\3#BI0L:WYG7$6;ZPIJ#\-K_S>2O;^?Q-RF$S M(,P+-2T*@A;X*I%9,1V0Y(WO.?*7!9`S7]4X/#W)C3#-6;L2<`WE:GWB:+XB MTMGTQE<0+W-"8U@5N>$S7>,5TYZO/61')[WYQI<_T_9\!6'C9YJ!MN"J;[=6 M!7?&U50N[T>@,\*\T'[CX=!\X^(!F(+VR.D!9^L%?BM0-<<'7-`2^?AD0V6%!(^3.&QKP&<@*6FL<+P[95]N+!K:2TI3NE`'K5#GICJE?0..0?LZ` M5:"&9/*$II?,3^?\%J*>"-^`ZC4E8DJ=.K/.??&O#09K"PYRJB>)4$MN<,'!EOJ_\[L MN0.=EMS;O(ZWN+?#;`ND0B!+[@J=(&O;U+P$'MC4R4FY3<4PSO+:/OH/T7CL MM5T^:%N:>MUQ^/`?P:#<`!J8A_4/_@G],/)F)V! M-L#&E$YYS@1_\I;@ZZ)^MHJO5X`I!]^HU,#.SR(1^J,I?&>+*4&F@?U7GF#F M7Z>'S>PY9*$I)OKRBM]AD;'=/BTDW^EB7.S;'$ZP%3LJA=C7@)*.<^9NSK-U M#PL2/IL9Q_K\=:N#\H_+",X9AS5B6QS^2F,;Z>K%5N97(R0]IOH]#[C#XC?# MUV5$#0[1M"5F@O)EDA]F/BQ(-,VD#[\98GYC/<%#1,N#/PA?[("MMLV"U-76 MT1MN2UOBV5&G)IXU0ZKVWHFU.I@9B*J71>X\^5J;3K.-$H(@/HG(T# M>+'4&-C89305`2RID1^$_-^JW\6,EY>7NO.ZLSF`(] M[*ZS'9BJ6G8>K4X$)N\M[OKIS/=DI/V>YE)+@#''/NO,=U^4A*%B;6&UHRW0 MBUJKW/Z)GUD.H,FYWHY47L#A'Q@P]D(_F%R\@N4"+);:&+QJY'LLM`/37YF_ MIZ/YX0JS2B<#8&Y?"-5];:Y*75&SJ=91B+(6^%=/T"S5RO'XM%,Q^"MW'&R5:;Q(A5Z'K79)X!$:.?-+R/7?AO[+=S^8 MAK"2/53`!04.D:/T;;6F?53`#07NB_9ZMU$!5Q0X)H`CUKN%;K_/\9JRW3N; M]Z^\,WO,0]M==CM%5W7SM)W3W*G*#=W#!HB^+C\?5XQ[-7*WGE=]=:[CZI$;E'3BX4:&"QQ M'.L3MP6W?-D]S5?7UR%;RY2M5F/KK4&NGI0H.:W,UEN#5#TI86D#;65[,*X* M_NHB]:1,4P_0,(XKM?760/\+-/NK1OM;!Q<4W,UKL?76P0T%]_0ZE/%JN:+@ M@CX^S>GT6^46JM4WBMH>HJVWY@U5I'@4M4<$6^\PDV9=_=FL3?DHZI^XN*U7 M)D:Y>/RDJ&?B[`#*+!@JA'M.P&6!#HK+`*U;#S$*$`(]+(O>A7KHYJ^Z$FSS M4+C`-5L*,&"8`*.NYTS^>^7=,X?Q9TJ`6P)WY8\-):W9%<$4P?" MIA.LRV"SJ/UBFA3GKEX%J/,P6KZU;RDP*;ET^IN@&XWA1M:U"R`:?,$ILU3> M!;,#E*7P772]-=M)YNMJP*U_G_,.J^BB:[:JWN?LPX?['&N6XZ$S(.0=)P#+ MYIK;O?S:A.*C;!A/9:&7.<&":QB$WVG6R;4"@&^R MW7EG6G"S[[?6N5MXC<-8GXK!S.(O++E"_0%#)X7WX3^!AF"\(_:)T]VRZ:?;(L M.BL2ESB'0ETA(YX6`6<-6YEW(H6QZ#5OI`M''`03.,U9PX>.\P^A660)GQZ5 M`#VS?-4P9[#=+,I=+X/M]8`\B]:;11;QR?'F8`^/6RM#O)M\&1[RAL! MMZSP734#$]X$2K+`DF#9R$^)*]N-W5'BG`O']444L$?8T!?7=_Y:G'7A]Y_^ MRPT_]_FS)<*)R_[QX6OW_N>KFT]68QS"?Z^?KVMR?_L&>AYWE@??BOI_"SE7G=V?5%]_Y3SP^'\DW[E]VO5]>_?\J\ZC-] M]G#U_R[D4I\%_S?[9)T<=+AG-9L'#>Y5^OIXE_!Z^F\<)N_OX4_XPP#PJ5?* MO$%^NWGP7_9H_/D_FD>-S]O^DW5[_W/WYNK_=1^O;F^L[LVY]>7;P]7-Q<,# M;O5'W*O>]X\Q!GX$7*\9[U;CH`6G_-GZTCW[GY_O;[_=G'^R0LSK'=MH"";G M4G0=C MC;_U,!$@6H";X1(^V+-LZ]*%#_HV2)5@[$O%W_H8^D\,K73KA8=#BTOW@9)< MK&\)/3".HUR`+UKR4$Y:K<9G="3:WB3^2_.SY0?F%VZNOCX8G_ZP9_48[-_J M18)[3`C+AO^S1JS/'=NU8)DGSQ;Q9P'X"0:VPPZLJ]`:PFX0AEZ&OLL(==:8M$)X,O7*CP;)_/;EKFN2S!0VXITM`IXJ!'`G`CJ"Y!2G[DBAT=K";I1"?I%R8Z*I*?)8,"E-5/5 M3+7S3+4(S0<4O0*""M1=$('%2*-)%_00_A]L0J1#IGH4H2 MK=X$K`B\0;_B[2[H0WKUK_S9_\K"`/\(.QH#[0;6A-F!.$@_P3U4"T)Y14Y` M/W%111#JMF?)#3J6_444G/8`-`--F_`257@FF1LCQ_`$`$/*3,"`DIG4:^26 M)VD\I`$2%GL=@R8A+_@>L[!_%BH4\)OG>Z`%F)M3JH"?.(%AN_^,@%W`U#R5 M".$N?`-@L,Z&]ACA;C:!Z[V_@F@<.A/<&6HNR(+P[*T3^CWX#CY^8-U%@8AL MV"(L;BQK:">632U88`7SE2ZH,7"6`?,-573/\J-`8U2J@N967E!/$]BJ16[= M]GS2&95N]MD:^B^`MD`A%10J#]'C^?A4!"3J,%3UX$G$]"#"TD;+EGUU$98T MZO`,_V!`XO0`67CH44*@TM8(_^B#M@KUR0N$YMQ3Q%T-0\ MP+M`A1.ICK"Y9Z&FJI13V-2(!6B<)Y1/:AEV![*>J'T:'4DBZ'+E8RWE-BOE MY,ASHC@'W3=]6\D9//(.$B.V.I+,KZ5AGTDBW].*@!060("Z>YK2V`<\@'-/ M*$"?NO41M?3L-?@#FE^"6F:9!#3KCA7QZ_9H]6@LC3&D0D.DG#PHMZ6J MF?*-#;03']ZIO?A`/"``B7K&F!83J`MD+-W_J`^"!$5*X*1212-I7$KU-M9M MR2_VY$O_%VA/@7=@=04(V($K]4\NO5+`;Q)>_&;DV5&?JTF/90%.WW](^AX# M*]`70FH^_YF+.'5,UM\S!_7WO;\+C!W\71UG!L'-1F>OT6BDR(/04^TJS9/I M55#)QIV&PP!8;80-.97A#%J]AVY$K5ZWFWL61E8(,`Q^[9'#$/5P$)R3O=B% MA\9`P!D<#[H0Q1`TT'#@^B]"Z:,Z]<*RXYATVJ%GN\*G-]FD"^@T9I#0V-\_ MK!S]K<.#PS161CC$`"F2SCJ+@62K8Q_=#D@Y8]5[T/+CYH,`?SB-/1)IGA9I MUF.&RBK=V&%K^L!A/W0H>;#AMCSV1'V/K1<_^(L832;UD_,##:=7,.U"./"* MB7/OZ+0]!6TM\C>T@6X/Q3):FQ9J)1P8#VUJ98DJ3DXY&-("D\2VR_]".O&8 MM(XY]IVQ[+AF!/BY%^Y93-8R#'2F"AJN8!5@^VWV!"J2X[NNW=.!&2VOSI+P M1WP[H!V0A%`,X?+5]NPGDNL`!'!LGXP$OX?%'K1'`RA-[@BUA+OH_2@[_>AI M"(^\T)YP!]E=[<&3X1PW`&E8^KZ##T4$*J,0@\B-(R4!<&;0ER(C=<$M<@_W MT243:L^DVOR?D9Q:(R08(PR[$(0,8;"#B78O,)3E-&0=I`$!%>$MC'@,)P7, MFOL+_AQB;J4%)]QG`38KTG3YPOOA\%.ST?C;9XN^L^_:$UC_TX"_LO[G#Q;H MU"Y0-J*7GL/?QWB4\O?X_4'\4S^&S/PQ2'[$9?`W8]A[Q7AX=M7V/;OUNVE]7#U\\W5Y=59]^;1ZIZ= MP1WP>'7SLW5W>WUU=G6QX1R([^%J73QT5Z4>9:6PDA)8Q9'!A3AD#B65,2@7 MN;3T;:5-.\S)ES>0831XTA&(`4!WLN^_>%-I&@49(?A&E0NBDT->AMP9DJ8/ ME[6.G22N1FD(D(\Q84`-2P`T0"JBO!OL[U MB/=.KAUC&(EA7C.7@^UL*V/8,0F@2CJKU?3O399\$Z3U78B0#,`J$PVD2RCV MM,Z0`4C,Z"M%O9KB5W:L+V&X%)X88UA*>FU!!E`<86QXA7#J`?Q&ZAEQ>W<$ MNW?LE(?RYV[W+N6=#%"5!T4/W9[:B@"K8&3_Q2RFD4$<27ZKL9(,H,`/R5^E M>3:(ZR'A0RR)5GY/QR@[!?%@!T`((0$?1(`"?'%?=3H`-?B542@B7E@%`^W! M`%.Y*&#+0-A0-'<4"TI;5L#ANURCHHK>':NHY!H@6^>);+\9S\A54%IK$;R( M*,?7Y4$86Y;X!:9*YJQ^$JN2#]%9DWOJP'I`#'.2W/J"X-X8K*QGD/>RXA6M MQ=FXSCV:$@<`,MH)(YDP%[F4&ABYB$DXA""6W6YB-0F#4@IDY5KD2B9L;DI/^D:79%Y M7M/*G?&M9HYK%I-7J4@8;RQ,3DDYR[7N-\-Q2RDTB8O:],W7,J>6.2O('+!( M_!?T4LH+]=R/>B$Z)G5Y=$6BYSY.KD-REIE4@=&^`M/GX'?T$_:U&D*:1=_( MF:)8EF$9I27'6)9'RLB2WA5M*BA8G*-#E-(XZ&?,O$(_*CJG4?&"@$NF,N\F\8B8*W@&ZI M+#V90Z=>W9?^I]C+#';T>&\.!U`*BTD4OH@8FUGHO&68$1AER$J!NFW M$.0H][%/DJH)P-J)40^M3J7!AS,BQD,NT.;&)#,,I1JAPCVPA>40L?W>9%__ M#$#;[@1CPG->FJ/&36U<1+T_I30DO58(>5W->:O*QHMQ"J"2EES+TEJ6KB!+ MC1XN%8E-RVQ(@^RI92*F*[P`#Y%9)R@JI8IM)-?&^7K['(PA^9,/YM.(A4._ M+WU;^#X&2E@4OQ(D#\8%O4A:./!2#LS#`V2H@S0L9105M-P!*NXJ=5-0+@CY M`+@8PL])]A*6J2I#FV)C$HD6E;P+\H(A-'%('M[H]\`:92'EP@I`QOX(OHIY M)7'V,^YO!')0V8>^9UCY:2%C"*+D<1=SQL`&-^2:7%,XC.0H)C-+02)S9C&O M&I3;W#NS%B.U&"DK1AY]W]7%./$\FNI,0,%B]T]*H)`[_V MO:=]E\IP9)NL-3@Y`O;,V8N@V)&;K*?(/WV_D0:/!1VZ)!8^57.;R#^-V>`C MX!8RE72=CG30RG1[V21!J^S:B.A)NP;>B[HK56*`ZDJN[MCYB4!*0T5_DU+, MTUDWB3O:J">)/*H.BBC+DAPK,AG/K-F1-D&2Y1&)V+E+B(BC:[3OB(J2!7DJ M,*YH7-JJW'A*2R')7KWJ-K6SXJ64;YJ3SC.M-!S8FR_2BB8#O#`^M<1_N2 M5\R,AIH^2;I(J1)!NB'A,;1IV;\BIC0"?1W*>CN\=]@(4T/`E$RN+Y&ZOS*7 MU;QP+NXZ)^@J+^]D*^,H@*M;)]V;H4V%'7P/W;.T-OSV8@=]TS&:I+VK_>"S M/5"-!IP\E$*FHJ!'%)V+`WPI2`?;DIX$\F?&OD8X&0=S:RTSFQ0U+5H*CU6[ MXN0"<8ILP&P7%0"YCR@$-/P[Y8&UYF$:IJE)5+ M;D1\6*`>R.3K=!US^CE0O%CPY$MO,^8C!6+(QTIAQ%.(ZY3QJ2O,],$XF;IC MX#5]!LPAW;_MD]8!9H^T M7Q9.`"/CV`\&MHR/_QD%7("6JJH51.Q2CV2$SMR-> M6@`5=HRZ-UL51`$.@:ZI"'('R0O4ASD])8/C`..(I&D.R8\8[6I@Z]R%R5V*!)XD1* M=DFHQZH9JP3?%CX^-Y%5!UIN&@TOY/:$&0L32;P*Q2,"%GM*94:.J@51C07P M5KD'-=(.G*%2&ST=;M(=)&0*D('JN)T`>PUES9E*PE&--O(+9O75J\Y$.Y8L MRDE0:$B"X);]%#"9@U2KIK4PB4/;?2";D)-V>.;G^^57M>'B;#89TA5*AS-6 MEI6PV+)`7\1D>S3-]EB3Q%_)G2(?#6V)ZJ4S5=M',9V$)M'P:SU MU(611!MEGT1U63UA!3(&_$(F^^@DMI`$-"DGO#SOJ@9#MENS4\U.>N^_Q2I- M]5=,RO(R="=DG_#%U^X&LKK-YCQ2Q166\#%]&:PS[&$F4^>1OCWIJ)!A]=1W M_2C$S%#--=\.'@[B=`%;CL@HC*BG<^>IERA%T2D=*<["3E]JV>LPKI.9\7TS M@7R1>W!/=S?2"?]F9$5%8W"T49N7"Y&4^@ZPKX&J*U#N$L>U^4C( MW`3$OTQ^()="_/9:O-3B1>^=ANSM3U\KK@[SW MA+1**J^LQ/!UA8PMC/1FK20;]J7,$J#'9?C,=">\ M02R_B*U<\K*F8)2>T[B\A`J),(Y"]?RJSDC*O3ZV/*2>!6AK*N7%K&11)4@S M2F4<TXM"6I)H/=^B5PBIT!@06L<#[CR@#ZC M61Z0983"91):3^Y'3#:(*#J)-S7VUPB8V;%7._AUW^^D9DYY@['(2W;J0#^/ MBA8\V]PE)SU5WL77DT1M(6$@=!4M1B"CM0$AP;4S)B7QQ5WUBJ M^L;R;(IC2'L?XQ1VTNA5H3GVN`8"8WMR$#]U MA06:<O(L.7G3F9*(N>U5A9I+W>$DP62&NC%=UQ5GRBB/M^F7(W3A*:^BN M<>+!]"HV)B(^L>QJAM&M:[4?4X5'>L,Q=L+D(%+MJ*C:2!:H2P<@YC%1JP!& M\HI&E,>FA9HQ;K;ZUBT#37^=J6ICBD#L5)`].4H#MP8'^ZX(C=T5FULDCLY2 ME*@RG3Y>`T7FM;I=2AJEEU"\_1&)_@?9^']`57PJ\T,Q,0H+V;T.PU1)QSNT M-(-QP$$D*`ZW=8F=3!PV$P\3AE.ITA0,3B5(TT,>Z-N4&V,)T%TT.28NW"CRH8 M3"O)]$1IL"K'E.%0K^^C^CZ*`[X.DG;2A1)+*ST?HT6V\>/GWP ML97WCEC'U"\":.#*3'Q2,A58I<#*;>G"(\H[)=`GZ##"%D6)+-,[I0:XNA"& MMJ=2F(7V5Y/A'T\NT"^4!3ZZ7PO]T=5M?A-[0(.?L_TDUPT34Y,WI[>B%[#' M8Y?+]Y/YPIZXYU&S8.E-H3@EEN:.QBY1JTH$1C=<&/A)*Q3MTI?F$$W.0:![0HF5TF]+6\K:ZY]0<+O M'@0/1A&]\,8>+8'P5O/#3S>W-];5S:_=AZM?+ZROMS=7C[?WV`'XX?>'QXNO M#_#9F?7CY?6/$KB\=:?A.F-X(;E7H)"^_@^;+`%8Z\-/#?C?<:MQ?-0RE\Z\ MVEQ;^NF,$UN:$%OM#S_M[S>.8RJ<]>KIK5]REP5GV(L>4U,67_GPPT\/(YMJ M[^[C6T%)>1,/J75,,!X#&R7;PV34\]TE`.@`25Q]_2;72KTLYYS]T4L>&3/E*3U`F&/EKVXN/_QT?`K$<-AJITAA MSNH:5H^/HD\W:D:%&E&A6_:7'GK?.IX]]!X8MWETVJ:I]W,6R[9Q3WE:I"_G MAH6W@T=9!)9S9FWCS-H9^$YFP[>/I-QLGA"`)59?'=!YQ'5:!&BCLRR@\'?Y M!33NNSH`_.@;5*($:#T;FG,:[>:"I['BAN@+5V1I MR:&"\FZCW(,SW\/)>3080?Y,KF(.11;2E%M]>:_[VC(VM!-F;;_,/+(%E MXLM=H&HQ:<6O9')$`F&()TJ+BCH<:;#BB('-T?S<=-,2=<=0T\WGH%T9_/^E7Z\);&DFW'?R331>YE%>B=K'Y6[J^OU;WQ/YX=.N4L:QS%"*#..`EW\U<2( M\=J)V?KJR\3\)`<]<_3NQH>?VBG$++R5->#"(([*<3%'PP9<=*K%!9'3%\R_ M/S.J9+I)BXHOD^0K=[)^IXO-Y>)>=8O[FX<^CPI'C;YA55"`+! M_-__W_[^I>^'-SBO6?=B@B7V]_667.[]]6D`7\$D_6OXQ7JE/P4^AC*'83C^ M]../+R\O!Z^]P#WP@ZCO\ M_;]_Q%?Q3_C_"8K_'U!+`P04````"`#@AH]%1,)R1!@'``!.50``%0`<`&YI M;74M,C`Q-#$P,S%?8V%L+GAM;%54"0`#M%B/5+18CU1U>`L``00E#@``!#D! M``#E7&UO(C<0_EZI_V'+?=X0DNM=+TIZ2L+EA)1<(LBIE:KJ9'8'L.*UJ6T@ MM.I_[]BP"0O[>G!=D_L4LLR,GYEG;(_M-:?O'R/F34$J*OA9HW5PV/"`!R*D M?'C6^'Q_Y?_2\-[_^N,/IS_YOO<1.$BB(?3ZN3UIN3X^,_O7_N;O[U/O3N/=^;S68'(5K0UL)!("+/ M]TT[C/*'/E'@(3"NSAHCK<'C,("(^Y4H3'CQK&3-I>JUW[]XU[;>=2L&@"P//`CC1\S&<-12-QLP`M\]&$@9G M#4ZCB0USZW"A_ZK#I\"UD!14PS-F/G<[";2HHC`,@8EYTP@T$RI-!+`EA$]" M@[HC<](WLN4P)'5V`.):\"&C4PC/E0)=.A8;:CN`B" M,).'O1%40%?&T@X`KR1$&S2A[&M2Z4ESQQE5$5&JZKBB?*'A(R;)IY-8%K%3VR$_\ MRXF4R%,ARB>Y%;`K+)[+)&XB@]@D?MR@,#F[+R6::A)%UII/,7MB_8$447K< ME@V*7+P3A4V+L3%+6,,3,@2)91M6;3.@PY'&SW4Q8'I&3N`77SL3[[5,60_[ M`JW#T8XGVODGR$OWI-B^1#^).IV%(Q=8N),P)C3\\#@V`S9.P+=Z!++L6%1* M>U\X*^5,.I7';E`IL)+2\SN<9S7"__#7A([-I)_?P?+5G"$OF[4\^*5['OK7 M7*N"OJOBZ)J2/F54X[('@]C3(G@8"8;14B:@>IZ30,6J]?2'%5SET#N1[66) M6.\'"3\D1<^(4G1`<;PJI*N2 M%;=X+*@-*GGF,,^VI%EUIIC4;)6]8C#;#8>K\_,@$!.N8\@X(>`3.8&PTBA: MRD5K),X=+]\N)TB("V8:Q4+3,RBM38Z_XR_0BG:O7+G!5J38NJ(8=8*A2 MD9DFZ>`2*^4,IX8EU;8;7'5`_4W(AP['-74`*F_5E*7@0&ZGA3US>VX-OL.5 MVQ/D*\JI&D'X48BP%$5K"OM&T1I\!X>;M`/:.K9P!!_>@XS:T,]=4R?$:MH$ M6,%P0_1$VJFH"V,R7YY2WDD,,1T3UN&?D)+[&;`IW`BN1[F;.=O9=:!KI)&X ML;>PG9>E![F:]T0KO"-00V_#H:O#T0$+X'R*G=YT_WN!X"+!5PNE"Z)HD).T ME2W5M$99C?H","*_'=R3Q[QU2IZ6`_WM*VG<6,CDN>EP59%POVR..D%DD]TCI6<0!$G)2:9V* M9]P.Q[]'F*EU+%*[),A?7:>+.\#+>AYM;+6D`G>8F*Z8$Z;G2\AYW6--<`_( M6(?L\)'!I5#:%,G+UUCRQJE-40>HJ#!>;>(OYL6OE9C;@>W*/:PH"WA)2#I` M2U9:I7&2P.[PB-4#AC:'BSM!S!P>A9'9;-(F`:>P=#5O$8(OHT#-A/V=;!B-@OT]HC$`D\RBUT5D$[ MW'TZ7(,$M?1HF31%1UA9*@Z0DY)2FV<-6?@=W"O-N(U4PQ;HMW[AV`57/LK\ MO9&L82`VB#A9P8V]EC31$)J^K=] MGNEI_@M5.VIB3]-C=P$HOV)SZ#3J^0IE#:.N:=P<@N$?$\006D[]Q?)SL&YF%6!'A60HOEN(LAQW>UEF?D#J\"P'@I-5GN2<4!7HOEN(" MOXO?CJ_OF&,3>N+'F2I0G?JC3M\!U0F_TZG^>4NJ-W^(QCQ)P9*\$Z_B>QKQ MY?CE?8W,7U;9B=471_U.HI*>&&\<'0/*7-2J-#B4,_CB4F?;@*1GS5L7:H2, M0%U13GB0"%3UA7VJ$0>2XQLNXE-==KCNMW=P(%17&*25&];S@ML,^6H.4%P] MK5/VXG-&UL550)``.T6(]4M%B/5'5X"P`!!"4. M```$.0$``.U];5/CR++F]QNQ_X';]S/=#08#$V?VA)N7'L[2X`!F9D]L;"B$ M5-BZ(TL>O0`^&_>_;Y9D0+;J5:IRI9G[:1AW52F??$JJRJS,K+_]_646[SR1 M+(_2Y.=/>Y^_?MHA29"&43+Y^=.O]Q>[QY]V_OX__\>__>W?=W=WOI.$9'Y! MPIV'QZY4\O>;32^GGPVG;OR__^<747 M3,G,WXV2O/"3X+T7'8;5;^_DY.1+]:_0-(]^RJO^5VG@%Y6JI'+M<%O0_]M] M;;9+?]K=V]\=['U^R<,WN:!-6+P]ICG`X9?Z'S^!NG9V_I:E,;DECSN5K#\5 MBSGY^5,>S>8QQ5C]-LW(X\^?DFA65HSL?:T?]1^G:1*2)"#' MYJ1?&]8`E)MLXB?1OZK)-$K";V4>)23/STCA1W%^3UZ*4AV`XF`&Q+XK9S,_ M6]P\WD63)'H$=23%*`C2,BG@BS$&Y041Z8BBV]@&0%TF3\!NFKV/KBHRJZ<) M+1=I4'T<8$;.YC`U*V8U99,,8EM,7?*5QC(@]&VZ\..B\R3E=C<@VG5:$/C4 M+/R'F&B2S>QJ1R1-A8E&,#$'I_!IGJ9Q"%N0\S_+J%ATG'_2<6RM7W>P"2(S M^(SD-X\W<[J_@HF?PV>8P#J-S^/`AC]+(I+>#H= M=TRR2LN:4UME)!/?!1)3-<%*7RQ@6PL?H*#24,?/A.)H1B;5;!85%;/=9!4, M8$"\JS29Q#"SPE&>DT)W@>7UMB:8INXD@VSBFW$Z]9,)R2^3YB?LC,#^*2J, M?3'$#]D(3#^?7L3IL[FO8&-$`P#.TJ"D`\.7ZAPVK,7B,GE,LUGUF54563S& MFY!^%KS*N?RS.?2;J1@EQ9_C`N#`C+&-BAN.O.CQ(ZTRZ%["UN-LSLCLP>2F91T==R^8DY! MHBPH'\CNFPH,"LLF6#J[_6/[LO7V*`2*YA#_SUZ?$_@.)JV=[_,;><.]=88XDOZ=&C8K4 M54/O\&!%XG>21]FJ[##17D==SCFMK_MCELZ4U+=\9BJ5NLQ!@G1.9:7;FC2# MY?_G3W2$:B;_%*1)`1/S/*[ZP=M`)O2/]W^/4YA^/W\JLI(X9^TT]G-8_BN/ MP^@E4IIVZWV\PT.+7`J^B0)NW^F2\,H$PZ9XWQ5;31G/5A9;!DWMQM[AT"(_ MO'V`@!RFSMD\<="P"1IL+T%>:U]FDZC5_:5%IMYAL1D[<,78&,8B64:-()#W MQ\J^D,$9J[EW>&23+=:.M/#87-VY):SLTZ<,7MYPZ];RAD?#INS M8U>0IF1M?;><."> M&(:N1:2P('"LXJ_.MN1^/A5MPN&?O:%-'X26ZED:Y6RS7P7G*-R9(^@U_&-Q M340O0;.9-[1JF-HAH`6`0X0S;P&L9',_"L]?:.0(&27A33$EV0I,L:4CZ^T- M$1@^NK2IXN*PZJ)LW1&#E*"__4B0VYYTS+HM%"QF'6F:^@(;RZQU")%R MRD+(8=&9]Z`9@-H(RZ/24T=R]!B14+[7T!C%.T)@WDI(8C.K"Y)#M3/O1+6_ M;8*0\\KKXATA,)0[D2A$Q#GE=>:R6.9WO(H*GR3X)2M)V(8NVM&HC^(=V3RX MM\FK+D@.U9I'*O8=IX=WA,"%THE"$2`.7(0XRXPHXM!+]#$,2[CH"MM$H0<%ITY:5:/NG_SXU(4M\MH[1TCL`>`C#!<"ARYFVA:6AIHL3/>E/O&,&FOA,Y3"0<9MS%7X1A5`LS]J/P,CGU MYU'AQP*".#V\8P0[]TX\B0!QZ'+F!;FE28@)"<_]+(F220YF8CDK*V_.6\8> MESEY9^\8P@>#Y4WN'5CU3QE(G*RTSK&F.7@^ M6.HD8-J6W$EMLCYT]N3>`0(G(N\E4?$>-G%\^`3*O0,$7D6^_CFKE0S0A\^A MW#M`X&3L1IL`T(=/H]P[0.!6[$:;`!"R3,I50<&BORRHJ+VN\ M`0`["N>3C@6G@PQ94N:JZ)6<^:@LIFD6_>O="2)E<[VCMW>(P`W5AT4V(FQI MFRR9+_.\U*:N[@0@<68):-+61(,M\9,E[TU9T*L%Z,T)FKPU>@)2!$0O2H0_!"@`0I@%,!)9]9_;8<+"EH;8$EFYI.#T`'@*#OB=; M32C8$EA;PJKM9$3=`"@":[XG9RT\XOS439U4JUWVLXWGT\/M.Y\>VEQ(M,^G MA\KGTT/^BN'@?#HGP>=)^@2O3U1S!G^L4P4_>5=DXL=U97S.&32C%8"UN7[T M.G4>MDJ+<@%8.6=657PM#/>L9JL:WLMMQ63HLM:AK'67`/ ME:,]\[TFQ7NPJ&!56&D'B)`ZO_G+`P,`LN-=VT'M>QC*X>B1IHH*V8FO4I7" M?:0>,SX;[W(;.ZI-6I<,T5_@99W`YO^)/*?9'\![P,W&$;0&29$ZL-H:EL(0 M'K)NRBSK='OI-EII1^Z"#KI::59KN6A;:4?\NLP,N?\R5IK5PBR]K+2C5OP' M%\!V66EV"ZETL]*.F"9Q6^[MLM*.D-QVTD/E:*TTNO.B]]C"?VA:T9,?PZN; MCXI3/\L6L/9*L\E5^H,&4"1#ZBPG&L"$UMZFME",V]2W<8-T[+!62<<-DM5: M,MH;I&/NA4LLN?\R&R2KE6-Z;9".6TD>7`#;M4&R6_2EVP:IG3C-EGN[-DC' M!X@W2&HJ1[M!>KN^X?Y!=ZM3?F9*71.0]^ M5:9A1F\UJ:)@MME8.'&V*G0V%DY0U60XD=]WW)#[+V,LG*"MM'#2JK3`!;!= MQL*)V\H)7"W*=JXGMBHD6-0T8F-!3>5HC84J]O7;^A([RC(_F52O\;?%>Y.Q MOZ`_C9[]++RI(#2C9J]+63ZPZ6>!9I%&]@N6*3M*0&;=]$7Y'1H6.5AP)(O2 M\'LF#LBR\#30*E+KU][4XJH!F5%6F05UBL59F=%PBTK@.HR_^LZ&$EL=BIXS_"+-'DE4E#1%9SG-+7Y6&$\#K2)U#MC[ MK'#5@*Q:1E^!1I%6J+"WFSC*`%;,1*#ULCO))I,Z1OV1#)_0EXW$N,L M"H3NQLU(`.I'6FEC(Z:B7#78:J[8_]P[FK#]!`.RML_X0*`Q;`5I#*XOCN:Q MH@2@_K^'I9\_BI#8GI+>_MYV.`$3:PU:*J:]^^*N7 MB[G>01J@93O]#2[4A*T\E4&C]Q+P1DD>!;*4(&O/!!7_E;T.+&6(JVIMWWR3 MKR:CR22CZ>QD8_.QLTQ`$=)*#"Z]"T)E<>:SVU,L,PO)*MP-+?)K#P4E(ZU< ML9&UG*D-SI0[012W_/ MIA^T3XQV14,[AI4)8*MBM/?WK#KR.L5H5UIL*[LM]U;%:(/$>&.T%56.-D:[ MVAO MK?K'E&_]9+#=T<;KK`5LH%FZ409I;F[:_OX\SP-+&5!(K`67X9!^8 MQ91DETF0$6B0GY'E'QM(MI4\V1L>X`QTM#GG5%2",GK13+9Q'=,19=4(&T[X M9C\;5(XS,M'B+%14BC@.<5-!#;?IPH\+%#=W7"9+:.0J>B+A90++QR1ZB,DH MSPFUKG_X_YEFI[&?YRJ1#EV&\_8'[N+R@BD)RYC?-[8`<3S3&1MXSZ3VY!"Z*LNO7:4%RL.3IQG"+BZWO M'VQ=L?5]J^XA[4#^`]5BZ_L"#\['"^2WNKKT"JP]4"JVOL]?.K`&\A_@*[9> M:;&M[+;>\WSF\=Q M!BMQ-/?CR^0:OI7WSR1^(C_@PSD5+7Z]Q@6-X2RB+EA^#`!&EE;01*3(-.!` M8'%V)ZZ67VC".-SQNLQ@G:99\:HEI*F0' M(*MB*CFR>5T`'X[T,9[J58A:AX/L2,(P73BV].9YV]PAP6E&PJBX\(,H!EM# M[)%FM05I$?BDQ>\`P_',AV+[`.`L&T^C.([F%UF:%V*%L]J"E`ARGK05SH=B MS-$]272FO%)GP($@<4F;$@ULR*[+N<_2$K8O(85\2RCDH*AN_Z$_ MI-EIF66@@CH*3[)YTQT*]&'3J["1K5TWS,ANM=$!44_L-)/N-;H/"CJRZK10 MWCQV([?_1&&I`]EE,PBG#*X-+)ZY(]L`=\F`5=H?+--P0351GM.+PZD'36>/ M(!@`@"%(5.S[4DMW$E(-F,M^5=OR53[R57FT=GW<_@`'02B'=4)E"C"7=:K& MYS3*"K(^P[08%8P`D!`D\=GG5*H"I&5/5D4C>/M#!&ERUEF5J\!. M8J;EP)2A3;^L59.+"\=.>J*UZ(FA52=?MSB5(3,HJ"VWG9L`+*H:AU'00^?2 MW;NYPF"_Y.5W?S;S+Y,G^*!601)78_&J(>@"PCMTKK*G+^.C+T5@KG@[1^V_ M)AGQ8UI4'O81X=C/9(Y4;@<0V*'S5%GE$OG%ISX(M*/.[;P&@%,*PZ3)2]Y&N*%6B_*3A'_\ZB M*3KI'\?NL@\1LNWEOK/PP!_^"WQ,9U)*5MH!)`0>I]9D9U/!D)Q#@K.0XQ]1 MHD9"LYVW?X3`0:1*0EMR#@GN"GZ7#SGYLX2-VOD3W:TMI%7^.3T`WM9Z?Y2@ M<9AS5Z"F+:R\WCJO#T!TZSE2HD"9M28H#F_N+D@SS1NNC8)I`J6;"&=A"FMB M2])M`@2YEF M;ML53F29?0"AS8@%G-M,L3*094[S,_R?V`RB<_%91V]O9/K#I^ MM(YU!:QPJ%3$ARQ]>0.<(MNVVB/71GZQ&9;'6?0$N_5Q[`?5EEVZL+([`$@, M-W(IOFEL*D7(L-V@>TOBZB23)@8T0.;?%LU_D<4N*P\"2L!3K'E#*["N=K!= MAMN44OJ];C<&4&Z+17?E0:>99-Y;DX*XU` M0`1ENGCSGG%2R9#>7-JP-,],-;'L33P$H4D:RF4#L),K;.!TJ%XKZ4VE:4+S M/55/B%C]`*I-SR;*S8."0LSE*IOA?DU2Z>+#;.\-!SB*VBH0P&9.`,M6SU*J<6_S/.2 MA+_"1'[')V59:S3X?"$X,.S+>P?(V'+)5Z6_BN`C%OI4NOH?2!*(HNL4>@-L M!*>,W9E6AH@M2_TL>HI"DH2O%]'4B0-CDE535$"JN".`19`VW9U/%738\MM7 MY^`M"H28 M:Z!$EW?/EOTW/RY)#X97^P/TK39S-$!BR\]O6-G7Z=C/*IG5O`OO[0$:@C., M/N8*%Q2Z-'SZT:C6;-%+]]8(0"`X`.GQ9JTAP99JW\"CNMOD=0&`""*[>U`E MQ"5.GM]4\B+LJ\"XR4D(?^1I3$U5NN-:.I+SF\>;.&1NX"RU9O2]=1>SZP&SPU=W5HQP%2H[O&G+CR?ZS M6_Y\L&?3'-8[K670L$H8%X"5/#Q;1;@'>VX/3;E:;"N[+;>5;#J+FL9QV-E# MY6ASXF[I13Q@$(T>\B+S`U$IE/6F@`N#H:BU2+`Q8$MY@\U;OI3T>YJ&^341 M\<)J#K@0&(%L;?-WK&P4R'+;;M.%'Q>+I:BB]V6E(6!!8/SI,,*2'UG*VBL< MA:\6R(_`HM/2_XKDR++'3M.\H&;9^O"^##<+ZNM8Z(L2#+"J/" MWCQ6']6[-`XE%#5:`AH$Y^%B7?/Y:0'!EL=U1V(8<_*=)"3S8T`X"F>@7HJN MB)[($J]HY5<:`,`C.`7OPJ(./GS97CD!%4U!ZC/XD,?IO`J/E'(J[.<-]A&< M>W>A4@$6MF2L=9@:2QL`0G#ZW?7#V4:"+>-JZ1E.)I=)D,YJ=S"?'49K@(7A M%%MKS\&%8>?"QA[L%%.2U4(J;`L9K0'6UGD6N##L7./8G9W7VLJUK,OW7.QA MX'4!@`B\#%S-LXD2@\&6W=4`I_8.`0P$=JXF)RWYL25:P?Q06FI6V@&4K3-L M&0"PI5!5DV7E./A=8A#_YO'>?ZEC?N#WC/@Y.2/U?U57HUZ#@](0&,T=%B\# MJ+&E:JW,YM&3'\7T4/(^;<08+:LG?_/S*%"8'QU'!/4@L,%[?`ITH>++#&M- M[M>)+0ZPX_7RAOL(_/FZ7DL)'&RY7YI3T-Q["^I`L(NR^K[6$+'E>/U.HLFT M(.'H"8S=";DNJ8;H96I^1F[*(B_\)`03N/[B).%9%)<%$;FTNPWH#08('&UZ M_/=!BBTA[-S/$I`U?XU;5.=;TA/@(O#,Z1&K!$FB7Z%7JYAW0QM@]V9\-@8'6[:>#.ADKK'+."@^>#W=D` MF'#$H5H@"VU\JOGR_X,!`JYNQ MOZ"_5;#>L27A./836F%;7@?>PN-@>X_C-@`&VYS7UYH6D$7R?I#9A6MKYGR: MR39TSH[DSF?S.%T04GVC;RJQI#L#;A]`BL&;9^U3P?$'BM6!+8XYD*OYD65=O<.3,*_*^:U:K^J_N=-88#V:@3?^7T!VM M1H[,,ZT-]B/XK%?OJY?8C>W&H`B;KIB.QJ,VD^RIP8.+S'&]*J;2#I[7!?!9 M==(HVW@\U:L0M0X'F0_;,%VXC"9SO%EP9W.J9]X_I_?3M,S])(0]_#U)3C,2 M1L6%'T1Q=5.%Z(84I(@@&TF:`#P69 MYWG3%^,-#FTZ#=QN.W35@,S5W?CL0#T'6I(9^V0#,%5S@;=O2I(B2,O`SR01N-00!$>1F:&B8@\!<102. MBG^)_)CX4X6/1+LEB(@@14)#R3P(YHH;<+1\EHVG41Q'\^I"2=EUI.VV(":" MD"4-3?-!6+_SM5JN"4WQCEXDQG>K)8B((,I(0\\\"-A*#MQG:0EV2TA-V%M" M3=B@J$KSTQ_2[+3,,E+=:Q.EH<3,TQT*%((P0,F0L==-&=A*'.B@J'T::28U M,[H/Z@V&.$*5NK';?Z:PU(&M'@/".8/+A,4S>:07N7;P6R@YX\]C6D!S#*J) M\CS-%M=I07(=A[Q@``"&(/"H[ULM==M+-6"NX(/:^RBIE28[M3M3KN:>3B*&2X\KIX@R,\UZR9]B6+06.[>94EK=2_Q^\$ M(-W>YJ;&@CIS35C8KFFUP!V.S9@]$F5[M8$Y4_Y'FA33&+X=2>''DL"A=E,0 M%H$;3?9&,-8R+A:.PITE;"S31_.+-+LEPKS(M98`!X&'I4^V%1,0AQ]G&1KU MW$O">B;)[WMAM@=HR`*8=+D2P.(PYJS$T&I@_>OU`+<`O2JP%(YA5T913$0T MJ@\"2D`6-Z7+K2Y6#N'.PE%6Y;_P`WF..:\+`$06FM6/S'5D'.K,^2B^D00T M%D1^?/.(EKI<`"(*D MMEX+7`L-AQ9GGH_7#S-LFZCQOSR\@C7Y.DV"^G\$;"GT]@;'"/+B^I"H#)+# MK3/_!P>TVH6).:T+TG05_1X5T^:(@FEA]\&@;`1A-7UFU";TP\EI=E?@)PCH MCB%?OD4-@6G52KW/CO98WA##S2I]IDQ'R)Q9L.%Z/?1RB:@^W>I3HH>;`O0V M.FB@SI*9D"0`Q5P)ZNXH]_4.OIK,5WI]X/KS>#5S5+IY@Y.-E\;1U!]C%ZL$ MRFT)'`Z+YR\DHZ$_OX*.<\Y!$;LA@')>SD9=^0S2.(B,5:Q1T3CW((#7%&1T M6W5&I#J9DIL0C%6:L:9F'*R:BL__*1\ M])B-<\4`AJ[!");MY_+6@E9P`FH"EM9:`QN&AKQ&* MF(B0%;4>EUDPA;?^YB&.)E6MW;.27";78+W4&3=5>(&(-\41`+W#@V$C?&HA MQ5;+FB/\'0%;-?PG\455S*5]`;+#DV&;Y*YC-%<[QBJM-+.J(ZMO70&PPQ-B MFZ2N0317K,9LH-1]>E?.YW%$,N'WM]T:8#D\2#;#'`^5]9HWKT^^24;S>98^ M^?'-XSA+PS(HX#]%2D<$/`&95]#.2!Y-$JZOK=MH`-6U[=S+B=H'M;E".\;> M1NI[A)EX6N9%.I.^C>NMO8,]U^:Z@;>1C0I;O9[V!U]K`010#D]Q+2UY-2AQ M[9Q-';I=IA4HORDXLBLJ.JD?Q]%B'Q[0WJ#\(Z([ MHIF4D95V@`A#7/OZ5.&3.R8TVNW$J9Q@J]83., MHT2H,D.:!*]#178_/X&`7D3=[*FT-O-"69))C*W!-`,PB2VI5?5H8GV;0NK-^M\3MY MR*."BGN7/A;/TBL@>.U!7`0E(/M0)T:&[B"5A_1[EN:=]E=51P"+(!^^IYM, M!2*V0]11$)2SLDI(.2/SC`11??Y+YC&IM)^$HUF:%=&_JM^Y$`7,FWH$*!!! M7GW/.6)6&>9.>2U_':Z)L)")H!L`1>"HL/5E>`.([CB7)_&O.7DLXZOH470H MHM`;8"-P?MCB=1VG^`#8[;&BR7R^-7V*S@B%[;V#+FGU:D()D_58;4$8F\?= M_`P]L788>TF^]!_A3&X##KZ!33M0/<&/SV,/1]Z`7_X?':/F_#P#J^:A64<> M9:B'>V?`M1?Q;0A-$KR%CKS>3*,]C61YHJ3'8OQ.@!5!44/EUX_-J0P>LL/, MZS29I0EL#K-FJ0N%)5;<$;`ZCY+IM+JJP$)V%LH76?K1E74%O#B":51HT26T M"1'9H:=E2G$MHG:YE2V>#BNZ/<&BDF:+\Y=@2N,RY$LGKPO@1.`W4WO3V$R* MD2%+$&TZHW::1Y)RL-O8,39\DE/`6R)SI+ M[H_@G'[#=1K[.;P3=T4:_"&QE[E]0($VZ=2+-&40)J&6#0>9[[DII-2":C<& M3#C,8(G6V53Q\"!S'QO@")==:Y`LM![@.Y)%)/\VAB$)[&C"2FZI'2OH!6@1 MF+*\5X;S+93!0>;SK>4][40:LQ>@1!#?T84T`1QD7MY:WK-.I#%[`4H$M;:[ MD":`@\R/^[8$4$.\6-#PZS2IZA@H;A99_;S#KS:M7ML;1CXD9`[:-4&E>Q)F M>T!F-=U`?^O(US^;.`$L9'Y98X0AW4<:8TZVG73GSJ6E7M)$;6UKM05H"/)# M!.\+9\O/QH'-3SL*PZ@69NQ'X65RZL\CT:VB2OT`*H*0#VW*%#!A2_ZXI0'` M"0G/_2R)DHG\L)'=`<`A2-[1)DP$!EMB12-MY*:8DHS"S,B4+A=/Y#()TIF\ M(H?R&*`"!(DV^B^@'CYL&1?5V4E^F>?E^^$,RPQH-`,@"&QL3?]_2WYLQ?&J M57=YB%5/0J%5MM[8.W19'*_KH0P;A;@:GB-JZKES5E5T'X/QGX;UG#I-DR>0 M'V2]>:S_+B(P0.](`$TE5=7[#>P-,>0R=:"\)V+.]'#H6F%B^LV/2V)A=JB- M"ZI"X+TV,CET`'/FAC//S34IZCW`E3@&:*4=?`416(]ZW#$`<+@XP19&XN?3 MBSA]=E+HM&_,R.&1PU6Q6\S(X9'-R:T;,U(I4.(G;LB-)V8D)\'G2?H$[U!4 M.\RMV2R[[)FEKB5D(3&5Q_";7]GU,WH5 MJFP^L#L`-@1N(\VCZA:U.FI"DG=K8%2`CB!> MJ!_'QM2`+=*HC6D4!&D)B][R=D.Z)PV"K"3A5>0_R"\L[S8@*`=!#)*M[X"Z M!K!%*:F;T_6=C"7\MOS'E'G]JYF!05D?T7G56R/88JLXF.BZF)OR20L&`Z4@ M<$D9\4E+46*+W>+@N(@2'XPG,]0+!O,.3Q#8D$:HEZ+$%I<%``)"POP"]'%+ MJ@C=L9\5BS/R("D+S^T&0!'8"5T)8M,MQXLPJ$H1OY%W&92`P'`P2[HN>G$L MEX/L+!">WB($_Z&1PT]^3!UD=;S@^L97,`ETA@%%(+`-]#[E^O@X(3/NTO"8 M"$8P>[-L`1.U"@[59GBM/T#?NJ`!#6`<3IVY\.[*^;P.D//CU^C+R^0QS6:5 M$:&P$5,<`>!OW<9;"QJ'67..O.LTJ2::RBY9W,$;?D5PUJJE78;O30*/P\=@ MLR'/9VE0+J_9J\/&&@B[!SFK1N.]/KWQT"M!<+.LBS?L>];00W!>:+.H.0AL M660YYUEPE:3ERR--`F\/8Z]`#V71C>$5@)-E;5^0AD":D\%[$_ MX2A]I0W([#!(HZO6&1"L!`[K3O7:87">A&=@R4CF_$I;P.#07]IW\C.@6(F1 MU:7C(LH#/_XG\;,+^$6VJ5YK#3@<>C/[4L($8R4TM1LI]911IZ71'K`X]"^: M(:8%QTH$J=XFZ99,(FJC)\6U/^-]O5A-`8%#KV!70OA([$1GZI%Q"F@R/[Y, M0O+ROPBKQ`FW+8!P&&S1CPXF%#N1E:I\+(/"WC^HXN6=UQR@.'2Q=F5%C,9. MP32]%^4BBDEV"B)-TDS\FJRT](;[#KVL_5X2!A`[88JJ3-QG?A@ED[O%["&- M.1RLM`&A'6:3=-4^`X*=^#_-I>*]&&5='NBF+/+"3ZBLXG5#T!'@;:$UKHJK MPWWO?_M"G_;@YZ32R?\'4$L#!!0````(`."&CT5C/O5HX#X```2B`P`5`!P` M;FEM=2TR,#$T,3`S,5]L86(N>&UL550)``.T6(]4M%B/5'5X"P`!!"4.```$ M.0$``.5]>W/D-I+G_Q=QWP'GN=BP(TK]L&=WUIZ9W2B]VK6K5NFD:OM\C@T' M1:)46+/(&I*E5LW%???#@ZPB">+%!P#U1NRLU5)F,A/X90)(`(F__.O+-@;/ M,,M1FOSUJ_=OWGT%8!*F$4J>_OK5I]7UV3]_!?[U7_[[?_O+_S@[`Q]@`K.@ M@!%X/(#+H`A661#^GE?\X/V;]V_^!,@/_WAV"<.S;]^]_R/X]=T??WC_3S]\ M]]U_@/][]_'_@:N'%3@#GS]_?A-A"065\"9,M^#LC'PG1LGOCT$.`58LR?_Z MU:8H=C^\?4OH7QZS^$V:/;W]]MV[[]Y6A%\QRA]>/,0 M;N`V.$-)7@1)>.(B8KKXWG___?=OZ5\Q:8Y^R"G_31H&!6TJI5Y`2$'^=5:1 MG9%?G;W_]NR[]V]>\N@KW`8`_"5+8W@/UX`J\$-QV,&_?I6C[2XFBM/?;3*X M[M8BSK*WA/]M`I](9Y$O?$^^\/Z?R!?^4/[Z)GB$\5>`4'ZZ7P@-^KXAJV1Z MB[6TI><=S%`:727]%&YSV]?\H0BR8H#N=7Z;VJ_2(HA[Z5WGM*GQ+>S7SB<^ MJ^V+@R;LU[XUSK$U+GAMC1N5:\V8_/L&Z]#0#KX4,(E@5.E'N"5QE0JG\9B& M2"(V#1L"8Q*2/5.`^/WL*@MU;,D"]A7&15[^A0];9N_=E-/Y# M^>O?%LDS3+#LPR7*PSC-]QFABD>GW?%6<.>=99N#1JW5"(U:(%Z?S@%U@H[QCG^Y.]FR*JQ M^0"MNA5ZV"(<@+((T#78##Q/?4R/H7,T:VY_NKI=+>\75P]>>@6')PVW$(#) MGE^<5%FN+]+M#B8YG7C?PY@,@1=I7N0/FR"#9`X=W06'+38AUXC)0P5;]ZW! M+='&ZT.!^_7LG%"#ND"OHOLX_=]&^IB=[Z$OG->UUAE&!DOVUQN$;=%VA]H0 MM%PW':(4"JC4&:!R2\>I)'LT;(W?-`^KY<6_GYW/'ZXNP<7RX]W5[<-\M5C> MOJ+P('>)WO%!QQ]T`D2"MGOJ]N_?E4Y/?O/;?7H(X@)!V8`F(K3FDD)-VS`Z MTBA'F,&Z1FFX)WU">VV0SLM?YCP-W\E_GY MS95OH%?/DW508P_V5W_;H^*@$2?;A-9!SFG*+;G(ZF*3QA',\G_XPW??_QDP M%J]"9'=[MT$B:VQ[V*#9KK)!F49DZ#$+D@8RK"/*Q+[.3&`7V(@(/R/L('-_ MG-]?_;B\N;RZ?RC-_5^?%JM?W#N4,4C;OM83H19#=)`E*'G*[V!&0YQ.L!:R MV`_;8NW;(#L/TEN%S"U_=`QJA_7,+ M9?C5Q)0]QR@3UG=!5AQ669#DV$E1FNALD*I9K;N)AC5<&JK)%0"3"\GW`.MO;J9DPA_-[]?_0)6]_/;A_D% MV4+TX*A,#ZSJNJ%'$^^+=+M%!3O'D$07:5+@@0HF(8*Y48K94(YUKS2ULXW4 M&C^=O3?ORX M6'V\NEUY,*ST0VHOIQS_X,E-FCS=H&<8S?,<2L]3RLGM;OR+M6XCA5`"2@H8 MK2='4@PL6-Y^.+M9_(0G5?.'ARN7B-=!3&.'70LN]L:4NRS=03QSN\,-7&`O M(XG3'>DJLQ'%3(SU\<30RC;>*O89H`+HB'(4X>>29:#%'GG8$*2V1Y3^,+6Y M68>74T2GY?H:)0$>[H+X+LT1"9T::Q0]=@=;=%I6\?.X)(().Z6?Y&F,(IHX M.`]B>OZ!N\@MI\"ZM)8 M!7=&Z!CP!IJG>II;3=T(D<*E9Q0PL;F(A6N893"BNGR$VT>82?#=3>Y@4=JI M-;_X+,DJJ#!*#Z`B:W9^Y:5J0TO:*=W0TN@1V]"Z[`4M`9)@A7R#$KC`/VHMC6O$[M;$=8TE>1-"!BB=+ZOAL11W ML@[F<")<``M`8@_;RDU<$:%U3"NW/6WMUFI"6:VO)SM'\EU9G?ZW#=>+/1X9 MDD(;M1R](_#R>G=C>`9*2L_`K-:_TCN@]+Y@6X"7;HA+P6(Q)1GD&UD2DO[9 M?MJ1:<5U._ZUXZRBJ6)6DX:UON32A%Q'.J@L>0NU:I12,G>5(YF6PDJ1,X`) M/"D+*5<5+W!F()E,V:)67+FOJK1`,T`GA=U[41=:A74J.:A:3;?O`A1=O9#: M8'">1,MB`[/&X"+/OJNY723C-6SJR,T3+E"RT8-AE!&TYCDNCQ8/,PTR-FQ* M!'?D+`K^B9B94C-#SZ9#!M#LV*$PPZ6C18'N8L#U(D`]^9\!&H1=#A(JC=DH MX1O*M?#L!7*%!R[E$S(YFS_'A[NG%M+CPE-.XC2'`R-C5FF*)3U1(^#)",>3 MNXF-\.)CD;%B2C$>>#$/"\<>O<4<^X+B"WPT*'E&,:`'8 M).)K`6GD4O5%6(>P@77<58X3ZW$DTJBE9BNC,,2RQ?Q\<;,@)6%I*16^MM7E MU?7B8K%R[SFFZ&S[5C]H.O$^_;T+&9-+#U/O`M2(_=O*,+*D4CX^,7GE+9H[ M&[I0LN<1M+AO6=NW5B*#*$C.S:(U@I%Z16\DQ;K/F-DH+7\\`_6B,'6_[]K`=&VX[7&Z#V/)'F\>IZJMU.S&+=QR3:M]'&,L\M MM_(@`6U@0MMA:);9O:.H(-3V"CW\6%R;AV&Z3XI*&SR%Q+_)]C#BQTW9`MY$ MBOU5OI&-7"J@Y#Z6XR=+I5(`Z)KN.3ZN,HZQNYJQ06ELM>'CWNMZH);+2?2% MK,5S,/N\2+\@"NAP M)W%T<.,R9V"4*_`B1Z"9&_`@Q:RE>W.[T_.<@'XNP`.$WV(K^R3&NOA5RAK M`->?=W2T"G)YM(]HM+\F?!IG7A09>MP7=.VX2DG*UJ?P;F8D]]A4!-;Z'D>OJCU-9X*Z^ M2`,[\O(B'<"Q6Z4[3;3@SI,ZJ;3=TK:KEG::>(AR8]UW00:>"27XG^_>O'L/ M=C`#.8G_?P9_?/=N]H[]C_TJ!\&^V*09^CN,_@S^]#W^RY]F?_SV.YHK_=,_ MS[[_X[?TGR4QHNW!3L;OB[S`/]`#A[3&TS(LTD?\K>_>SP!!#27[MWU\./YF M!K"0'0P+]`QC#W8&12#N*M$M1K#%#8XHHE4R@_@N0-$BN0AV"$]R99L9(@[[ M&Q="W;F\_9$2$%*P2$!)['@WHH\%]'8)2D`HL\#J=H,<0]S6@@Z`;+XZ5`0H M@5'U#-<\#/?;/=V0OV036HDSZ#`[>&-(PR+^:2'&!(Y/Q7U=XP,EXS>NWQ/J M85G=#&^6*/JHXY\-,H.(L(DQX/S(@G3+23/6=["8KE> M!2_R#7,S22XVS0UME<&2'4!IR`!,"/B:B/F&7GXA]3JQ+.<;Z",:7EZ&;!@> M8W;W#MH3S!W[Z/V1[#)!9Y28\R(A-SP1-W$"6N?(EY99+`^=FR7@!NN/%WTH MC1Z*("M&L:)\BV!2;:^2:'I=W:8V]5.:'FQ2==[!T-NY$K!Z=Z-(OL=5NTGD MUW:7KBW<'ABUR#`6^72#2&/;3`-ZUH^DXJG_71HC\J:;3K4S"9.K`Z?=%@B. M7)*<8$7MU;,UZNX0'*U4]H7-S'OU1!!*$ZK40>\U3!F;@XR\U(J.%Y).Y#,& MK@/XM?RO-^^1#;'*O7?H((M/C>O"RIZ'?,KAP&G: M1@@F((F$(XF_T-K8U541DKUY3'ZHL?KK(:.;ZMZ#C%#953+3$)(6E\%ID)"EQ`T,/Q7H?@^KVEGMW'@)Z;D4^&/$."NCJ MCZ=B%G>%==5#2:W(KJ_.UL<:]YZC0I"PP*TGPYVPU)J^1^B+\*>RH1ICBBJ' MOGK1`(OK502/;.X]S!2AVL4$/?'`Q787H(P^BYU=HGR7YD&\7),[63?H&4:L M[)S!^-1+G/VQJY_5W$AP%`.6>&95"B*9$R+JC,HZ%JOVU6=':@MJ<5RSV+WO M#L$V-W(.!K:.3R=HNZ>>^OY=Z:?D-[^M@A>8DT_@_XN6R3W$H_@>XM`2[4,< M,U<9GO,&(4F%:KCJ8(G6O'6X[=P@0X2!2AI8)J"4!XX"05VB/]YJL2W.NMMB M(KNC--P3MZ*9?#]!P&'`76@;*1Q4T6W46&!SX4S.Q&&]31;.(A8'"V>A]OQ2 MDY[OQ+0>SQ_ZF./#/HP*1?SB60="-B\E4$>]AV'ZE""S;7D-7@=7$M3V\#<2 M6.2N,?GK*2,9Z-YSM)''WTLP@IW-*VZX#PN4X_'N(LU-5KQ*3@=7WE2V\!?' MCAR`LOCK0R,8Y]Y_--'&7XHS@)K-<2B'N`'(INHE]N\XI?FM\JDGY1:E%K># ML4C')CY8,RZ:Q*SQ54^8^>M6(]OKB9\9(),?J0QA.2"]\W.0X346.42LF;V1 M,-A-SL@T;X/E1.L/_`<8X3(=,J;&UK(62I0WDA*:$+=X^XW<7C@/6N[(_\=!`B\.<:^A9T@V>M0'S MR'A;E^>O)T_>)+$GP^Y@\'.N/@[RK5;V:Q>]8)J9W#74%>&B$J"N=1U5]KB* M+_X.OB,;6I:V<>^@IO#LJ.77`YMV"VNB@DX#R.68E-X]QI%#*RG51XB38IS: M%G:5NBR9V9VH.KO7WMC?9N)Y34.]<$-#F'85U>R#48N/6\+/M>O_69K@'T-8 MFZ'K.Z2Y*/O/7)I;R[UK!S^#>@F(AA!_G7,$R\G]IJ00&^_>8?N"F7L*81_OVI3OY*S(-30=I]4783\AK&\=E_(L64E"J78?[/B^\XJ5 M6?/%.<>P-.VRU+U+FD*4R^OVPJ<+%^S.0-/D.TM#YW-2%!P5AQ[.V5^X0[<= MT"(RAQ9O\5#1Y48/'HLKZ1[[^Q1-E%9-]*C?1#X%BJ&.)`XAXWB1B^#R,2CV M&2W]QNX!K6"VO82/?<9Y75$.`X>VM;(P<1)RO"-'Y``BR..(,-QV[/\W**'_ MOO`_6%]-BK^X#:!<^7-5'OX-9%8A02(Y\H7A?P*B'*QM*=.C1 MIK;+'/OX'@`6QD:Z&:#RV,E`)M%C#Q^M+5+-MO#)Z7LY@=CW!WB`O1!PB?(P M3O-]!KE+O#_".+I.LX=`S_6-)5EW>7-;V_`^2:C&;5"_VPZ(F#,LYXP(\L[- MA]O?&,>[K5]CZW,LQKUC]X1VVZ$'X=K5$XAW0;;,'@KRD@(]YU+%((G_Z@IP M_%"BQ#+ERX.8E]2G8-SE":?CX.2Z8,Q@(_/V\W-?HP1$:1P'67YZA,Z#+60S MJ,H?8=3#J2LWI*KD\^,3?]KNQS,Z=KL.2Y3NQGC`BY#\G!YM9WV`N@AGY3,7GA,T<+=/W%AT=/>QK2]!/DY0N_7;C2\8\N4+GU MC>7I"5A#!VEP>N$E35MT7:7&Y9^_Z)K4=)I499)KS^E`G8[[""'GRH=NT-_V MU;L)]`\0-XG9T_$R$8Z]2FJ=TKUJW.#$7C[+[9.G]32S=+FX9N;NR.Z;VZF! M*O<_790Z>;R^1Z)"B]OE$_<&J_?FR_$>YR<&F?=J,A,&P)2\4>];3J*FFD%" M0LKETKTT5NY-M_(L#]'+%'\S$!KHDOB*+[D'3B5EXD'(X=XWA"OU+K^8>9%P M,+;!SU2#`D9*1W";9.#4T2;]W]QFJ7-K+KTN>W$43,5?`/;0_!O_KM!CX%\552 MH.(P?T%=CX!V4EE#:[>.W,U/0@$8"889)G)TA&=D=6UXA`0%%:Z5$)@*G>Q[ ME^DV0%QMN5+U)HE57+:T:_=RU;^,P"$@Q]#3%A*[>KP.0W%WV[SO7+""".3" MN61FT*)S<%.YJ2=_#;EH5JT`\Z+(T..^8.X1-*R-T"2R9=)9'S MWK&:HC`)$7K/:DOC@X.7=G].L]\7R5V6AE`ZUQ`QN'MEMZVYY(U=0HIG(J`D MGH$/V70#NNG[NBH[R-_/4'*VR]*GC&J?[_"TB>RBEK67@I"PIID7=R?ER!*^ MORN!E0.ON$8)RC45;3,`I9 M.AN8,))W?NW5Q?+N-ILRFK,OTM4,_:87\S8[S5B%KR="30ZIT]#U^D.5Q/'& M#E9*K[,8KL@I#G;.Z7*?D2*6;/9`.[5>[^KJ!68ARJ6'\/H(LQ]L^E@\92RI MOE,+)X[CR!@M5(4)6-'X$RAZ0YZ+`P/Q_GIF)==IMH:HV)-#D678FG!6TOFU M5SLE\(EUE835)OO=E1#N=!FPM-IGQ7TI$$WK8+40O\M0*#M6:$V#5Q?/]-O6VFYJI0Q-4)IQ-N[>K'TMI/[Z!GA^8Q(KW9\37%]G,AC/X'R)8X"M;67HW"OK<&KB^OZ;6LM,?-% MQ^C^[=V9Q_GBX["A[T^8]O$VLCZJS7LT7C[<0W*_'/^>/+=-BG'L@Y@\"?:M M*LK:UL9-Q+7>YNX21D>M0$TM0/3R(!([[X>.)$BM#8.R#;-C&X:U-BS(0XI? M'V"0Y1Y4%'482SJCMLM`\GHBN/&*0-0"[R<,[&,J^>KB_:@]Y&D6Y4L=(R;M M.XWLRG^E\6/\2#;VL#)5&'L]HXUX.>1B6.FES:L;/_JUN;MLS9#\@EHP=V`<'DM>32Z\-5@ML$4IR%*KJB$WXS5>7+Y>UG[4GC%ZX`4BG75Y3]EOIK1.>)Y&YZNN)=^HY^Q$^UN+A`)U>7;P< MTOY^)#M.X>6+"KMC=HPXD_$%Q^;!D<7^X1"ML/(JLQ%-@RPE';B/ON;<`M^" MUE((_L556TW:F0WP/69.ZK$3+NVE[FHOZE'M5O@K@M=&!'368TM;SS9VZ=\! M(7#ZWLC(ZMKTIDXDM!U``@./5F&Y:&YR4C^)[G"'W`9;*'S-9-K/^;=VZM=J M,F0[?6G%5[N]6E4,\!3C!<-@-]&),`G:[FG<>/^NC!KD-[^M/J>K3;K/`_:% MCU!P'UY&;,UCI1JW<8?I0$4(""7XE=$Z_Q2Q+3(7#J'N23%+D M22[;Y-,58#\OHVL9MUZJ&($PDULR.\[DC&7@HZ&!5G,_1OCDDD(]P.E1MDBT M+&65E-T,P>G#[I\;=%>ZW7$ MDWKK/1X:<:>[]5+MUO,J:]778T?;X]9SUU<0XRYA'F9HUS5W'*-#&N)?3R1K MMLH$P:OV`<^3XT.::%"$4C;1JXA('?XU6A`2.I?%N!-N8+2/X7*]2"*X1@DJ MX`UZAM$"+TB3)_08PWF>PR)?D2UO680Q%&0_EIA:RKE$*8",N2<19U0&.`D! M3`KXEDZWL,A06.ZI MR7>]A.1V=[S$6K=15J,$C,B7_5%%RS>V6[2:W9NH7Q^<;E`"%P7Z+K.XQM?F5\`,JP/]()^WM`=,:05?;0_E]>@CBXK!(0NQ[MVF2[F`6%"AY MDD!9PF,=KS+]VZ`L:0$CGH$ZN7L$*GNB#3/-;K"'I9LT>2)5!"[A8_$Q*/89 M*A#,[^&.Y9KRY?HN0TF(=D&\2&[A2['Z#.-G^#%-BHTL=`Z4:QV30]NAC5LB M[XP(!$0BF3!6,F?@))7L8!WEDK<@B63`1`,FV^V,>NQFP2C\1_=N.PKHVZX] M(N+=N+^F-SMV3@U?6Z5%$$^U#TQDFWA-UT$WL7ZNO$`'U.[W&1XV:594ZNCO M*G2Q.=Q#Z+1"MF-`&T:\&:#J%GL((PHLDKS(Z&%*17:_B]@Z MFCHU;F.(@N5$Y44&?G3%;>)=C),VRE4@<85MK6RWF,4QSJ5IVQ9H9CXEIBF`:D"B^R&"$BNL@1#$J#O(L<3>MW12Q0-\V#A@9J.A\20[+6KN1 M&58W]8`^O\SN-BB.T>XZ2_-"WN?=M';[7*`OY_L9*.D`)?3AYHNVZF],5+>& M5QE2&GA5PV2<:USS)%K!Q"1H:3([N]HEM4AZR8O\#[,"LUAG!?9][<-]_\[0 M'A=WJ=0H%-VJTH6@O1GN*DOW>/$8D9G&/20SC9!DWY(G\HLTN]AG&9YYW-%7 M;!5K.W-1UF?$/:SMGEJDF1<+0EOVV)PC]T5D>^X\#(Y^>F#565],@OL:%;C\9$B%D3C+:W+:\ M=(U-1WF>9H?;M("*BA\&`ES.<>66*>>Y54&#(S^@`OR;ZYK9R4H=F!GE:,*K M`4W)I%<;E^,M$^G^I;!-ZE&8'53\_GN4H:4$%-:GKJ;%KR&#[GV;;AA:D#)08T> MW(`['^+#"*;,P,T;E2W67$$#6`WL:Z-J`-@_)1D,8O(<"AZWH[L@4VW]21CL M`EVF>1L;1UHZPR2U/3)_]L"47=``A6;[#X`$W6UN`6^5[56'&I1L=N&AMH(; M>NDA@78(`93)%ZQH]DT#,48=,P`W_Q8D\,<[]\N\>C)K2EFTC0-*L%C&`$CT,-.GL8Z"E)X?,-#5LAP&Q,UJ\5;A M_C&'?]OCZ?G5,YFC'Y2OX`DY[-\E%.K.72,\4@)*ZM>KH;S0J6HD8')3G%FC.5Y-N77Z_\:D$E;P#^&K/ZM9W=3-XD>`VAGEQ M'Q3PH2`/>MQ!W.=)$3S)JBR8"'%\>UAAH?(B;L4/B(`98"+`289/5XS=V.KN M'K(.>N4WD_6AZ\I#KX,0SK?I/I%5ZA&S./:^AO9*_!%JP,A]XQ...=G!O,CD.[RT+E+&Q MH@>$P:<0/X$A[L)\%Z[D@5X,J@&'%IGG*161VREKHPLXP!I!A@/8%\`%2]>^@=E$4KR&?IL6Q=; M1>]1;AD_#ZBQ'?QK4/Y]"FM\2-_PEP)78F M*:@L>L9)#5*V<+E>94&2!R&9DJ@W>C68[?N*CD4?& M.JL^I8U(SKD,X6C/R^XR](S7FG=Q$-('3Y4;WR(&Z]XDU+R-L9(0'"D=W_>: MW`";/B''3]L/=,!C\;0TC.E&$[E75'/(_/Q0_XOJ@+^!$/MGK4TLY-?K,=MV M9!?(/)BB63+'ZJEM8PQRA[I[`M"-GREG;EW$3OU&.'=I`*R(239?XNTNTN34B-`56F3R_'$\XB4:O-8] M1<<>KI#UD:>6DF)\X,CH'G3:7=4&GF$_V09?0=[[O<-B89;!J*;@(L_W,/J$ MO>1D@1*.AM(<`=34YF[(4BG@**8%728*$%G@),SM$&#=^KV.]?:]N!?FN_UZ M`.!MIIOK^MT@/`)&])`)^P-,0MF!`BUN!XEH'9OXI&X+KS5&<.(D9WT8E%TG MJX<9F3,CXYJ1NR.G>V\TP"6?TS8$I<53KN@913")\KO@0`XYL!/#&%$44!)' M4S':/^VJLH1+@E0,H.0XGI?VQ*'L663U_*L6XK@SL`9P"6V2SEBG5@!Y?7%M9P9Z&[$4J!3/F9I07-`(K;YM=,D%/]^B_9; M45Y6R68W3:NV0H&GVO(#E$PNCV^;VU/3?\>(P',0[^EA;I`3R)"\R:XYYP-) MFN!_0+@ED9V<6:W]*\?:Q@<0%/2,=\I(M_$S_),^&ZPEPD!;7M(P[?D816J8(&.OQ`2O&/0.8 MGU'D$WEK@=&AD3-W:*+=E+H)2OG]"S*JE70/H9/>P2Y!M][\U(S0'8]1 MI^1L#T.8ZSQ_#_T5NMO-TDMPP^?AE:"Q69L*#WET/2<;4&I$#FI0U33DZTZ1 MY03]JWL4\&W)EY;J;DA[_;U(PG0+CV<+YH]YD06AK%:'D,,Z$L2ZMV'!*,&1 M%/Q:$7MP&D31!6W,:+6_S5.ZSS#!0[0&#,+=Y$ZN!'9HW75-+@*Q2B='H*X.)3:R&)TB]!^A&YK MRL4Z1E#!VN7Z7E-7Y$5@[D0`%Y8EW6]_3J$QEW`XAY",PS.P2HL@G@J;1+;N MK*%#2ZH;R+R;,ZCF"NZR0'F1D\?D7W8PR;6FNF(6![D@H?9\.@63TE>F*V)O M)L$&5BQW,`L*DC,-C_;`DLT]V%5@XK-#.DBRZPS+-9W//*1QI/"!!J43Z#=U M[4(\6*[9U!@0(O%2!GF'I8[+UGZ8`^RM"7#7PTP>@JX M&L?$_J2W=!UB2W3B<.\Y6NCBEQ3:T'*WSC!87WBPKM!:3WBP,-;0FRV0TU>U MCM!=/[@"]W%5QO:O;M)(Q)G`/:0E$ MVJA6XL,BL(L-S)@:&HFA3FK[P.[4N>-T#2LQ0-:;',I]R0SIV4*IJO#M`=3% MH.&@KD*,S<,B[+4EIDTYHL@W3,4L#HZ+"+7GSXN4#VE5$;VD_L:#W=,^9I2X M]V03504C_L2+#H:<1'R]2.\VP@NC(?NSTWF*5,MR&NYMY-:(V$XA2L;O#&YP MNZ%G>)HH8<]9KE?!"SMHC7^?P2"'EY#]5W<.,U"X&X<8VB+=?M20VEP$T/&" MEJ8.7OR:,8W=%,U&P.,,753,0,7BB>>.XA.=#C^B0]B+$UB[DZKSYP#%Y(+E M*JV=2=^D<02S_#S(4:@1''I+M!X1^MO>QC[Q\8;;@Z,XL$I!_99"*7$&J$QO M0L*X;4$\'P1%D:''?4%;H4A!R%J!7O@M9=&4&B4F5X'K!#[%C8$^T@X6HSB( MU2M0[;!6A31I?EK"Y>(ZE,0&^4@F',XQ1%L(O\/`G>SE6\W<=G]#JR';O<-I M0*[C#I4>WKP=6L<;4OT?2@V'T$(VA+ITMW',UATMW3MF3T@/'`&='18*-S#: MU]Z"NXB#/%>^7BCCLG\L2&H#=U*FI&Z\'$@Y/'HA4-TKW.D8W2ZQAZVK[2Y. M#Q!2A9:T@(WR"24)CW5G/+!#H`G)ZJ)+2`$GL` M'VGCP&5]%,)QZI\ MJMMQ:ZI&DIS.L^G5H_I&.PI,X!@N%B5Z#[CI+U>,Y#ESF[?=NC)E]&H2'SI6E'C-KI6WK(# MNO8BQ2-HL@_Q8"COVPY"NYW;I6E'>>**QI?N%39PHW\5K3N@@W]$00R#C49D M[J*TV\6=NK;[N"3R*SZ+6[G1S:HF'M#/=)R'Y'0E>I'WEW7[NU)5;OA"B M*T8T=89.JUJZL=:.,2E&1`.3*C@,JOJ?;E&>I]GA-BU@+H>E@-AVA?]NC3OJ M695T@!+Z$H>D+=ZJ4*]L;GLK81H0YQE&XA,MA+C"'U2\RRIFL;Z>E6C?Q@T; MM&JT,T"HO7G-5-41[36G7B^X!9+RO7D9DQ=@$C[C+H23-P^ZJSM$!U(C/_#^ M$<^V-_'AGHSXL2)=T45J.6/1J2V7M&!4@)%Y,6&:0'%["1J@0(?2&KZNA2`'[-D^IVY'\84N3'K)XBMYP8'$@OPZS8@? M2'#&4=I_^8[3E9O:EQ0`D]"@Y/@E.WV%UU*%;2)<@`CN#3H9'&Q/&I.(!7%U M+2,!O:.I(J^WN#8$YK'/R,T' MK-TMMIS]0^(+6MS.R@/(;1)>L2_9_*@-,(4-+BH$:.!+5"Q`&US.)]MZQ?MR M)LR`00'-G)TQJW\;D(\WCYJX?FWD ME3;MFFO:SYI-Z\$Z;N08H+D*G"0`##I8L-VB8LOB-=O>?H))B*#PUHT>F^U# M!RHKNIZQ8QP`LX`&C_N#9R9=TSJ@8-`O`V!S]0+Q6C`O/B6HR`5;0")"N]#H MTI2[+H-I`"$"E$JZS3/UH#")TM8P*\1%`Z4*4(R%2^&.DIC4(3:%NT=<1TMW MC>SCY-+#R!CX52^M=5)ZA"GXDN'[>[V8XM(TM3B[A[[9"X>AF^0 M^+YI%Y'E,[DM#;D#N32GAU272.T=Q^UJT>997'%SCC)?SMLS+&YC2#QIEO&Z MFCE+[1%/G_.N^?.-#_MXQOTEF$GK=I:]K-;'(-FO\ZZ39##Y6.,GNB)J\L]7"2W M\*58?8;Q,Z2'D&2XUI9@_SR&MFW2$YQ89P`S@T4""#M@_(`)<'R(8WPK MD;Z55D]^F&&5.Q'2!ZC./?$!XM:)?H&!K.2/!J\OWM>PQ\3O&",@G%XZ7#_# MD(9A'O@8CT)-[Q)!T+E?K38HZ^E6-59?O*INC8E343Y_?:J764AME@<>Q>%/ MTZ$$X+-_(G>5/NQWNQC!3#H[[*)V=C*WJ;/PL.LJ!4*!5W<5*W M`RFBT[I"F`RY*5K*7B;SW2Y+GX-XN;[+TF@?%O@_14HD7C"+$F$^ MM*\TRW=-^]HLA-8R`94HDB$HA8&C-%")HZG54J#+&T*C-<%J`T%`BSF13$,8 MY!NP"U`$T@0$58O@/^S*%MD=6R2L6H2]A4KE@XBEW`HL=$>?>GCC^EKO(/=H MWOL=P3>L#F3D>`F..1?[O$BWRH&,IW8QD'7HW.&TE(H^*E'1.1_(3!0OE(I; M'LA$2.D8R.0P<;GP,5KJ>+&XT9OW^[9V&:*UVZ6)_F+$?6'#FY3LE3_#:)[G ML,A_A'%TG68/00SUBQDJ93@L8*BV3U:TD'`#R@X8/R`"SM9I=I9C$>Z/B_;N M4'%M0J/>M!B(,_)$>'&XPYU%CKA>_6V/Z#ORYP>-8B1:W/9#M99-':5M*-<, M4#[VY'O%Z5FY$H->XZ*E:9=Y@$6M:B9:W/Y@45K?1`N+S@]_]N@W;31.4/WD M>I\EJ-AGY`;J-7HA/^7T1BIYJ&6Q)8M"R):(ZS4*X5$5>EJ)%%/&\V7Y@<,Q MOV`W)S-JV[31?!1.<5R)!T?YH/X!P+YP@CME.G[$E^.2XX.ID:V8"DD#W.=G M^)BC@BCTD*Z+S\K"J6)ZN]"6Z-T&:DE*$5<1^P(X5?,WX*/7]A8K30@GOS<: M57JTN.U7H="RB:M_[G)!K49<_`43HK+U"3/P,M!YDU/61L M;_^>M5("GXB:*F^?L+%N('F2M-9B4>T#[@/"V$[$O1`TB0=Y,$A_RN%Z']^@ MM2R+KL7MSW#=L,EP@&.\@#![.G)/:IT7@SB/2>V17`3(`2OUUM1;6G>DF];N M"EV@KWKIY'R?2-GN!)/R]5X9D_5@*K5`,P7I/K>CWQ_MB*+; M&?8P=9LFVS2!19#5"S1I;".J&*UC2VE)&U\UAD8!9J]V#?7ZAWOIWJ!S?,": MH1WH1;A'+$>;,WJ-M/^JCKNRLX5M789SQI2[/#U4NX(4\UJ$=-,8N# M^K!"[?F"JB4I.-)Z-%RJNH&OJ*K3!^/-N67;&@IZIW-OLZT+/S8KM-I?-A%W MOB%13]!(`DF3S'KP:&G9ADG)(]Q=+=N.#>)FM3J=*0L[,TC*IR\M4A?3 ME;:V7<'BK!XLW&-!U,8=4P])`UL\35P$!3WDL5P_%&GX.SGZ`;.<9(Z*P_R1 M5+@-97LHFOSV3Q%KVM7QR&U$:OG2XEAY&J.(IO6/XLC1(7!13E7(I7SRTGTI M_!_^\-WW?P:7<(U"5.`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`D M=^^5_=',G788"&6;VR?_N<_9`U+DB`96FA[:6J7WI(Y[B&*(;6%I*9*)6Z7C M^?OTGW:PB3-Y:_+[0,=/SD#Y479ZD)P7`\K<19`3CJ$6!TB)71W-50)0=V=5#H>5-J?,`^S_9+\/+ M/I5+B1C<;%1U:D`HS4JGN$K+_UD;!\GB,QH3;1(B#6U0&%O+WJA@3^+IB_X8LMM#9$B*4?#HS>N8YLCEKYGU@ZU+[\3S68B>Z<,` M1@[9X//`!YMV:+I=C^9A2%Y]85Z4I8<@IHO>[,@T(PL\'WVJ`V]J M-Q*"S:7G5)=*Y?N7"CX//*=IAZ;GU)A\\QR5/<>_>NLC'6'JBDV5<[SZ2G-$GTQB9P05MQA'D6KWBO3@-A!Z5"61^%,I$U1"0265 M1OCRN"D3++U1.;7;3=,DE?7E"@Q[9E0W/Z7FE[[CX=(+M($_V*/?U?^ M,>U\MG4LP1X?+A&TA/J@R6.UQ8L$6[STX&,I&YR$2XN/#&Z8@LA6Q81)6N<5 M;-:.XQ_]CZBHG<-YK""KM'RL`V=28;[$!+G%A@?.CL)\/.HQ2@-T6>BM9VN@ M6=.;M:'LW(.O41(DX4@>+!7FBP?++3;TX*.P5^3!9@UPLO`5C,T::-;T8&TH M6WU$((0PRJ]Q:]Q#>I/Y+LB*PR5\E/FJG,W%LP$R*SHJZE-R0#``2@9`.0!A M`;9<#S>J`S7ZIV#7#^ MKDGU3:;KSUW-Y/4K'^>&CV_.RHQA]*6/QY(?:A)FY?U9T)%W=NFA`^TE/HJ.%D7'3#I*J.NZ]\P^ MJ.6*N?6&K,43P/O=+J;W'X.XNO^X2-9IMJ49*9WKKKH2[)\1UK:-.W5;XSQ= M=@4U9F]6@2,9>8GR,$YS\NI,NNXV^0?W7FF(5N[P<1^H#CB1)M`IXVERZ!#M>MAI'$?0!(Z]<669/05) M>;OE5$B`W7RYPQU>G5I9KLNI:A"?2@R<@M$*OA3G6,W?)0/0^)^R/E)-T%K< MW?#:)V:@\1$Z\:Q_AI1X.'ZH7OJA-DK\2CX&Z-<DK0&H7D:4MV>H-4H\'6A#AJ MZH0;70'VI[NZEG$3P1,C.'&"BM4C5^]OXJ>/'^?WOX#E-7A8?+A=7"\NYK;(92;X_:`YX`I[F5Y!)4\$XL_51ST%H\& MO'8GOIKV72S8P)T\"4T:CU:*U::5)?S5FF.:=91K34J?WT80L7". M?VA'$ MP&WO=K9EO7LE#3FUY]Y5U;4O\2I"X<(M6B>^W-97Z-3EA@ZF!(34#__N;.TN M1Y(>2CM87XT38]%,AA:U;[N$3(LN5I+@-MJ*! MI9O4*CX$VG)/X['%YHD.$$*WH)`U=!T/ZE:>%@H7&(M9$"^2"+[\.SQ(L<#1 M.@`#KZ\`#24AH)0`D_J`!T%K\X"0-O54B"COYYZ&,/G,4TQN%1<2K;DC1N6- M[/HTPX\YJ*KIZPC1:_=IP\8UBF%V@3_ZE&;RH-&B=!`RVKH*`@8E`Q6=#]&B MLY'Y6"%IX:E`L,J"""5/#X?M8\HU?FE#B\9JQ[?U:W=Y^7?`"-SV=6=;UGM9 MTI`3SPU.+[&RQVR6^R(O@H1H(Y\H2!E=S!KDEHBF$+5'2:HGGT"-TX<8H=-' M'=,+[0X:`3>H! MS=-K&O"W=T+D9XB>-@6,YAAYP1.\W9-G0Y=K&BMJH>(\R%$XQ[-/%.\+Z9N> M?05:/T'2V_(V4BM!H)0$F"ARM)@?26:`"J2GT$J1;D^9C-\,0=D,R;$90C:\ MLM_&@>NSZ#F95]6I-QU=R6O=P MM2W<=+#D(#EGYKS>^:NY4>=M#V,OC>Q(X;J:8[KW.TWLM1W,"'A6'VROE\NJ M72$F]7#*`GE)1-XP8?^0^%8/62X><#>V5UAIK10R:]R2]^(6:^]N[7C$?4B? MVKPU]YBC"`79X2&((1ZYR&+R!B60OKLC0:V*T<$=.84E_*VQBF$&"`N=T]&7 M3'\E;.R-+!_>@M3J(OZ&F'[_N'ZF99YEY,$"LKX\/YQ(L//0/!PS9EMVOT#SR+U``VH?)24*ZG3EAP'] M\@R4WYZ5M96/GS]=!L_IW6FF@P?.9P>P>H_+3(36U^/^UVFVAJC88WX.=.K*P;Q&!'YE9*ZOO(@;N9&$5K6PQ7A_FGK>92B$ MU2I>%J:%+/:CJUA[#BWU]<,,4/)3GLF#"*;H""[P:/6"Q7M1LB6IFL7U_2C9 M,K3[CI07*U#=OE!<5D*V]V]$QL;#)J$)$Q3I)J'CW=C__LD2,FF))P4**18_:6K6@6` M>/))7(G,Q#_^[74:[3V3-*-)_/.G_2_?/NV1.$A"&H]__O3;X_7GDT][__:_ M_N?_^,>_?/Z\]PN)2>KG)-Q[>MN[]'/_,?6#/[-%_;W]+_M?CO?87XX^7Y+@ M\\&W_<.]__/M\*?]_D^]WO_=^W_#[_]_[^KA<>_SWLO+RY<06LC+%KX$R73O M\V?VG8C&?S[Y&=F#CL79SY\F>3[[Z>M75O[U*8V^).GXZ\&W;[VOBX*?JI(_ MO69TJ?1+;U%V_^O__G[[$$S(U/],XRSWX^"C%FN&5V__]/3T:_FO4#2C/V5E M_=LD\/-25,I^[0E+L/_[O"CVF?WT>?_@V4' M?LK?9N3G3QF=SB+6\?*W24I&/W^*Z;0HQ;S_K:K_KY=)4$Q)G)_%X56\B0H"0@ODNF,Q)F1A$2U+73L/GGSH]Q`,K4*%CY_E^0D&_IO_A,K MJ]>#Y3HVR)GX*9DD40@3R]5?!6B@-C&)Q1)])>)9E1+\;:]6L2",.8<)1$-F>#/_8@M3`\38M`[G99LC,=B M.O73M\'H@8YC.J*!#XM#$"0%K`[Q>`@?#F#^6?RI/58-6[6[\#RRV:K)\K.H MV-HB9-8S>1N65P2SKO%JMCL9F_5/HR'[$X]9%P65MS()P5(`.C\A.8S,R-Z, MM-*L!2B#=.S'])^EX@.=YT5&8Y)EER3W:90]DM>\T`>@V=C69M5F*)JU;7>& MG;?>8(I]K]G:'&O8-T4C;7?3E'RMMFR>59KU4UC=\JIE2#:W:CM=,A28K(56 MCET-]4_93EOKUT,._RW/#(/18,:,5>P(`],X&PC0)Z@`BRE;Z#=:STP^T^Z& MQU"U=5IJ\2S:<)K0;,WN.;597R4-V-]*&I(OJMU:QPQEIVAD&W/&Q<2/QR2[ MB>M3V"6!_1/-K+%AKL;T-_89;^"UNVNUNTVL=A]4E M`XF7T&ZAGTL(8*00X"E<8&"?V,347]Y%P$>C)%CZ3L1N09)4)2KVBR?[P-E3 MQNY_\D5#D?]$HK)Y3[NNU_]V^B$?W<[.95+>RV0D^#).GK^&A'YE_6=_*8%\ M_K8_OY7Y5_CIO3>U3CQ6%N^UWLN*>_W];TL=KE-ZEBYWWD^#1?/PUS4^E^^5 MYB6^SLH#]N=@0J-W51BER;219.>]272!%1ET,9FQ7]FDG:0PN?W\:?_3'L`< MD32%34DO&?E1)X>R59@(Z5TIY_<-#ERRJB5@GC@N!S]Q@*QZ$8!YY)HIKN37"5KO-I^='F)V.$H)ZQ2Y@9V":&C)JH`N M[[MFSW2^4]F$22X(&:WVU?=D3-G)-L[O_*EHBN45!=C'N\BC&(O@D/X-/8<7((+4 MCV[BD+S^!WF3DKA2%I"?["Z+7#`"&C$;6RZ*-%U:*N0['E%QP'^ZBV3*\0CX MQ&^,N:8122\`QSA)Y8-RJ:37/W!J"MUL2'*@"`C$;*]Y3'T6[/'P-GU*(@%U M2V4`*4:+C)(T#@@!79CM,//5()E.D[AT\RGO$+-!D;.X%@90OB9**H),=M)F MHXM,P/8FIAP0TM?5&[FV;NKJ`3!&%W-U-1OYV5,)I\@^CWU_5ND:B?)L\06^S(6,5"_,R.(=/_FD&YKV:=^#4"*,K M[^71HPW,TJ7>,TF?DHSGBR3+LW(2*WL[]-]* M)PN-X;99P]Y!W]6(U.[X>;WC.H-VPY:]`Z='?XO$\H>^#?%T8G;XB**TX?7R MWIK*Q66MH'?0P)U%U0O90!&4]'KNO53XPEE69%GW.Z&82\&U+A8K\I0;[?GX M%;S>@;/%9:E#6HL&OX;7[\C5 MR"BWQ$MR8[.-V5C1;L/K.;T-DPB?/VK,@'5B',ER%+@84'X:TWC\W@>=H26H MXO5.7`VRU2[I#"IA':_G]-Y#2\S\X22'U(GA(TRAX6#LB/JB,8945;W#?5=C M21@*9K1D&;3B'3JUB1M1PA]WIF`[,1+KR6,<#+[:Y\N@T#*:A\1ER+W)4D\(Q::$PYB"6BX02^&A&%BNXQ-&CXH+ M>TZ+UHM[1RAN^@5.*AM1+0:$)P36PK;Z5I(`0ES8ZSN-,VB^D5Y&8"D` M%L,N2VE-XQ?T^BCN4`3\\,GD(+`4]XJ'R'DPFC:?*^6]/@IO*`Y3,DIY(&R% MPV*@EB7BDYUKX9^]/@J3E)@/P2EVT75;8:\8Z'H/O;@C6G$T4,SKHS!$F-*W M!L%6M"L&&F$?-_-I>/7*'.C)61P.\@E)ET0D-T>H:GM]%-8)4])UD=D*G%V] MR'2\M.HNJ5X?A67"E-UU#+8B:O,D]R/'(UIPL2B?J&75O#X*HX3VADF)Q59$ M+991JQRNWC$*6X/AEK?LM8`K8^.1^Y%Y2_TG&M$R+B@.U[VT-S*`5[QB%$41!,5\O3&$*%&4G+6#E.:0N`+56B*IXQRC,*8U4 M0(I)X/MA;!9#L+VKGE18@(2)%'Y)"^C_FM!D>T#]5KQC%$Y`C73"%*9`37;2 M''=19'DR)>DEF3'G.`VE$-3PCE$8Z1HI@`R2@.R=--H9#7Z>\J,PR36B6(!& MP*ZY&0[3(?$NB8,FYX'U>MXQ"C.=W2.!`*9`%8PM><@&NA[UWDD'SWXE*`&M MYB8[YR.\D>%'(L,3;`>YII0K,`HTP-@0B&%@+[M/_>Y'A2PP@U/:.T%Q=E-0 M)KQ;X\(1$+R3-KU:5D\5NZM%O1,41[!&U'*Q"'C=23O=61C2"LC0I^%-?.'/ M:.[S\@\K:G@G*,Y9C5B601*0O9.VMGOVD&M,PD4&D+,@**9%:6]\?_54R+NZ MLG>"XAS62`4TT0DB=7;20:T&L;0^+CV9?1,'R;1\./N.Y(/1H_\JM\>9M.2= MH#B]-9LJ&D`5*,U.VN76A6:TR?=.4'A>-*)>@$;`KK$ASKUQ7G7DV>`>WSM% MX:]A]QPO1BK0B8W-=UM-Y:CU(O;[R]@.TARL]T;'@UY8R=O_YBR=UD?Z"&"O M[-B;7I8><36`@\)VIA*XZ."E0M:AM`>_960PNLIR.H5]AR>!`20L^O]*$I>6-Z@ZR1E9=@Q8KZ^2G=>#9H#F:(PR353F^:(+25C MP*!%[T$\^C.*J`K(!H7IKIDVR%%9RLF`@7%A$("^!N@V`;)#8DFS69+YT6"TDLK/8+YHT!S(%(5MK^%*N1[T[%%8`L#MHK=3!9"MK M!H9!_?'(:/T9TD$)#C09MCP@8C@.L>.UVCS9H#40Z0Y;)QL#MI6Q`X,.7<,Q MNO27K"4YOXE!>.6;\FJMT:H/8MMANZ4!1%O9/5!H1I(2.HZK6*=@^0FE."S_ M-_(U;1$;MPGBW6$[YX:P;>4AP:!5'"^\"K.)*X5>$R"\';9PFJ'L4E(2R9M. M1DJBV0@(<`<-G4UQ=BIS"7FI"2U-8OAK0&J+LKZZF#;E[1_LL#&T&=KVQ:Z7;]M'K(=C?R/@@;C.H]FB=S*JW!I6&@[//0 M?ZN65O7@W*QA8-S=B_;O6LFWB)045F:1[`Q.+<\T?VLPLILV#J)!83RP0;!J M6MA,1IV8,.J9M1Q.$^0I-UJ;^16`EQ/WP_J[GQ=I&0=3N<@\DG3*^MM@$.LU M!;!1'*EDI*B&H@G23@P\F'9HP"[`:%3`?,9\2[Z(G&2!15 M\?9[SH*&/M1JM7)^F#KS>T#%L"T'A?`2\)X0^G1C`[,8S43X$/2XE/ M2$X#@.E@W=O&N^#[A]^!/`Z5#\ZW*VO&8OA.\?HG`D%+'%YU:, MY.]'POFB0>$&**9-,%&K(/W]3CA?-"CL\_7 MPMGV!H6#7(.M]0J&#D5L+FOLT$\':8DZ+%V0%Q9/[6V8J`&0&XHK&A&C.ALS M.;8.Q70NPRXQ9F=%/DE2^L\/RY=2%U8K>OM'*)S8-M$!/J8NA7#R\-YD66%, M?%4)!(3+AM:8]#J>+L5J\K`.BCS+_3BD\=B0]5I-$!4N4UICZM=`X8C+;(/_ M6_I7L4BN6/X#B0-B]FR#N`D0'BX+7`.-4*'K4L1G[9&#!CM#C=H@,A3V.C.% MT`;6IY.,V75(&Z=B/Z3_]>>Z!\R(#Z639)7OK),J8 M$T[AQA&EWK&E3-_0RV%-"#5/B'>&=<(FK+3O[?'T>\OAF7'SUWZR0BB-6Y@PT"RTOWDJ1_@JH%PG=@):4!'EH[[SHQ M2B"M^7_@>\;-O4G`^F-NQSWG^TS3P_LQBM&C$JK>B?Q8?#&"_X#7\$1^C,+X MPF-"XT1^+'[9'#]AQB?R8Z?&$R$!JA/YL=!L\F.>R(]QW3X(1YP*0X=.Y/Q7 M_<[R"S]-WV!147F9:-4'J>&RQ:SP*3X":$*S=+)??53:44Z\^?:R(TGQ3MQE M_&BZLSQ!X:*GE*K>UO($X^N_+6\M3W!9/&I,:&PM3^P][6LA,J:U/>6)T^.; M4/*J/>6)O?=U=SMNZ03E\6U]C*DP=&@S^;YB_)&D?][$PS0)B/2>AU\!Y(+K MLGR%,3Z_,BP=NOEYAWE-8YI-2/A+DH1:'"]5`+G@.@R:<8=T1K MVPW%0`9HCW@:?+XCL'3;DR>Y'[FZ0^"F6W9XJ$.;;_ET]Y)?G:((W+,A>+W3 MXRG&M%@MGQY/41S_>4QHG!Y/[:6WPGQZ/'5ZPA=*7G5Z/+67G6JW3X^G*"YO MU6-,A:%#IT=^XOLS]I3GN(1^_O919+ZFG+WX:3A/BU\+"[DK5-EN;'\+V,!E MCUC1$X%6M2,&2\?=&4EI$@*B--]IQ?R%/4:;W<3#$L\OJ=SWM86O`2MH#2KM M*:=0$!TZJ9=GO2H"\K)(F1-0-6;*.+GZFR%7KR0-:":-$S5O#.2)UHHC4:R& M."W9!E#HS89CZSI)1X3F!8N_G0^P%J`$;3VIO:F-*$@-G5^/:U4,V;^ MM?.RNZJ:KK>!:&-5MKL-M)=]K=H&7L6[K9:_DPQ&UED<7KW.2,!>*$G83]O4 M5MTN>"#['T^)S:33I>QRFTINODUB)HS6=7CM6T`'"I/X=I55((8NI<"SN"C] M0>AXP@8WX/+'9+&M'Z8TD-Z];*<'0!TN@_^V]PQJX=A*[=<5B](NZ?8/:'DR M$HZMW(0_RC;9D<)OUC&@>A<-90ADUJ5TC19W?8Y&@68/@+H?T#IG))PNI:3\ M+V\)\QO`7Z_2.+2=ZCP(_8*\X%*Q[?;&Z!T5\U^+@35I32=FPK1 M>(T4R7:_Q2%AKY/>P?ZNVA81R:^]A*>[-X#$JZZ+D=*@-T#IKEHP70A*H/L[ M^="314/##?H&K?''`V'J>E"\+6M+EQ MGX!>7$'>2"PZ4G$)`@-V]];4S@*X+*HM;4]6/@H$X7*)W_8NA"L/@<):N%!% M$Q'H,(L@UL#`@_V^.X?>9H&!!_LH[A=L"%[DM+N.]P<+##S8QV54KS&QS)FP M\S],QL*#?:?V8"$!ZSRM=[M#&0O+I?X1OB(89=QRWL$!+A.E<)Q)NO\CQ05F MHD/+AUSB,D*3*_ MZOIW(G!F%1<&C#AL8*WQMZPO*DF@"+43L,V,%C2$C6HIB$D20=_.9K,T>28E MCDS.OV9UD`,..]$V-<)(-B@?6*CI]%5$GDEL-"&L5@&@.(PKCJ8%OCQ:>[%A M]_)1'!S@RAZ@W'**,%B*^<+`Z5E4-DY"_JAA%O`XDYEH]!H`N6%UD2X9%1PY M#+#]'2L%Z;;^+:`#A9703-5:$H.M6*G5I.T[I).7)`M26HJ@ M#36L-0\BQV6[;%?SUI#;"F#:Z2D018#^P0%63]TV%%$N!ENA1VY3P6TJFWQ" MTILX2`D4R"[)_"];2&NB^++7/\1EA]Z.JNH(Q590T$XK;BT93.600].RA2UG MY.%_&WA"8?'>KO)JBL56[$]-?;?I3G*?O/E1ON$[E`*[VWO;$B\/?D'OH.?N MI9]@0L(B(H/1#TF!^W2:_OA(4!YPH MS-.-*>+<3$FA6O* M0>>VL4ES('<<%P4N=@TK4K#DPN)4I:H]^MM-#&+R*2CRE!L][92@+6>5KO-HK3)!*' MN$,4-@;UB%-AZ%`@QFT2CUDB#K:$?/?S(J7,['M/9O,POL%HF,*F@\[\Z":^ M@TW*XPN)GLGW),XG,OHW:A>DC,MUT5 M`DNG2Y?OS7*.%BYCRJV=,$[C6`@\+M229LU8VA"%47 M[@<9I)L8I%&4+@7R*\#UPM[!$0Y7(259?))%B-"=6FPQK'4W)ZH"LD%C2N"Q MIL/Q*AH41Q_!Y&4!(0KS@9P!SBV+&`S*2[++=`@" MB.CL.DVR7,X3KRQ`0^$K8%>:*97FRN8SQIH`CWUEJ+YN'J($V:94GZ M5EHX3-8C20,@"Q2N%9NRJ5RUE#)`$2JNMS`=]%&8 M]UK7";40\`52M^QYTD=AZC,]EPBA(`HY;LT#I>_4VB<4O\(+\=RB=7215`ZMQ%:%WRG+E1B0''&W("TGZ+4^)'[(D` M6.C#H9^J3'K""@#6J1E/FS`%`EO/GMD=7*7->$7/'M-"94!75`/$3@UJVIQI MX;#UWI9=YO[=C\FO&?43.5,KQ0"14].4-C/Q'G?UKB5@")H'#):CQM M2U`)>-ZM5`'+OFHW<4Z`H/S>STD9ZA(.21HPOL:R4`3]1D!R.!RO)+SR-<$4 MHT`[=M+;:AG[M1^0LVE2Q*HP&UX5$`X*3ZE-%6`5D8#NG7S=@HEC,*IN="44 MUXN!$'!8K8QI74^S6*X&`4!BT-AV]ZY@$`2DX M')+.24Q&-*!^-'B)29I-Z$RZ+JLK>0:EOU0R/$=KD@T'+@\IQ*0^JG;X.TZM5WDD^2L+K[(^3!+X\$[+WL\[?U MPHMBRE!Z:`,B/9'+_*]BFJ`V+!<8RV3K5` MI>2"Z%"<,\+2>,S[((#HK@8$NS`$DIRL>$PN!FP`D?`J+(7`M&]FHE8:]X)C$+G-0UM//J@7Q0F-BV M;FP7"Z,3#_"NP%.NHMSR7K^'8S^N)HW/M@15"^_4.KA02:;3)-:SQZV5!3F@ MV%%+2!)Q*2Z:Q2?AH0#7W0JN_UOB';L6XV24AAV@I_;\66NXSC8^6#WZ>TF(J, MB8IJ`!R';<&87WUTW0AU9P"KG<]EF1"SRH%9[8CNR$OY3W+[HTX#(#$4UHCF MX]T$IZW`^!RTSO5CF%S4O_M103;0CN7Z(+0=/X@:P+054N]>-VJ&NKMDZ*R$0`(K+Q0W&]`H66U'P M;I?[#R'H[N=%54`JR.X6C1F6(K,5!E_C>YMAE[!IA5-K1D+X2Y9$S(+!MK/S MJ[9L,!K,2%I^+3N+0W8_DY()5*#/Y#;),A=1F3/PYK!86*9,V'GT<4AMI7C MOK?OU#`A)&"=I_5N=RF:<.WU<9VI\F-9[^WCL"`P`0A8XG/*1X'BY5)[QX5LCO*7)`FS.R)CE5<<9(+B@,_G2GPP MX./HT)NE]\F;'^5O3T MFW2A$!LA=$A8#:?D+2"I[$)YY0&@>R@[4H(!,?3G+9N%*O< M]A7.^=PDMV&)JH!P4-BQA+SQ:9;#L154AX'KFF#TQB^(`(4UQ)#1-02V(MW< M3\6@EUK+ZU(Y$,(.FC\X$&R%J;GGL531)9>2#ZP`?#!Z]%\K#TGX/25^1BY) M]:?N"KQ1XR!N%(:5!@NV!=Q="F9;&D5GSSZ-V#7L8U+SR9QGGC_W,QIH:%?# M%D&T*.PT&TQ"IF"[%/S&&5:+(25W:!;5\OH'*&[)3&WR"D"VXMS<+U&&JF]O MQ@!!HMAUMCI35"!MQ;VYUY8_"!U/P63EC\E=P?*2L`?X0-2#(L]R/PYI M/*YFR3B\I%&1$]E53[,&O1Z2/!]&NK,)5ELQ=A@6F2L_C0%GMG`SU]<614T0 M%0J[L9E::(&R%4GG]@FD%6AL#EV@GK^%Y.01I!4"=)Y#$E0!LGK.;F(_WD.M M$@N5>=^5WO?B6@`&A:5/+FS!G:L*UM_O$:V^ZM+KX=BIJY@3$"['AKGTWGS#!P4P`ITL!`=:?G.GU4-B%1=R)G&84@+KSO)#-)V=Z/106W29< M2P!UX7FALQ<_#1_A*XH%>JD[Q"%(86C*(*IHC4A=.C9 MHJOI+$K>""G'ZJ"$I%Q4A'5`.CB,*JTQ+S#+R`72H6>-ZHOUK484*K<\2`6' M6U^SE4J"R5((AMO-1YS3D!G=Z#-Y($&1TAQV7%>O052$)+P&*;)!551L#49K M%IJ85JBVO"@0> MN;?]ZKW&I&\5-F@/!(#"LJ1'E,IN;`R\"Q;E2_*4W\0@IJ+795`0=,D)O^HAL[PB%V<:40;4>U/&AL.T* MIO;OU)_26Q:>()_65\L!,A36$I',.9,Y'X(E2VK#B5S`RH,_(EE.\V`B9V6U M'$!"X3-EP`H?@ENKIV@;E,0YC8L`1*#8`ZT6!%`HO)L,>!%@L&4AM,O,K]2/ MB#_1F,?62P(N='8C!36YEE+)QB6G[N MIX_"J&;MM"'$:"O'RQ89O3)]#ZCOU`@G%/TZ0^O=MI6.Q;)--"M^\:=3_R9^ MABFG=%&_'2J,H^(J@-2I$8XO>9YM5(4!]3/@I;UPI?^/::$RFRJJ`7"G)CIM M\K1P.'[P6\#PY4[,032>>RA;,8+<:D8*JJB`E%(:@;3DDK@!O MX67M[:O'/-(VNTY2-@`DVK!2$F2`PC:DQQ6?9RXD`:T[F5BXF@WCL)K;U&_W M<,N#6%#8B39A6@),$!JRDPF`EQWT%X\FW(/8RGQ-X9"D`9/`6*8$^HV``-&Y M?IEJABE:@;KLY!-?R]BO_4`=*BZJ`L)!YV2VF2JL8A,0C\/N=4YB,J(!]:/! M2TS2;$)GTK&NK@2@T;FEZ1*JBTY`Z4XFGF,"&8RJVR_9"E\K!D)`X6ZVT<*^ MAD=`ZDYZC2V6(]BHLC/+_*(3]C%W21Q4_R/A6J.VUSM!87';1`6T80HT8R>? M!!,(3.^QTHPE-:F?C_^@^:3>HKE1P-*'@2@49K]-]'$;$A*H\D[&0)X%`=ME M9?/Q6P/+4HB:37G&;7E]'"_>;*)P#4$+=&@3\^8VLQ2Q-SMH=4'M/C%1K3,@ MZ2KV:TSB@"5&I5D0)5FAE9G>J!VO=]H@99$P.&_QY=4/B[(-Z52#+J*P$#20 M*^=(H076;2(A`;M7KR1EGG._Q10DP+^=Y1<$4$X/]OJ"YQ`F0(,B[X\.4\(+ M5%%1P.?TU"Z3NHJ?.@+,^7J6.BV_*.44!7Q.-QQRN:LXJF-PF\)=0,X#S`RP MNU"$_=<+>8??G!Z!C0GA]-YM-AWECF)MS;V5W#YKUP7H3L^*&ZU,^@`M9;M! MX!RTZ3WDX3>G+B:&O)E<1);(+*6Y<4KT=S\N1OX\.N,BR7*9?\EZ81"$4X\2 M*Q2+8'4IYSB@&HQ^RUE:-Q"+]$"[5!(DX=1KQ`K!7$R6,NY@8'=8I,$$IJG! M4T3')3.7!;F)[\AK7@5)EAYS,M8U6P#).?4LL:(-1EC;2Q".1DT>2)#$X7\2 M7_9>A;(NB,NIX:A-U5A%:2OM$&*E8*&T#77BO2H("Y,ERJI*K("TE>4(A4;, MG2P?DX=B-HLH2:4KQWII$(E[F];&O(MPV3:R9P90T#Y M+XHL3Z;**6"UM'>X[]Y&9V$*X./"D7BHK?7?:,4'@6"RZ=E:XRM8[>43VN:] M^VT2CR/Z3,*S+"/O=^]FE^Z"Y88U??O1M.2^7%85SOU*HO`Z21_\ MB.B_WJ-H`X"Z-Z9(2>"/#T.`77B9YY[%(ZI>`EB4`=@H`FX,>>*3O8(*Q=6[ M14Z5+W/62H$$4#C#K%`BX:W>;Q17\I9N*2B;NJ9*[I;*@11P1+BL$B.XA5CO M>Q?>7/_NO^I15R\'\''$LFA2M][W+CR7`V?=&4GS-_:(+[LMO_JKH#.VRSY_ MT\@9HE$;1(7"E]?*NJF-MPO^`4*P6EE$-&I[AP[ MZR*-:/PFKZROV6E/\0DB<*;*3.-54^!#T8C&I!W<.4AG+W`2U*%OYV] M+X`84>0ST6:<8W>T+0V43_W\09XRFC.(#\DH?U&^+2,J#Q!1)#/9A'`YMBZ\ MA"Y>4&\U$MIHU`91H4AK8F4/H8W7\:M$+6\B?DF3K-'6LJP($D)AC=$FTW#K M4`/9)4>$LR`HID49"7=)H/L!K6[;R2PB)7-Q>#9-TIS^L_Q=*!Z)WMCZ!`@? MA5UH0PVS*XZ-72!.*UV,R9CUR.VEF`CJ'9%FW))4`R&AL$:U-2N]0[3E'Y$G MN1_AU(+?,C(JHELZDMT*:=0&@:$P<[6E$ZM(VWL?ROU]:J-8YI:O57O?K)W: M5KXA#3'FE87.N/<3D`J*<6S+L]]_$_8@XW,./VQ,EFNZ$"]LRX M/=Q&FE56-S#C]H0FF]UZ3Y-GA51>WXDK@6!0&&BT.>2K@`I@%^YJ[Y)XFL2P MGTGK*6TT%@-Y11"0^Z@ATW5`!U(7+GG%.)7SOZHJ"`F%F42'2E,EJ"/LPH4N M>WXFAK;?KEZ#"?-Z4$_YHBH@%!26#CWR^,3+L:&\K%V9X&37*]+R`-%]]([N M;*V!Q.TEJ*V\SQ_F6.H@NW(.V=M=UZ#[.I@G+.K`Z M<>BVBC&`2!PKZ@8(I/KPA.%RS(#R2E)#L?+GI<@E3: M$R2U0#0H3`HBT@0C6`6H"S;C"N1%(ZZYM4`T*)PBFG`M`=0%6W$%\K(1U]Q: M(!H4`4!-N)8`ZH)!^'U1J_:C++X@BATFL1Z4_A:69`&"K\."56";303DC+9I&1"XHP^DYLX2*;JG";:;8#<4)A4 MS(>[&4);^3IQ;-%E=_WBPG!603'D&VS&5S#@2,EIB51V>93=9%GQ<3O%H[-6 M#%0:A<5$1(^`S#4$ML)#9G`^3]C57)H[OL!8O=61CL_5PMZ1V]2*#6D5X+"5 M,Q,5N97V7I8/1PRKCI5:?9'$,)=D@'4PJOZ>4YC;'D@`114/,&S6L-?'$5+6 M0&DVQ-Q>LDXTRO6['Q6D!=W2:Q?$C.(2QHIJF4`6:-9.6OCN2%[MAF_E;F=+ MY6`&1V'M,6.>`T'`Y$[:[QIM%-WFG[6Q490DF#4VUU5[B:O8;;*!S;>)N(YQ MS;>)XG2SQC8Y'K6XO`7];'(=)2^&B;BMNP:^]\/,(W"MFG=T?.#<$&+H"'AT MC&M9$XI580ZIH<$3F)Z1X,LX>?X:$EHQ"7]9)1!^\F[)V(^NXIPY/?*OECFE M`"RNE:Q&P3)9PL[C<>#39:I"(+P47BT",)TN3$+)KQ.TWNU.N.%M:!\^.D9Q M%Z`>8RH,7?"S@],,6QR&:?),82MR_O8;;"YNX@%L='SVW,E9D-/G\M"JL9"; M-P:"Q'KX+RD6'@$;X;3DK(?AF-CPP'^,PHK8E#\M@\"QT&BXDS;#L_"_BJQZ M!(G%7X'8RN'QF-RSURL#&I$E_(^)O>FD[4\#5RC<1.VJXW:DUB'O1)TDE1(M MU:GN'9V@2#N_'=W@ZZ6^G#KD#5D:&<_]TF`SG9$X4VD3OP+(!<6=K4O]D4FF M0X^N@_12EIO_DE1_UN0U]S746#GU&P'YH?"J=JE9IM+JTN/MZ]A!X(0^ER^4 M&FE8K1Z("84%U)187?58@[JQ1RBB)-7KXIZ1CD+@J2`I7[^%#8[!01!6D`_J?]$(Y6_4;,&0;`H#,]MS4'Z,F@O83IF M`W;U@' M(#V';O[9EJPXGP*QH3!+6-0!_G+0CN!:R]>^S:GFH9A._?1M,'J@XYB.:,#> M]*@NN5C`/4@J8"8-!S//>B]TW)F%E8"SOK/=FDRV.B-?KP&`B.)DIR)!L&/KZS+3WY&2N'^-U!+`P04````"`#@AH]%^QU86B(,``#K=@``$0`< M`&YI;74M,C`Q-#$P,S$N>'-D550)``.T6(]4M%B/5'5X"P`!!"4.```$.0$` M`.U=X7/BN!7_?C/W/[ATIK/]0`B;W;U+NKD;`B3KE@`%9^^VGGW]).>]"1;O/]Q%?C6$V:#<-K]O6#_^\.TW[W_7;%IWF&*&!/:LQ[750P(Y#+F?>:IO MM<_:9]]9\N)MLX?=YNOS]AOK[^=OKMKOKBXN_F']:WS_;ZL_=:RF]?S\?.9! M#D+E<.:&@=5LRG*XN\`!L@1B)0%O$NI*K98L MHWU^T0;IGM@H;`N_;<6)&U'? MD._/`\AX.U-B$":4"T3=%Q`9T(F)[,J&#K71LY=L_FX5,K291J%WMJ$6/0`'5Z26I.>1XF^3J0D".. M5^XB7UZFY"@0^H2YR%>)TW*LH8BX/%]')4F5]JX*)VZ^`B3DB`,!8KW$/)<: ME9)C"Q=+IBD$4G)*\?"285?V?&W[NFPAYK+0QX#`%4V\6OJ((A&R]2W<;RHD MI#0*\C/Q!&M)Q"T0:H(49L3=Z!U62A3`AUC6>T1I",X%G)*ZET^62T)G87(+ M#V3[OI*`'5"WY,7#Q-:[!F5:+W0CZ6,ZU.M30<3:ABQ9H`IJ6`1JQRBQ*3PM MWL,S0HF"V3YO@UM,U;X"T3GF-ITNH)PA>(@.M(31H->?3/_P^XO+/UF]_JW=M9VZ191O M$8@O;OWPN:@_>)$W<_VN%->=Z0?K=C#ZJ>[C6D9';(XH^:6#GAFX>I/>S7KE=/RS0*`L36H]F4 MS"D!;X@@;'%5:$[H?`Q=R24X8:F@K)FT[_=)FS[U^S6+6A9M^@2&AFQ#U?8#,Q^7^WS8PX_@UT:3NL)- MW4:$KEK,4W-+&'FVHG]-FI&&]GFF6SBC[E^:-YUXZ+D?PR"D_%K-B8Z32;A& MOMAT@9=;<\VW]VM^,OK4&3AU\S=4]3`4&&+J-7KT<5S;.T_,%?YZO\*'(P=B?/)<)>A_/- MYL?^0W/%9\+MP6AXUQS8'Z'M=Z;3>EOCY#"[3+A=+.QNGQ!V6Z_2,NI=C2(1 MN"/GP-DX/'ELILD4C5NOXBQJ%HX,R[<),4H8N7E=.$2OB3HJ@-RF)^>YF91, M]+X33-9,G!+);!-S6,S,4R;H/Q35U-0=.Z?;IBL_R4Q19ED@,[^K.2F[S=7# M`A&?.W@EHO2ME6*B9LXRBP7:+3#K59*QE>1:3I$LT\9=8P-ANJ-3'E(N0=YY>78"3D(K-PL1JUWQS%JTLS$9)8I73>`NZB9'NWP"QA]M@K\5$268#@T05&]7T])P6D6 MR8?OYJ,4()-PB9D,J5LI^(;5^H*&`2/'&K9+8C7-\M'CL6:!"O:K:Q%T@&,M MVNLS7]:NN+]M'Y``=]L'**A'8%;(A$5SCV31G302G^8R"%V5E4%%WC53O:9\ MU&R_;EZTSU;<>ZG]8T"\V'@!"+IF!5:*YB M"_N"IT^:+UD=9;_A4!03H!RUY+KYDD4I('F'S11!LJV7WIR,)>\`FT)@MA4W M=Z=RE#GKI@B4C9*Z.A5"]AR<(AA>M.++YDL&I5#L'ZY3!$.J(R].+G__W)U" M`%(E=54"0O8,'S784#R7L7HQS^4SMJ,EW=>E=)OM=R?#*.@\MR"(+U*\^22C MHI"V<^F_9%("H?$\JR(M)=61%R4ZK/G$I4(5LJ]U*D_YAT4=AR2DP])@S,=L ME1]Y55YZBI(S[A2@K4VZSB.7!^E!XXSGH.HHN"MX1NC<%CB0(53#0HG4=4.P M2,Y0E13,"4GH.4K/BUCR-2LEOB^W-%)9'H$R$9%,O6-AM$P+(9!]'.W*2>XO M.9`.@9?1ZXT?NI]3]/$A85`OSJT*`%IC'$ M02N@#&2Y"L,G^`G3"(]9Z$4N@-]>L55O,JVK1MHI!FCJY"?$0$ND'UI4SF0# M/AW+SZ&S""..J#>&X>@>!X^8[5GCA0$B].NV5@TNC16C2'#BX=%L:T>OLX3H M%IJ[5.>5L:LPTL-\]7W9HJO*6A:=QJ*/Y"D,,#A$-[&],M9HD6DLZ3+L$0$S M0N(3L:Z,&?FP-#;TV'@!Y9#E+0NYJ(P-^;`.]Y$.]1Q,*TI,09R%K$RZ&PL# MPCF$%.H=E(I::L1:C--G[#_AW1PJ:JP):C%;%X0)O%]?5;76"+:0O;=A]+]C MKQFLQMX//+I#08!LM9:I=M$'X\H8:$2GL>B!,@P!$E;\QV]T5,8>`S:--6J, MV:L#AT45&@X/(M18]F=$\0=.4%@92S*(-,AO,%6G2!TDTW$+YJ\K@SP.E M=4?5#->."\WNH;TM_/5$CG9^96S(1:7MQ>GKK.IX>/5U+J9N>DS+5U^[]\35 M8BTG,M&C&G]V.O>I^2/>,R@%7Q(R> M:E:%V]ION.Z>"ZN("97I+KFH=`,VD3M)U5EUWL-SL)/S_:X#RJJ???U.D3-X M%T&I&T_0.C[@GL9;"A".S.+]+@'_1"B-@RQ=O%2Y]S`G<[IG=!!2+!!;?Z$> M%,L^QK^^ITV2]IC&Z_$S]R*!4TIN%,/%=IEJN'5FQCOG(C>SZ^ M8L94R('ID6E,L2DX!6BU/1S_MV6PNT3$ZZ_DR0#R<_-ER(GJWR.QP*RKWG04 MZ=&5U75>IUJFJ;!A2.7OEW1<09Y(M5[U,4#3K8$9?ARO.G850ZGC2[X%"3WB M.62?`;F+ED3(SX%.;KC:U:83VZT.L&XZ"&T9*@/*<*LS..:!DOC?M^(7\90I M_P%02P$"'@,4````"`#@AH]%*8XCTR5^``!*E04`$0`8```````!````I($` M````;FEM=2TR,#$T,3`S,2YX;6Q55`4``[18CU1U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`#@AH]%1,)R1!@'``!.50``%0`8```````!````I(%P?@`` M;FEM=2TR,#$T,3`S,5]C86PN>&UL550%``.T6(]4=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`X(:/114&SM\9*P``SZ@"`!4`&````````0```*2!UX4` M`&YI;74M,C`Q-#$P,S%?9&5F+GAM;%54!0`#M%B/5'5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`."&CT5C/O5HX#X```2B`P`5`!@```````$```"D@3^Q M``!N:6UU+3(P,30Q,#,Q7VQA8BYX;6Q55`4``[18CU1U>`L``00E#@``!#D! M``!02P$"'@,4````"`#@AH]%:Z#;A9@R```22P,`%0`8```````!````I(%N M\```;FEM=2TR,#$T,3`S,5]P&UL550%``.T6(]4=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`X(:/1?L=6%HB#```ZW8``!$`&````````0```*2! M52,!`&YI;74M,C`Q-#$P,S$N>'-D550%``.T6(]4=7@+``$$)0X```0Y`0`` 64$L%!@`````&``8`&@(``,(O`0`````` ` end EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`!0@H%]0$``$P8```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F=%NVC`4AN\G[1TBWU;$ MV.ZZKB+THELOMTKK'L"S#R3"L2W;[>#M=Q):-%4,A(:T[RQ"ZG7!MVG)HS8KO00NI],K;H(OX,ND##/8 M?/89%OK)E>K+&C_>DB1PF55WVX5#5L-TC*XSNB`I?_;V3.:W'8Q M7R`&XWL3ACM_#WC9]PV/)G46J@>=RE?=(P9?._XKI-7/$%;UX2%[*,-BT1FP MP3SU>`)UC@FTS2U`Z5T]7NM>=_Z5^T#^N#CS\2+.##)\OW'PB1R2"(,@G_D/]G;HL>16)[#? M2\)6^>P`?\X^PF&T,W'W9.(@R"5 M#G8%][ZB>)>(S?GI@6^::ABZ>0MV3S8?GP7,?P,``/__`P!02P,$%``&``@` M```A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G M:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-` MZ^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$` M[M'D,`("``!/%P``&@`(`7AL+U]R96QS+W=O0MX>_=GWQ6_?(CMT)>&%DM3^+X:ZK;?E>;'T[E^;@H[G; M?/YT^^@[E_)'L6G'6.15^EB:)J7QQMI8-7[OXF(8?9_?;(>P=RD/P\Z.KGIV M.V]YN5S;<+Z&V;Q:LWBH2Q,>:A)3/!W&O/7[BP_;;5OYKT/U<^_[])\][.\A M/,?&^Y07=6'G4VFFJ6B/;T@6&;.Q;\#)]="%$TY,ARZW MVW12?\=H?Z8Y]Y\ZXP1AFOK7+$P(CJR4X<@*P;E41G.)P+`R&$9@2)M&!&G$ M685518:7J#H\*ZLG"N5_?$."^1K!6&E@;UA9AAB(LVL(G4/E$VQ0$NL)J5N6+C0N^_IY"3K/G.>)\&G'\ M0EF&+Q`8TD9#$`YKYW*&N9RUEU4?<"@8*T@X4!`.%:!N6 M0,/2]BMH5]HG!0^*M$M#L#:L;>4,K9RUK9RAE8NVY@C4'-&V3X'VJ6U7V*V4 MGY-_VU?7 MX)L7````__\#`%!+`P04``8`"````"$`EP#U:)0#``"7"P``#P```'AL+W=O M2Y*8(%DXS]H4AG__N_G:YN_O=*A3^\B0-XJ@GRE#1//:#Z+4G M3MC#CVM12#,O\KTPCGA/?.>I>-___NUN&R=O+W'\)H!`E/;$99:M;R4IG2_Y MRDNOXC6/X,DB3E9>!LOD54K7"??\=,EYM@HEI=7J2BLOB,2]PFURB4:\6`1S M/HSGFQ6/LKU(PD,O`_OI,EBG8O]N$81\NH](\-9KTUN![UTH"J&79KH?9-SO MB1U8QEM>N9%LUH--$,+3&[6EBE*_#'*<"#Y?>)LP8Q#>41WRI;05I9O_,T_% M-.#;]&-3OA1VST'DQ]O\KY#:]W*E@H%M\>@Y\+,E/&^U6N6])QZ\+K/C39"7 MD'Z107A/\2M$17C'C+@D\ET]RH+LW:71/OM!#"7,LTXA,ED4DML`+A+JR[EQ MK*)9YE`W'7WHPI5C&71(&"P&Q""FIB,5%:@H992OR8"#THUZ@W2*C%]@QV'@ M:H3MM)%*^T(W!Q7LI@T5*J/J?$U'05%UD4P!!P[*LA^)2?\01BW3)29D=^)0 M4W<<)-#&5?I9-^),1B-BSUSKP77HHTD?J$9,YA)-LR8FPS)@JHSGNBY#S:EN M,LNF>N75*MIS4]_C,$O[-2![0D9C8*6(`[\3UT)NU05L:T8,5GLE8%_:E!M0 MFA;3'7=,9F1@5(J.TRPW('2>B*T_6<90MQU7_SVA;(9M_L3O;)`'(5*MJ,Z0 M&I.\!PS+`1.Z[8(NUL&-(#?8LW6CZ*`QL=G,93:!A&EYY2LIQTT@G^!N-*)L M!+7"FSJ85;E!F6&9CP:=@G'B.'IU)X9+_B)=N%TZ&"_Y'%\N\UY"^'!\-'X' M8R9?RMD)'8P;3-C:0*NP>@DHJ,(M*@\5Z-4XXP3PJ#1X_'1KN MD&<>RJM2R4>#Q_.C`\^P#@9;:4")AD=A(0@KU<5$[[^/>`1^,D4.0CB:2E:: MJ)Z>1@<=7!^E$DT#U7(J'6-Q&=]E&P_.#(7O_,.I5&)J$%LE+:]*-24J[E=8 MG`7UL/V$"Q6B*F"@E%H^+>A45-YSSYF!,5-S(L:D*?#\#<%S:$ MP54;X&I6.0110/4:Y8>JC^PTH&VTX8DRX496_SM6JUYP.)A*;N_P,``/__`P!02P,$%``&``@````A`)4_H]?O M`P``W`X``!@```!X;"]W;W)KS@+*/8>(9&"K M]..9\`0R"F[&D[GTE+`,",#3RZEL#<@(?E>_5YJ*\\:?1N-Y'$X1P+T#X>*% M2I>^EURX8/DO#4+&E78R,4ZFP-[88>CSR8$FHN)ZQ@)OUQ6[>M`LL!0OL6P] MM`*'MX#T\O<0^R*$T*23+]*+\@7D.93E;1N%Z^`-,ID8R$Y#8M^[0Y"-V-\0 ML@#`[DX1@G,I3J%RW3F_,9*3;$9SEU$;,G$8M1%13=KB"*EKNA`]P_/C@0[71(Y=#2D MT26-`:LL\OO3V.6?MZ<$.WF(G84UI#L/W3:+SO(1.A+LT%DX=#1$TXGKW"MM MVC>-B[J@%B$$>C(\00KM4%HZE`RF.T66L>9K4W*4^?.:(2V>S:T=.]MW9S`] M:;*LB[K3;%)2$0LA*9:'&&>7Q43[_?D'M54\=E7<8/3'OHN@]G&S]Q)TY'P@P;:N MQW5I3`8U)E*?_WBQG-5-93:E"ZCWL55HR: MFKYDZ,-X3JH3V9,LXU["+O("@2#F^ZB^W.S@+$I_(-UR=:,&] MC!QA:CB.82M6^G:B7P0KU6'XP`3<*M3?,]PB"9PLPS&`CXR)VXL\?M_OI=O_ M`0``__\#`%!+`P04``8`"````"$`TCHZ\"D%``#]%0``&0```'AL+W=ONT75;OLI+7;.W^8*W[=?/K+ZLS;U[:(V.=`Q;J M=NT>N^ZT]/TV/[(J:SU^8C7,['E391U\;`Y^>VI8MI.+JM*/@B#UJZRH7;2P M;*;8X/M]D;-'GK]6K.[02,/*K`/^[;$XM;VU*I]BKLJ:E]?3EYQ7)S#Q7)1% M]T,:=9TJ7WX[U+S)GDN(^SU<9'EO6WZPS%=%WO"6[SL/S/E(U([YSK_SP=)F MM2L@`I%VIV'[M7L?+K=QXOJ;E4S0OP4[M^1_ISWR\V]-L?NCJ!ED&^HD*O#, M^8N`?MN)(5CL6ZN?9`7^;)P=VV>O9?<7/__.BL.Q@W(G$)$(;+G[\/4?@D)!:C`2*2,QL%?SB;>(DIO;"59\9"0#?,RZ;+-J^-F!70,^VU,F]F"X M!,M]9,ACB/6C4(&>,'(OK*S=&]>!*%JHS]LF3H*5_P8YS17F`3'P>\"$.F)K M(^)DQ/C`>*`-R:"T+Q>B9R?`@IW(IJ#[@`.42F10L1%Q,F(T*I"UZ50$&*I/ MDA`GL>[[`3&+@>Z6#&B>%W,\"_#:A;B&],?)PO",F(4L8&C0VO:3HE%H*6`' M3X]?@'46MX:?!X20\,F`YCB=XUB`KR4>,<0S&=`\PT:G(8NFB4%4/M^%8I$> M>IPD1@$0D\H"I$D0&#VTQ7G)4",D#AK2Q9\3$6"32&H000Q)!1G0/-_-\2S` MUXJ`&.*9#&B>0\@X#7I:%>0J,_H;(WH%(B34"%8&3E_Q,RS2:0D5FUR+$#5/ M;\O;P3+*E0)1.KA,CNC>A7!-]XXR][DFE&264(:7E/+.+`E10T6'C.A)F260XEIQM4<4B);D(Y$,#96< M6!)4OBLE(?*H$-%T;$35+D0E%2\<05Y)`,S& M-3JK64(:7E#2=+RP*#9$.16;?D3H=E\D1/71#7Z]XMW4U,74LZF55Y!SZ8FA6 MW![#M'GIBV9)JD2;&\*\?"J0NGU:3#Z25_$-:D9%4"=IFRS,HT9:U`ORD;I& MAKI>*0C*(Z2<''167UBJ*ITH/OIV^"D-C2YHJ'4152`L1F0TS':8M;;%+/V, M;/VT-R@5RU$IU?;L)RT>L[0SNJ2=UO8TE-+LE'[:I"*^&-#].>T`EJO,CC'* M\*!`6*3`,[,S3%N49BEH;"MHG)K?%Q0(J2R\\1C!0@W3%I59>AJC,&K=:UZ6 M%8;(*1W1^B>>):<2?4W,%8AZ[Q76"MV0T(D;`W60IL#^&ADCJ+_O6+*NYNT# M!A[1M,WZN9Y)M+Y)K?Y5&'4EA*^T1M^H>4(%7^'PD:IBS8%M65FV3LY?Q0M; M"-^-A]'A]>\^DN]WPP0\OIVR`_N>-8>B;IV2[6%IX-U`>`T^W^&'CI_D$]@S M[^#93?Y[A&=6!H]$@0?@/>==_T'4;WBXW?P/``#__P,`4$L#!!0`!@`(```` M(0!G"6YYB@@``*TN```9````>&PO=V]R:W-H965T?_^Q60^^E[MZ56VGP^1F/!R4VT6U7&U?I\/__%O] M=C\M?BO+_EVFWF>_OC[G54O^_*^;)IM%F/TO'X=K29K[9#7^%AUZ=& M]?*R6I2B6GQLRNW>%]F5Z_G>/G_]MGJO#]4VBS[E-O/=MX_WWQ;5YMV6>%ZM M5_N?3='A8+-X^.-U6^WFSVOK^T>2SQ>'VLT/4'ZS6NRJNGK9W]AR(_^@Z/G+ MZ,O(5GIZ7*ZL`]?M@UWY,AU^31Y,?C<;%9N:M@>F?]H7C]7R_W;=)C=WDSN MQEEBY8/GLMZKE2LY'"P^ZGVU^9\7):&4+Y*&(O8U%$GLV]U/DLGM%56R4"5O MJZ375[%/W1BRKX=G2:\V=!N*V-=CD=Z]<1<:V]=#X^0F3R=W]]?TJ5V@C0_[ M>JC2OS=&?I2;22/F^_G3XZ[Z'-B5:,>Q?I^[=9T\V,J'V>+']CA_3DT?.V]< MD:^NRG1H_=F94=LY__TI2^\>1]_M/%T$S:Q+^.GG MFF@.#`$CZ_IHW4Y.:KU[@1P<.K%S>'BR60!IXS9/QI,OS(L7V#,ZLDN3Q!J%FC16Z`Y%%DL,2K*L+1-UG5V9_;O.B>TN0CLB8^\]\YK\V+T% M!X(#R8'B0'-@"(CLV`V&VG&+(+,;[_D9X1I-A[;3VO'-\KA+9UY#;'$@.)`< M*`_NFWF6C)L_\;OHBPI#BD;&[9Y(C9\W[,3<\"1^E)G7$,,<"`XD!XH#S8$A M(+)C=^?^=ISXTK3T&F*'`\&!Y$!QH#DP!$1V['[:WXX3\]&Y9:/C-<0.!X(# MR8'B0'-@/+@E$_;X&)$]ESC9T9/;D3T_"5TC;I.?-%Y#;'(@.)`<*`XT!X:` MR-:7V-9Y.TY\:1)Z#;'#@>!`0N:Z;E^"9IC]#8KDL+9%:>'[[$9XOX$."K+HBH3=^L)0(T M$H@"HH&80/SBF[C#HGOM)>ZP[V_31X/8)LLRLZ;D=-B:*H`((!*(`J*!F$#: MT3SATAWX_5WZ>!"YS-O^:P+I+"$9HB$%$`%$`E%`-!!#23Q)W7G>WY<__>V# MDZ3"`UA"(D+PQ8D`C02B@&@@AI+8ESO8^_OR,2`:KPP6GQ=U+8A@TPO::2O< M;\MV4VZ)!**`:""&DMBF._")S7YY,_$Q(;*;M[M8F)XD2P1_G(A0B/KC&@4: M#<10$OMS"8#XN["'^KQP87KRE%$DG`@@$H@"HH$82F)?[L@GOGJ.FP\*T;AE M=&8UDA@2 M;'(B$TX4$`W$4!+93%G`.6^S4;-@D[>_)?M5&$03_]E`FB:L'XH@:)>@`"*! M*"`:B*$DMGE5L$D[@DW.SXP@:ET40`00"40!T4`,);$O.^/ZS]+4J2\%[B"B MOGRSE@C02"`*B`9B*(E]N:#1>_6E/I:<7WU!U+HH`CFY'@4TD4`4$`W$4!+; M9%&FWYZ:^FP2VCB((VIZ10!00#<10$MMT">+ZR>MS1S2J.?\`-.7AI``B@$@@"H@&8BB) M_+G/9ZB_\\/8J"^=B4'4CDD!1`"10!00#<10$OMB&:;?II-U9!G8=(*(^O/- M6B*"YN0V)*&(`J*!&$IBNW:J73&,3LV2*?PZG'E1:ZH`(@(YN0U):**`:""& MDMCF54DGZT@ZL.D$$;7IF[5$!,W);4A"$05$`S&4Q#99TKFP*+L2#C]",IYG M"B`"B`2B@&@@AI+8UU4))^N3<(*H':P"B``B@2@@&HBA)/;U2PDGZTHX/)D& M$?7',X\`C02B`O$KM?N[06AD*(D-LXS3..`(T$HH!H((:2V-X[ M1!_E""`RD#,7@!0TTD`,);%AEG,N[#<=^0;B=\[33`%$`)&!G`SD"IIH((:2 MV"9+-Q=L=J2:#-8AI!I[L9>/)RIZ.&]^QO M!_N+GIMR]UH6Y7I=#Q;5A[OYZ^XL'NGQ5O+7U-V^8WR6/-@KEY:/CO]A+PN_ MSU_+O^:[U]6V'JS+%UMR?'-GI_+.7S?V/^RK]^9ZZ7.UM]>$FW^^V6OAI;VC M.;ZQXI>JVA]^<&]PO&C^]'\```#__P,`4$L#!!0`!@`(````(0"VIF!\&0(` M`(@$```9````>&PO=V]R:W-H965TV$]-_OV$[8IDQ5EHM@QZ^?]WR1 MXO$D>W3DV@@UE#B)8HSXP%0MAK;$W[]M[U88&4N'FO9JX"5^Y08_5N_?%9/2 M>]-Q;A$0!E/BSMHQ)\2PCDMJ(C7R`4X:I26UL-4M,:/FM/:79$_2.%X22<6` M`R'7MS!4TPC&-XH=)!]L@&C>4POQFTZ,YD*3[!:FNA[Q/R3UE%[;?7.&E8%H9U=@(<"0$>IWS`WD@0*J*6D`&KNQ( M\Z;$3TF^7F!2%;X^/P2?S!]K9#HU?=2B_BP&#L6&-KD&[)3:.^ES[7Z"R^3J M]M8WX$6CFC?TT-NO:OK$1=M9Z'8&";F\\OIUPPV#@@(F2C-'8JJ'`.`;2>$F M`PI"3_XYB=IV)5[$T2K+[I>K#X#9<6.WPC$Q8@=CE?P95,F9%2CIF0+/,R6! MY=N728C$)[:AEE:%5A."80$K,U(W>DD.E']G`BDX[9,3^RL0HX'J'ZM%NBS( M$4K&SIKUM2:=%01,9V=PN]W9B4N<>L\T3K(9Z0-;A^.5/T[2+(;/K/C+=/$_ MID[L3-&<[NIW+L$X2-XR#L,4:C[2EG^ANA6#03UO_*"XQNLP2G'D-E:-OL8[ M96$"_+*#-YY#`^((SANE[&7CAG7^#ZE^`0``__\#`%!+`P04``8`"````"$` M)GMTFXH"```O!@``&0```'AL+W=OOJB$O8*S4;4Z3**8$6J$+V58Y_?7SX>*:$NMX6_!&MY#3-[#T M=O'YTWRKS;.M`1Q!AM;FM':NFS%F10V*VTAWT.).J8WB#I>F8K8SP(O^D&I8 M&L>73''9TL`P,^=PZ+*4`NZUV"AH72`QT'"'^FTM.[MG4^(<.L7-\Z:[$%IU M2+&6C71O/2DE2LP>JU8;OF[0]VLRX6+/W2].Z)441EM=N@CI6!!ZZOF&W3!D M6LP+B0Y\VHF!,J=WR6PUI6PQ[_/S6\+6'GP36^OM%R.+;[(%3#:6R1=@K?6S MASX6/H2'V.+^9&;PGV"EYE.^X[+YDAX=Y0N'ZP^#^'J,J3 MW'F6G%Y1@N(M5N5ED:7IG+U@*L4.LSS%)&/$:H_P%4!Y@T9T=ZCQW\G>2_%@ M+\5GS&M;A@!R#]J.E*U.$9?OTD9*,$/G*_'@G"+Y<'&69F/+RX"9#&I7!X'1 MS9/QS;Y.&;;OQ[GPAQ`W4C`Y4A`P!PH.`B,%V*#G>_?@8^_3HYL#YKIOEWB\ MAS/LSX>])([?MX.D,*"AD168"E;0-)8(O?'#ER+E$!W>A;O49_DHOL3WHI\N M-FS@O':\@B=N*ME:TD")E'%TA9),F/BP<+KKQV>M'4YJ_UGCPPS8^L5?````__\#`%!+`P04``8`"````"$`5"[(WI\#``#B"P``&0`` M`'AL+W=OV<)W2C-2'P/[U\_%N95M%KA"?$(;7,.=G+(*";AD!X MHD'SG*0XINFQPK50(@R72(!_7I"&=VI5^A:Y"K&G8W.7TJH!B3TIB7AM16VK M2C=?#C5E:%]"WB_>#*6==GLQDJ](RBBGN9B`G*.,CG->.VL'E';;C$`&LNP6 MPWE@/WB;Q/-L9[=M"_2;X!/7OEN\H*=/C&1?28VAVM`GV8$]I4^2^B63$`0[ MH^C'M@/?F97A'!U+\8.>/F-R*`2T>PX9R<0VV6N,>0H5!9F)/Y=**2W!`/RW M*B)'`RJ"7@+;AP>33!2!/5U,YDMWZ@'=VF,N'HF4M*WTR`6M_BA2FU$O,CV+ MP.=9Q`.]-P;/SL'PV05[DYD_7Z[>8P',MGG`9Z?BOS4/1]6D+7&,!-IM&3U9 M,+>0-6^0_!5X&Q#N:JLJT5?[?\6&*DN1!ZD2V$O;@CIRF)#GW=3SMLXS=#4] M<\(QQV!$'4.V4,K&"E"-D$"B`0XDT&S1F+`SS\9CB3X^3VSV[+'>GW/-< MJ.-TW8U-(-&`@6T8?]/V#+#K-9=!INW%T%*H.`OUNUBNEG.CLI$B7"H;WXI( MM(A!#HMQ#K=++X/,')9&#HISL1@I0"4%&8VFQ0Q(-&!@&4X-O>S7RRW)IM65 M855Q-*LF$)M`H@$#;W*%,$['VR,A@TR/:\.CXJCJP3HA_X:,2#$N6<0FD&C` MP/1Z;/KV#,@@P[1O6`H5Y\H<*X+FV002#1AX]N!\T"M]?0I:MNG6.)##,^GB M)AHA\0A)=&3H4+Y[WCT+L!>-ZNJ9PW`FZ4Y5V`6)1QRY&ULG%==;YLP%'V?M/^`>"_8<;Z(DE3MJFZ5-FF: M]O'L@!.L`D:VT[3_?M>8`#%M0ON2A.3XG'.O+P=G>?V<9]X3DXJ+8N7C`/D> M*V*1\&*W\O_\OK^:^Y[2M$AH)@JV\E^8\J_7GS\M#T(^JI0Q[0%#H59^JG6Y M"$,5IRRG*A`E*^"7K9`YU7`I=Z$J):-)M2C/PA%"TS"GO/`MPT(.X1#;+8_9 MG8CW.2NT)9$LHQK\JY27ZLB6QT/H@O9P?5^>RI5!R^2IY\YP6#;L,^F1W8"/%HH`^)^0H6A[W5]]4. M_)1>PK9TG^E?XO"-\5VJ8;LG4)$I;)&\W#$50T>!)AA-#%,L,C``KU[.S6A` M1^AS]7[@B4Y7/ID&DQDB&.#>ABE]SPVE[\5[I47^SX)P365)1C4)O-Y@BMGZJ\.ZKI>BG%P8.9`4554C.!>`&\Q[JLBZ;2MPJ%"@W)C6%9^3/? M@QH4[,[3>A2-EN$3=#2N,;<6`Z\-!C>($-PTEL!&U]+K+3XJ&[!1-BTW5F[M M%UV9ULB)##F5,943F(OS-IHA11)HRK`.+F59M(+/Y;((:P(F!\:F! M\\(&[`J/&UXK;#'C2O@-31BVX;TU8%=SXFA:S%G-Z7LT#=C5G#J:%G-6$T:Q M6^>PS36+7.V9HVTQES?7!'_GOCJ_N0;L"L\=88NY+!R]1]B`7>'($;:8R\(8 M;IYNR:;G8QB/\Z57JTXM$-0.KQWL&A39R0Y(VYN3&PJ;B.DT?=BN5ZMEUTX&370`_/5@VE!\W./'>S$X<`N]'.1(#>>*FJS&>;4T0;' MZ2PXH3A0OI^.!+<*=?46]'KU]CAISULYDSOVA669\F*Q-T=%#):;;YMC[,VH M.H@V/\`ILJ0[]H/*'2^4E[$M+$7!#&90VG.HO="BK$YS&Z'A_%A]3.'_`H,S M$0H`O!5"'R_,2;?Y![+^#P``__\#`%!+`P04``8`"````"$`DMT?TYL"``"6 M!@``&0```'AL+W=OQR'`4A1KQCLA!=E>.?/QZN;C#2AG8%;63'<_S*-;Y=??RPW$OU MI&O.#0*&3N>X-J;/"-&LYBW5@>QY!Y%2JI8:6*J*Z%YQ6KBDMB%Q&%Z3EHH. M>X9,7<(ARU(P?B_9KN6=\22*-]2`?EV+7A_96G8)74O5TZZ_8K+M@6(K&F%> M'2E&+JTXJNFV@[IS([19G]*U@2FI9F@#HB!=Z7O."+`@PK9:%@`JL M[4CQ,L=W4;9),5DMG3^_!-_KDW>D:[G_I$3Q170Y_\Q%51OH=@H%V;JRXO6>:P:&`DT0.QE,-B``?E$K M[,D`0^B+>^Y%8>HF#P[),/SF!P%29S.;RZ00'PYSIU[:NAJJ>0>P8D#P;JG]OQ&&3"_;0>4 M8+%W%NQ2H%(-+7Q>Q8MH29[!=W;`K#UFCM%?S!BQ>0,Q&R`$=`WBP)Q3<;9G M,^C\^R)MTD1D/-"[.M8>,G>]L85M3C9&`L"1_Q=@DW(,E(,#43*?*/"8&^?A M8AS;O!T;Z4K&NMXWQ(*G>B;?7'M,XO0DR?5$T;^B(TUP#4Z]>E^3!4\TI>'X MJVN/\1XE:3J.PJRP#.=1K\G/`7_26ZXJON%-HQ&3.WO'8ZASV/7C9QUE<"S@ MLD[V-S"6W#X9`C`6>EKQKU15HM.HX250AL$<%"D_6/S"R-Z=PZTT,!#<:PWS MG\.!"P,`EU*:X\*.KN$?9?4'``#__P,`4$L#!!0`!@`(````(0!Z&PO=V]R:W-H965T&ULE%;;CILP$'VOU']` M?D_`Y,(F"EEM6&U;J96J7I\=,,%:P-1V-KM_W[$-%)RJ95](,(Z)",E['",\#Y-$ZY1FK3S'Z_NUA=H,\J4B=D9+7-$8O5*+;_=LWNPL7 MC[*@5'G`4,L8%4HU6]^7:4$K(N>\H34\R;FHB();YZ>*UHK2R)H213HEP5K9,=6I5/H*B(>S\TLY54#%$=6 M,O5B2)%7I=L/IYH+\\3<^,.UW M&8,=:-L]0?,8W>%M@I?(W^^,03\8O_##/]W(1],VCX++Z,Y.9?J M"[^\I^Q4*(BT`ANT&]OLY9[*%-(`L>;A2K.FO`0*N'H5T_4$-I+G&(6@CF6J MB-%B/5]%P0(#W#M2J1Z8ID1>>I:*5S\M"+=4EF31DL!O2X+#>7BSPJOU_UE\ MJ\AL]IXHLM\)?O&@U""F;(@N7+P%YK_O"+:BL7<:'*,(/(^1!%N?]L'.?P+C MTA9QL`BX]@@\1B0=0GL/&GHAX,UT(1JLA6BKM;*#71C VXUXA%CQ@)`1>F M"]%@R.9@O\N>U2JS"%/19B$9+(SB+E\35X--/?4^KYRX%@'7'K$>(Y(.X68" M2G*Z`1H\%A*-PQPLP@HY_JUHD@[A"EF_1H@&CX7<.$(L8F4D+/%F^2?_-C'V MNJ\#N2;6087U@ M]ZAV$%?*9BQ%=\,%-.)_]P[]DB/).:('"QE)@'3'NN6TQ M-D]1&$1K1V[2(Z[$Z!XW.5?8=D3H3_U)=8OBT&*TF'P_FT6S!>0JUPUX%CK" MDQY[)4NWP.FR;,,LR5'-T(I\NQ;7,DQSW@N&NM`R>= MTY?TF"LYL(NAG&E5#:.*6]:A>]):S.`3T*ZL30^(-D$0+<,_E6Z;CQU,[+>Z MHN)$$UJ6TDOY60\:&%[M5_O)J1UI^@&PO=V]R:W-H965T`"$A'PJIFE3=)FW2-.WCV0$3K`)&MM.T_W[W MXH3984UI'I)P.9QS[KWV-:O;YZKTGIA47-0)"4> MTK3.:"EJEI`7ILCM^N.'U5'(1U4PICU@J%5""JV;I>^KM&`552/1L!KNY$)6 M5,.EW/NJD8QF[4-5Z8^#(/8KRFMB&)9R"(?(Y$>*E9K0R)9237X5P5O MU)FM2H?0550^'IJ;5%0-4.QXR?5+2TJ\*EU^V=="TET)>3^'$YJ>N=N+'GW% M4RF4R/4(Z'QCM)_SPE_XP+1>91PRP+)[DN4)N0N7VS`B_GK5%N@W9T=E_?=4 M(8Z?),^^\II!M:%/V(&=$(\(_9)A"![V>T\_M!WX+KV,Y?10ZA_B^)GQ?:&A MW5/("!-;9B_W3*504:`9C:?(E(H2#,"W5W%<&E`1^MS^'GFFBX1$\6@Z"Z(0 MX-Z.*?W`D9)XZ4%I4?TQH/!$94C&)Y((W)_N0^CZP[XQTN9U3S5=KZ0X>K!8 M0$HU%)=>N`3"&(Q5%BO@*,?O44;P6PTQ&$O9"CC*L-B' MYXQ@-^=>0PS$-"2:S6>]=MB`:>0`'&-XUE@[^OIN0;!K;'*Y;PW$JH@5<(07 M[Q%&\%N],!A+V0HXRB$,\N$YMV@WZ5XW3ICS_IB&<-"Z:W1[%>+:P\$VN"6A M&8/V[IUS\/K0"@W(5KN#"XYW M7#FGSD2+,(#/96LN,+"9+(PQ:,YXP#NAX;!O M_Q;P%]=_`0``__\#`%!+`P04``8`"````"$`PB7A MTP4+``!600``&0```'AL+W=O)\08PA)E&34N/YK5UJM9G:?:>(DJ`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`23EA&HF:84E_DD))6;*ST5$S M&>ZNZ*BX'-_0(N9`D2'3V`.:DLT-=TC3]D0N@5^;.ER"H/9+8>9X.6%=3J-F M]'&9*@X$!Y(#Q8'FP'!@.7`9(!W[!;5#QT%]W_>&?LRQ7M9A< M7K++49'C8S@NXO'6,NXS=C&,5\*4=T M.D^CYBKZXMN&SJNH:#L7',B3-10?HCDP'%@.7`:(-W[#(]X<]R2HF2<3[DG4 M1$_&I4^%?+)$068)!S(O,;JYAA**C]`<&`XL!RX#Q!&_*1%'PFP9>?N..Q-& M<6?&;+9$371FXKNBAZO\\`WT+.+AUC;)@>)`&?-\_[D90 M,S=*[D;4M/U4'`@.)`>*`\V!X2`\6! MYL!P8#EP&2`=ASS7H>6=G%_E*SJIITF4-0U$`)%`5"+Y4DM_DH8Q!H@%XG)" MS0B1+I_QYZT#14R"9#LM)_14ITF4FQ*'M42`1@)10#00`\0"<3FA)H2 MA&"5>W'FAA'S&/%DQ-;Q:9&%MN0))P(T$H@"HH$8(!:(RPDQ8=@M1.[DIX)S M$F6K(A`!1`)10#00`\0"<3FAS1\*C:&9(H-P%"(V@D$`5$)])N M%FSR&1AB@;B<4$_\Q"9WQ?'(,`SR4Y\JDBCW(@YKB0"-!**`Z$0^7R%@B`7B M!$3(%T9^+.Y(8^)%1`!1`)10#00`\0"<3FAS7?+CL,8`H_O MDTG47O8*B``B@2@@&H@!8H&XG-#FNX7%\$NGTW?OD\%!JY$\?DZAUH`(B@$@@"H@&8H!8("XGU(20WCHL M!3'LG;@;>"*LAIP((!*(`J*!&"`6B,L);3ZDM[SY,V=`#'UD/2QAG^3)L!IR M(H!((`J(!F(2^73GM##$Y81ZPM/CB;WA0&J$)#WD&;$"(H!((`J(!F(2.;)" M\)-Q>1'B18A,9'X<]V(G9YEAPC]5)%&V,@`10"00!40#,4`L$)<3VCP/D2>: MCRGP^,I0\JA8`1%`)!`%1`,Q0"P0EQ/:?,AQ^),_;/LJ8*,EDF?!G\TG4-E@!$4`D$`5$`S%`+!"7 M$VI"MT19QK!X8IF`1)F&M78((!*(`J*!&"`6B,L);?[O1)R M0IL/Z>[\)#6*89`NC?RY6Q)]FJ3(\:*`.T@D0>N>!**`:"`&B`7B!I\L0\.)`BK_D_I M2&N.`"(3B35*V#L4C-!`#!`+Q.6$&M,M4HX.1,H1?PZ31&WC%1`!1`)10#00 M`\0"<3DAS8^[!<6=_-3OL),H:QZ(`"*!*"`:B`%B@;B*[ MYCB*VI8K(`*(!**`:"`&B`7B&$0:(!>(^KTJ-X4'R MS%OC4*#DCZO'/!Y60`00"40!T4`,$`O$)7)X`:.N=,N4XT.9$MR`3)F&Y=.% M:R1H%!`-Q`"Q0%Q.://=,N7XG$R91&VK%1`!1`)10#00`\0"<3FAS7?+E/XE M<=@BX*6J)(IOX`WQC:CJE$`D06N?!**`:"`&B`42WGL/+>U^5K0FOL8>WR1> MUNOGNJI?7S>]>?,]O*(>WA?]H!^OSW\9ACJ_UDR]Y>3'Q2\$A[\```#__P,`4$L#!!0`!@`(````(0!ND(1D$@0` M`%\.```9````>&PO=V]R:W-H965T5-S(7U=IE(]]U>)6*+*\.:_>?OY^_AJXC55)E22$JOG;?N72_ M;7[[LCJ+YD4>.5<.>*CDVCTJ52\]3Z9'7B9R)&I>P9.]:,I$P6US\&3=\"1K M!Y6%-_;]N5>62AV5SCP^QW^>-JLLAPBP+0[#=^OW2>VC%G@>IM5FZ!_4/HC0Q,,]@:CG]L*_-DX&=\GIT+])<[?>7XX*BCW#"+" MP);9>\QE"AD%-Z/Q##VEH@``^'7*'*<&9"1Y:Z_G/%/'M3N9CV:!/V$@=W9< MJN<<7;I.>I)*E/^1B'6NR,FX9GV7L#A;02/PFFS M$REF[@>M`"B04]W4S M"6L%%,>)BF9%_ M2P:#+9Q;;$/-V%3$0\6\QS=HH80Z+69]`E/Z-C4.`IV>P#`P$;:DF5XCBVQ# MK!D,)"B^CG0;!<5K%^+M:QE,+!32:"AD"-OIP0+?]\T!L?%\IC\W0&&YW0^* M8@LT#,WW;DDS;[FF`=-?W,Z.B`1])+%F,-#FCZ"AV$9;6&BD(32&*;%R%I%` M0],,!AJLS?NSAF(+;6&]>4N:_LT1&3I6+*\-&VM###;<8ZT>]/EJP$$V8[_: M:%F3YD;Z2-`'$6L&`W%A(MY>'2BVT:Q>L25-_^:(#!WK9/%1_K0Q!AR#UJ$G M\#9=J[;Q[,7;B32^@276+28/-NF'"\JHM=_N;YU(YZ)AO276-287-NC'N:BM M&\UN,;46*B-13Q%U%BKH>/Y1/?5!)B@VZ<=!J;6;H(-=6.O_U-T860ATBNUO ML'`[21N="8H]6P/]9.91ASR$(G@':FF:L(/P"N0PB/SO-T8BUY<^`1+PKII.*$ M9_4Q[-E7Z_4[XFF,QQ_+'N'W!=J]ZP,XWM?)@?^1-(>\DD[!]^#2'P50S88^ M$.A&B;H])^^$@H-]^_<('W(<#H[^",1[(=3E!E]P_33<_`(``/__`P!02P,$ M%``&``@````A`&)APY54!0``:1<``!@```!X;"]W;W)K?YX9?S&S^O91'+TW4=6Y+-<^&XU]3Y29W.;E?NW__=?3 MP]SWZB8MM^E1EF+M?XK:_[;Y^:?5NZQ>ZH,0C0<>RGKM'YKFM`R".CN((JU' M\B1*L.QD5:0-/%;[H#Y5(MWJ2<4QX./Q-"C2O/31P[*ZQX?<[?),/,KLM1!E M@TXJ<4P;X%\?\E-]]E9D][@KTNKE]?20R>($+I[S8]Y\:J>^5V3+'_M25NGS M$?;]P:(T._O6#QWW19Y5LI:[9@3N`B3:W?,B6`3@:;/:YK`#%7:O$KNU_YTM MDW#B!YN5#M`_N7BOK=]>?9#OOU3Y]K>\%!!MR)/*P+.4+PKZ8ZN&8'+0F?VD M,_!'Y6W%+GT]-G_*]U]%OC\TD.X)[$AM;+G]?!1U!A$%-R.N:63R"`3@TRMR M51H0D?1#?[_GV^:P]L/I:#(;APS@WK.HFZ=!VPAR0.L<%8I]T><1J^D\]0:YVHD;,4&PR26\P(]\0UC]M#X=(;)-ZLJ]XA*>#88)`6X9ST M&%U*@^1;78]H&MM38]*(&*POSCG52>/#V!EK0^D2(R+^1>%WU9L*=,P0TT_, ML?<3&R3B#$48*NSR"@ZIBAN,+0=GZ5;W5_O>PXA+3K'SS'/V]DNO4'RS;KZ'9%U8X,Y5\N""GS2`;1BZU#C@U114A2M3<8%(@'ZUZ"JMIK=F,W2.MY M5^NC=M\F=H@QL6/3!>&=&"=GP&3>RHA+[7\I/N\J?D34,S88\SJBRINXYKZ[ M`Q^D^!I-$DH5WV`LL;!'W-@,TG;UIQ6T_:92&8R].,[2(^[B@_2;=_4[HB\6 M@\&$$)U(>HPNI4'*S5&#[5M!MXS/.JW^\'8H73>ZE(B>W]9QWM7QJ#T7YF2= MA5IU&?`OK#7B+CY(K3FJ]>WZ0(Q=']:(L[AJ*=A7M=L[UVAR,FA]&`S6QY0* M2I_5)45T^`M2W=MVIT)"Q/21ZK&ZI`:I;WA%?K-&0L38BULC[N*#U#/LWI<[&F(PF`[R4DIZC"ZE09H*[4MZ7^Y6"&*P`].A M=-V(E+"SB;V[0E1[D8CCL?8R^:JZEAS^X%U&L:,:LV7,58N)C"?0:=7CP<4` MC_I]4^+VOO*';@+A^JJ]^F77]Y MRU+ME94BX?E&MPU+UU@>\3C)CQO]OW^?/R]T351A'H? M(YX5D&*?I$GU7B?5M2Q:?3OFO`SW*=SWF^V&T35W_:&3/DNBD@M^J`Q(9R)H M]YZ7YM*$3-MUG,`=R+)K)3ML]*_V*G!__,.2XZF"Z?;@CN2- MK>+W)R8BJ"BD,1Q/9HIX"@#P7\L2V1I0D?"M?KTD<77:Z+.YX?G6S`:YMF>B M>DYD2EV+SJ+BV1\4V4TJ3.(T2>"U26+#VP<'SYK!\'H=;!NNX_F+!Q!,O)VZ M.D]A%6[7);]HT'(`+(I0-K"]@LRR+#,H;G]9H!YRS%4MPIX-@%`R;*NH&58)!P,AA4X5X4;GSDI)E!D7G8HF>.T M6LV?"AZ,:Q0\6!WMVHWC23'!^^@)G#24()Z_M"S?=8@D4"2+I>NT)0K]YD3Y"#5`"/ M`J!D47<6[?7^F(*U5+'&.TF*"704W34G0* MY>8*3=")JE#$W.]`=5W=[4PA:EH+S6Y=4;^#VV^/B].U9J.F?[$-!%6T M2<8M'Z7NK;=&@^XX=RR7-%DP(E#1)MFVW>/;G2EKNW(OVK!`19MDVG;7M3U2 ME%VC&:D:)ND3J&C$UN\T>H^?=U8?:M`4YN0Y(K`'HBK4)%.WNZY.FVC7:-JK M[VKE\GR@/%<2]WYL]3ER%'%QNOH:3?_J&PBJ:),NK#'NZ@`\/_CX=@NO8:#8(Y_H+V$8DO/VJM@DWR<:?KXYV5UVB&P3#' M-3X(1CQ^?-W!&;C3773=-1KL+M?VR5.H/$=_['M*'"N&AV0\!F:L/+*`I:G0 M(GZ6!V`''HAN5_%POK-7.T<>D\CU0![:Y77S%H`SV8^P/":YT%)V@)26 MXP6FY?GN"7T<8',,L`\0'SJOK!_D%M]];MO\#``#_ M_P,`4$L#!!0`!@`(````(0#\B"6K_4,``.3E```4````>&PO6Y^\W8M^A0J&.EB-(BM2'94V[-0&1E,T9BN00D#W> MB;TH`D42;1#`H`!1[*MYA[F:B-T(/<$^A!YEGF1__W,RJ[(*`$FYVU;OQD2[ M;0*HRLH\W^=_3F9]^_;DUF19C?CF?S*[R.1]G%X_+Z:S(!^5E4OOBV'K[Z=O]J;]!=7Q7B>=<:#;'\\'\YO MLH.QC\^TOWT\?_7M8UWJES_-WD[&\\N22P?%H/WK<7^^E3W=V;.\\:_^X M5_2WLIUG:WZ,TTB>G?W+X7!<9`?SXJK\GTNCQ1MZ-].B_>/.]N8_M;_KL,J! MK?3-*+]H_UJ1X:28#2>BQ"#;R^=+(U?7O1F6_7R4_53DL^P-SM\=%![_CTX.B[ MK/M3M[?_MLMON]GC-X>/UXR^"]]G+.(`7G[(_K&X:5^WNYC-)!OI8M=1)LSX MS7!4S+)=2'R[F4^*\KL>#$W/6/$]FV[QT=[^T?=_;V, MO[K'AP=[G1X?7G<..T>[^UGW^_W]7C=[]*Z[ESW\JGWSP3CK74X6)2I<;J!C MHZ(LL\G\LIA=#\LB*Z=%?W@^7-:3?UB,UNM))'I>EL5\2:QV\_)R>1KOX=)D M-BR8Q;B8MW\_F173?#C(B@]8CU(7#:!_.9SS%U/W&6?]P.S5S^U-YOGHSFLF M(S%-8Q;_NAA.I6XK9^2CK7Y27/]HF)\-1\,YJVHOZ&@RAZO3_"8_&Q79)N(T M0N`&?#.;+XE2^V+C3WO$3M^L93VHUI#W^[,%PT:ZM6_:793SR17B',G9OJ!) MM%L6Y!?>V/;_^U=EEB_FETC0GXO!'[(7+_GUQ<:S)T^-E2^^V7CY[(E]M/O+ M;%B6HHO)3JU:68[PGVF+:X6CCKUY`DO<08CU>\PF%>H@@\/1M-RB7I]]P3\MY@L01,13S(?[RJ_M9TN)#OYC.W7IG@WR>?XYQ M#5J`:LH#U%KP"$$:3$:C?(:61UU8,NG-NX.\U\K1)O/*RUT][G7II%:?]O4U MOW_A4I8&N',UZ^Y8O:!U5W_.FD:$I4,XC+YG4U,$(N2E.&>-J'5[^.JW^TW*S@Z/.ZN]>)IU/JTS873`M^Z6'9! M)[/)8-&?9V6.TU_IXTXG-_EHE?=RHS%;,_`QL@D]<*/]23G',,N9!L?=GMPN M5\CDVB3:/W:+D;SQ1G91C!ER9"/E@ZOAV$)*&=_V+:=%23S;O[1+!TQP-#$? MWK[.5T`N%_B+>?Q]);'#C&X;YZB8KS3WJ#"2 M%QT"X=/*J^+=63Z?SX9GB[F%'O.)_(D"SM3FMU?P8S&\N%1\DI,,YA=%-E[( MPHMSZ=UXS]H:$-66P[ZP8CA;J&'ZM.TS"A!,%M\3B MNQXFK+\EB1?V/(2ZU[4NGLPJD9-#`H>U-[_.1SEF#%G);@WUPW4;51!VQ_6[ MDW&`$R0[M?WMRM=E"&.#+G/&*C-GF1UJ>E<2OA7K.[6Z^\GEYWN M]]F;P^,?UYOSRBSEBC!7)A"=P9^(W96>E"+;K.A/QGTR5V5/KD1\J[_[I%O9 MHD1W(69M\-:/O%<@)/VA>S1+(JZ4Z?[9OFA3TOBVB9XS/AJK[,QO#`:_??WN M93Z^(&ALSL7R1+,3MR0058*C.3]T.`K.SL)CN_ MQS.UF.&X#^!&>O]H4/A?7XDA6N,2O_AN(SL#Q!F/M1B4%N$$7UI](0#5^DN. M3[_K'!W\#XMP+,!Y_:Y[<+3?[;;'.IY=Y.,@<,:EUXL2'$WFJG,F,*D_7\HM M=K8^?;SK?]D]9S`3K)A.8LMGR/?ZYX1_E7]69@HDNOW@\:MO^Y/19);ANJ_` M0'?TS>P-(*-?TAM>(?!'Q75V.KG*Q_KU/+\:DDWZ"/KBL0UJD.G?E=.\SS`H M85G,WA]B&=W33E&%FX MN-D"5BLB-(AJ7V?G@EA9#;,)5##CP*`^OCYIC/T/D(4P-F`CB=T?!B M[()3+M#$LC\;3N<2H5]'(E]]^C]?5O9)``J9%)"L`MS591K*S_)IL9"@34%/ M!/:7BC;ARF(*A;U8H-QYCD#P[34X2&',#_9+<6DZY".$_,?7)QT)^1(?*Y[` M_'M/)Z"1Z#GV=K082)*1B7JL3N_I-]O;)E>=WK,7_'DU&12CLK8V5=D"*9B_ MBE:P_OV+6*-4L-&._Q+F^QORSY">_X^%>?XJ%2&/WU#1`"=X,%3'=\I,A5#( M"*SV+R#"@VLP.M.D>_L8$?'/\\6TWG_ M!N(0E!*_P@3NC;BX;M_*3A:S'(@K MP92I.BJ%-?0]_\!J;-%'>9 M[%@\$/BNR,B^U`J*#T!2>PL+%T4"HC1B=)YN`J\Y M/!==^>\+E\(0^;%JI[HJ;8:BN=1"D?&"N$F$]`CH?#@#V:JG%/UQ]DA1CYY9 M_];I$4#F!&;H4&-%#5><+`J<.[AWK_,MIAZTBBR)7+,"!.X*65UZ8(86W(UJ=@0*DC=8'I. M)X/;$S++<737-;E[K#F240%C0D"FU^(E&E'39QT9*BJ42MG$F&B6DIN3<*)- M=0471#42ZLL#6!5W=B=;V>%\L)4I/HJ76(SD#DK7 MY\/^Y4(P+7]=0^)'95&0L\",G>VOEH0QH8[%X1(%CZ<;:4G(9:4++ASLXW M]D'F6,^?7\X@)(D41M&3;NR_FE8J0]PH4-*Q\K19EW2=D0C*;9#@L5CF+T`( MG/9\-+D.T,,J6&BKD<'DHW)BV8]4*`$A0]%2QO3ADV=;SU`1,'NQP1QV]!AQ MHO6,IL@'?A3^3A?@]83NV>2,Y,94$0;-EQ=ISASL;7+Y]JT"4I!H=@^O#M M)I,ZTB.!ZYDC0UYK<<>`B:GC@J8L6#`Q&OZLQXS!@,PFC4D9LKPN'@^*,YH/ MU(=`2U,-[L@$H17D0L`R?>21BN!93/>C\$0#A/6J!%]6LT[<*UAJ*WN;CP'U MK;4(\X>,F;*XN.26:XSA&:X7A]E:%<#" M8BZQQT&O\N)FO*(JX^++!=E;69XO1HI,S"_/8.P,4R4+T]#=S]!8ZJL"XAC3 M4K:P^`1JE0V]4M)O<0;88UGF!'HEW5V=X_?'?74!G5".\_NP?X20M;Q9@])[PE(3E^F M>CTV]N0^V-@OG8REIKL5HH3NAW4FR,6OA$V(T9_#V\A4&5<)"%&@62E]COHB M"R$]$6`PNMF<7"OR;&)D=\!Q,D`!B(O(W/4E+M+,)Y%IP`62^,6MHD6"W+N+ M,@[H%XB@GGT>6GQ8H7H;S._6(?%H9"NR8S/96&GU;#.XLWKM6BQV!,S>8OR2 M*48'2\2#]^1^JQM`Y8`8-OC;Q"?>R883SA`(Z\$Q,/K5Y4"-IBM04TF'APD> MWC&UE4$%YH/E83>O9&8M;@_"(?4B/03&)VTK8Q4:B\WO='T=QBGJ_RGXL,O,^)9J&`DI>KJ8+2 MDLK:0N5L7&*4V+3B88T5`?D2>XFD;+4(2#Z#LZR(^V8+9$#,QEU[H\X\_\!$ M%!G$!X>D)S\_%]*J51%B4?AA79XPV<*\XOIRB@UPWZ^W.46N"V':0#>H4R&\RWL*D"0ZC*PK#03#$ M:"*&XRGNZ#VHN"I+A$FXK/6T7LF:>S``+263@C=(Q6*$U<$FC>#2$";,*NU% MX*)[0<,JAM5FMJF&NXKOM'C[8Q^9H\X`'_X6]#%:6=D3D'_`>;IILTO\*8OT M3AH*ODC=)O;J"FZ\9[D>^\+>9'$V5^33"2:AON^+(,)5GY")G2,TM9&"QY@$/D]F M`QD35WO+ZJ)IB?J?^J)F_J%L'8%A+`+22`TC1HT4BD7+#R=F///T'>TF=@/1 M48"GJ%F&#@9"29J93ZLZLD_X&HDB%&9JYSA;_L!`84Q9RJ`@5,9QFCP1W_E( M0S7R:@J2Z/B=$B%&P98'W^J87(A1*QSJC/3%`N.*2@4@0TCZ;%"WQS(2,ESY M``G.P>>"W:PI$J@;ZK"-46SF4BM*&)1)K$2F4N'5F?R\VIZ21'*#0(;?<'2;9S>;\6\FFX]N2I#*%8-5JE$+1]:8(M0CU/J3$$?B M$/F:LG3M7S%:0/,JVF'KS?O4RM"TBU10L8(LYHM')LE,3*"B+JAQXQK#SV+5 M.2?+%6J/SBT)@<%MF\/Q1OB+?(/R*YW/`,HF?;"YP+8M+'1#'$9@7W-^&N-G MY$D8%/`K'\Y$6(&2%556)MT:LV&Q%!$Q*]6OS8I3@D;M++8:LH6'C2-!&*6&[B:2I[]665?J(A-,@B45QN@4X&O2+UF4YQZ MDWJK@)RLM1G6LO=%#'$/8-+U1G2'4K5DF4")%7@N5D9[C]@&DN#-/95%D(P) M6U"*NVGUJBA=`E)E!()TY2/."(E9IJ2[DM^#'<;^TD.319Q5DBJG1?!LA3#M$(5NWXE7&M/A'V6!V MX,$[*4N\JQH\3")Y+I[!HS$(YS%_BRS!TCL'9-,2<^4^B"'D)T'=V.NA'$8T M\IC9=/FLF%\+X=;7YQ@ZM4M0KI/PZZLV']('UI+9%.&>I4N27OY!;\:$"\C` MHMC$F('QB:V]))&NQ_E2=J"2<+1=4"4-+U9%C8E?O9*0,&TZ6JF5I&$8P9-3 M4V4;V_DF.E;NOG9,0K;#LRR:^`/$7F!Q_;%V4^CU#@]T"Z58S'-.Z$H9PK)= MFV1-PR8OP$4$L!E+ZFO^!N@<(E0S&CY')W8(M82)LQ_.Y##FSC?!C5G.0VO`I"*N_LATV&_GD*'ADB(QUEDDM5NI=)/!`\J$PZ6#6,!Q%65W$XIN[I-T]8)E1V MR<',D79?N+N@Z+2C&6F[-`*H;=O*A3&^$W(%VAQ#:@$'!*:HPX\EZ_8_D;*7 M-%@8RA6MN.(5^@+E1]+%B:LR%/@5`#2(?F`HL.91#@`R.75=AWX- M6:13'&6U=TC&,V3;P5_9HN/?=J]/%MH5'U0T8Z4!\Y-UYD$R(DO=&979#O%+ M#*LQQR!>,LM0')\==I=F^058EB7!M90U!;(SP!K,R:C0*NVG2@+Q+R*.O5HM MHX(A/8:*:#N89"V9L60!?M.\@2)QG5R5E4BAECL87G#EK*_"5HW)A<:320L@2#2607CUJ^%(]!;1K?KC:NK=@`58ON%[?!B8>4#)8Z02',."H[G8_6\"`7E:62OWW[:).!I+]"XN2Q&A'`AA`!&2[Q1K5:.IK2]$9PQ0\&5S#2&Z)G MBL^XMX,QF-RB%05\$<&R&3J@4AL304P+0T;4OP/I9(M<+FP[1DRLXDZ:NKQM M'(,\L%@Z.:S/;6*K<3ZDL8D8$TU-S(+$\#YG='B8",5C)%5ELSY]!HGS8G_5 MF6]XW;13J)),E@;/2'G')GB\X"PZ[>IHLW)FJ%K8C(AB5.6.>,R+;&ZT6I6@ M)>7&!*U2%MO/%Z5"F%!VLKJH1XE0F+R*6%BAM5UPAE>N.DL"F:N,1YUB25!8 MB=S\56YG` M4X0Q?H'W2OX78RH,[.`S$=:DTD9!"ZX:\&0RMV`=8DCY_]89ZA+9^[=I6 M5;)<@QLA]Y=//WM0Y1ST1%-1*!YG*.LGBJ5.F^]L&55'E>V+T%6C"=%/=;,Z M93XL$'K:5'<62F1D1P&. MD%BLC`!7"3=J(#$G(L1`(O/F\<*Q/@2=Z(4B&F2.=<20.O5.0J)L5CQ`^REH M0;OWI"(+/R>.6^?;)`:USSQPXC\Z9':Q25P.[4OLKVW.+(C%(]&-?='JWP?8 M=)Y(4(.T2S#161 M[5;0)XD7&W`SE@)86(&,"S`XJ^RJQR&Q=F9=M[H?4(8N.+5KB'WA%BN;2;N: M1`ZQOO541DZ@+J%!6YD"/>\SJ\UYE[&Y@Q$-QP%ZL"SR9C>U'X;]8EL&?Z*NWT_?FO'9>I17T(3 M#\;THM\8FNQ!R)M.]S4Z&`YKBR&5J*1"*QN9M.'7VKZ\(=9+21(7*YNJ1$=4 M8L5"N2?I*M2V$S54)?>K4R#BQ$=`@ MK.O/]4JQ25P5]K>9QH2:D!.$U5A$Y.&+2&2TP[K#5\^0YNB]+E7250_O.S/W4#@[O&CGN9WD^K6/ MHAV.B,+PJKJ1M0<:4B:S'#2Z^/U\IH=K&6P0E5PQ"14HN("2#"&P+UR.144D M?G7_/^>VT)TC&39"U0VW49*UT=0ZL34PLE<+2)5IKK`F\U<_^X^;KCI_N^O:$L^#L^)2EZPR%>LTN*MI^$;K8!G[+II!G]V'Q/9^_ MN@/_T\>L/<]$+F(R%DV3^MTPSJC\Y*9@2S38'*95V@P\2M4/OB8&E\\DVJRV M;:!D_T`$"849S..S-&=,P2J'JC;->R09(#=*+FT45^/E'U/93A$HOPNGCTV* ML/LO0[+JQ@H`-966(@X6V[&L"]JZ)Y51])DQ$X\7!S MX8W*D3(*7M02)E(NIO*`MDW1&LD-BC4(IKVN?CB33WKM0E@]1XBB=F[JEG1P MR"1WCA-,)5+VRV!<(2[5L5[AV!KI%C9.9R'@L^*%4I\0A!0?M"&=5,8KND$U MHG3!FUC7Y>[@^)EY;7ZT#/G#"KE->?=Z$O1T+Z@W<]4FP+4+B;OSKQ88"^(( M@YIYL@`7Q2F-N8YQQ\U.,U/C@(U5$.!MA!>[PY(35-LBC/;3N*SYP)V=[=_% MFQ/[8?$)^Z)_YS"\I_%;06"T\#GMTVGWWE0)<&`(:#T_<>G'(4O*=7XN*6,NG^5!,2=>;^B6. M->0EUQT!^$8V[LPQXAFQJK.+Z=$R`_K,/!$F^M/'^UE02PLJ6WFK+%6/C58W M$MZ.(L&&(D9FZX1:V],#%*?EN(XPQ!,+6W0,B7.TWE<9I7T5;]W[YTF&GG@E2#4PF6)D)* MROY3#M%M#_B#:H3M+SU4P=#7A_!N-#=OK+LC2&7[Y\WV%^/'>?NK^-#H?I=. MAHP7(!#G0"SR)CHOQQS+NL$:*V@KQ+J;%'''LY$4"&\LI9/K[S3AD/.\QTV> M'SSEI0(OGG/!1W=$@I.E@Q_BK.WN-1"E#:O#6[ MB8&)3WGAYZ/$E?SUGK3"QEF$U)Z0.2/-!@.%/5^,E3.%UCW'>&/1$^>6B&W3 M#B\9U-/CGSJ'O15`3;V7?=?VNT?'O?UN=M+YJ?/Z<'_I1VLK.0FO1EIG!:UV M]G70U"]5KO*I)T\_^S5+;[V"K,RM66[$IFQGN^3T=`R\R3DQGEC]"U/Q M."9.X92P9G:N&I4U\5B-+K=#I(YT")CTG2TJ?O)#)W;)NZ]Z0Y5HGGV7D[/8 M#N=XB$1O!G0$C,>6!6%(%K%K#X)E='L4>$_H#!FQ4<8&B*?L^.8?->(!5["9 MQIM,>,,/)714.D%Z4GBKGT!X=A!,,BG'"K6"[\O%\CPWLL,3M<-J['R[Q*E6`/,&A,!CO)Z/WBA[Z+F*V@SA"I2VQTP.4-6O`/&9`\LDZ<`=T MJCZGT]/^A[Q_,IXO!ZHIUCOCU&(90+&4+N`2I;^$:Z:>3.2\<=8'YHQOO5PG M7^VM9T:C61$^G"MBX&0>/!#AD?Y;1^RMU?`+N\`:Z=;S"N=I7_LV-JOMD?2) M#CXUJT"2N7CS6^RL`WRK3N"I,[M;9L+*=G9^I]6Q&M[4(E$2>@Y/J!!9%7;G MZ^3W<&2MR573,H!HA*XZ352)F]=0)9IJ6!'9Z:_(\1*.XU<3M1Z^]<029!G. M0[)`Z4P?[44-`4:^E6*^H.I9"5&L4J>1_,5ZA@Q3D!;G5#`A0$?`BJNA]BK/ MH)!M`U.SF5:R,O:/JH:L4XB:Y=?2LT1>N8]S`E4:447]B%75`8I.E4/UN M&'#E&!B,N(2Q.?M@!%:I_L/G3EBK=%G-JV&R?G-+[J)G$T$,E`Z.T`RQ5@>[ MJDCLT!<3L_=-FGBX<-RFXTB]G_^F-Q30X"3Z)0LU5IL6ZX?53Q4I)5LMU8^J M@!71O56;;"PEI-7UVF"UI:QI"&J+%>RMP=(H%@^+;32HEZVDXC";OF(=3!.Y M_0FW:>NWL45I23N>M$>M-4E!VF_^X@Z+;'AK)!&-0.%;U((LO*D4T3'>IA,F MA96#EV2N#AC\Y1W_H3.^/5!`*,6"NN9110VT/]N!Q'VV-%-)//8B/"AB#B#U M_1;ARC"?;%1^K7JX"6@M%JL=62+D>GSSYK]4=%V[6F.&@I1))D@Y=N8WD,*G M?WM2^*8XXPQ`7,83M]#`"N)`U-Z&A5XKBG4\%HVR":"+ALM%,JC5T7^QQ%42 M)@S$I>Z^(I;,(6S"-2`E&>2O(VJMF<7BYV\K:\_^]F2M#@>>//-7I7^6L,5D M`?(^2WB6)@MWVL14)&7\?O_+3=\]G;:$KC7COYJ4I62X6\J:$;LTU(+>$.DN M^TXV`37Z[KQIKLDR@=_A=&Y"G3K&Y=AIG,2@T%N(SOBE';0K[6CY-9CO8BI%L'0\U?O;@/&'^?Y_82@VRG*MCQ M[^Q-M?YW7/8)S;Q^-DS7VX*^][=I*W7I@I>2V;UN7\0+Y/V7Y=BQY\^!^BG(@)NQ:@0M@^C9Q&6!EYT2=@#@Q5TGX ML6;:TITQ#3QDHQQ^8$TM!`^I9=?L1:4<3!(6$M9+%D5IJ M/K8_!SKPP/1Y0*GQ:2$&75KT,D=8]"T+ILD)9=*>>CUN>RM]((T1K/[I-@U" M-\`:5M:(!UA"1VZ2'6/\T@E^*^6V4M+]!I1K+L7X4-$NV]=!F,;$1,Q7D@Z0 MS,[!T(Y1S`9]=L]#BXKN3&3'(I.&W!KU@OG1Q3H64X/I&!BH&?`"J/YLZTG" M9EV:CN.^(KG5A$/"IJLDL31@0RF M'5]_%F7:3O)XG'4P,Z-/'[^Q&._IQJ>/"6G;H+W+*XU7?2R/T-YPIDT5YIM' MTRNE_((*SK>PS_P./56J6#(2IT;'(/$@?F/7I8U=-59=7>./11E!H.*#E!'* M7KX7O$D3A6^Z4B9=(])H.1V#VT\3W3M,BBS,@$<76STEN3NX"D5NS2[8T`!KGB06 M.*K>MOK5)QAEFM@JE8EHD7A<<0_?*U+S9O5`-ZI0MWE MT\++FHL_2\*HY M(7%3$OS*:*RU,,D6Z/OT^FF9L6O1)HJR:4L;OK"2MG74K"9Y]X.>6HLRCC:$ MS"V/Z9(7PXS/&/>9>57E_DLL8)O.P6[6.=K+]@X.W_7V][+#XVXW.]D_]1?0 MMVTHVW7T%E+HL3<<<>K=(+--N2<8`!.)6Y*.;^Z3=/RR^<0W5)DABM&-N*.8 MG,^1-*RDO;HA4JZ:@\QG.D)CUA=$]DPXG`_`#)6;#$1\@9WUR9+I M`-IH@9VVGKI[3F;=0&;!L2(LTHIQRG:IN\U)G(R"1I%@S0AG2O:%@7']3M/D[N]2(3 MYB;?$::]1FZJ8I$+SLNVX$2YJN4&HMM+M'`QZFJ_12(ZF+W%C.MUGE.$C=&^ M(^&+K7U9I$_5ZY>SY=ES5U)J4+5`!$&XVMUBMLQ?((S+CUP6R:^MZT,/YO6= MU@7R:\@D5#,KXH=:+Q/NZR9U!-'+\MG./D+:;1=7*]MCKAAFN?E, M]J^6U=NNLIS'R(ZYB%L20OE5IVW38^:F$,PS:49[S]K MK==-LJ%)Z^):4# M5\_(E6;_&UXW]L9`Z#2?5XW`Z+Z^YZ5)4F-`LCH?X%?O$JBQ?WCXEAZ9+]T1 M(O+O_I6Z03Z#=75WQMV,$ZMO[Q'R![?&_&UY6;G*)_^/]%7+]M.\7L M)6*':[+STLC)%,D!EZS)%=H>>SDX>[+V?>KKH@GS[Q).UY.H"O;V\WM/;*GC M87EF2=CH91A!_1*JSTE=VEO#.LW,[?E3?Q^Z!:?/7CHM-)5P1GA%7^\[5MR> M8&WKPB(BW:7U`8_='2BU9ML6`6UN:7^G6#,T'#;#SG@>4,GI"BII9J<+7F)H MS#O-)]F[*=L'%K.A):K6.)P>O6IH6H`CJV.&#$E[#!/JH?D`5WB_8?K=N9^[ MNF]IUX=PSL,COXZ\KIN?%UVB9FK6ME$R'_DE7]E>#$-$PJVA``3*SUOO^[QI MFE-\B&\W.!:)EZ*`-(7S\]G7L3AG4_UB5LPVLM[P@OG\#1Y3T MX/#O_V3E_)X?\UPE3N&H*T%"*Y[C6=G3V$$7L&\O:S+I<@$Y>(TBR]`:'#CQ MTZU0<+W:7)3BO#B.N%_Q!"5?(BWF5>BOKDW?_L*+8M@#XQTWWL?./ETNJTLT M=S[00G:3%^&`0>H]#S2\>6"X7Q>K6O#2JW`D'T?%O&SDL@DO#^VTS8."_\"AZU2FI5.@T8EC#36/WRQ\0V]%^8'7OZ%&(4J MJ+XQF>*O3ZH^`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`;+WPBO1-<,+?H)C?=F%"HW7^N)AU0( MR9G.*V=:KLWI78D?1JP@.^$]VU\'=(QB=ZA_*J<+)Z&8MH<5B1D#%K:DBK?( M<"6J+I;*:(+`\A2)8)+0>.@Z#R_23K<#)Q=50C2*(LT45[Q63^R/FRXM`H0D M6@S^?6H57+7OO@@-<]4LS:+K-<*V[C`3E%@?X3*#,A6L/R*A,V(2*4T)O((M MKEKQX=9J7CWTX4[8U!IT-E+`IAV[/[0##_J'2VJQ$@VK`>SB9)4F,'[\"*8_ MW!LFKJ+]U9`SD@X_)]!G!O7KTV[#LSS.-%W+?>.>:E]I;TU?Q3$2V;2EF7'A1A[]+NXN-CRCU99+Y);] M&Z`RE]D_TD1`NOV6\."&K79*O`=8./XT+L3GN"&KGK95>XY<+;=^5B"*H4S$ M9/S$S2[6'NQ';Y63E%\4''V=3WD;`KD$<:G2;*T_3GJ)Q#U^K*@I.=,&"K?( MB7`V&F];4?^3K:_CT0X2V]IKN:#(EC*)RJ8'66I)W"IAD_P&CK2]72Q$WVN^ MM/[O5#,T'?QFZYOJB\:4P^,JLG%2!6\1,S[Y+G&)K@*\>/"YO3"BGGP+*9./ M)DK$QPRO.+:@:EWVV*UT^^^9OYD#E.]%7'+(#J_T,AJV#L`3?#!'=-!/9 M)R]@J::0-6D%,4,N40D&B-T]6*0D5EI_J$/=4AUI&K>BA:[PF/MHZ;58K\E7 MP8I?1@HL*4;'PJB[B4K@$3UQH%CS1857>G61IF,QTZ;9/H4[)EG^,:ZEDH_/ MT0J;!:9Q#"E20Y\P;E>DJ#+ZZ!S6452$@0;5O$SRH?&D"A& M;VEMF,'E\QN:)R?H(&+U^@6`YY@8"(@2^UR=H2"'U2#]LJ/FEY)5AIB6LW') MYOR5MK0V>GIIRZ\&M3.0-:KVS5U-X3VO)]&[\0A%-#*0/?@KF789)#-?H?$ECC-]F0R!S6M_3M M[-P'#[GSD3TX$P(HBVM&3&%S9%/P%Z4$WPF'%KP]71"Y"9I2[:D`'8R71RYZ M.\]926CL$4\Y.9\+,-CPSCG5`O2N$1WM:SB0-F^HX=.O-F1<;:,'?FN'8B2-!OWZ/1CMW_2$E=MCWY4%JO7IXR'OVFS?]*9!8U[L+7J7 MZTD8<*&*2K8V$DSUC\_*]NA/.4K_W[/G?MYY^\W6C_16JCK0Z?2>1I2VTWOV M`O`%TXC8('YU5JQX+$J]'6?1E/S(%=M8!,Z6[!TBYD;V_B]OY]+;5A'%\:]R M%RRZ<$K:(L$*R7D52\2VX@14$`LG<=M`:*+8H2#QX?G]SYD97\_I?SYGEHQ\$_2RMOA"YW.7=W6_2;@K3L3GT5=(ZE'@"[*G8,8)"'V*RN_5+F5VCL>G8P.A^/S9GAX.+D8GX_&;YOIY/O1(;E:FQ=3!"'IA8L,SH?' MA?79A"M3[VY\#]CWOU?S"H.">@AFEIU(2"A5L.TD:BZ+N"*#1R,K4D)94905 MZA,)^@S:Q&SICM&IG"-G,\"9\],>\6!S$Y5.[[@TBN4`*K._EE`S&S'XQ[H! M,;HN.RF-KL516\FJ'>;<">P]MLQ/\^M@>^2+_W\#3<7!^/[.G\O6(2'_,!!" MG0\R#YHQ?$_H2;J"M'=MUJ!1:\L\"&A90M4OO8.UR?;;K_3>4ZJ%4P M&O%U@0`/J2EK;\S^.(:$`=>B09O`1+8&20W22;B*^.CN\7*E5S4,]Y6W5V"> M`7[^H4W+-)^1S+R1R'Z@N4[V\P;GTI,;2P!7@'LFMGA9Y!\7>U,3+77OYWK/ MX03S_B//!VS#]'TSE!79@2AB)BVYZGB:VCMH$@`&8Q'L1&/Y4&I3H&Y'$),H M,;_Z2&Q>C`X#\,,0WL\I?^PH1DL(+[FP@T]"835G0>=_VN."ULGSW@2_(%*X MJ">J#QL';#XH;HJ*7^@6U?!RL?J\P']!M"25)XZ"';T"GR,P;"]&JH:.!VR[ M;6T%)O">:J+B6\3DQLUR4.%T-([J*_K<_`=7=.U[=TW"FG,,^U'?2Q2N[X4" M]%[M+0!_\/-0?!A#29AS0\I.MS"*.+PJ,82QKW(A>^3/A]4<&H.IF=VCN^/= MA4G"!&!ZGNBESGU^>X.2SO?A*CL?7`?+UHH]:(J6,G2]>--5(7ZCE\7Y('1O MH[;@B=:*^%X"SUR^#6>SQG3/B'.T$).HK/Z-Z7'\DA>N5E:8T5)[Y( M/+P6.Y+OB-02X:$`U.A=R&1J9/[--Z_9)J?LD,/+H3C>!R=LD-]7&H7?KSB4 MWW5\F'0`'Z2#/['U@8XD>4O&QUA/:((>A;K_BC?,$K\21V(2XEB(I!F8,9U" M>W-1H`EF/`CU*H:WA`T;-WXO4HB'@$BK14#I-SZBY%LDR`U>7XFC8M6"'H&2 M>.X;95DH!))X.&>>;ET+S]'#\)J+6=&=#1[BR5"@RC.D-_-MURK:]J;.UC]Z M3!V//9_((G,ZJF/E[4ZV5V\ONO24=<[;ZO0K!73SIA9("L\A)Q"W9.RO>7&N9U0R03.JD%T_>C[W1';09WHT4SYBK;;<3L// M%)$:KD3G`H=CL(^^U.J?3.X-U`=LD-A.PACRVY&`/KY]" M$)R;Q>SH^:+@EL> MJ]@)4D"C8HOV?.?W-QBK\_T\A37?=6Z$WY=-4&^^R2?<@/(P8G47=0#>UC-` MYX;#I=TQG.Y!JH8:;#'Y&F/G9**PT/E:JQ@TB_ZMMQVW751GV=*E[2X:5W]L M2;A@M*A'4M;5B4N73\)FI9;^Q85-".OPP'OWT5Y4+!'4A)I`)DE:.;NI\B@] MX:R?-.ISSV#+0`\2_L(@UM"U4^BD[H.=O+HZ[<6C#I&N!]T':%:;^ MH:](4_D&GC%$:V,[]]Z*MK:C[[L_0*&>U'8_OU+)IQZV:0^U@T;S#$6O"\)2 M;3]4LH,/IIL5;]MN-_6<@5XY;P"3IYA2H_WYN@+O:CDL`,J05`%6.`@!ADZ# M)4#2".RJG:X%>B"WT.P3"OEU,ITG57C,5^-[@*`CC[;YEZ:]UX.X5V^7[36` M(06KUF[[Z%XLCT;W="[^5J?K/]HTW8E3"FE_C1?A-F]=5,V&&H)3.>HGA`=_X/9TH%,3'X=)5\]V*#@ MMF?E#6H'$@L+U@XD%7#JXJN\#)",0%=88L*1#IIN=JNS<7XB.!0@U:.K6P1] M#W*JA$^ETW/53_.SL<`CZ?"*Z_.Z57\AW5XA!)H.,'D;YE-EO/(^9*/:*4E:>\X` MQI5YH("H+E>]Y]DM;>!>.C27S?:CSZ6M;R4AV!IP" M9#,[44(,GR5OVS]R\_=&;*XD0*^[@@+P$?M#!--\U&(%IB&A;W.&>E42'3_7 M#>]((FM';<<#4TAYF$?2OM2;LXO796AI;77]K=GS.@!UO6/X^.]?3G??\6F[ MS$9^/JS@S9/6V].:]:[#$JOK8\:OZC/N/$91:*AOPGICYCM%C27GEYY+ZN\? MG&>>V[\=,KZ^Y2UPW97TMPN7=R/M_5[T-;P'">V'W(LYP,P>,783GO4`NI@A MP1M%-+5('P9'780^S5*>BH*J?12V8%'TK>CLZR MUK)O+<;U]RT%[D8,J!_2%$?`3CG!6!@>(8)J?E0;=SKP-CH*9WORUD48>9MQ0I%RV%=5GR[H&R#&HXI,*[^3KVZXNBPQ"WO/P%OO( M;L#M%Q8EM]JUUM-,[?YN0:^1/=C_)E]Q-4-6+R\PN3?79^#=HX0&F`[0W5;$ MJ$0]PW7OO`:>$6ZA/*M!$\)9C+\?7LNUS/T04-F%68.'?]NTYY;YC2WF<^_, ME50;[D9\/#K13JM*,X(XY39$'6B^V)C_IW^8HX?-HG'5^>RHCCUPN-HH6G&; M]%;;Y]FA;-[41I.HOB)>M:+/=H=EXV;WC0_>_SH_'J&Q&#@WQ,`":E^;&WKA M^33%-)ONM\MT(PN-7O8%(;G?%57K^23 M6(.L`*D8].XP]2P)S>FXB0[+1,3J-2/!%K-$+X1QL>#,%?P/M!Q4*0-@\G$` MO5$>LKC>30>WD^#@YBC77`1'+1?!$$^^'M2FD-["W-NJS[#MRC8+;HC5QEMV MX=YZ.&66SGJG&;\+UOQ?MI?SZ?_7O!7'P3K4;=4>X)J6=)R%"J`$S3[&NNU6 M2%"@RL+E3S-92R&O5^8V4,<=YI+3]L3-!ZO<=/E^OUPN5]_^`P``__\#`%!+ M`P04``8`"````"$`TL>-*E8,```Z=```#0```'AL+W-T>6QED5!293-A@^5HA+[BG[W MSBQ?L^)K*:VX#G`G7"Q1VIG?/'=VN"2OOW_R7.VS'>ZY_M=[\V*J:[O(\M>6&_CV7'^V=_KW-[_]S?4N>G;MCX^V'6E`PM_-]<KO5H^U9N]?!UO;AFTT0>E8$'\.'WFX;VM9ZAX,\MS?L]R][GN7X>DSA MREN)$/&L\--^>[$*O*T5.4O'=:)G1DO7O-75NP<_"*VE"U"?!H:U2FFS#P7R MGK,*@UVPB5X#N5ZPV3@KNXARUIOU@-+-M;_W3"_:::M@[T=S?9@=TN)OWJWG M^J6NQ2(O@C6`^,-_]D'TW>_B/Z_^^.I5_U_??O>/G^SU/W_^IOC=S]_JO90- MH0DVJ*?YNE]+%KZ.*?<2"6ZN-X%/!!F#FE!;5Y_\X(MOXG?@#"`>_NSF>O>+ M]MERX<@`X:T"-PBU"*P,\K$CON79\2\6ENLL0P=_MK$\QWV.#P_Q`'.,Y'>> M`V;"@[V80[=\EH@FE6F*,#B91GB$RN2!2!8>K)?)^G>)3!RO<3.O4_3'\6)2 MU,LEC5?1+PHZ/(579BO")WQ8SG73A!PRZ/=1K=1@9V(V6_2!7V?,+L>=238R M1^9$JF2<+Q;MA@Q'IDQ5-C`TWTS>=J9.^Q&*/*)7T6>GENO'<\>Z=]L+]H/P6>Y:-BZ:3&?LW-R9SCG8<\ MYP+R64!U&[UQG0<_KD5V^RV4NZO0V48H?>9[\AF?6:XRY-FL6`Q3:9:7PX,Y MV0Z\SW'=K*(>C;'FA",WUU#<1W;HF_!!2][?/V^AXO1A'8*&Z\6_:_CU0V@] M#X:L[A(;L`M<9XTH'A:LSDVD75S>F8L[QI<@$T510=0T%Y,S$+V[G2WD(UW, M9K*)#DUX22;Z9HPOR41-^&\A3:?)3&/(`IG1TR('UZ7]UY/9;#8=7$ZGTYDQ M&A@&4_(R\6C'7]M/-BY5I:FIB&`,"&:CZ>QR"$#ZQI2QZA3!"`!,QN/I>#`; M&O`_F]K.CT"V3F%IKMBJ!($BJQ($BJS*ED8]"9D_B13H$BFV*D&@R*H$@2*K M3B1GX(ERJQ($BJQ*$"BR*FOH28Q5Z+XJCE6"0)%5"0)%5I56?"89>*;[N3-;>*59FTNKCA!<6\>UYL54CK%.70;B&OD%Z[F>`*]7X MV,VU:V\B6)&&SL,C_HV"+?R[#*((3BK=7*\=ZR'P+1?>]M(1Z=^:D7#:#Q@LV2:P]>^WLO:)T&>]2 MOP0UHFZ;!26B$QG^`(9FIF:<$!X!.I2PB.D"%CWF47E9&, M$).1#!"4D8P0E1%"IRRX4DVN@SV<\3TTL&E.^_VXH2G*IYX@`5[B,>4@R)BB M/AN'E&BT<4Q;62&_%&+C=H@O5AV72-HPHBAGPX`2*1M&B,K(^TUJ78YXUKK` M]%R"Y$#?W,^/@P&,XH$IGH,DF.0G[.#&IUJ$TUVYN(WDB=1`H=UT)2P#89*. M.5"M;+D;R7<'J6#R1FQUKI54$5"4K&S7_8AEPM\W664"S;Z;ZZ<-V3X">WIP M?P7N3L&WT%%/WL952/P!(%8-&E8.TJSMUGW^L/>6=FBRC3Z,!3N*G?O\TRTK MG_+/[(2,9[-VI1Z3^3$,(GL5L8U([&1,%9Y1!9Y!0D@$SRG\C0K^H"=A?9S" M']IAI48$O2CE#\XES%^F/^"6J\2IP034J>OPR$0`38\4`1A!!0+<(I;H`-Q3 M!0)83*8(P$%S!`"GQBM.B8,!R6;@`SE+X'\NEI!C4BDYEF>4LBK]`O\:*4TN M_9ZD9I)OP=%S-<.'&@`GL:Q*L:I2##$[1%JN`OA0HP(39ETY4QZT&S*_`QWD M`)0IA"1=#A"D@3J-R/-*DG.!IZA&;B76(<0I,!6IA@!PE$`@AA@HFG\'%(.B M&9AZ@Z(IF$+@YN#Z+"$U)J@EN!E2$0;`HR0J\GP]X&:,#M5`(*C*D,0;AJI2 M),6@*D?FIABJ2I$$@JH,22VA*D52#*IR)#&%JA1)((!&E&1(:@E5*9)B4)4C MG+>"`W:HX\6 M?H*E:'PV[&E3W>L%)&E_X]`9>825F'+^T%_7M3;,I>OG!"RG*Z)1UFF"25(Z!F@HF3+%<88+F,/DT M9+-&7Z7,41E)PQL.?.;2<-,\"A&?%*_+H+C.D8I,J5K: M,!<6_!QSQY!TJ:4[1#JWMM'&0'9X4`]-`,%)VUZ=+U9BP'YE79BD+:'&F#T" M%+74Z'`I6@?*9,WC5I"*D=RDLN[1Y47*,6Y6C1?NUE!K8UZ=1UE)L2DGIG[1KNJ<[:>6;-:J3X$KBZ>:DF:<': M7SRLU">M\\,]P@]>Y+1_>G6HM/IJQ?S%+D[P7)2RQV%.4F5%+S2X1/O)"],B@K7@<-+MF$RN6"$ MEX$O+81F9^$:B`("A_BU;&Q5V*+VRDZ.%.O:\U:RQ(J5:U+XC2RW:FKF5:FE M`*&-+Q_+5*XMFE#0"0'$S:.ZJ>W:F8-0A-V?%LB:5P(G^##E)]'%`RV:E$^1 M_'+F*,V>.+?RLU+![[^.66G$5PB%,O*E*;T![E>B=-YU"MV',RG]B/,-&)YE M93!G!@FN+S1)R*W="ZA?CM8!6J9U4K#QL=H*OY!^B_DPR^3-F]UH_Z][H&VF M;!X=7F935S-)FV=.C+Y*/R@*\&L2K-W4V>;L`U=(U2>]NO0A%'Y'K>%D?&?67_OT13>-BF^6%`FO5@8_(C-@=9Q.$?BV;(%:\(!RX)50R^*$;?>& M#=[D=AG\S3*R[>`:WB<=]OCU?Z]=:&]6Z#Q9G8/KU^7><>%6@-@,P:WZJ_T. M[D)U&Q],-E?7TOD%PP0F^MK2`?4QK!-(26G`G MD=:TX)*:A!9>7)/C,F`#;5M<,"2AQ>M^+*A[H\R.[#*T'!>*+(*+TLKMB-F! MT`*1V]+*[0B&H[1`Y+:T5V!"M06N!N;6EE=C3`<(366%#W MEZ5VY'T5KQD1P45IY7;D?74DZ*N45FY'WE=1Y+:X`=T1$V9$1T%%/)K<9[^4C0RV,J MN;UX_S8$_3NFDEL*Z!&)#/A"7*+,1B->NX:@=F^M=9IU>8?!>48$!CP!;+5W MX`2M$Z=%>?=(6<(NKC!`?#SB-BA"Z>]JZEF]%0?BL MX750&3G>Z&-!L*>!7F(-\3Z,95T;,EDL\.K! MFR*T(0.C8S2\_^&6H39D8'1,AD^J6#^)D'GG;_>9A?A MPVL8%_XBE#[8^RBT,O_C0VHHJ)@/>&.TC`:?(N*'SJ1W<4OJSP]P'[14B5CN MD]C!&EH$^%_V$5$CCB)$AH)YZ=Z)X*Z::1!S)!"6"([[`*Y-S$@<9!1!&G^S M0A^CA0O=`Q^MD"B_TA.J__53?I,\IO<(GQ/);I^7K0=`46M[8^W=Z#[[;P0,40P='D@W[W=P$:ST'QM7.A4=;AHFP"?B/^;&Y3C[$\-G=/P$V7&*2"M';90_]O/D_```` M__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H M96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B M0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$ M(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S: MWIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53& M`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4& M.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y& MK9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#% M-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\ M]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V M">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!# M\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G M^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U M."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X M+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXG MW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@= M/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5G MY*8TO;>$#6C\S21 M0*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09 MHW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3] M$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76 M&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA M_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005W MU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X M,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"? M[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4 MX9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F M!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q M\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q M)4TPP:&PO=V]R:W-H965T/9`2>Q"AC93M/^^UWC0(S9%OH2PO'QX=SK M:_NN[E^+W'DA7%!61BX:^:Y#RI1EM#Q$[L\?CW=SUQ$2EQG.64DB]XT(]W[] M\0>I:R6GB?2(RFP&+&*E#"R9[S`$E[YP1,5)SBK)Q6Y M%_C^U"LP+5VML.1#--A^3U,2L_14D%)J$4YR+,&_.-)*-&I%.D2NP/SY5-VE MK*A`8D=S*M]J4=>?$%3S@3;RQ'(>=IH/^:% MM_!`:;W**$2@TNYPLH_E$KDSEP'\B>@,E[6 MH3]?>2^PFNF%L^ES4)>Q;1AJZ91LK`&]``I(#,"#`-HH('XSBK]71&-6D979 MYC,;#8!VZSZPG/494\M\W*<$XZY*TJ>$_J+E=`*"\AH>D")#,1O^0^2WNG4J M-YH3MD%O;2"V@<0`.MZ@>H=[4^3(AM:TF7*W%MV8DQHR.]^E[O"NRY1U9 MY;S1G*NUK0W$-I`80,<;[/GA>57D6X6J.88W&XAM(#&`CC=U\1MGV_]/!46V M\V9MX(WF&-YL(+:!I`'4F7@MWH[-Q7ML*K)M,[3VNN88-FT@MH'$`#K>$-S2 MPW-8LV\M\(5DV.LA<0])3*3K4-T)@U<9^I->_GI;^T+2!U(PZ6_M"^$:0MQ# M5">DOE1SM&'=V.C;MR#\0+8DSX63LI-J6@(X25JT;:@>`G5B6_@&+>&N!-QK M!Z#/J?"!?,7\0$OAY&0/DOYH!D<*UYV2?I&LJN_\'9/0X=1_C]#1$KA<_1&0 M]XS)YD5]H.V1UW\```#__P,`4$L#!!0`!@`(````(0`G?`SALP,``.P-```9 M````>&PO=V]R:W-H965T36+`:A)'L2GMO]^UG5#;A#3T!4A\?')\[O6)F=^]Y)GW M3"I.6;'PT2#T/5(D+*7%;N'_^?UX<^M[7.`BQ1DKR,)_)=R_6W[^-#^RZHGO M"1$>,!1\X>^%*&=!P),]R3$?L)(4,+)E58X%7%:[@)<5P:F:E&=!%(;C(,>T M\#7#K.K#P;9;FI`'EAQR4@A-4I$,"]#/][3D#5N>]*'+-L*P9`%VBAYVN>!M,`F);S ME,(*I.U>1;8+_Q[-UFCJ!\NY,N@O)4=N_/;XGAV_5#3]3@L";D.=9`4VC#U) MZ+=4WH+)P=GL1U6!GY67DBT^9.(7.WXE=+<74.X1K$@N;):^/A">@*-`,XA& MDBEA&0B`3R^GLC7`$?RBOH\T%?N%/QP/1I-PB`#N;0@7CU12^EYRX(+E_S0( MU52:)*I)X+LF0:-!'(TFM]>P#&L6^&Y84&^60*]+V?2`!5[.*W;TH/=`.2^Q M[&0T`^9V7\`0B;V78#4%ELRAF,_+X70Z#YZA`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`I M6_WE<`#@+6.BN9"M&PO=V]R:W-H965TPB&*@F?L(+)SS1KM2"2KJ`;]JN2MZMCJ[!:ZFLKGP),VTW.H0)C.Y*L2/%CD!Q6F&PWUI^?G%W4X!VI4EP^2)Y_Y@T#LZ%-I@%' M(9X-]%-N0I!,9ME/M@%?)D!=H2';%[.:88(S8 M=PCCOJ$]N(#UD(#>7C28-A3]]QYVV@S8:.M8=RX`W'_$3H3,$:N)UL,<$BYZ MEI%8:/;M8@TXQ4#>:ULO>UIKRLY!8NOR7>`O?=\?(_9C1!#/$`>'B.R-&1H+ M)^!VK08\UAI-7-HYR,II#:,HG&O9.XS5XKH^25J$BV$!(V_AZMVNUX#'>L.I MMP[B]$8PH*?.NOV!UF%"&`P31CI7_Z/3@"%M'ZK@(``,@&```9````>&PO M=V]R:W-H965TM858P8!0Z-37!G3 M)H3HK&*"ZD"VK(&;0BI!#1Q5272K&,V=DZA)'(93(BAOL&=(U#4_;FTR*%BAVO.;FS9%B)++DL6RDHKL: M\GZ-QC0[<;O#@%[P3$DM"Q,`'?&!#G->D`4!IM4RYY"!E1TI5J3X+DJV(TQ6 M2Z?/;\X.^FR/="4/7Q3/GWC#0&PHDRW`3LIG"WW,K0F&*9,EE#`/!$@MO.`$'HJUL//#=5 MBD?38#(+1Q'`T8YI\\`M)4;97ALI_GA0=*3R)/&1!-8C203;*YU'1V=83\Y1 M,(XGL_G_A#`^LL!Z8KD^!,C4B0#KR?GZ$(A7U!5H0PU=+94\(&AZT$RWU'Y" M40+,MC)C6-^O#)3$^MQ9)^<*:`W=]+**YXLE>8$6R(Z8>X^98?0/KG&';V3X]Y#9J[;K#[K MOF'3-VS/#!L)OSRVC> MXX5I8=_M>>/%M'NKS\9/`M]H@JF2K5E=:Y3)O?W*QQ!-9_4#Z#Y*0$;X\GOV M=92`FD/[)DI`U*%]"X/,V4E'!(.DI27[1E7)&XUJ5D`(83"#+E=^%/F#D:VK M\TX:&"%N6\$?@T%!PP#`A93F=(`7D^X?M/H+``#__P,`4$L#!!0`!@`(```` M(0#BJ##S?P0``%L/```9````>&PO=V]R:W-H965TV]C!]G1V MMNT\#,.9ZX//N=?7]O+K:U,;+ZCK*]RN3&=FFP9J2WRLVO/*_.-;\F5A&OU0 MM,>BQBU:F6^H-[^N?_YI>U7YF48KI%E]>4%-44_PU?4PG]. MN&N*`5Z[L]5?.U0>LS7E9^B:HGN^7;^4N+D"Q:&JJ^&-DII&4T;YN<5=<:A!]ZLS+TK. M35\T^J8J.]SCTS`#.HM-5-<<6J$%3.OEL0(%Q':C0Z>5N7&BW'%,:[VD!OU9 MH7L_^=OH+_B>=M7QEZI%X#;DB63@@/$S"5 MZ04S_\GV'`@W#J@?DHI0FD9YZP?<_,6"J")!XHXD\!Q)G/"'2>!S=";P'$G" MV<+WY\'BZ?,S@;*F)/#\81*+64.=CHNA6"\[?#>@?$%\?RW(8G"BT#2XQ0YF$Y(-85F93Z8!=O90*"]K=^$MK1=(;CG&;/481X[8\0B224(;J\!> M!1(52%4@4X%\`EA@@G`"$OP_.$%8B!-+MN#E?K^&N/Y)H-@-4WS;2]D6=LQABYQFLZ=AL0:LM>01$-2#
M"J6`,C'++8$6'["NE&NQ$)A/R8(2[T39%Y9^[+Y;$7 M0=S'1"-*1X+=SI9%)1I+JK%D$HOOZ2SYR!*2U$A&D*/@9'M[ MIP;@*,"+@`3+1C#$A=XY,4)9_SL1)(P8$4]4RIXA@4N-<'S?@:.DXH1&DVHT MV?=I\ND@R0JHTJD5_VJ9$`[9H1&!KTX<4I;`3@0)AQ@23!QBB+]@#GFA8\./ M8I'&DVH\FT<)RJ*XQ8YH\\=J9E<$=G!M4'=&.U37O5'B&SG^AV"%0-G5)`XB:+Q0;@J> M!A'T41V'J\R&[FM*_)9<<=Z)W[H1G*ATGJT7P=%#QS?S:,.N2NH'YA'LU_J` MK1_!C@>X)0;`U>9:G-&O17>NVMZHT0FTVW2CZ]CEB+T,H^\'/,"EAJ;@`I=8 M!`W9GL&N>,)XX"_D`^):O/X;``#__P,`4$L#!!0`!@`(````(0!9^O:PI@(` M`#<'```9````>&PO=V]R:W-H965T#.P=+1MM&J6-U$I5UN3:"%6G.`I"C'C-5";J(L5_?M]=K3$REM89K53-4_S,#;[>??ZT/2G] M8$K.+0*&VJ2XM+9)"#&LY)*:0#6\AC>YTI):6.J"F$9SFK6;9$7B,%P2246- M/4.BIW"H/!>,WRIVE+RVGD3SBEK(WY2B,2]LDDVADU0_')LKIF0#%`=1"?O< MDF(D67)?U$K30P6^GZ(Y92_<[>*,7@JFE5&Y#8".^$3//6_(A@#3;IL)<.#* MCC3/4[R/DIL-)KMM6Y^_@I_,X!F94IV^:I%]%S6'8L,QN0,X*/7@H/>9"\%F MTJ$H&=`TC34=6"4`/%E0^#$8?<.G.(51I"K@4-XW$7K MV98\0N58A[GQ&+B^8GH$`=%>&=2F*SNP4W:E=:G<^,!0)KXL,_N(C`.G&*ZO MR:_G/:]7]IAYVR]#/_./"#DPE!QN`Z6WI>Q`T*T#T*)/9U1-:*/IU73@5KTO M9Q>)SEPMQ[QMXX=QL((-[_>*VSC6Z"+CZBXOVX$>FV['@<=2761V9L?-XT&[ M.SOQ8C'!CMLXUN@B8SNKRW8V8]GW*^?`8RD?&;2<'U3^0Y9<%_P+KRJ#F#JZ M(13#I]E'^_FXCUTUWL;GR;Z=FZ1_`7.KH07_074A:H,JG@-EV)9(^\GG%U8U MD"5,+V5A8K6/)?R@.'R=80#MD2ME7Q8@3/I?WNX_````__\#`%!+`P04``8` M"````"$`VFD*U&4*``!A,P``&0```'AL+W=OU?#?J_:K>O'S>[Y MKO_G']%OLW[O<%SM'E>O]:ZZZW^O#OW?[__]K]OW>O_Y\%)5QQY%V!WN^B_' MX]M\,#BL7ZKMZG!5OU4[*GFJ]]O5D?[K!=;79] M'6&^_TB,^NEILZZ">OUE6^V..LB^>ET=J?Z'E\W;P4;;KC\2;KO:?_[R]MNZ MWKY1B$^;U\WQ>Q.TW]NNY^GSKMZO/KU2N[]YX]7:QF[^@/#;S7I?'^JGXQ6% M&^B*8IMO!C<#BG1_^[BA%BC9>_OJZ:[_X,U+?]0?W-\V`OVUJ=X/SO][AY?Z M/=YO'HO-KB*UJ9]4#WRJZ\_*-'U4B)P'X!TU/?"??>^Q>EI]>3W^MWY/JLWS MRY&Z>T(M4@V;/WX/JL.:%*4P5Z.)BK2N7ZD"]&]ONU&I08JLOC6?[YO'X\M= MWR?O3]7A&&U4J'YO_>5PK+?_TX6>":&=1\:9/JWS]=5D.O0]>M8Y1]\XTJ=Q M',VNO/'P^B=^8^-'G]9O^!$_JDW32OJT?A]ZWK7QHT_C-[F:>L,;?WJ^?5/C M1Y_&S_,_)`P-RZ:B]'E116^,'WT:/]^_FDTFX^O93ZKJ4/9_E?_^<@S!SIKFT$0K(ZK^]M]_=ZCF86J<'A;J7G*FZM@-OUU MTIX&Q(_&`PT$%>5!A;GK4V]1RA]H$'^]]R;>[>`K#;RUL5ETV'"+I;50HTR% M#20()8@DB"5()$@ER"3()2@D*!TP("5/D`IAUE'].N>P:V&:>L::YE&2C M4[(!"8%$0&(@"9`42`8D!U(`*5W"U*3-+5/S?+(I:ZZ8)FZR`0F`A$`B(#&0 M!$@*)`.2`RF`E"YA\JB=/--'S6S_+-N:4%P\@T2^346^M5:GA$,4(HH0Q8@2 M1"FB#%&.J$!4,L2U53MF=R2?SSUU-!+)9Y";?8@"1"&B"%&,*$&4(LH0Y8@* M1"5#7"RU1;Y`++VCIJV=S9F%IY%(MIE,MI.5=0Q:1XM"1!&B&%&"*$64(

1?@"A$%"&*$26(4D09HAQ1 M@:ADB(NEML87B*5WTDPLL[DF@9P]\(U,MI.5S:Q`'4:4I/XI<4-$$:(848(H M190ARA$5B$J&N'YJHWR!?GI?3?&L#`MUWD3/A M-6+"`PH\@VY.W1-:U"H36<15%MJ3.5-6(J`PH\@UR5P2IJK=PT$KFBA<:8-D4&C6AR;Q\W%@+&UFK6Q!Y>^<(@P>B`AU+:]6TD7>$.D3]VH[0QS+6$0;QP2'6JN7(6+F#0Z,Q38:.>-`1X!B9 M6.,V&6.+>#9`1T"LU#JVN9YA57.+VJXOT+&T5DT;>4>HH]>O[0A]F&,=H9%* M!T=/L9PM1\;*'1$&L0D;1P0X1B:6W\H26_23$0&Q4NOHC@BPRFWMW1&AK6@\ MV[6^M%8=(X+:^(L[0D44J[!!?$2(Z7FI;M65HSLB-!JK-?[K??=R`5Z1"43# MP>EW7"Y,[-$/EPN(G-K(X\;'NYJ)-F38AMSZ4+0V"V5M"FNE(XLUL61A^4"2 M)]K_?VG!0^]((S&0Q(%P::W<@62.QN>6>Q.[]8I,(!I%9Q2+K=7-#_L/(J?< MIZO_P">W/F=K4U@K4QM^TB]-*P_-RSO M/](4^\\YN=B]7BBPHA)4R/GPG6B0H\P248`H1!0ABA$EB%)$&:(<48&H9(B+I8ZU M;A[^1"QS"FZ/YPOUU24:QR+9Y,&XM;([M`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`V=*\H[X"?S3&$9VRM[+[$]\25)PO'91[!A&1P/SC9XC:'#(*,A-G1I1R M7,(`X*]1%:0U("/91_^\%3,2>3FQO.B<:3U[N,3]X,C]/B.") M(\CVL<.3.:XF"WNZ/S70!?.#)_-SQPT4)FL_4'@RQ\6H@:Z8 M'SS'#-2BO=&W6IAUV7;=X)L!\Q>*WUXSLAK8/FCQ'J,I&KKNJZ:#;B,B+T1E M8T+PT$XMS)3WK>W9:^L=NCMG-L$#&]EBQRU(*Q/94`5[%40JB%60J"`5@`5) M&#(!#?X_9(*HD$SP&`(.[JEQE+"Y!7<)5;!70:2"6`6)"E(!2&'#E!3#?KRX M\#H3XXT)?X4Z*^$$S*9?V_HR[C02:F2OD4@CL482C:0BD>*$)61\G,089@0\ MA$#5AJ9&+O238.0JQ1V,ANIJ9*^12".Q1A*-I"*18H#)"C>PU M$FDDUDBBD50D4J"PKHX/E!C+@5(BED\CH4;V&HDT$FLDT4@J$BDJV.Z'R,[GR^\&( M5S[2A.+!1A2:RT+)8,2%4E%(2@F,2$V),R>'NT=9`,S30/SD-#`";Q)"7,@C MVS&CU;!9A90X<%05W):RVYX9V?T^OY*_C#3->(QF\DPS%36E?-DP4#5A]NPG M>Z@7D;/'D`-[II`')=0=MW+O^>/(&]">(U*M]ZWG*>T1\>_O*C%'=Y6$HR]4 M4OY]KR+GB)QW_NL\L^FA"39$WL0!0PZL6O<2J<<*LOA%-)6,XD.4(]R>0/?/UJQ1+F*MP8U,._Z!O&#XX63[+P```/__`P!02P,$%``&``@````A`$\) MHK#@!```\14``!@```!X;"]W;W)KSV=SW9!ZK0Y*?=O[??SU]N?.]LHKR0Y2J M7.[\'[+TO^Y__FG[KHJ7\BQEY4&&O-SYYZJZ;(*@C,\RB\J9NL@<_G)41195 M\+$X!>6ED-&!@K(TX//Y,LBB)/?K#)MB3`YU/":Q?%3Q:R;SJDY2R#2JH/[R MG%S*-EL6CTF71<7+Z^5+K+(+I'A.TJ3Z04E]+XLWWTZY*J+G%'A_L#"*V]ST M89`^2^)"E>I8S2!=4![9Y"!=^L-]2@_Y) MY'O9^]TKS^K]UR(Y_)[D$KH-<\()/"OU@J[?#FB"X&`0_403^*/P#O(8O:;5 MG^K]-YFP&,D-CF\.-1EC%T%-+,.)41JQ0*@)]>EN#1@(Y$'SN?`W!R MJ,X[7RQGB]5<,'#WGF59/268TO?BU[)2V;^U$Z.BZEQ4VF-41?MMH=X]F#=X MEY<(3P_;0.*VICI#5Z6K2*@.D]QCEIV_\CW`+Z&S;WO&[K;!&W0C;GP>:A_X M>?7I/`*HIBL)RNB79&]/BXS.B`R-IU(>:D,?AMMAQ!08=(9^]XMGZRYOC5S[ MA-3N/I]0!\(6\R6.V#'YEAK&P5C@GVO'!EUMG.`P7IWXO*M,:RP@CF\L.A-Z MU]G&(@8$EWI>.D-\?8L>1ND`C04FV./"[%S@K(WG@LXZ5&,9X#%W": M/C^%&*4#-!:=B^,D0JOZF)]#H;,.U5B&7!B/`K405J33DC8 MA\/PKO>Z^#DC\C;0,`&8+)SP?O=2TVV:+T9PPD`#I3'IG$('ITEZ`94/T!J3 MA9-%(5C(9JO;@^HTHKNEJ!?(4R>U<)#".]WKYHU!-0I`$E=K'GY_.09E484% M'S&GH2XPJS`L'90F*0,;2D-KLLS)(@[L#B[9C;8-U8%9Y6'E8#1)']A0(%K3 MD!&W*,2:W1X2Q>F7J37IY^ZZ!&C?1'R20)"W@>84"(Z7NG>D42#$?#6"$P8: M*(U)YW3]WM4?C,_/^CD;730 MJ0_/`O6VM2:=DV.#P)5K/"?R-M"<`B'P4AL" M,>[;EB(-&$P&)IV48X40DQ2"O`TTYPHA_J]"4*"!8E4(QP8A)BD$>1MH3H40 M%H5@_&Z$1%"D`=-(!'3P^I\+X=@AQ"2)(&\#S2D1PB(1(W8("C,P&MG0CYYC MAQ"3-(*\#;1&-H8:$5HT8CT?L;Q2H([2FG1.CB4BG*01Y&V@.34BQ&MM:,1M M(:!5NM#[UFE?F"K7[$R69SD+S)-2R]6K_AXQN'YJ;-V#WOW'%\M3'NX MN:\?_(+N+_#@=HE.\GM4G)*\]%)YA)SU:2[J)[OZ0Z4N4"<\NZD*GMKHUS,\ MK4IX#9MC5X]*5>T'0`ZZQ]K]?P```/__`P!02P,$%``&``@````A`%!U[L%D M`P``9`L``!@```!X;"]W;W)KTG,M2"@HEMUM]*NM%KMY=DD#K&:Q)%M2OOW.V.;D)!0TA<@P_@O>>:],*FX*%8^&82^QXI(Q+S8K?P_OQ]O;GU/:5K$-!,%6_EO3/EWZ\^? ME@Y7,J;1$=L\M.!S'DFA1*('`!?8B[8USX-Y M`$CK92L7AJ^3Q=UXPB#;D"3.P M%>(979]B-,'AH'7ZT63@I_1BEM!]IG^)PS?&=ZF&=$]`$0I;Q&\/3$4048`9 M#">(%(D,+@"?7LZQ-"`B]-5\'WBLTY4_&@_(.)R"M[=E2C]R1/2]:*^TR/]9 M'^*0+,;08<#W$6,ZF,S"$;D.$MC[&'D/5-/U4HJ#!S4#E*JD6(%D`<#=>D`( M^F[0>>7/?`_NJB`)+VL2WBZ#%PA,F$5;(<(K5<"6H>`ZB#U^G MB+6BZIR@;D].)*QNU@@L,/8/+#H;]BJRSF)JKX$[;>(:@>/I8'95(1YL=FU3.TI:#H[E6^::C0VBH:_G""\29FIJF%S1] M:#"0]F0XFCHT==\0#A3[?5D=QK[TL^9 MW+$O+,N4%XD][BM#>(U7UFJ7V@RQ<,_MX\7&[EA!]0_L."7=L1]4[GBAO(PE M@!F:=X*T6Y)]T**$KH=51VA8;\S/%+99!J_R$$LE$4(?'X`YJ/;C]7\```#_ M_P,`4$L#!!0`!@`(````(0!HO)>7_0,``$0.```8````>&PO=V]R:W-H965T M&ULG%?+;NLV$-T7Z#\(VML2_8P-VQ=7"M)>H`6*HH\U+=$V M$4D42#I._KY#4@^2!IM\DI9*!D#S@Y;,/O:)VB M51CM-EJ@?RBY".MW($[L\@NG^6^T(J`VU$E58,_8JX+^R-42;(X&NU]T!?[@ M04X.^%S(/]GE5T*/)PGEGD-&*K%U_O%,1`:*@IOQ9*X\9:P``O`W**EJ#5`$ MO^O_%YK+TS:<+L;S93Q%``_V1,@7JER&0786DI7_&A!J7!DGD\;)%-@W=EBZ MO3DR1'1>SUCBW8:S2P#-`J%$C57KH34X;!,RX;L4/\L04E-.OBLOVA>0%U"6 MM]UJNHG>0,FL@20&L@R##H)<1-HB5`&`74<1DO,I3J%RUS5O&:E-+J/)Q(V7 M7(&XB'2(6/2D'8X@G":S`VQ"R MZFJPG'N!#>1)UW"$8L^AZ6X_;=!38H[-T0R8&7H8R'4]KML< M.@BFB2W(;3X:[1*:^/W28*XSX*I@;CPQV$S#BUQ\_4GWL-QI!;>-;4L8[Z]G/)J5%ID;M333-8;5(H M[HMB&ANUTU>=;*.)UWZI:T9Q;W>)/32KD1FU$+D;UBCVJI4T(.N5LU?=@PK>>9>OZ6-"_]=<,EY`_MK)P8:3FX4>SV3-"`3?DC. MGMX]?WX!A-&I`A-?':+76L<`A_UD_>'+_3Z&88NXT^F%OMQ%:5 M'/)RK-8AZPG4A5^Y,%;TU&\VM,QEWEQZ2\*/ M)"5%(8*,G=5%'<&9WJV:CXA$?43HSX#.`'?X&A_)[Y@?:26"@AQ@:SQ>0N-S M\Q5@'B2K]:5SSR3:!FT*ANC+H'5.'[M.5Q?=L_KQF:7*!RW*A.5KE4QU5:%YS(Y)?EZK__SM M3Y:J4E91?HQ2EM.U^D5+]U^I,XH:UJ MFU7MS[\)O9729Z6\L%M0),=?24[!;%@FO@`'QMXX-3SR$`S6>J/]>@'^+)0C M/47O:?47N^UI38 M63,6GLU8PYP24U^\\/MFHP'/-HG9RTE`NK43\&PG8C^=Q:(9#,]V!J_;:#4B M8%XK8DQ-8VXM7UD,F'2=!SP?*D^NJ":JHRXV-ZJBS:I@-P4V,*Q_>8UX.R`. M"+=5)FKB7G??E1W4&Q?YR55J+:BH$K;*QV:IK[0/*.^XH6P%!9QX4(PN93=` MF74I[@#%[%*\`A33*2R'Z!8795P@+*\4S18@OLZP`Z3UV%X ME[=V#X]3EZK M(/4H%63L5E"6=:E-R'R)\)V,6TN[:XXKHP:Q9\@\3\8GACDS4!GZ'8*)Y`,9 M1=M@+V,+M`%"&7S\9,=(Z(3/&\G)R,A'^8DZ$13S42=,P\39NWB, MAP,^#@1M@+<&HF-3!"I^"U.[Z5^"!D M$5K.K:!(%HE`,]VYCM-Q\0`/!WP<"-H`]P>[,X*%,C8AW]0,O+M>-X8/ZAIC MHXEM!<6L2P5A.QE#V\N5L0D"/1E$HOX(%HQ@^Q$L',8ZA04O+=F_\8+BY*YO MUJ->Q9X3%.';A.@(WLDPC$/G-PW4BOP.H=?Y911)[V6L MU_EE\)M=#*>SYXWD9&0D,FHK*%);$X&F\]NZ;O4[/Q[CX8"/`T$;&.[\`OV^ M\\NX82T?.8@:$[\2!\U4_[A,'CEG]>$`<.&U!7+M/%"YW MU^A,_XB*`54(CKH?A2L6M]-CRP"JYU]<<+W.(I'`+U*9!/ MC%7M%_X#]_\+;/X'``#__P,`4$L#!!0`!@`(````(0#,WNW7C@4``!(5```9 M````>&PO=V]R:W-H965TVRB&L8`D.V_?-#$V#E!G=Y>5A;O[U/7AX-(VZ2J(EF9L?I#:_+7[] M9?9.JY?Z2$AC@$)9S\UCTYQ]RZJS(RG2>D#/I(0K>UH5:0,_JX-5GRN2[MJD MXF0YP^'8*M*\-+F"7]VB0??[/"-KFKT6I&RX2$5.:0/]KX_YN99J17:+7)%6 M+Z_GAXP69Y!XSD]Y\]&*FD:1^=&AI%7Z?()Q_[#=-)/:[0\D7^1916NZ;P8@ M9_&.XC%/K:D%2HO9+H<1,-N-BNSGYI/M)_;(M!:SUJ"_<_)>]_XWZB-]WU;Y M[K>\).`V/"?V!)XI?6&AT8XA2+90=M`^@3\J8T?VZ>NI^9.^AR0_'!MXW!Z, MB`W,WWVL29V!HR`S<#RFE-$3=`#^&D7.2@,<27_,30=NG.^:X]P9#BR M(=QX)G43Y$S2-++7NJ'%/SS(%E)<9"1$H!4BCCVPW>&8:5S)M#+/N24/ M5-M.0ROS;KK?6.1!*_+<@?/HV=[/.CH1B="*Q.G%I"L#A%G6=A3:NSHZ%7G0 MWM=1&PJHO2/[YZZNVK(2V#^W=-;BE=06YCIMTL6LHN\&S';(K\\I6SMLGXG) MDN0^=47Z58U"<3*5)R8S-\%Q*+\:)M;;`A[5S'J#R9")F"6.L=6(E8Q@E<]D MUSK8Z"#0P58'H0XB'<0Z2'K``I\ZLV#>_1]F,1EFEASF4H*>>YHS,D*FK'6P MT4&@@ZT.0AU$.HAUD/2`X@PL)HHSGZ]HLEI8-*Q=_6IQ'77$2Q'3+JAM,:P0 M62.R021`9(M(B$B$2(Q(TB>*&;!"*F:P.>5X@VYYO7E6,2&8F-#TIM58,XH' MC:`WER#758-675!70(AL$`D0V2(2(A(A$B.2](GB'9BD>'>]D%AT:Y`EA0Z#,OY)V4T@FV*;UY,1+52D)Z5B*P%@:;GR:,ZE`U*"SAQ MIGR3'-K:3-UVU^7@0Z01=3'M1HLTXNZZU$CZ&HJ![-5"W_]'<)+YQ#`X'TK' M6);JF"#0]-R8JFZL1-"TFYQK3L9*FC=4TS8H+>#$@6-3=S?;U;S?BB"[=5H_ MC81(-+I%-+XJFO1%%9O!462S[=U9ITQ$=9T31YF7GGZJ$D'M>PT_5G$RAJ:S MS_&T#7B#T@)!W.[Q;05AA0$G/FU!")%"A!3BJPI)7T'QDYV8%4.OUVL;KEHG MT6,WFI5$O?H4:'(YAFQP5"`0U*.<<%N)>/79MO900JP2R92+2BS1%RJ)HJ(: MQ,ZP^L2^N^+8&X%6<@)-X$JO>$;JE%V)**=7=`)!U4F3-C@JD*A79!+Q*GNP M;6U]"&7`Y6:11!>96**O9!(9T,JH9K)C[W\WDQ^>X3@G#5C:''FPOUW,U%=- M$61?C%L+I)2E4+]$!2+*@<6_4\?+I(QZ;"J3^*7CP[L:UEF.?'AOP?S)]9_XER_]!JX/AW5(L+H+\$7JG![([VEU MR,O:.)$]F#5L][**?]/B/QKQH)YI`]^BVF=VA&^/!$ZF0_8RM*>TD3_8#;JO MF8M_`0``__\#`%!+`P04``8`"````"$`ILAS:[@%``!7%@``&0```'AL+W=O M]DO_[Q_TR]3WFC8_;?,C/[&E_\H:_^OJUU\6%UX_-@?& M6@\LG)JE?VC;\SP(FN+`JKP9\3,[PPL]Z'S3GFN5;J50=@R@,)T&5 MER=?69C7[['!=[NR8"DOGBIV:I61FAWS%O@WA_+<:&M5\1YS55X_/IV_%+PZ M@XF'\EBVK]*H[U7%_-O^Q.O\X0A^OY!Q7FC;\H=COBJ+FC=\UX[`7*"(NC[/ M@ED`EE:+;0D>B+![-=LM_7LRIU'D!ZN%#-`_);LTQO^]YL`OO]7E]GMY8A!M MR)/(P`/GCT+TVU9`H!PXVE1FX,_:V[)=_G1L_^*7WUFY/[20[@0\$H[-MZ\I M:PJ(*)@918FP5/`C$("_7E6*TH"(Y"_R>RFW[6'I1_$HFB8DF8"\]\":EI;" MIN\53TW+JW^5%.EL*2M19P6^G95X,DKNPI@((S<4XTX1OGKZQ)C^AN:XTX1O MIYF,R#B4K&^H`1WI+WSUA&1T1\)9?'>;Z:13A*]6O,TT4)&6B4OS-E\M:G[Q M8#5`*)MS+M86F8,UG3%%NL_ASU((N1-&[H65I7_G>Y"46FTT7P#+52 M=#+K`1DLL=$2HC"$V=0&,AN@!A"`1[U;D/O_P2UA1;BE":TU1SH`07OKPU\C`#'-;=S)R#US MZB"9@U`30?[`MF'Z<[O.A3"FK)`X[E?IQD%2!\DTOIA?IP.TCF(-1$D#LS[,[M<`MA3%DA9K@=)'60S$&HB2!^!(X= M=KP3V``^VI*$&4Q=6H9-$N\FL57=5ZD^WBZ4N1!%$'9)M"FCA&['G`AIB[F" MS*AW4@:4NE#F0A1!F*;H1`9-L;-\)O*JH<'.K@.X)@JR(C^V(]]+:<7TJJBA MS(4H@K!+HE<9+KT1>=79$/.NV1G;"W&@U(4R%Z((PC1%,S)H?C;RJJ^E])A3D5CABJ$E&DHIOR(.NY4&]&*>7B1W[7DH'.B4.E+D0 M11!V2O0RPZDW8J\Z'V)N-D-UB"$.E+I0YD(409BFZ%$&37F2261G;0]E\;CF M$#;8^0;HQW#)D+SNB6ITB'T'`6,C[G=VW#LI=1%5]PT%C:=&S3L0U3-*1>R0 M:&J&0P/$X0K:,U])^V@!-)Q+;VQ=:O).JE)>,M#12&2QK&'`VW:3-\/?O[9LC&J M#QRQ3QD=)/NVFE&]]*@'@XK5>[9AQV/C%?Q)O.*`&ZM%#ZLGIC6)YZ+1P5[F MC(QA1!IW1A(8D07NC$Q@9#)H[0Y&9-78.C`PB$_G<"@>X#6;PV%T`"]<[YGOV1U_ORU'A'MH."">7> M7JN'0?6C[8KU@;?PGB?K]@`/N`R>?T+1A7>&ULK)A;CZI($,??-]GO0'@_(B"H1#T9Y9KL)IO-V=UG!ELE([8! M9ISS[;>:IJ&[RV/R-K^3QORZ^?FGU8W6;\V)D-8`A4NS-D]M>PTL MJRE.I,J;";V2"WQSH'65M_"Q/EK-M2;YOG.JSI8SG?I6E9<7DRL$]3,:]'`H M"Q+2XKTBEY:+U.2&Z%6%<_(57G]]G[]4M#J"A*OY;ELOW>BIE$5 M07:\T#I_/4/V@G(67R@..:EM;1`:;/:EQ`!2[M1 MD\/:?+&#S/9,:[/J$O1G26Z-]+?1G.@MJ_TUM*RN.IA7)[$!$++-A_#TE30$9!9N)TPRCH&08` M_QM5R:8&9"3_[)ZWUJ;K3[SYU+7!W'@E31N73-(TBO>FI=5?W,AF@QI$ MG%X$GG=$'CBZO>-L<'2OLGA1NAJ'>9MO5C6]&;!P(.W--6?+T`Y`3127ASF4 M^T?5A@HQD1>FLC8A<"AD`U/T8^-,YROK`Z95T=MLL8VM6NR$!2L\DPUU$.D@ MUD&B@U0'F00L2,*0"9A:_T,FF`K+A(AA*X"4&BUL82%<0AU$.HAUD.@@U4$F M`25L6"!ZV"[L$?=7MZ@W%.,?;F%, M10V7$PA7JJL]U>HZ&(DLA8A$B,2()(BDB&0R43(`&Z^<@<=SFAFK@7(BUQ61 M$)$(D1B1!)$4D4PF2E2L@92.IL=1,6,U*DZT\NE'SF`TE`^1")$8D021%)%, M)DJ@<.X^'R@S5@/EQ'7&98E(B$B$2(Q(@DB*2"83)2H;3A$Y+-Y:3.:PCMM3 M6;QM*2Q46*=WZNI""]$W%DQ$#;?3!<1[3=8G[`3RAQ2$/7)@>,.N;,\\=?5& MHY6H?XRUDM%JU')L1]5*1RNAE0FM;JAJP:0:XG-L5QW3 M3C@NI,1P1Y_WURQ]46_E^EWGYLX7']#!S-(MM;FR,''E)*9GI*!BOA&`K'\6"+>N0[74ILS[/A5Z>J%`NW M<>$E`HU*Z1-*F>*F)H7U,5)2_MTBXLV0DJL>J=-'6QX[>[`:<\61/T88]5;> M@N?*7=I3^*+MT]*MCCRX3',K(6V M_G>L2X1%ZH_[4BC0N"]%`LW[B;5PETN\VI!4(OQ&J52@7LJ?^C,DE?5&3E&ULK%==CZ,V M%'VOU/^`>%^^$I*`DJQ"@':E5JJJW?:9@!/0`$;8FU-2VYS@KN\FJUA0,8?\1#GP^5SF*<7YM4$L%28_JC()^4E8=&=B: M_"-T3=:_7+M/.6XZH#A5=47?.:EI-'GXY=+B/CO5X/O-76;YP,U?9O1-E?>8 MX#.U@,X60N>>`SNP@6F_+2IPP,IN].B\,P]NF+J.:>^WO$#_5.A&E-\-4N+; M;WU5_%&U"*H-?6(=.&'\PD*_%`R"9'N6G?(._-4;!3IGUYK^C6^_H^I24FBW M#XZ8L;!XCQ')H:)`8WD^8\IQ#0+@7Z.IV-:`BF1O_'FK"EKNS(5GK5TG6*R! MY80(32M&:1KYE5#<_"N"7$DE2#Q)`L^!9&7Y:V?APIK/$A[3ZQN)*)\!P2GRNU1:%YW^*,9OMM MCV\&#`.4DG09&RTW!+:A86+ML87?ZR"TCI$<&,O.7)L&-(?`MGO=>QMW:[_" M5LEE3#2/F40S]#0`18,TZ)TP-T$NK9(QO`1Y@4^SI!XAB0S)%41 M33%L?U4QVTPP0>/0?7@[,1[8D/!0]I,W<2."%B!F#'*#E1YT'(/&?LR09(:D M*J(9!"NJP>8J^`FN&(?N2B">-ZH^2N0^ M"+%`?'CJ'\Z&LM,XB^Y.0DOF3JPH MKD?B,]N@_H*.J*Z)D>,KN_H$H'Y$Q;4L7H4P&Y`_Q==APCL[P>$:=^#5G.`1 MN]X]X(F\$+XR<_YH$<)A/L547 MY66EZ>.I-LHO6;DO+B\K[>^OWI>%-JJ;]+)/3^4E7VD_\EK[X_'WWQ[>R^JU M/N9Y,P*&2[W2CDUS=2:3.COFY[0>E]?\`G<.975.&_A9O4SJ:Y6G^];I?)H8 MTZD].:?%1:,,3O4K'.7A4&2Y6V9OY_S24)(J/Z4-O']]+*XU9SMGOT)W3JO7 MM^N7K#Q?@>*Y.!7-CY94&YTS)WBYE%7Z?()Q?]?--./<[0]$?RZRJJS+0S,& MN@E]43SFY60Y`:;'AWT!(R"RCZK\L-*>="?1%]KD\:$5Z)\B?Z^%_T?UL7SW MJV(?%Y<^[O'@Y-A!N M"T9$!N;L?[AYG8&B0#,V+,*4E2=X`?@[.ARQ-9_. M=#`?/>=UXQ6$4AME;W53GO^E1CJCHB0&(X$K)S''QL+2+?L.%I.QP)6QW/\F M-N.`*^,PQJ9AS1?M<&X,80W9_.W1F"\?)M\@`S-FL\8VNFRQX18DW0BMJP);%?!4P%>! MG0H$*A"J0*0"L0HD`C`!)3LY(1R?(2>A(7)R(=8<$/15M.,6W,55@:T*>"K@ MJ\!.!0(5"%4@4H%8!1(!D+2#[).T&YZ*>,81:YATA(S3+4/69,ULVIFP3:@- M0ER$;!'B(<1'R`XA`4)"A$0(B1&2B(@D&$QX=PA&K*'*X=+7Z&*J*$:-9O#( MSDBWE$+>=$9=KB%DBQ`/(3Y"=@@)$!(B)$)(C)!$1"0189:^0T1BW8K(A[ZF M""C&D0U"7(1L$>(AQ$?(#B$!0D*$1`B)$9*(B"0/+(AWR$.L97DH8K8[&5J" M"'$9`BMAGW2VDIE;Y.8-NBE+BM\9\?#L$%%`D1FDB/!\A2A$;A%%+)C.!#>E M5N+.B#\_$8DDJ6'UO$-J8BU+31%1:H2X#%EVV;I%-EYG(XY+F5K]SHB/:X>( M`HHHNEKRC!,BMX@BLJYS)1WBSH@_/Q&))%U)RR)N<6ZO*\1:UI4BHJX(<1DB MZ(ILO,Y&U'4FR^%W1GQ<.T044$31U9:)0N06443154GSN#/BST]$(DE7J-<[ M="76LJX4$75%B,L005=DXW4VHJZF+(??&?%Q[1!10!%%U[E,%"*WB")6OP+$ M"$E$+TE$'3HW246Z`1^3[J$Y%MGKNH39!;:;`UD[@XTVVWX3%EG=EGBEB?)B MR&60U6^1MMC*XU:T>R,[*))BQXC3F]U$%6,HD1QE M6;#GHEGS9IT7D1IJ(I^1'-E=MQPJSYO70;-[+8[FLVA/U3F MM"WV\AADP.36/\Y4!/2YU:+EGHYGBL$.,P?U(BADDC7^V^/PK>6>'B."*KJAF,^MEA_&#S$'LL]0_)!/Q'UNODW,K=C; MR'N[A-VE'B/Z6?TQ M[H_K#S$'G)GZ#,4/^437)SSZB7?Y*=3/UY<#G M-XSO;(>T5/A&:#OAX(W(=N![$W:(Y@Y\+QG`%P[T^P/XTH$6=@#7IPYIP_"= MM>VL!V]L;&,.U'=)\8JJM[9`6%-_P;`>^Y@W@

^1@W@"P>^I@S@2P>^ M!@S@,#K2UL*=21G?(#Y-NTS?&*'IK2'PWK8Y[+!@X[ MVY;F"(?;.;3*4]+L',JRX3_(`[KC\L?_````__\#`%!+`P04``8`"````"$` M^@^&3#,#```B"@``&0```'AL+W=OK:TJ,Y67",%-IP1.W MJ,A9.!Q.6<%E23W"0O?!4&DJ8W&OXFTA2NM!M,BYA?V;3%9FCU;$?>`*KI^V MU56LB@H@UC*7]M6!4E+$B\=-J31?YZ#[)1CS>(_M7H[@"QEK951J!P#'_$:/ M-<_9G`'2:IE(4(!A)UJD$;T-%G?!E++5T@7HKQ0[TWHF)E.[KUHFWV4I(-IP M3G@":Z6>T/4Q01,L9D>K']P)_-0D$2G?YO:7VGT3[UX-!U,9L-1`%P70)C?B--USRU?+;7:$4@6H#05Q]0+%@!\6@@H M0-];=([HC!+8JX'H/Z^"^?62/4/$XMKGSOO`]F;O,W9YTM8S_@@1.D/(X=9B.@QE[019 MVCA!O3?;Z403,J!_--'9L3?AK"TNX3JXTRXN)OQLALE](55P79>BMK2#&PZ# MTVH@Q?JK0>!IMIT0M-!8T!-X?2ZAZ:F231EB@T# MB;N:)F8P;^8@'DTQ*BF2MG]"S"SYN]N]1\` M`/__`P!02P,$%``&``@````A`(*-+')M!```>0\``!D```!X;"]W;W)K&ULK%==CZ,V%'VOU/^`>%^^\X62K)(0"%(K5=5N^TR( MDZ`!'&$RF?GWO<:&\<=LRJI]B8R!6AU@"&FJS,:]O> M0MLF^155&;'P#=7PGS-NJJR%Q^9BDUN#LE.75)6VYSA3N\J*VF0,83.&`Y_/ M18XBG-\K5+>,I$%EUL+\R;6XD9ZMRL?055GST=J&E4> MII<:-]FQ!-UO;I#E/7?WH-%71=Y@@L^M!70VFZBN>6$O;&!:+T\%**"V&PTZ MK\R-&Z:N8]KK96?07P5Z$.%O@USQ(VF*TV]%CZ`D>,7VAH>J(0)-M: M=MRMP!^-<4+G[%ZV?^+'`167:PO+/0%%5%AX>H\0R<%1H+&\"67*<0D3@%^C M*FAI@"/96S<^BE-[79G>W)I/)L%T/@.:(R)M7%!.T\COI,75WRS*Y5R,Q>,L M,'(6?VI-9H[OPDO'DOBE.?!^%,3G?$\&'F>/VZBL%F[B<+($V>C)KK@>3".F:C-:J,K MM2AKL_6RP0\#]B\L/KEEM!NX(7#U-<8L&JKN1T4'U49)-I1E98)X*"<".^5U M[)[ M0U'O-"32D+V&Q!J2:,A!0U(1D51!CQ95L=9ET0;?7HO\98MA66"S?U+1/K0H MUK@HARR6(^Q`I5UHIR$10SSHE\+*3^25WP]!O8^Q1I0,,2+15"8Z#$$]42H2 M299`!U8M\:;TZ^`S%P#N;:!YL@T<@6-)D*BT]!T/6@R%$3'$@V\=(4W9.'L> MY'8'Q4)6&VN#IP9^PS>PYM_V M9<#(- MH=GH.%QT-EWS5^*W]`+T2?S6"^%S0^?9^B&&ULK)E=;ZM&$(;O*_4_ M(.YC##;^0+:/8O--*U75:7M-,+91C+&`)"?_OK/L+M[=<7R9AY8=^= M70:R^/:C/&JO>=T4U6FIFX.AKN6GK-H6I_U2_^N[_S#3M:9-3]OT6)WRI?Z> M-_JWU:^_+-ZJ^KDYY'FK@<*I6>J'MCT[AM%DA[Q,FT%USD]P9E?59=K"G_7> M:,YUGFZ[I/)H6,/AQ"C3XJ13!:>^1Z/:[8HL=ZOLIN3.OGE_-#5I5GD'@JCD7[WHGJ6IDYT?Y4U>G3$<;]PQRG&=?N_D#R M99'555/MV@'(&?1&\9CGQMP`I=5B6\`(B.U:G>^6^J/I).94-U:+SJ"_B_RM M$7[7FD/U%M3%]K?BE(/;,$]D!IZJZIF$1EN"(-E`V7XW`W_4VC;?I2_']L_J M+54XV]TY''F"W=_YC;N%<75Y<.1YMR\T80EP9`GCPP5-<%7@J\%40J"!40:2"6`6)`"1G8-.0 MG+F^^_%J(=%+'7X*U6+)(UZSF&[S[8IA@XB+B(>(CTB`2(A(A$B,2"(2R0S8 MS3YA!HF&U0<'P0UE9:QIT`@*4P@:R99M^J"^2A#Q$/$1"1`)$8D0B1%)1"(9 M!+OV)PPBT9U!?%AK2D:C?@5M$'$1\1#Q$0D0"1&)$(D1240B#1V>8=+0R7YK MV0.(_^2.2X1D5R@!5\0:&2LUT@=Q,UU$/$1\1`)$0D0B1&)$$I%(1L&S1#+J M]HY"HF4W*!E9EQI!Q$7$0\1')$`D1"1")$8D$8DT=/)J(#Z3;P^=1,M#9X1V MF^0YND'$903L%S846RX6#Z7YE-CP&!#2)G):T`?Q&@N14-3'B$)362CN@[A0 M(@I)GD'?)7E&^Y@!:1#;0Y$]KRNX8=@^KW@Y@GZ%=C%$1+:2$<%*1%Q&8#H% M3V;R4#R4YE-BS6FW-#25E1KTY_G@0Z01]3%=QX4TXOX\UTA$#*O@EG5ILF<AB91H#^5$#R?Z#%DPA/Z*YEB9 M@H!'F9WC,Z780ZP;\8R;NC&/NJZ;2+JRY:3/%!?ZEXJ6=.U*U3)D2E5;[55-&F5= MIM]E"(J/F^3A*)^CRTP%'-$B>3!-9<#E8A%'%YF8HX]D$AYPI=I(J_O? MS:0-LV0F1;;TG$9;*2UPG8%*2R1%$^B[+$1]>5?9,F6K-N(:,Z1;+1 M7;(QC[HJF["S9C#]S,?(P M\C$*,`HQBC"*,4HD))M&>G%N&NSH/WE8T,Y=,H:BKIBH,OU@3+^UE7F]SS?Y M\=AH6?5"/@;#_*T6/:9?JM>V`^^-4(TJGSCPFG2%3QUXA[C"31"""UP[`U+@ M`C[CSQQHVS&/9@YTX9C[Q53QT:^SE^)7UL.?&O" M.NN1`]]=,'\<.X_T*[]Z@;$#WR$@P>A/P-?W<[K/?T_K?7%JM&.^@PD9=J\* M-?U^3_]HV3[R5+7PX;W;4@[P?Y8<7JB&Y(5]5U4M_X-I?````__\# M`%!+`P04``8`"````"$`8K0,/*0#```=#0``&0```'AL+W=OPDV=P14[5;=K;0KK59[>3:)0ZPF M<62;TO[]SCB78A)*>"%DF)SC,QZ?#*O;URSU7KC20N9KGPR&OL?S4$8BWZW] M/[\?;^:^IPW+(Y;*G*_]-Z[]V\WG3ZN#5,\ZX=QX@)#KM9\84RR#0(<)SY@> MR(+G\$LL5<8,W*I=H`O%660?RM*`#H?3(&,B]TN$I>J#(>-8A/Q!AON,YZ8$ M43QE!M:O$U'H&BT+^\!E3#WOBYM09@5`;$4JS)L%];TL7#[MCOQ@L[(% M^BOX01]]]W0B#U^5B+Z+G$.U89]P![92/F/J4X0A>#AH/?UH=^"G\B(>LWUJ M?LG#-RYVB8'MGH`B%+:,WAZX#J&B`#.@$T0*90H+@$\O$]@:4!'V:J\'$9ED M[8_&`SJ?D,D4\KTMU^91(*;OA7MM9/:OS"(55HE"*Q2XUBC3P60V')'+($&Y M(BOP@1FV62EY\*!K@%(7#'N0+`&X6Q%(P=P[3%[[,]^#M6K8AI<-)=-5\`*E M"ZN<^S('/ILBAJ+*(YI&@72.LJ&G5W';ZJKE#4M@0+8-E@`8XGD"Y3 MZ*&H;0D6J:5H?$;15:9`VJY0ASKVJ,L7Z+R'S9&V-]0A=YLF9T1=Y0ZD;0]U MJ"V*=OG#%*:'2X?)/NBV=QUR-;V/`4Y_T*OLP6:?L%7V`)?W-Q]]?R>[;!V. M,1XN!M!M'WL&;7M&'7)EGGGEPO!YQ0FSV2I M]D*YQT&3PO351)LA^([B5'(:'R_ORN$X:'Z!X;1@._Z#J9W(M9?R&#"']G6A MRO&VO#&R@'7"A"H-3*7V:P)_0SA,8$-LGEA*4]^@-31_;#;_`0``__\#`%!+ M`P04``8`"````"$`:\-[F(H#``"]#```&0```'AL+W=O%"LEXOD%XXB&'YB&/6+[?H-^_ MGFYND2,5R2.2\IQNT!N5Z&[[\#\5-R+,"0NQ8RM2;"8J<+%Q]W>=J"C=A?%6ULT%OREI9S!18W9I?$U<[VW$K MBTWA3,?@?HVGH)UMJ,K2IZ!UM'75S?AY_F0!G"\W21^T,2J+?4&"YH)8E5O: ML)>AM+,-55GZ=#`4L\MG^>[--J=LA-IDLYD.L\%ZOEM5O$S'>'?0*H$8(-11 M!-T@?ZZU\)W^X$H,S"R6PUF;[`LW.\-)C_)X3N7@P\PV4X,KTP"GCAH83K=X M#*E&&DXPEH+`ZY,-J?%&4Y7 M20/N:T-M&N#TW^J`^_)0FVQ2MV=(7240N*\0M:E/RA^0"'\V&R%YYJ0]N+7) M)G7Z^;=$S[]*)HQW!^VL3/A#,N%-QY#JZX0)!L@6J>GII]XF!5[C1PI6R:Z6 M5Z;6SE`NB^5&EE&QIY]HFDHGY`>]"/JP8S769DF]][7R=.W3U7VYO+K--[`\ M%F1/OQ.Q9[ET4AI#3,\42I3K9_F@>`$E@!62*U@;S<<$_B90V+,\/=0QYZI^ M`&2W^>.Q_0<``/__`P!02P,$%``&``@````A`-VK^%NZ!0``YQ@``!D```!X M;"]W;W)K&ULG%G;;N,V$'TOT'\0]+Z62 M)%ULNT`7*(I>GA69MH58HB$IE_W[#B\217%L2WU)8O)P.&9V.?E<1O^_=?73P]A4#=IN4_/HN3;\`>OP\^[GW_:O(OJ MI3YQW@1@H:RWX:EI+NLHJK,3+])Z)BZ\A)F#J(JT@8_5,:HO%4_W:E%QCNA\ MGD1%FI>AMK"NQM@0AT.>\2\B>RUXV6@C%3^G#?A?G_)+W5HKLC'FBK1Z>;U\ MRD1Q`1//^3EO?BBC85!DZV_'4E3I\QEX?Y`XS5K;ZH-GOLBS2M3BT,S`7*0= M]3FOHE4$EG:;?0X,9-B#BA^VX2-9/\6+,-IM5(#^R?E[W?L[J$_B_= MEQRB#7F2&7@6XD5"O^WE$"R.O-5?50;^J((]/Z2OY^9/\?X;SX^G!M*]`$:2 MV'K_XPNO,X@HF)E1Y48FSN``_`R*7)8&1"3]V(84-L[WS6D;LF2V6,X9`7CP MS.OF:RY-AD'V6C>B^%>#B')*VU*N?4F;=+>IQ'L`^09T?4EE]9`U&&Y]TA8Z M+Z\Y"=Y)(X_2RC9-`9^=AC2(2+PIG,)W.B[ MA(>GW5F"Y.7*DQ[H;T/Q;=B4;208XMUWGJPZNWIGC8E5N/M\8G-%%,MC2@(!S#[3L0$Y8H4;&AU6"U>Y=7/6(SRYQS4IVE$'X M;Z=-KO+8/72.ZX`:4)\=H5>R";4WGIT$N^STB,].:N^P/>9L!L&XS4^N\_@- M"\:`7'ZL"X*3/:B7OB.W=Y=@EY\>\?D14+&^796^^>(^0;5PR#"9=\[K#+8H MEV+EA;'F?I5KH]:3M-LVR1?5[DB97RI5.DAZ% M=E-IAA"64AIZC:"D9Q&/8&DT!;K.GNV)+47#TJ#Z+`FS,NSDDDY2'H4>L+QV MQ:&(\B0+>8V]TY9JH9=+6XN&)28]S*JPRW*2]$@7!V>E&4)RB4C/$IKIMO)0 M5'F&=X$6Y2;2:K!+<9+R4"TS?74U0PA%1'G(J'+%I&=I"]$D$I,>9E7893E) M>N2->IA(/>2S9(CTD%'W`;5R6*]+6XF:9HMRDVEUV*$I+\M]A;A=30KM=J49 M0FA*T0DKB!V-RI_$YANILPTT-(^`;2(4_=U7S$?9]U*F+33Y>V*`(AOPPG+_9A8;B8!?G430I94($T"#<@(8 MVP/1#>`D(8%'2B^`GI#H9TC]UE?PZLA_X>=S'63B53XQPNUXM^F&S?MG3-:/ M$$%H+V\FAAGU)CF1WZ1L!K>&!%UA"P!E_(L!GP&KZR(#,4O(9K/C8#7L-M&9L!#^`ZB0["=P5MX0H"9J`L8/#-?TB/_GE;'O*R#,S]` MC6B]K/1#M?[0B`MT%SPVBP8>F-6?)_B'`H7B^CW*^TTWR"`T_[/"WUR MUM0J[&V<:=`]9TMQ#,?VSJNQV'5=UDUZC>A/\,ORX:D?-57FL"L!B!WVTW`? MEG&5&P7R=L]V;ZY)O-^6^'=62M';4>&`!Y!)?(\>[4[)>G)WOUH@5N3D*B5% M2J:K@M#I#26SUQ*?6L-]-@+U(/!OX@G`>N^??\Z^````__\#`%!+`P04``8` M"````"$`0U81Q98```"J````$````'AL+V-A;&-#:&%I;BYX;6P\CD$*`C$0 M!.^"?PAS=V?7@X@D65#P!?J`D!U-()DLF2#Z>^/%2T/14-UZ?N>D7E0E%C8P M#2,H8E^6R$\#]]MU=P0ES?'B4F$R\"&!V6XWVKOD+\%%5MW`8B"TMIX0Q0?* M3H:R$O?F46IVK6-]HJR5W"*!J.6$^W$\8.X"L-JK:N`\3:!B/P$J_1*MQO^* M_0(``/__`P!02P,$%``&``@````A`.:PGN[W`@``EPD``!``"`%D;V-0&UL(*($`2B@``$````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````G%;;;IM`$'VOU'^P>$]P+FJK"!-M@,2HP+KLXLI]01M8QR@8$+NQDGY] M!Z@=G"Q(R=M>9LZ<.3-[,:Z?M_EDQVN1E<5,.SN=:A->)&6:%0\S+:*W)S^T MB9"L2%E>%GRFO7"A79M?OQB+NJQX+3,N)@!1B)FVD;*ZTG61;/B6B5/8+F!G M7=9;)F%:/^CE>ITEW"Z3IRTOI'X^G7[3^;/D1GQHD M83FW`-A%<"D,'@VZQ'?9M^^/LTKSXWEK`Z-BR0>B8 MP,8Q1YK)G`N\7K!:*BA??.]S;EETC#M"^RK&J$ACIY"@5^P67;6SLL_\D(.% M`]L)B&/',"+8NA0(:(\O"44"5+FZP=`**0]<9 M@*38^GF#NAKX"ZA&RT6)%>(5\N@04H"I0^(%6J$;3RTJF:/0F6//=D(2.[\B MEZZ4<8".:[5JV*X7-1WA80+03A@#A-(E=+RV=18HI*N8A@CRL!I1U5E;V/== MZH,RZGT/!W>>NX3(B!!GP&B\&NH>Z94CINP>CILR':*NRIC+D?QCAN/JJFF_ MU6,,?["E8YM+IDYWM*_5)Z>O9`.\)=3Z#Y^X)IHR3._4]1@-J_2N MZ\:$&C+NM.KS.7H!W[QY7E8\BJBBI79Y.KV8PN^BMV;HKS\J\Q\```#__P,`4$L! M`BT`%``&``@````A``%""@7U`0``3!@``!,``````````````````````%M# M;VYT96YT7U1Y<&5S72YX;6Q02P$"+0`4``8`"````"$`M54P(_4```!,`@`` M"P`````````````````N!```7W)E;',O+G)E;'-02P$"+0`4``8`"````"$` M[M'D,`("``!/%P``&@````````````````!4!P``>&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"+0`4``8`"````"$`EP#U:)0#``"7"P``#P`````` M``````````"6"@``>&PO=V]R:V)O;VLN>&UL4$L!`BT`%``&``@````A`)4_ MH]?O`P``W`X``!@`````````````````5PX``'AL+W=O&UL4$L!`BT`%``&``@` M```A`&<);GF*"```K2X``!D`````````````````W!<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'IS99B*`P``.0L``!@````````` M````````%3```'AL+W=O&UL4$L!`BT`%``&``@````A`,(EX=,%"P``5D$``!D` M````````````````3C<``'AL+W=O&PO M=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/R( M):O]0P``Y.4``!0`````````````````WU```'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`-+'C2I6#```.G0```T````````````````` M#I4``'AL+W-T>6QE&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0` M!@`(````(0"Q&9P)<0,``&@+```9`````````````````%2H``!X;"]W;W)K M&UL4$L!`BT`%``&``@````A`"=\#.&S`P``[`T` M`!D`````````````````_*L``'AL+W=O&PO=V]R:W-H965T%M'Z MK@(``,@&```9`````````````````/ZR``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`.*H,/-_!```6P\``!D````````````` M````X[4``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`!ETZ4#+!```?1$``!@`````````````````$L@``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&B\EY?] M`P``1`X``!@`````````````````P]4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`)6SX"]:!0``^1,``!D`````````````````4.H``'AL+W=O&UL4$L!`BT`%``&``@````A`/H/ADPS M`P``(@H``!D`````````````````JOL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&*T##RD`P``'0T``!D````` M````````````4`H!`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`*?PU2&UL4$L!`BT`%``&``@````A`$-6$<66````J@`` M`!``````````````````1AH!`'AL+V-A;&-#:&%I;BYX;6Q02P$"+0`4``8` M"````"$`YK">[O<"``"7"0``$``````````````````*&P$`9&]C4')O<',O =87!P+GAM;%!+!08`````+P`O`+(,```W'P$````` ` end XML 14 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
BASIC AND DILUTED LOSS PER SHARE (Details)
 3 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Class of Stock [Line Items]    
Total 15,839,950us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 16,064,950us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Stock Options [Member]    
Class of Stock [Line Items]    
Total 378,750us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AwardTypeAxis
= us-gaap_EmployeeStockOptionMember		 538,750us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AwardTypeAxis
= us-gaap_EmployeeStockOptionMember
Series C Preferred Stock [Member]    
Class of Stock [Line Items]    
Total 1,551,200us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 1,551,200us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember
Series D Preferred Stock [Member]    
Class of Stock [Line Items]    
Total 13,910,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		 13,975,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember

XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)
In Thousands, unless otherwise specified
Oct. 31, 2014
Jul. 31, 2014
Oct. 31, 2013
Jul. 31, 2013
Cash, end of period $ 42us-gaap_CashAndCashEquivalentsAtCarryingValue $ 21us-gaap_CashAndCashEquivalentsAtCarryingValue $ 187us-gaap_CashAndCashEquivalentsAtCarryingValue $ 296us-gaap_CashAndCashEquivalentsAtCarryingValue
XML 17 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9
LONG-LIVED ASSETS (Details Textual) (USD $)
 3 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Jul. 31, 2014
Jun. 30, 2014
Long Lived Assets [Line Items]        
Depreciation, Total $ 0us-gaap_Depreciation $ 2,000us-gaap_Depreciation    
Property, Plant and Equipment, Gross 111,000us-gaap_PropertyPlantAndEquipmentGross   111,000us-gaap_PropertyPlantAndEquipmentGross  
Inventory Exchanges [Member]        
Long Lived Assets [Line Items]        
Long-Lived Assets       0us-gaap_NoncurrentAssets
/ us-gaap_NonmonetaryTransactionTypeAxis
= us-gaap_InventoryExchangesMember
Furniture and Fixtures [Member]        
Long Lived Assets [Line Items]        
Property, Plant and Equipment, Gross $ 25,000us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_FurnitureAndFixturesMember		      
XML 18 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
INVENTORIES
 3 Months Ended
Oct. 31, 2014
Inventory Disclosure [Abstract]  
INVENTORIES
3.                  INVENTORIES
 
The Company’s inventory consisted of the following at October 31, 2014 and July 31, 2014 (in thousands):
 
 
 
October 31, 2014
 
July 31, 2014
 
Work-in-progress, spare parts and accessories
 
$
9
 
$
9
 
Finished goods
 
 
446
 
 
446
 
Total inventories
 
$
455
 
$
455
 
EXCEL 19 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B,&,V-#'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DE.5D5.5$]22453/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I7;W)K#I% M>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D)!4TE#7T%.1%]$24Q55$5$7TQ/4U-?4$52 M7U-(03PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)% M3$%4141?4$%25%E?5%)!3E-!0U1)3TY3/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.5D5.5$]224537U1A8FQE#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-43T-+0D%3141?0T]-4$5.4T%4 M24].7U1A8FQE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DY/5$537U!!64%"3$5?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQ/ M3D=,259%1%]!4U-%5%-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H M965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DE.5D5.5$]224537T1E=&%I;',\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$537U!!64%"3$5?1&5T86EL#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DY/5$537U!!64%"3$5?1&5T86EL M#I%>&-E M;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)%3$%4141?4$%25%E?5%)!3E-!0U1)3TY37T1E=#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/34U)5$U%3E137T1E M=&%I;'-?5&5X='5A;#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQ/3D=,259%1%]!4U-%5%-?1&5T86EL#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DQ/3D=,259%1%]!4U-%5%-?1&5T M86EL#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C M=%-T#I0#I0 M#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T* M("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I M=&@@36EC'1087)T7V(P8S8T-S,Y7S=B,CA? M-#$Y,U]A864R7S4S,#,U9C8V.6(Q9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL M93HO+R]#.B]B,&,V-#'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^,3`M43QS<&%N M/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA M;&QE3QS<&%N/CPO6UB;VP\+W1D/@T* M("`@("`@("`\=&0@8VQA2!#;VUM;VX@ M4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6%B;&4@+2!296QA=&5D('!A6%B;&4@86YD(&%C8W)U960@97AP96YS M97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D.R`W.2PP,#3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XU+#4P,#QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V M-#'0O:'1M;#L@8VAA'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V M-#'0O:'1M;#L@8VAA&-E<'0@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]B,&,V-#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@86YD(&%C8W)U960@97AP M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P87)E;G0G/B`\8CX\:3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D]R9V%N:7IA=&EO;BX\+V9O;G0^ M/"]I/CPO8CX@/&9O;G0@7-T96US+"!);F,N+"!A($9L;W)I9&$@ M8V]R<&]R871I;VX@*'1O9V5T:&5R('=I=&@@:71S(&-O;G-O;&ED871E9"!S M=6)S:61I87)I97,L('1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3L@;W(@)B,X M,C(P.TY)35,F(S@R,C$[*2P@8F5G86X@8G5S:6YE2X@5&AE($-O;7!A;GD@;F]W(&9O8W5S97,@;VX@9&5V96QO<&EN9R!A;F0@ M;6%R:V5T:6YG(&ET&5R+5)E6QE/3-$9F]N="US='EL M93IN;W)M86P^)B,Q-S0[/"]S=7`^(&QI;F4@;V8@86-C96QE2!P97)I;V1I8R!A8V-E;&5R871I;VX@*"8C.#(R,#M7 M0E!!)B,X,C(Q.RD@=&5C:&YO;&]G>2X@5&AE($5X97(M4F5S="!L:6YE(&]F M(&%C8V5L97)A=&EO;B!T:&5R87!E=71I8R!P;&%T9F]R;7,@8W5R&5R+5)E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P87)E;G0G/B`\8CX\ M:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D)U&5R+5)E2!I;F-L=61E2!R96-E:79E9"!R979E;G5E(&9R M;VT@2!R979E;G5E(&9R;VT@4V5N M2!P;&%N(&]F(')E;W)G86YI>F%T:6]N M+"!O=7(@;&EC96YS92!W:71H(%9I=F]-971R:6-S('=A2!R M979E;G5E+"!I9B!A;GDL('1H870@=V4@;6%Y(&1E&ES=&EN9R!L:6-E;G-E('=I=&@@4V5N M65A&5R+5)E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M=#L@0D%#2T=23U5.1#H@=')A;G-P87)E;G0G/B`\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL M93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE2!H87,@9&5V96QO<&5D(&$@=&AI&5R+5)E&5R+5)E6QE/3-$9F]N="US='EL93IN;W)M86P^/"]S=7`^050T-S`P*2!T M:&%T(&AA9"!B965N(&UA;G5F86-T=7)E9"!B>2!3:6YG($QI;B!496-H;F]L M;V=I97,@0V\N($QT9"X@*"8C.#(R,#M3:6YG($QI;B8C.#(R,3LI(&)A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@0D%#2T=2 M3U5.1#H@=')A;G-P87)E;G0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0G/E1H92!#;VUP86YY)B,X,C$W.W,@8V]N9&5N6EN9R!U;F%U9&ET960@8V]N9&5N6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2P@86YD(&AA M'!E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!H860@)#QF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2`D/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P87)E M;G0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D%B2!W:6QL(&QI:V5L>2!N965D('1O(&EN8W5R(&%D9&ET:6]N M86P@9&5B="P@97%U:71Y(&9I;F%N8VEN9R!O2!T;R!C;VYT:6YU92!I=',@8G5S M:6YE2!F:6YA;F-I;F2X\+V9O;G0^/"]D:78^(#PO9&EV/B`\+V1I=CX\ M=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L92UL M87EO=70Z9FEX960[)R!C96QL3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V-#'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<^(#QB/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#(N M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[ M)B,Q-C`[)B,Q-C`[(%-534U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E. M1R!03TQ)0TE%4SPO9F]N=#X\+V(^/"]D:78^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P87)E;G0G/B`\ M8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!A;F0@:71S M('=H;VQL>2UO=VYE9"!S=6)S:61I87)I97,L($YO;BU);G9A2!A8V-E<'1E M9"!I;B!T:&4@56YI=&5D(%-T871E&5S M+B!!8W1U86P@2!F6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&EM M871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P87)E;G0G/B`\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@/&1I M=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6%L=&EE2!A28C.#(Q-SMS(&9U='5R92!B860@9&5B="!E>'!O6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!C;VYS:7-T960@;V8@9FEN M:7-H960@17AE7-I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@2!N;W0@8F4@6EN9R!A;6]U;G0@;V8@=&AE(&%S6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^ M(#QB/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@ M&5S($%S2!P6QE/3-$)T9/3E0M1D%- M24Q9.B`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`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT M(&-O'!E;G-E9"!A2!C;VYS:7-T(&]F('!A>6UE;G1S('1O('1H:7)D('!A6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GDF(S@R M,3<[65A2X\+V9O;G0^ M/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@F5D(&]V97(@=&AE('9E6EN9R!S=&]C:R!O<'1I;VYS(&%N9"!I M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2`S,2P@,C`Q-"X@5&AE(')E6%L=&EE6%B;&4@86YD(&%C8W)U960@97AP96YS97,@87!P M6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^07,@;V8@3V-T;V)E6%B;&4@)B,Q-3`[(')E;&%T960@<&%R='D@86YD(&YO=&5S('!A>6%B M;&4@)B,Q-3`[(&]T:&5R(&%P<')O>&EM871E(&]U2!A;F0@87)E(&-O;G-I9&5R960@3&5V96P@,R!M M96%S=7)E;65N=',@=VET:&EN('1H92!F86ER('9A;'5E(&AI97)A2X@ M3&5V96P@,R!);G!U=',@=&\@=&AE('9A;'5A=&EO;B!M971H;V1O;&]G>2!A M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!F;W(@ M=&AE($-O;7!A;GDF(S@R,3<[2!T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^5V4@2!T;R!O8V-U6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B2!S:&]U;&0@2!E>'!E8W1S('1O(&)E(&5N=&ET;&5D M('1O(&EN(&5X8VAA;F=E(&9O2X@5&AE('5P9&%T92!I&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!$:7-C;&]S=7)E(%M!8G-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="<^(#QS=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G(&%L:6=N/3-$8V5N=&5R M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!4 M15A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS M1"=-05)'24XZ(#!I;B`P:6X@,&EN(#`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`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T M<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0V,"4^(#QD:78^5&]T86P@:6YV96YT;W)I97,\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!# M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/ M4#H@(S`P,#`P,"`Q<'@@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-#4U/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]B,&,V-#'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4Z(#@N-6EN(#$Q+C!I;B<^(#QD M:78@6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^/&)R+SX@5&AE($-O;7!A;GD@;65A'!E;G-E9"!O=F5R('1H92!V97-T M:6YG(&QI9F4@;V8@=&AE('5N9&5R;'EI;F<@2P@9F]R('1H92!T:')E92!M;VYT:',@96YD960@3V-T;V)E28C M.#(Q-SMS(#(P,#`@4W1O8VL@3W!T:6]N(%!L86XL(&%S(&%M96YD960@*'1H M92`F(S@R,C`[,C`P,"!0;&%N)B,X,C(Q.RDL('!R;W9I9&5S(&9O2!T:&4@8V]M<&5N28C.#(Q-SMS($)O87)D(&]F($1I&5R8VES92!P28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A&5R8VES92!P'!I'!I2!B92!M861E('5N9&5R('1H92`R,#`P M(%!L86X[(&AO=V5V97(L('!R979I;W5S;'D@9W)A;G1E9"!O<'1I;VYS('=I M;&P@6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C(U:6XG/B`\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE2!D:60@;F]T(&=R86YT(&%N>2!S=&]C:R!O<'1I M;VYS(&1U6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^/&9O;G0@2!O9B!T:&4@0V]M<&%N M>28C.#(Q-SMS('-T;V-K(&]P=&EO;B!A8W1I=FET>2!F;W(@=&AE('1H6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,VEN.R!-05)'24XZ(#!I;B`P:6X@,'!T)SX@/&9O;G0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P:6X@,"XU:6X[(%=)1%1(.B`X-24[($)/4D1%4BU# M3TQ,05!313H@8V]L;&%P"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`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`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\ M9&EV/FXO83PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!# M3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2 M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CYN+V$\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4 M.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C`N,S@P/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^,2XX.#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,3`E/B`\9&EV/C,W."PW-3`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,3`E/B`\9&EV/C$N.#@\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C,W."PW-3`\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,3`E/B`\9&EV/C$N.#@\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO M9&EV/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE'!I'!IF5D(&-O3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]B,&,V-#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6%L=&EE'0^/&1I=B!S='EL93TS1"=-05)'24XZ M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4Z(#@N-6EN M(#$Q+C!I;B<^(#QD:78@2!I2!I;F-O M;64@9G)O;2!T:&4@2!R96-E:79E9"!R;WEA;'1I97,@9G)O;2!6:79O365T2X\+V9O;G0^/"]D:78^(#QD:78@ M2!I6%L='D@'!E8W1E M9"!T;R!B92!M:6YI;6%L('1O(&YO;F4N(%1H97)E('=E2!P;&%N(&]F(')E;W)G86YI>F%T:6]N+"!O=7(@;&EC M96YS92!W:71H(%9I=F]-971R:6-S('=A2!I;F-O;64L(&EF M(&%N>2P@=&AA="!M87D@&5D.R<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<^(#QS=')O;F<^/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^,C`Q,"!#2!E;G1E6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!C;VYT2!-871U2!$871E+"!A;F0@86UO=6YT6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X@ M,&EN(#!P="<^(#QD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^,C`Q,2!02!N;W1E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!N;W1E(&ES(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!M87D@<')E<&%Y(&5I=&AE2X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^3VX@36%Y(#,P+"`R,#$R+"!T:&4@0V]M<&%N>2!E M;G1E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!C;VYT&5C=71I=F4@3V9F:6-E2!.24U3(&]N('1H92!(6%B;&4@;VX@=&AE(&UA='5R:71Y(&1A=&4@;V8@2G5L M>2`S,2P@,C`Q-2X@5&AE($AS=2!'86UM82!.;W1E(&UA>2!B92!P2X\+V9O;G0^/"]D:78^ M(#QD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^3VX@1F5B6%B M;&4@;VX@=&AE(&UA='5R:71Y(&1A=&4@;V8@2G5L>2`S,2P@,C`Q-2X@5&AE M(#(P,3,@2'-I86\@3F]T92!M87D@8F4@<')E<&%I9"!I;B!A9'9A;F-E(&]F M('1H92!06QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-VEN.R!-05)'24XZ(#!I;B`P M:6X@,'!T)SX@/&9O;G0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^,C`Q-"!02!N;W1E("AT:&4@)B,X,C(P M.S(P,30@2'-I86\@3F]T928C.#(R,3LI(&EN('1H92!P6%B;&4@;VX@=&AE(&UA='5R:71Y(&1A=&4@ M;V8@2G5L>2`S,2P@,C`Q-2X@5&AE(#(P,30@2'-I86\@3F]T92!M87D@8F4@ M<')E<&%I9"!I;B!A9'9A;F-E(&]F('1H92!-871U2!$871E('=I=&AO M=70@<&5N86QT>2X\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6UE;G1S("AE>&-L=61I;F<@:6YT97)E#IA=71O.R!724142#H@-C`E.R!"3U)$ M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0T-R4^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0T-R4^(#QD:78^,C`Q-3PO9&EV/B`\ M+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^,2PR-3`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V-#'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE MF4Z(#@N M-6EN(#$Q+C!I;B<^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P:6X@,&EN(#!P="`P+C(U:6X[($)!0TM'4D]53D0Z('1R86YS<&%R96YT M)R!A;&EG;CTS1&IU6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P87)E;G0G/B`\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@ M0D%#2T=23U5.1#H@=')A;G-P87)E;G0G/B`\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/E-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG7,@<')I;W(@=W)I='1E;B!N;W1I8V4N(%1H:7,@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P M87)E;G0G/B`\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P M.SPO9F]N=#X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS($-H86ER;6%N(&]F('1H92!";V%R9"!A;F0@26YT97)I;2!# M:&EE9B!%>&5C=71I=F4@3V9F:6-E2!C;VYT28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!F;W(@=&AE('1H3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B M,&,V-#'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UEF4Z(#@N-6EN(#$Q+C!I;B<^(#QD:78@&5R8VES92!O9B!S M=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,VEN.R!-05)'24XZ M(#!I;B`P:6X@,'!T(#`N,C5I;B<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G(&%L:6=N/3-$8V5N=&5R/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT97([(%1%6%0M24Y$ M14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X.F%U=&\[(%=)1%1(.B`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`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-24^(#QD:78^,2PU-3$L,C`P M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C M8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M-24^(#QD:78^,3,L.3$P+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y' M+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/ M3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52 M+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V-#'0O:'1M;#L@8VAA2!4'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4Z(#@N-6EN(#$Q+C!I;B<^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE M($-O;7!A;GD@2`Q+"`R M,#`X(&%N9"!E>'!I2`D/&9O;G0@2!O;B!A(&UO;G1H M+71O+6UO;G1H(&)A2!R96-O2`D/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A M;GD@65A2!C;VYT6UE;G1S('5N9&5R('1H92!(:6%L96%H('=A2`S,2P@,C`Q,BP@=&AE;B!C;VYT:6YU M960@;VX@82!M;VYT:"UT;RUM;VYT:"!B87-I'!E;G-E(')E;&%T960@=&\@=&AE($AI86QE86@@=V%R96AO=7-E(&]F(&%P M<')O>&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2P@9F]R('1H92!T:')E92!M;VYT:',@ M96YD960@3V-T;V)E2!C;VYT2!O=VYS(&EN(&5X8V5S&5C M=71I=F4@3V9F:6-E2!.24U3(&]N('1H92!(6%B;&4@;VX@=&AE(%!R;VUI2!B92!P2X\+V9O;G0^/"]D:78^(#QD:78@ M2`R,BP@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<')O M;6ES2!N;W1E(&EN('1H92!A;6]U;G0@;V8@)#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS($-H86ER;6%N(&]F('1H92!";V%R9"!A;F0@ M26YT97)I;2!#:&EE9B!%>&5C=71I=F4@3V9F:6-E2!T:&4@0V]M<&%N>2!O;B!T:&4@,C`Q,R!(6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2!.;W1E M2!$871E+B!4:&4@,C`Q,R!(2!B92!P M2X\+V9O;G0^ M/"]D:78^(#QD:78@&5C=71I=F4@3V9F:6-E2!.24U3(&]N('1H92`R,#$T($AS M:6%O($YO=&4@:7,@/&9O;G0@2!D871E M(&]F($IU;'D@,S$L(#(P,34N(%1H92`R,#$T($AS:6%O($YO=&4@;6%Y(&)E M('!R97!A:60@:6X@861V86YC92!O9B!T:&4@36%T=7)I='D@1&%T92!W:71H M;W5T('!E;F%L='DN/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@:6YC=7)R960@ M:6YT97)E2X@07!P2`D/&9O;G0@2`S,2P@,C`Q-"P@"8C.#(R,3LI+"!A('!U M8FQI8VQY+71R861E9"P@;65D:6-A;"!D979I8V4@;6%N=69A8W1U2P@ M86YD(%1I9V5R($UE9&EA+"!);F,N("@F(S@R,C`[5&EG97(@365D:6$F(S@R M,C$[*2`H9F]R;65R;'D@:VYO=VX@87,@4V5A2!I;B!#:&EN82X@5&AE($-O;7!A;GDF(S@R,3<[ M2!T:&4@=&]T86P@"!W97)E('-H87)E9"XF(S$V,#LF(S$V,#M3:6YC92!$96-E;6)E M28C.#(Q-SMS($-H:65F($QE9V%L($]F9FEC M97(@:&%S('-E"!A;F0@5&EG97(@6"X@5&AE($-O;7!A;GD@"!R96QA M=&5D('1O('1H97-E(&%R&EM871E M;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4Z(#@N-6EN(#$Q+C!I;B<^(#QD M:78@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^5&AE($-O;7!A;GD@:7,@=6YD97(@86X@;W!E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q M-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^1V5N97)A;&QY+"!T:&4@;&5A6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2X\+V9O M;G0^/"]D:78^(#QD:78@2!C M;VYS:6=N960@=&\@4VEN9R!,:6X@=&AE(&1E=F5L;W!M96YT(&%N9"!D97-I M9VX@;V8@=&AE(&YE>'0@9V5N97)A=&EO;B!%>&5R+5)E'1E;F1E9"!T M:')E92!Y96%R65A2!O9B`D/&9O M;G0@7!E(&-O;F-E<'1S(&%N9"!D97-I9VYS+B!4:&4@8F%L86YC92!O9B!T M:&4@9FEN86P@=&]O;&EN9R!C;W-T(&)E8V%M92!D=64@86YD('!A>6%B;&4@ M:6X@4V5P=&5M8F5R(#(P,#@@=7!O;B!A8V-E<'1A;F-E(&]F('1H92!F:7)S M="!U;FET6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^56YD97(@=&AE(&YO=RUT97)M:6YA=&5D($%G6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@ M,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q M-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^5&AE($%G2`D,BXV(&UI;&QI;VX@;V8@17AE M65A2!T;R!P M=7)C:&%S92`D/&9O;G0@6%B;&5S(&1U92!T;R!3:6YG($QI;BX@07,@;V8@ M3V-T;V)E2`D/&9O;G0@2!H860@;F]T('!L86-E9"!O2`R,#$P(&1E;6%N M9&5D('1H870@=&AE($-O;7!A;GD@<&QA8V4@;W)D97)S('-U9F9I8VEE;G0@ M=&\@9G5L9FEL;"!T:&4@=&AR964@>65A6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#$Q+B8C,38P.R8C M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C M,38P.R!,3TY'+4Q)5D5$($%34T544SPO9F]N=#X\+W-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)TU!4D=)3CH@,&EN.R!72414 M2#H@,3`P)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@5$585"U!3$E'3CH@ M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE M/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE'1U6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,R`F(S$U,#L@-2!Y96%R"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M M1D%-24Q9.B!T:6UE"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9 M.B!T:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`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`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="`P+C(U:6XG/B`\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X\+V1I M=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE M'!E;G-E('=A'1U2X\+V9O;G0^/"]D:78^(#PO M9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ M,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V-#'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0M M4TE:13H@,3!P="<^5&AE(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC M:6%L('-T871E;65N=',@:6YC;'5D92!T:&4@86-C;W5N=',@;V8@=&AE($-O M;7!A;GD@86YD(&ET7-T96US(&]F($9L;W)I9&$L($EN8RXL M('=H:6-H(&AA6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P87)E;G0G M/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E, M63I4:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E&5S+B!!8W1U86P@2!F6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@8V]N2!H860@87!P2`D/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4F]Y86QT:65S(&%N M9"!O=&AE2!N;W0@8V]L;&5C="!I;B!F M=6QL+B!296-E:79A8FQE&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P87)E;G0G/B`\+V1I=CX@ M/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE&5R+5)E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^ M/'1D/CPO=&0^/"]T6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P:6X@,&EN(#!P=#L@0D%#2T=23U5.1#H@=')A;G-P87)E;G0G/B`\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^5&AEF5D('5S:6YG('1H92!S=')A:6=H="UL:6YE M(&UE=&AO9"P@;W9E&5D.R<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T2!R979I97=S(&ET2!E'!E8W1E9"!T;R!R97-U;'0@9G)O;2!T:&4@=7-E(&]F('1H M92!A'!E8W1E9"!F=71U6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\&5S($%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE&5S($%S2!P6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0^/&1I=B!S='EL93TS1"=- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^/"]F;VYT/CPO9F]N=#X\+VD^/"]B/B`\9&EV('-T>6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E&5S+CPO:3X\+V(^(%1H92!#;VUP86YY('!R;W9I9&5S(&9O2!B87-E9"!A<'!R M;V%C:"X@1&5F97)R960@:6YC;VUE('1A>"!A2!A;F0@;6%Y M(&)E('-U8FIE8W0@=&\@"!Y M96%R'!I&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T'0^/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^4F5V96YU92!F&5D(&]R(&1E=&5R;6EN86)L92P@ M86YD('1H92!C;VQL96-T:6]N(&]F('1H92!S86QEF5D(&]V M97(@=&AE('1E6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#PO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^ M(#QB/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^061V97)T M:7-I;F<@0V]S=',N/"]F;VYT/CPO:3X\+V(^(#QF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@97AP96YS97,@86QL(&-O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^ M/'1D/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#PO9&EV/B`\9&EV('-T>6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4F5S96%R8V@@86YD($1E M=F5L;W!M96YT($-O6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\&5R+5)E2!E>'!E;G-E(&%T($]C=&]B97(@ M,S$L(#(P,30@=VEL;"!B92!S=69F:6-I96YT('1O(&]F9G-E="!C;&%I;7,@ M;6%D92!F;W(@=6YI=',@=6YD97(@=V%R6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GD@F5D(&]V97(@=&AE('9E6EN9R!S=&]C:R!O<'1I;VYS(&%N9"!I M6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#PO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN M(#!P="<^(#QB/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M1F%I6QE/3-$)T9/3E0M4TE:13H@,3!P="<^1F%I&EM871E(&9A:7(@=F%L=65S(&)E8V%U M2!A2!B96%R M(&-U6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^1F]R96EG;B!#=7)R96YC>2!42!F;W(@=&AE($-O;7!A;GDF(S@R M,3<[2!T&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M:6X@,&EN(#!P="<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P:6X@,&EN(#!P="<^(#QB/CQI/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P="<^0V]M<')E:&5N2!T6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^5V4@2!T;R!O8V-U M6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO9&EV/B`\+V1I M=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL93TS1"=W:61T:#HQ,#`E.R!T86)L M92UL87EO=70Z9FEX960[)R!C96QL'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO:3X@/&9O M;G0@&-H86YG92!F;W(@=&AE M(&=O;V1S(&]R('-E2!A;F0@:7,@969F96-T:79E(&9O3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V-#'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#QF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^5&AE($-O;7!A;GDF(S@R,3<[ M2`S,2P@,C`Q-"`H:6X@=&AO=7-A;F1S M*3H\+V9O;G0^/"]D:78^(#QD:78@6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@0D]21$52+4)/ M5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@ M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.3PO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`T<'@[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE"!S M;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P M,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P M,"`Q<'@@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA M>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^ M/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4 M+4E.1$5.5#H@,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=- M05)'24XZ(#!I;B`P:6X@,&EN(#`N-6EN.R!724142#H@.#4E.R!"3U)$15(M M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E&5R8VES93QB6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO2`S,2P@,C`Q-#PO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,S6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,"XS.#`\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G M('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P M=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P M,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`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`P,#`[ M($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3`E/B`\9&EV/FXO83PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO'!I"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,S"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P M,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O M;3L@0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C,X,#PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'!E8W1E9"!T;R!V97-T+"!/8W1O8F5R(#,Q+"`R,#$T/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@ M(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXS-S@L-S4P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C`N,S@P/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@ M(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXQ+C@X/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!D;W5B;&4[($9/ M3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/C`\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS-S@L-S4P/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\ M9&EV/C`N,S@P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P M,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@ M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ+C@X/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E' M3CH@"!D;W5B;&4[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV M/C`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L M93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6%B;&4@6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P="<^(#PO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P:6X@,&EN(#!P M="<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^070@3V-T;V)E M2!W87,@;V)L:6=A=&5D('5N9&5R('1H M92!A8F]V92!D97-C#IA=71O.R!724142#H@-C`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E M.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!A;&EG;CTS1&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0T-R4^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0T-R4^(#QD:78^,C`Q-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`T<'@[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PR-3`L,#`P/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)W=H:71E+7-P86-E.FYO=W)A<#L@5$58 M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)W=H:71E M+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E# M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@;6ED9&QE.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D52 M5$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q-24^(#QD:78^,3,L.3#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z M(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P M,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@;6ED9&QE.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^ M/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/&1I M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2`S,2P@,C`Q-"`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]D M:78^(#QD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)B,Q-C`[/"]F;VYT/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P M)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#$P,"4[ M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)W=H:71E M+7-P86-E.FYO=W)A<#L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`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`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`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`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXH,3$P*3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXH,3$P*3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@ M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0V-"4^(#QD:78^5&]O;&EN9R!A;F0@97%U:7!M96YT+"!N970\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/4CH@(S`P,#`P,#L@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!#3TQ/ M4CH@(S`P,#`P,#L@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE: M13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@ M(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'1U M86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V-#'0O M:'1M;#L@8VAA'1U86PI("A54T0@)"D\8G(^ M26X@5&AO=7-A;F1S+"!U;FQE7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5R8VES92!0&5R8VES M86)L92P@5V5I9VAT960@079E&5R8VES92!065A'!E8W1E9"!T M;R!V97-T+"!796EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT65A&5R8VES86)L M92P@5V5I9VAT960@879E65A7,\'!E8W1E9"!T;R!V97-T+"!!9V=R M96=A=&4@:6YT'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!3:&%R92UB87-E9"!087EM96YT($%W87)D M+"!$97-C'0^ M0V]M<&%N>7,@8V]M;6]N('-T;V-K(&%S(&]F('1H92!G'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R M92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!&;W)F96ET=7)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XR+#`P,"PP,#`\2!3:&%R92UB87-E9"!087EM96YT($%W M87)D+"!/<'1I;VYS+"!/=&AE'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6UE;G0@07=A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]B,&,V-#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U86PI("A396YS;W)M961I8W,@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6%L='D@26YC;VUE+"!.;VYO<&5R871I M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!.;W1E M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!.;W1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^2G5L(#,Q+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^2G5L(#,Q M+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!$ M871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!$871E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@ M/'1H(&-L87-S/3-$=&@@8V]L2P@ M4V%L92!O9B!3=&]C:R!;3&EN92!)=&5M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@4V%L92!O9B!3=&]C:R!;3&EN92!)=&5M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4L($%M;W5N="!097(@4VAA2P@4V%L92!O9B!3=&]C M:R!;3&EN92!)=&5M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U86PI("A54T0@)"D\8G(^/"]S=')O M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!.;W1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!. M;W1E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!.;W1E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6%B;&4L(%)E;&%T960@4&%R=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V-#'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V-#'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@ M4&QA;G0@86YD($5Q=6EP;65N="P@1W)O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@4&QA;G0@86YD($5Q=6EP M;65N="P@1W)O2P@4&QA;G0@86YD($5Q=6EP;65N="P@57-E9G5L M($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA65A'1U'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^-2!Y96%R M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X- M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2P@4&QA;G0@86YD($5Q=6EP;65N="P@1W)O'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,&,V-#&UL#0I#;VYT96YT+51R86YS9F5R+45N M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O M:'1M;#L@8VAA&UL;G,Z;STS1")U M&UL/@T* M+2TM+2TM/5].97AT4&%R=%]B,&,V-# XML 20 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
ROYALTIES (Details Textual) (Sensormedics [Member], USD $)
 3 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Sensormedics [Member]
    
Indefinite-lived Intangible Assets [Line Items]    
Royalty Income, Nonoperating $ 0us-gaap_RoyaltyIncomeNonoperating
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= nimu_SensormedicsMember		 $ 1,000us-gaap_RoyaltyIncomeNonoperating
/ us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis
= nimu_SensormedicsMember
XML 21 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
STOCK-BASED COMPENSATION (Details Textual) (USD $)
 3 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Jul. 31, 2014
Nov. 30, 2010
Allocated Share-based Compensation Expense $ 0us-gaap_AllocatedShareBasedCompensationExpense $ 1,000us-gaap_AllocatedShareBasedCompensationExpense    
Share-based Compensation Arrangement by Share-based Payment Award, Description Companys common stock as of the grant date or an exercise price of not less than 110% of the fair value for a 10% shareholder.      
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number 378,750us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber   378,750us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period   75,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod    
2000 Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 2,000,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_AwardTypeAxis
= nimu_TwoThousandPlanMember		      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period 378,750us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
/ us-gaap_AwardTypeAxis
= nimu_TwoThousandPlanMember		      
2011 Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized       4,000,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
/ us-gaap_AwardTypeAxis
= nimu_TwoThousandElevenPlanMember
XML 22 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
NOTES PAYABLE (Details) (USD $)
Oct. 31, 2014
2015 $ 1,250,000us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
Total $ 1,250,000us-gaap_LongTermDebt
XML 23 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
NOTES PAYABLE (Details Textual) (USD $)
 1 Months Ended
May 30, 2012
Feb. 22, 2013
Sep. 24, 2014
Mar. 31, 2010
Oct. 31, 2014
Jul. 31, 2014
Sep. 12, 2011
Short-term Debt [Line Items]              
Line of Credit Facility, Amount Outstanding         $ 1,000,000us-gaap_LineOfCredit $ 1,000,000us-gaap_LineOfCredit  
2011 Promissory Notes [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Face Amount             100,000us-gaap_DebtInstrumentFaceAmount
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndElevenPromissoryNotesMember
2011 Promissory Notes [Member] | Frost Gamma Investment Trust [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Interest Rate, Stated Percentage             11.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndElevenPromissoryNotesMember
Debt Instrument, Face Amount             50,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndElevenPromissoryNotesMember
Beneficial Ownership Percentage             10.00%nimu_BeneficialOwnershipPercentage
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndElevenPromissoryNotesMember
2012 Promissory Notes [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Face Amount 50,000us-gaap_DebtInstrumentFaceAmount
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndTwelvePromissoryNoteMember		            
2012 Promissory Notes [Member] | Hsu Gamma Investments, L.P [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Interest Rate, Stated Percentage 11.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= nimu_HsuGammaInvestmentsLPMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndTwelvePromissoryNoteMember		            
Debt Instrument, Face Amount 50,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= nimu_HsuGammaInvestmentsLPMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndTwelvePromissoryNoteMember		            
Debt Instrument, Maturity Date Jul. 31, 2015            
2013 Promissory Notes [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Face Amount   50,000us-gaap_DebtInstrumentFaceAmount
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndThirteenPromissoryNoteMember		          
2013 Promissory Notes [Member] | Jane Hsiao [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Interest Rate, Stated Percentage   11.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= nimu_JaneHsiaoMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndThirteenPromissoryNoteMember		          
Debt Instrument, Face Amount   50,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= nimu_JaneHsiaoMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndThirteenPromissoryNoteMember		          
Debt Instrument, Maturity Date   Jul. 31, 2015          
2014 Promissory Notes [Member] | Jane Hsiao [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Interest Rate, Stated Percentage     11.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= nimu_JaneHsiaoMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndFourteenPromissoryNoteMember		        
Debt Instrument, Face Amount     50,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= nimu_JaneHsiaoMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndFourteenPromissoryNoteMember		        
Debt Instrument, Maturity Date     Jul. 31, 2015        
2010 Credit Facility [Member]              
Short-term Debt [Line Items]              
Line of Credit Facility, Amount Outstanding         1,000,000us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember		    
2010 Credit Facility [Member] | Maximum [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Interest Rate, Stated Percentage       16.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		      
2010 Credit Facility [Member] | Minimum [Member]              
Short-term Debt [Line Items]              
Debt Instrument, Interest Rate, Stated Percentage       11.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		      
2010 Credit Facility [Member] | Frost Gamma Investment Trust [Member]              
Short-term Debt [Line Items]              
Line of Credit Facility, Amount Outstanding       $ 1,000,000us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember		      
Debt Instrument, Maturity Date       Jul. 31, 2015      
Beneficial Ownership Percentage       10.00%nimu_BeneficialOwnershipPercentage
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember		     10.00%nimu_BeneficialOwnershipPercentage
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember
XML 24 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Oct. 31, 2014
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
2.                  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Consolidation.The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Non-Invasive Monitoring Systems of Florida, Inc., which has no current operations, and NIMS of Canada, Inc., a Canadian corporation, which has no current operations. All material inter-company accounts and transactions have been eliminated in consolidation.
 
Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions, such as accounts receivable, stock based compensation, warranty accrual and deferred taxes as estimates, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Such items include input variables for stock based compensation, accounts receivable, warranty accrual and deferred taxes. Actual results could differ materially from these estimates.
 
Cash and Cash Equivalents. The Company considers all highly liquid short-term investments purchased with an original maturity date of three months or less to be cash equivalents. The Company had approximately $42,000 and $21,000 on deposit in bank operating accounts at October 31, 2014 and July 31, 2014, respectively.
 
Allowances for Doubtful Accounts. Royalties and other receivables are recorded at the stated amount of the transactions. The Company provides an allowance for royalties and other receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance at the end of each period are determined using a combination of the Company’s historical loss experience, customer-by-customer analysis of the Company’s accounts receivable each period and subjective assessments of the Company’s future bad debt exposure.
 
Inventories. Inventories are stated at lower of cost or market using the first-in, first-out method, and are evaluated at least annually for impairment. Inventories at October 31, 2014 and July 31, 2014 primarily consisted of finished Exer-Rest units and accessories. Provisions for potentially obsolete or slow-moving inventory are made based on management’s analysis of inventory levels, historical obsolescence and future sales forecasts.
 
Tooling and Equipment. These assets are stated at cost and depreciated or amortized using the straight-line method, over their estimated useful lives.
 
Long-lived Assets. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In performing the review for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized as the difference between the fair value and the carrying amount of the asset.
 
Taxes Assessed on Revenue-Producing Transactions. The Company presents sales taxes assessed on revenue-producing transactions between a seller and customer using the net presentation; thus, sales and cost of revenues are not affected by such taxes.
 
Income Taxes. The Company provides for income taxes using an asset and liability based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382. Tax years ranging from 2011 to 2014 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision.
 
Revenue Recognition. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured. The Company recognizes royalties as they are earned, based on reports from licensees. Research and consulting revenue and revenue from sales of extended warranties on therapeutic platforms are recognized over the term of the respective agreements.
 
Advertising Costs. The Company expenses all costs of advertising and promotions as incurred. There were no advertising and promotional costs incurred for the three months ended October 31, 2014 and 2013.
 
Research and Development Costs. Research and development costs are expensed as incurred, and primarily consist of payments to third parties for research and development of the Exer-Rest device and regulatory testing and other costs to obtain FDA approval.
 
Warranties. The Company’s warranties are two years on all Exer-Rest products sold domestically and one year for products sold outside of the U.S. and are accrued based on management’s estimates and the history of warranty costs incurred. There were no material warranty costs incurred during the three months ended October 31, 2014 and 2013, and management estimates that the Company’s accrued warranty expense at October 31, 2014 will be sufficient to offset claims made for units under warranty.
 
Stock-based compensation. The Company recognizes all share-based payments, including grants of stock options, as operating expenses, based on their grant date fair values. Stock-based compensation expense is recognized over the vesting life of the underlying stock options and is included in selling, general and administrative costs and expenses in the condensed consolidated comprehensive statements of operations for all periods presented.
 
Fair Value of Financial Instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2014 and July 31, 2014. The respective carrying value of certain on-balance-sheet financial instruments such as cash, royalties and other receivables, accounts payable and accrued expenses approximate fair values because they are short term in nature or they bear current market interest rates.
 
As of October 31, 2014, the respective carrying value of the notes payable – related party and notes payable – other approximate our current borrowing rate for similar debt instruments of comparable maturity and are considered Level 3 measurements within the fair value hierarchy. Level 3 Inputs to the valuation methodology are those that are unobservable and significant to the fair value measurement.
 
Foreign Currency Translation. The functional currency for the Company’s foreign subsidiary is the local currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date while income and expense amounts are translated at average exchange rates during the period. The resulting foreign currency translation adjustments are disclosed as a separate component of stockholders’ deficit and other comprehensive loss. There was no foreign currency translation adjustments for the three months ended October 31, 2014 and 2013.
 
Comprehensive Income (Loss). Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources, including foreign currency translations.
 
Loss Contingencies. We recognize contingent losses that are both probable and estimable. In this context, we define probability as circumstances under which events are likely to occur. In regards to legal costs, we record such costs as incurred.
 
Recent Accounting Pronouncements.  In May 2014, the FASB issued an accounting standard update which affects the revenue recognition of entities that enter into either (1) certain contracts to transfer goods or services to customers or (2) certain contracts for the transfer of nonfinancial assets. The update indicates an entity should recognize revenue in an amount that reflects the consideration the entity expects to be entitled to in exchange for the goods or services transferred by the entity. The update is to be applied to the beginning of the year of implementation or retrospectively and is effective for annual periods beginning after December 15, 2016 and in interim periods in that reporting period. Early application is not permitted. The Company is currently evaluating the effect the update will have on its financial statement.
XML 25 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
SHAREHOLDERS' EQUITY (Details Textual) (USD $)
 3 Months Ended 0 Months Ended
Oct. 31, 2014
Apr. 08, 2013
Subsidiary, Sale of Stock [Line Items]    
Conversion of Stock, Shares Converted 13us-gaap_ConversionOfStockSharesConverted1  
Common Stock [Member]    
Subsidiary, Sale of Stock [Line Items]    
Convertible Preferred Stock, Shares Issued upon Conversion 65,000us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		  
Dr.Hsiao [Member]    
Subsidiary, Sale of Stock [Line Items]    
Stock Issued During Period, Shares, New Issues   2,000,000us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_DrhsiaoMember
Frost Gamma [Member]    
Subsidiary, Sale of Stock [Line Items]    
Stock Issued During Period, Shares, New Issues   2,000,000us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_FrostGammaMember
Private Placement [Member]    
Subsidiary, Sale of Stock [Line Items]    
Stock Issued During Period, Shares, New Issues   10,020,000us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember
Stock Issued During Period, Value, New Issues   501,000us-gaap_StockIssuedDuringPeriodValueNewIssues
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember
Common Stock,Par Value   0.01us-gaap_CommonStockNoParValue
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember
Share Price   0.12us-gaap_SharePrice
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember
Sale of Stock, Price Per Share   0.05us-gaap_SaleOfStockPricePerShare
/ us-gaap_SubsidiarySaleOfStockAxis
= us-gaap_PrivatePlacementMember
Series B Preferred Stock [Member]    
Subsidiary, Sale of Stock [Line Items]    
Preferred stock, liquidation preference 100us-gaap_PreferredStockLiquidationPreference
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		  
Dividends Payable, Amount Per Share 10us-gaap_DividendsPayableAmountPerShare
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		  
Series C Preferred Stock [Member]    
Subsidiary, Sale of Stock [Line Items]    
Convertible Preferred Stock, Shares Issued upon Conversion 25us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		  
Preferred stock, liquidation preference 1.00us-gaap_PreferredStockLiquidationPreference
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		  
Dividends Payable, Amount Per Share 0.10us-gaap_DividendsPayableAmountPerShare
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		  
Preferred Stock, Redemption Price Per Share 0.10us-gaap_PreferredStockRedemptionPricePerShare
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		  
Preferred Stock Conversion Premium 4.20nimu_PreferredStockConversionPremium
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		  
Series D Preferred Stock [Member]    
Subsidiary, Sale of Stock [Line Items]    
Convertible Preferred Stock, Shares Issued upon Conversion 5,000us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		  
Preferred stock, liquidation preference 1,500us-gaap_PreferredStockLiquidationPreference
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		  
XML 26 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Oct. 31, 2014
Jul. 31, 2014
Current assets    
Cash $ 42us-gaap_Cash $ 21us-gaap_Cash
Inventories, net 455us-gaap_InventoryNet 455us-gaap_InventoryNet
Prepaid expenses, deposits, and other current assets 37us-gaap_PrepaidExpenseAndOtherAssetsCurrent 49us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Total current assets 534us-gaap_AssetsCurrent 525us-gaap_AssetsCurrent
Tooling and equipment, net 1us-gaap_PropertyPlantAndEquipmentNet 1us-gaap_PropertyPlantAndEquipmentNet
Total assets 535us-gaap_Assets 526us-gaap_Assets
Current liabilities    
Notes payable - Related party 1,200us-gaap_NotesPayableRelatedPartiesClassifiedCurrent 1,150us-gaap_NotesPayableRelatedPartiesClassifiedCurrent
Notes payable - other 50us-gaap_OtherNotesPayableCurrent 50us-gaap_OtherNotesPayableCurrent
Accounts payable and accrued expenses 973us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent 909us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Customer deposits 4us-gaap_CustomerDepositsCurrent 4us-gaap_CustomerDepositsCurrent
Total current liabilities 2,227us-gaap_LiabilitiesCurrent 2,113us-gaap_LiabilitiesCurrent
Total liabilities 2,227us-gaap_Liabilities 2,113us-gaap_Liabilities
Shareholders' deficit    
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 79,007,423 and 78,942,423 shares issued and outstanding as of October 31, 2014 and July 31, 2014, respectively 790us-gaap_CommonStockValue 789us-gaap_CommonStockValue
Additional paid in capital 21,930us-gaap_AdditionalPaidInCapital 21,931us-gaap_AdditionalPaidInCapital
Accumulated deficit (24,428)us-gaap_RetainedEarningsAccumulatedDeficit (24,323)us-gaap_RetainedEarningsAccumulatedDeficit
Accumulated other comprehensive loss (49)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax (49)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax
Total shareholders' deficit (1,692)us-gaap_StockholdersEquity (1,587)us-gaap_StockholdersEquity
Total liabilities and shareholders' deficit 535us-gaap_LiabilitiesAndStockholdersEquity 526us-gaap_LiabilitiesAndStockholdersEquity
Series B Preferred Stock [Member]    
Shareholders' deficit    
Preferred Stock, Value, Issued 0us-gaap_PreferredStockValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 0us-gaap_PreferredStockValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember
Total shareholders' deficit 0us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 0us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember
Series C Preferred Stock [Member]    
Shareholders' deficit    
Preferred Stock, Value, Issued 62us-gaap_PreferredStockValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 62us-gaap_PreferredStockValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember
Total shareholders' deficit 62us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 62us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember
Series D Preferred Stock [Member]    
Shareholders' deficit    
Preferred Stock, Value, Issued 3us-gaap_PreferredStockValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		 3us-gaap_PreferredStockValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Total shareholders' deficit $ 3us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		 $ 3us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
XML 27 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Operating activities    
Net loss $ (105)us-gaap_NetIncomeLoss $ (118)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 0us-gaap_DepreciationDepletionAndAmortization 2us-gaap_DepreciationDepletionAndAmortization
Stock-based compensation expense 0us-gaap_ShareBasedCompensation 1us-gaap_ShareBasedCompensation
Changes in operating assets and liabilities    
Accounts and royalties receivable, net 0us-gaap_IncreaseDecreaseInReceivables 0us-gaap_IncreaseDecreaseInReceivables
Inventories, net 0us-gaap_IncreaseDecreaseInInventories 1us-gaap_IncreaseDecreaseInInventories
Prepaid expenses, deposits and other current assets 12nimu_IncreaseDecreaseInPrepaidExpensesDepositsAndOtherCurrentAssets 13nimu_IncreaseDecreaseInPrepaidExpensesDepositsAndOtherCurrentAssets
Accounts payable and accrued expenses 64us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (8)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Net cash used in operating activities (29)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (109)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Financing activities    
Proceeds from notes payable - related party 50us-gaap_ProceedsFromRelatedPartyDebt 0us-gaap_ProceedsFromRelatedPartyDebt
Net cash provided by financing activities 50us-gaap_NetCashProvidedByUsedInFinancingActivities 0us-gaap_NetCashProvidedByUsedInFinancingActivities
Net increase (decrease) in cash 21us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (109)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash, beginning of period 21us-gaap_CashAndCashEquivalentsAtCarryingValue 296us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash, end of period $ 42us-gaap_CashAndCashEquivalentsAtCarryingValue $ 187us-gaap_CashAndCashEquivalentsAtCarryingValue
XML 28 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
COMMITMENTS (Details Textual) (USD $)
 0 Months Ended 3 Months Ended
Sep. 04, 2007
Oct. 31, 2014
Oct. 31, 2013
Commitments And Contingencies [Line Items]      
Operating Leases, Rent Expense   $ 17,000us-gaap_LeaseAndRentalExpense $ 15,000us-gaap_LeaseAndRentalExpense
Manufacturing Costs 471,000us-gaap_ManufacturingCosts    
Cost of Utilities 150,000us-gaap_CostOfUtilities    
Payments to Suppliers   1,700,000us-gaap_PaymentsToSuppliers  
Payments On Approval Of Product Prototype Concepts And Designs 150,000nimu_PaymentsOnApprovalOfProductPrototypeConceptsAndDesigns    
Purchase Obligation   13,900,000us-gaap_PurchaseObligation  
Exer Rest Units [Member]      
Commitments And Contingencies [Line Items]      
Purchase Obligation, Due in Next Twelve Months   2,600,000us-gaap_PurchaseObligationDueInNextTwelveMonths
/ nimu_ExerRestUnitsAxis
= nimu_ExerRestUnitsMember		  
Purchase Obligation, Due in Second Year   4,100,000us-gaap_PurchaseObligationDueInSecondYear
/ nimu_ExerRestUnitsAxis
= nimu_ExerRestUnitsMember		  
Purchase Obligation, Due in Third Year   8,800,000us-gaap_PurchaseObligationDueInThirdYear
/ nimu_ExerRestUnitsAxis
= nimu_ExerRestUnitsMember		  
Sing Lin [Member]      
Commitments And Contingencies [Line Items]      
Payables to Customers   $ 41,000us-gaap_PayablesToCustomers
/ nimu_ExerRestUnitsAxis
= nimu_SingLinMember		  
XML 29 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
BASIC AND DILUTED LOSS PER SHARE (Tables)
 3 Months Ended
Oct. 31, 2014
Basic and Diluted Loss Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
Potential common shares not included in calculating diluted net loss per share are as follows:
 
 
 
October 31, 2014
 
October 31, 2013
 
Stock options
 
 
378,750
 
 
538,750
 
Series C Preferred Stock
 
 
1,551,200
 
 
1,551,200
 
Series D Preferred Stock
 
 
13,910,000
 
 
13,975,000
 
Total
 
 
15,839,950
 
 
16,064,950
 
XML 30 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9
LONG-LIVED ASSETS (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Oct. 31, 2014
Jul. 31, 2014
Long Lived Assets Held-for-sale [Line Items]    
Property, Plant and Equipment, Gross $ 111us-gaap_PropertyPlantAndEquipmentGross $ 111us-gaap_PropertyPlantAndEquipmentGross
Less accumulated depreciation (110)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment (110)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
Tooling and equipment, net 1us-gaap_PropertyPlantAndEquipmentNet 1us-gaap_PropertyPlantAndEquipmentNet
Furniture and Fixtures Leasehold Improvements Office Equipment and Computers [Member]    
Long Lived Assets Held-for-sale [Line Items]    
Property, Plant and Equipment, Gross 85us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= nimu_FurnitureAndFixturesLeaseholdImprovementsOfficeEquipmentAndComputersMember		 85us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= nimu_FurnitureAndFixturesLeaseholdImprovementsOfficeEquipmentAndComputersMember
Website and Software [Member]    
Long Lived Assets Held-for-sale [Line Items]    
Property, Plant and Equipment, Gross $ 26us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= nimu_WebsiteAndSoftwareMember		 $ 26us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= nimu_WebsiteAndSoftwareMember
Property, Plant and Equipment, Useful Life 3 years  
Minimum [Member] | Furniture and Fixtures Leasehold Improvements Office Equipment and Computers [Member]    
Long Lived Assets Held-for-sale [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Maximum [Member] | Furniture and Fixtures Leasehold Improvements Office Equipment and Computers [Member]    
Long Lived Assets Held-for-sale [Line Items]    
Property, Plant and Equipment, Useful Life 5 years  
XML 31 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
ORGANIZATION AND BUSINESS (Details Textual) (USD $)
 3 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Jul. 31, 2014
Net loss $ (105,000)us-gaap_NetIncomeLoss $ (118,000)us-gaap_NetIncomeLoss  
Accumulated deficit (24,428,000)us-gaap_RetainedEarningsAccumulatedDeficit   (24,323,000)us-gaap_RetainedEarningsAccumulatedDeficit
Cash 42,000us-gaap_Cash   21,000us-gaap_Cash
Negative Working Capital $ 1,693,000nimu_Negativeworkingcapital    
XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
ORGANIZATION AND BUSINESS
 3 Months Ended
Oct. 31, 2014
Organization and Business [Abstract]  
ORGANIZATION AND BUSINESS
1.                  ORGANIZATION AND BUSINESS
 
Organization. Non-Invasive Monitoring Systems, Inc., a Florida corporation (together with its consolidated subsidiaries, the “Company” or “NIMS”), began business as a medical diagnostic monitoring company to develop computer-aided continuous monitoring devices to detect abnormal respiratory and cardiac events using sensors on the human body’s surface. It has ceased to operate in this market and has licensed the rights to its technology. The Company now focuses on developing and marketing its Exer-Rest® line of acceleration therapeutic platforms based upon unique, patented whole body periodic acceleration (“WBPA”) technology. The Exer-Rest line of acceleration therapeutic platforms currently includes the Exer-Rest AT3800 and AT4700 models.
 
Business. The Company is developing and marketing its Exer-Rest® line of acceleration therapeutic platforms based upon unique, patented whole body periodic acceleration (“WBPA”) technology. The Exer-Rest line of acceleration therapeutic platforms currently includes the Exer-Rest AT3800 and AT4700 models.
 
The Company received revenue from royalties on sales of diagnostic monitoring hardware and software by SensorMedics and from VivoMetrics in prior years. SensorMedics indicated they will discontinue licensed product sales after current inventory is depleted and, therefore, the royalty revenue from SensorMedics is expected to be minimal to none. VivoMetrics ceased operations in July 2009 and filed for Chapter 11 bankruptcy protection in October 2009. Pursuant to VivoMetrics’ approved bankruptcy plan of reorganization, our license with VivoMetrics was assigned to another company; however, there can be no assurance as to the future amount of royalty revenue, if any, that we may derive from this license or from our existing license with SensorMedics. In fiscal year 2009, NIMS began commercial sales of its third generation Exer-Rest therapeutic platforms.
 
During the calendar years 2005 to 2007, the Company designed, developed and manufactured the first Exer-Rest platform (now the Exer-Rest AT), a second generation acceleration therapeutics platform, and updated its operations to promote the Exer-Rest AT overseas as an aid to improve circulation and joint mobility and to relieve minor aches and pains.
 
The Company has developed a third generation of Exer-Rest acceleration therapeutic platforms (designated the Exer-Rest AT3800 and the Exer-Rest AT4700) that had been manufactured by Sing Lin Technologies Co. Ltd. (“Sing Lin”) based in Taichung, Taiwan (see Note 10).
 
The Company’s condensed consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. As reflected in the accompanying unaudited condensed consolidated financial statements, the Company had net losses of $105,000 and $118,000 for the three month periods ended October 31, 2014 and 2013, respectively, and has experienced cash outflows from operating activities. The Company also has an accumulated deficit of $24.4 million as of October 31, 2014, and has potential purchase obligations at October 31, 2014 (see note 10). The Company had $42,000 of cash at October 31, 2014 and negative working capital of approximately $1,693,000.
 
Absent any significant revenues from product sales, the Company will likely need to incur additional debt, equity financing or a strategic collaboration for the Company to continue its business activities. Management intends to obtain any additional capital needed to continue its business activities through new debt or equity financing, but there can be no assurance that it will be successful in this regard. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.
XML 34 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Oct. 31, 2014
Jul. 31, 2014
Common stock, par value (in dollars per share) $ 0.01us-gaap_CommonStockParOrStatedValuePerShare $ 0.01us-gaap_CommonStockParOrStatedValuePerShare
Common stock, shares authorized 400,000,000us-gaap_CommonStockSharesAuthorized 400,000,000us-gaap_CommonStockSharesAuthorized
Common stock, shares issued 79,007,423us-gaap_CommonStockSharesIssued 78,942,423us-gaap_CommonStockSharesIssued
Common stock, shares outstanding 79,007,423us-gaap_CommonStockSharesOutstanding 78,942,423us-gaap_CommonStockSharesOutstanding
Series B Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 1.00us-gaap_PreferredStockParOrStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 $ 1.00us-gaap_PreferredStockParOrStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember
Preferred stock, shares authorized 100us-gaap_PreferredStockSharesAuthorized
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 100us-gaap_PreferredStockSharesAuthorized
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember
Preferred stock, shares issued 100us-gaap_PreferredStockSharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 100us-gaap_PreferredStockSharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember
Preferred stock, shares outstanding 100us-gaap_PreferredStockSharesOutstanding
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 100us-gaap_PreferredStockSharesOutstanding
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember
Preferred stock, liquidation preference $ 10us-gaap_PreferredStockLiquidationPreferenceValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 $ 10us-gaap_PreferredStockLiquidationPreferenceValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember
Series C Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 1.00us-gaap_PreferredStockParOrStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 $ 1.00us-gaap_PreferredStockParOrStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember
Preferred stock, shares authorized 62,048us-gaap_PreferredStockSharesAuthorized
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 62,048us-gaap_PreferredStockSharesAuthorized
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember
Preferred stock, shares issued 62,048us-gaap_PreferredStockSharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 62,048us-gaap_PreferredStockSharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember
Preferred stock, shares outstanding 62,048us-gaap_PreferredStockSharesOutstanding
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 62,048us-gaap_PreferredStockSharesOutstanding
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember
Preferred stock, liquidation preference 62us-gaap_PreferredStockLiquidationPreferenceValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 62us-gaap_PreferredStockLiquidationPreferenceValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember
Series D Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 1.00us-gaap_PreferredStockParOrStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		 $ 1.00us-gaap_PreferredStockParOrStatedValuePerShare
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Preferred stock, shares authorized 5,500us-gaap_PreferredStockSharesAuthorized
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		 5,500us-gaap_PreferredStockSharesAuthorized
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Preferred stock, shares issued 2,782us-gaap_PreferredStockSharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		 2,795us-gaap_PreferredStockSharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Preferred stock, shares outstanding 2,782us-gaap_PreferredStockSharesOutstanding
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		 2,795us-gaap_PreferredStockSharesOutstanding
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Preferred stock, liquidation preference $ 4,174us-gaap_PreferredStockLiquidationPreferenceValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember		 $ 4,174us-gaap_PreferredStockLiquidationPreferenceValue
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
XML 35 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
LONG-LIVED ASSETS
 3 Months Ended
Oct. 31, 2014
Long Lived Assets [Abstract]  
LONG-LIVED ASSETS
11.                  LONG-LIVED ASSETS
 
The Company’s long-lived assets include furniture and equipment, tooling, websites and software, leasehold improvements, patents and trademarks. Tooling and equipment, net of accumulated depreciation, consists of the following at October 31 and July 31, 2014 (in thousands):
 
 
 
Estimated
 
October 31,
 
July 31,
 
 
 
Useful Life
 
2014
 
2014
 
Furniture and fixtures, leasehold improvements, office equipment and computers
 
3 – 5 years
 
$
85
 
$
85
 
Website and software
 
3 years
 
 
26
 
 
26
 
 
 
 
 
 
111
 
 
111
 
Less accumulated depreciation
 
 
 
 
(110)
 
 
(110)
 
Tooling and equipment, net
 
 
 
$
1
 
$
1
 
 
Depreciation expense was $0 and $2,000 during the three months ended October 31, 2014 and 2013, respectively. Nine Exer-Rest AT3800 and AT4700 demonstration units are included in furniture and fixtures at an aggregate cost of $25,000. These units were placed in service in fiscal 2009 and 2010, and are being depreciated based upon five-year estimated useful lives. In June 2014, the Company transferred an Exer-Rest unit with a net book value of $0 from long-lived assets to inventory.
XML 36 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
Document And Entity Information
 3 Months Ended
Oct. 31, 2014
Dec. 14, 2014
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Oct. 31, 2014  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q1  
Entity Registrant Name NON INVASIVE MONITORING SYSTEMS INC /FL/  
Entity Central Index Key 0000720762  
Current Fiscal Year End Date --07-31  
Entity Filer Category Smaller Reporting Company  
Trading Symbol NIMU  
Entity Common Stock, Shares Outstanding   79,007,423dei_EntityCommonStockSharesOutstanding
XML 37 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Oct. 31, 2014
Accounting Policies [Abstract]  
Consolidation
Consolidation.The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Non-Invasive Monitoring Systems of Florida, Inc., which has no current operations, and NIMS of Canada, Inc., a Canadian corporation, which has no current operations. All material inter-company accounts and transactions have been eliminated in consolidation
Use of Estimates
Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions, such as accounts receivable, stock based compensation, warranty accrual and deferred taxes as estimates, that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Such items include input variables for stock based compensation, accounts receivable, warranty accrual and deferred taxes. Actual results could differ materially from these estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents. The Company considers all highly liquid short-term investments purchased with an original maturity date of three months or less to be cash equivalents. The Company had approximately $42,000 and $21,000 on deposit in bank operating accounts at October 31, 2014 and July 31, 2014, respectively.
Allowances for Doubtful Accounts
Allowances for Doubtful Accounts. Royalties and other receivables are recorded at the stated amount of the transactions. The Company provides an allowance for royalties and other receivables it believes it may not collect in full. Receivables are written off when they are deemed to be uncollectible and all collection attempts have ceased. The amount of bad debt recorded each period and the resulting adequacy of the allowance at the end of each period are determined using a combination of the Company’s historical loss experience, customer-by-customer analysis of the Company’s accounts receivable each period and subjective assessments of the Company’s future bad debt exposure.
Inventory
Inventories. Inventories are stated at lower of cost or market using the first-in, first-out method, and are evaluated at least annually for impairment. Inventories at October 31, 2014 and July 31, 2014 primarily consisted of finished Exer-Rest units and accessories. Provisions for potentially obsolete or slow-moving inventory are made based on management’s analysis of inventory levels, historical obsolescence and future sales forecasts.
Tooling and Equipment
Tooling and Equipment. These assets are stated at cost and depreciated or amortized using the straight-line method, over their estimated useful lives.
Long-lived Assets
Long-lived Assets. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In performing the review for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows is less than the carrying amount of the assets, an impairment loss is recognized as the difference between the fair value and the carrying amount of the asset.
Taxes Assessed On Revenue-Producing Transactions
Taxes Assessed on Revenue-Producing Transactions. The Company presents sales taxes assessed on revenue-producing transactions between a seller and customer using the net presentation; thus, sales and cost of revenues are not affected by such taxes.
Income Taxes
Income Taxes. The Company provides for income taxes using an asset and liability based approach. Deferred income tax assets and liabilities are recorded to reflect the tax consequences in future years of temporary differences between the carrying amounts of assets and liabilities for financial statement and income tax purposes. The deferred tax asset for loss carryforwards and other potential future tax benefits has been fully offset by a valuation allowance since it is uncertain whether any future benefit will be realized. The utilization of the loss carryforward is limited to future taxable earnings of the Company and may be subject to severe limitations if the Company undergoes an ownership change pursuant to the Internal Revenue Code Section 382. Tax years ranging from 2011 to 2014 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. It is the Company’s policy to include income tax interest and penalty expense in its tax provision.
Revenue Recognition
Revenue Recognition. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, the goods are shipped and title has transferred, the price is fixed or determinable, and the collection of the sales proceeds is reasonably assured. The Company recognizes royalties as they are earned, based on reports from licensees. Research and consulting revenue and revenue from sales of extended warranties on therapeutic platforms are recognized over the term of the respective agreements.
Advertising Costs
Advertising Costs. The Company expenses all costs of advertising and promotions as incurred. There were no advertising and promotional costs incurred for the three months ended October 31, 2014 and 2013.
Research and Development Costs
Research and Development Costs. Research and development costs are expensed as incurred, and primarily consist of payments to third parties for research and development of the Exer-Rest device and regulatory testing and other costs to obtain FDA approval.
Warranties
Warranties. The Company’s warranties are two years on all Exer-Rest products sold domestically and one year for products sold outside of the U.S. and are accrued based on management’s estimates and the history of warranty costs incurred. There were no material warranty costs incurred during the three months ended October 31, 2014 and 2013, and management estimates that the Company’s accrued warranty expense at October 31, 2014 will be sufficient to offset claims made for units under warranty.
Stock-based compensation
Stock-based compensation. The Company recognizes all share-based payments, including grants of stock options, as operating expenses, based on their grant date fair values. Stock-based compensation expense is recognized over the vesting life of the underlying stock options and is included in selling, general and administrative costs and expenses in the condensed consolidated comprehensive statements of operations for all periods presented.
Fair Value of Financial Instruments
Fair Value of Financial Instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2014 and July 31, 2014. The respective carrying value of certain on-balance-sheet financial instruments such as cash, royalties and other receivables, accounts payable and accrued expenses approximate fair values because they are short term in nature or they bear current market interest rates.
 
As of October 31, 2014, the respective carrying value of the notes payable – related party and notes payable – other approximate our current borrowing rate for similar debt instruments of comparable maturity and are considered Level 3 measurements within the fair value hierarchy. Level 3 Inputs to the valuation methodology are those that are unobservable and significant to the fair value measurement.
Foreign Currency Translation
Foreign Currency Translation. The functional currency for the Company’s foreign subsidiary is the local currency. Assets and liabilities are translated at exchange rates in effect at the balance sheet date while income and expense amounts are translated at average exchange rates during the period. The resulting foreign currency translation adjustments are disclosed as a separate component of stockholders’ deficit and other comprehensive loss. There was no foreign currency translation adjustments for the three months ended October 31, 2014 and 2013.
 
Comprehensive Income (Loss)
Comprehensive Income (Loss). Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources, including foreign currency translations.
Loss Contingencies
Loss Contingencies. We recognize contingent losses that are both probable and estimable. In this context, we define probability as circumstances under which events are likely to occur. In regards to legal costs, we record such costs as incurred.
 
Recent Accounting Pronouncements
Recent Accounting Pronouncements.  In May 2014, the FASB issued an accounting standard update which affects the revenue recognition of entities that enter into either (1) certain contracts to transfer goods or services to customers or (2) certain contracts for the transfer of nonfinancial assets. The update indicates an entity should recognize revenue in an amount that reflects the consideration the entity expects to be entitled to in exchange for the goods or services transferred by the entity. The update is to be applied to the beginning of the year of implementation or retrospectively and is effective for annual periods beginning after December 15, 2016 and in interim periods in that reporting period. Early application is not permitted. The Company is currently evaluating the effect the update will have on its financial statement.
XML 38 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Revenues    
Product sales, net $ 0us-gaap_SalesRevenueGoodsNet $ 0us-gaap_SalesRevenueGoodsNet
Royalties 0us-gaap_RoyaltyRevenue 1us-gaap_RoyaltyRevenue
Total revenues 0us-gaap_Revenues 1us-gaap_Revenues
Operating costs and expenses    
Cost of sales 0us-gaap_CostOfGoodsSold 0us-gaap_CostOfGoodsSold
Selling, general and administrative 71us-gaap_SellingGeneralAndAdministrativeExpense 85us-gaap_SellingGeneralAndAdministrativeExpense
Research and development 0us-gaap_ResearchAndDevelopmentExpense 1us-gaap_ResearchAndDevelopmentExpense
Total operating costs and expenses 71us-gaap_CostsAndExpenses 86us-gaap_CostsAndExpenses
Operating loss (71)us-gaap_OperatingIncomeLoss (85)us-gaap_OperatingIncomeLoss
Other expense    
Interest expense, net (34)us-gaap_InterestIncomeExpenseNet (33)us-gaap_InterestIncomeExpenseNet
Total other expense (34)us-gaap_OtherIncome (33)us-gaap_OtherIncome
Net loss (105)us-gaap_NetIncomeLoss (118)us-gaap_NetIncomeLoss
Comprehensive net loss (105)us-gaap_ComprehensiveIncomeNetOfTax (118)us-gaap_ComprehensiveIncomeNetOfTax
Net loss attributable to common shareholders $ (105)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (118)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Weighted average number of common shares outstanding - basic and diluted 78,943us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 78,942us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted
Basic and diluted loss per common share $ 0.00us-gaap_EarningsPerShareBasicAndDiluted $ 0.00us-gaap_EarningsPerShareBasicAndDiluted
XML 39 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
NOTES PAYABLE
 3 Months Ended
Oct. 31, 2014
Notes Payable [Abstract]  
NOTES PAYABLE
6.                   NOTES PAYABLE
 
2010 Credit Facility. On March 31, 2010, the Company entered into a new Note and Security Agreement with Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock (“Frost Gamma”), and Hsu Gamma Investments, LP, an entity controlled by the Company’s Chairman and Interim CEO (“Hsu Gamma” and together with Frost Gamma, the “Lenders”), pursuant to which the Lenders have provided a revolving credit line (the “Credit Facility”) in the aggregate principal amount of up to $1.0 million, secured by all of the Company’s personal property. The Company is permitted to borrow and reborrow from time to time under the Credit Facility until July 31, 2015 (the “Credit Facility Maturity Date”). The interest rate payable on amounts outstanding under the Credit Facility is 11% per annum, and increases to 16% per annum after the Credit Facility Maturity Date or after an event of default. All amounts owing under the Credit Facility are required to be repaid by the Credit Facility Maturity Date, and amounts outstanding are prepayable at any time without premium or penalty. As of October 31, 2014, the Company had drawn an aggregate of $1,000,000 under the Credit Facility and there is no available balance remaining.
 
2011 Promissory Notes. On September 12, 2011, the Company entered into two promissory notes in the principal amount of $50,000 each with Frost Gamma, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock, and with an unrelated third party for a total of $100,000. The interest rate payable by NIMS on both the Frost Gamma Note and the unrelated third party note is 11% per annum, payable on the maturity date of July 31, 2015 (the “Promissory Notes Maturity Date”). The Company may prepay either or both notes in advance of the Promissory Notes Maturity Date without premium or penalty.
 
2012 Promissory Note. On May 30, 2012, the Company entered into a promissory note in the principal amount of $50,000 with Hsu Gamma, an entity controlled by NIMS’ Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao, (the “Hsu Gamma Note”). The interest rate payable by NIMS on the Hsu Gamma Note is 11% per annum, payable on the maturity date of July 31, 2015. The Hsu Gamma Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.
 
2013 Promissory Note. On February 22, 2013, the Company entered into a promissory note in the amount of $50,000 with Jane Hsiao, the Company’s Chairman of the Board and Interim Chief Executive Officer (the “2013 Hsiao Note”). The interest rate payable by the Company on the 2013 Hsiao Note is 11% per annum, payable on the maturity date of July 31, 2015. The 2013 Hsiao Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.
 
2014 Promissory Note. On September 24, 2014, the Company entered into a promissory note (the “2014 Hsiao Note”) in the principal amount of $50,000 with Jane Hsiao, NIMS' Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by NIMS on the 2014 Hsiao Note is 11% per annum, payable on the maturity date of July 31, 2015. The 2014 Hsiao Note may be prepaid in advance of the Maturity Date without penalty.
 
At October 31, 2014, the Company was obligated under the above described Credit Facility and promissory notes to make future principal payments (excluding interest) as follows:
 
Year Ending October 31,
 
 
 
 
 
 
 
2015
 
 
1,250,000
 
 
 
$
1,250,000
 
XML 40 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
ROYALTIES
 3 Months Ended
Oct. 31, 2014
Royalties [Abstract]  
ROYALTIES
5.                  ROYALTIES
 
The Company is a party to two licensing agreements with SensorMedics and VivoMetrics. The Company previously received royalty income from the sale of its diagnostic monitoring hardware and software from SensorMedics and previously received royalties from VivoMetrics prior to its bankruptcy.
 
Royalty income from the SensorMedics license amounted to $0 and $1,000 for the three months ended October 31, 2014 and 2013, respectively. SensorMedics indicated they will discontinue licensed product sales after inventory is depleted and, therefore, the royalty revenue from SensorMedics is expected to be minimal to none. There were no royalties recognized from VivoMeterics for the three months ended October 31, 2014 and 2013. VivoMetrics ceased operations in July 2009 and filed for Chapter 11 bankruptcy protection in October 2009. Under VivoMetrics’ approved bankruptcy plan of reorganization, our license with VivoMetrics was assigned to another company; however, there can be no assurance as to the future amount of royalty income, if any, that may result from this license or from our existing license with SensorMedics.
XML 41 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
LONG-LIVED ASSETS (Tables)
 3 Months Ended
Oct. 31, 2014
Long Lived Assets [Abstract]  
Schedule of Long Lived Assets Held-for-sale
The Company’s long-lived assets include furniture and equipment, tooling, websites and software, leasehold improvements, patents and trademarks. Tooling and equipment, net of accumulated depreciation, consists of the following at October 31 and July 31, 2014 (in thousands):
 
 
 
Estimated
 
October 31,
 
July 31,
 
 
 
Useful Life
 
2014
 
2014
 
Furniture and fixtures, leasehold improvements, office equipment and computers
 
3 – 5 years
 
$
85
 
$
85
 
Website and software
 
3 years
 
 
26
 
 
26
 
 
 
 
 
 
111
 
 
111
 
Less accumulated depreciation
 
 
 
 
(110)
 
 
(110)
 
Tooling and equipment, net
 
 
 
$
1
 
$
1
 
XML 42 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
INVENTORIES (Tables)
 3 Months Ended
Oct. 31, 2014
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
The Company’s inventory consisted of the following at October 31, 2014 and July 31, 2014 (in thousands):
 
 
 
October 31, 2014
 
July 31, 2014
 
Work-in-progress, spare parts and accessories
 
$
9
 
$
9
 
Finished goods
 
 
446
 
 
446
 
Total inventories
 
$
455
 
$
455
 
XML 43 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
RELATED PARTY TRANSACTIONS
 3 Months Ended
Oct. 31, 2014
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
9.                  RELATED PARTY TRANSACTIONS
 
The Company signed a five year lease for office space in Miami, Florida with a company owned by Dr. Phillip Frost, who is the beneficial owner of more than 10% of the Company’s Common Stock. The current rental payments under the Miami office lease, which commenced January 1, 2008 and expired on December 31, 2012, are approximately $1,250 per month and are currently on a month-to-month basis. The Company recorded rent expense related to the Miami lease of approximately $4,000 and $4,000, respectively, for the three months ended October 31, 2014 and 2013.
 
The Company signed a three year lease for warehouse space in Hialeah, Florida with a company jointly controlled by Dr. Frost and Dr. Jane Hsiao, the Company’s Chairman and Interim CEO. The rental payments under the Hialeah warehouse lease, which commenced February 1, 2009 and expired on January 31, 2012, then continued on a month-to-month basis. As further described in Note 10, the Company vacated the Hialeah warehouse in September 2014 and entered into a new lease. The Company recorded rent expense related to the Hialeah warehouse of approximately $6,000 and $11,000, respectively, for the three months ended October 31, 2014 and 2013.
 
As more fully described in Note 6, the Company entered into a $1.0 million Credit Facility in March 2010 with both an entity controlled by Dr. Frost and an entity controlled by Dr. Hsiao. There were no advances under the Credit Facility during the three months ended October 31, 2014. There was $1.0 million outstanding balance due, plus interest, on the Credit Facility as of October 31, 2014 and July 31, 2014 and there is no available balance remaining. The Credit Facility expires in July 31, 2015.
 
On September 12, 2011, the Company entered into a promissory note in the principal amount of $50,000 with Frost Gamma, a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of our common stock. The interest rate payable by NIMS on the Frost Gamma note is 11% per annum, payable on July 31, 2015. The Frost Gamma note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.
 
On May 30, 2012, the Company entered into a promissory note in the principal amount of $50,000 with Hsu Gamma, an entity controlled by our Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao. The interest rate payable by NIMS on the Hsu Gamma note is 11% per annum, payable on the Promissory Notes Maturity Date. The Hsu Gamma note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.
 
On February 22, 2013, the Company entered into a promissory note in the amount of $50,000 with Jane Hsiao, the Company’s Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by the Company on the 2013 Hsiao Note is 11% per annum, payable on the Promissory Notes Maturity Date. The 2013 Hsiao Note may be prepaid in advance of the Promissory Notes Maturity Date without premium or penalty.
 
On September 24, 2014, the Company entered into a promissory note in the principal amount of $50,000 with Jane Hsiao, NIMS' Chairman of the Board and Interim Chief Executive Officer. The interest rate payable by NIMS on the 2014 Hsiao Note is 11% per annum, payable on the maturity date of July 31, 2015. The 2014 Hsiao Note may be prepaid in advance of the Maturity Date without penalty.
 
The Company incurred interest expense related to the Credit Facility of approximately $28,000 for the three months ended October 31, 2014 and 2013. The Company also incurred interest expense related to the promissory notes of approximately $6,000 and $5,000 for the three months ended October 31, 2014 and 2013, respectively. Approximately $532,000 and $498,000 of accrued interest remained outstanding on the Credit Facility and promissory notes at October 31, 2014 and July 31, 2014, respectively.
  
Dr. Hsiao, Dr. Frost and directors Steven Rubin and Rao Uppaluri are each significant stockholders, officers and/or directors or former directors of TransEnterix, Inc. (formerly SafeStitch Medical, Inc.) (“TransEnterix”), a publicly-traded, medical device manufacturer, Tiger X Medical, Inc. (“Tiger X”) (formerly known as Cardo Medical, Inc.), a publicly traded former medical device company, and Tiger Media, Inc. (“Tiger Media”) (formerly known as SearchMedia Holdings Limited), a publicly-traded media company operating primarily in China. The Company’s Chief Financial Officer also served as the Chief Financial Officer of TransEnterix until October 2, 2013. The Company’s Chief Financial Officer continued as an employee of TransEnterix until March 3, 2014, during which he supervised the Miami based accounting staffs of TransEnterix under a cost sharing arrangement whereby the total salaries of the Miami based accounting staffs of NIMS and TransEnterix were shared.  Since December 2009, the Company’s Chief Legal Officer has served under a similar cost sharing arrangement as Corporate Counsel of Tiger Media and as the Chief Legal Officer of each of TransEnterix and Tiger X. The Company recorded to selling, general and administrative costs and expenses to account for the sharing of costs under these arrangements of $7,800 and $9,000, respectively, for the three months ended October 31, 2014, and 2013. Accounts payable to TransEnterix related to these arrangements totaled approximately $5,000 and $3,000 respectively, at October 31, 2014 and July 31, 2014.
XML 44 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
SHAREHOLDERS' EQUITY
 3 Months Ended
Oct. 31, 2014
Shareholders' Equity [Abstract]  
SHAREHOLDERS' EQUITY
7.                  SHAREHOLDERS' EQUITY
 
The Company has three classes of Preferred Stock. Holders of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters.
 
Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $100 per share, plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $10 per share, if declared.
 
Series C Preferred Stock is redeemable by the Company at a price of $0.10 per share upon 30 days prior written notice. This series has a liquidation value of $1.00 per share plus declared and unpaid dividends, if any. Dividends are non-cumulative, and are at the rate of $0.10 per share, if declared. Each share of Series C Preferred Stock is convertible into 25 shares of the Company’s common stock upon payment of a conversion premium of $4.20 per share of common stock. The conversion rate and the conversion premium are subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events.
 
Series D Preferred Stock is not redeemable by the Company. This series has a liquidation value of $1,500 per share, plus declared and unpaid dividends, if any. Each share of Series D Preferred Stock is convertible into 5,000 shares of the Company’s common stock. The conversion rate is subject to adjustments in the event of stock splits, stock dividends, reverse stock splits and certain other events. In October 2014, a holder of the Company’s Series D Preferred Stock converted 13 shares into 65,000 shares of the Company’s common stock.
 
On April 8, 2013, the Company entered into a stock purchase agreement (the “Stock Purchase Agreement”) with 12 investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 10,020,000 shares of the Company’s common stock, par value $0.01 (the “Shares”), at a price of $0.05 per share, for aggregate consideration of $501,000. The $0.05 per share price was less than the market price, which was approximately $0.12 as of the date of the agreement. Among the Investors purchasing Shares pursuant to the agreement were Dr. Jane Hsiao, the Company’s Chairman of the Board and Interim Chief Executive Officer and Frost Gamma, an entity controlled by Dr. Phillip Frost, one of the largest beneficial owners of the Company’s common stock. Dr. Hsiao purchased 2.0 million Shares and Frost Gamma purchased 2.0 million Shares.
The Company issued 65,000 shares of the Company’s common stock for the conversion of 13 shares Series D Preferred Stock during the three months ended October 31, 2014 and did not issue any shares of the Company’s common stock for the three months ended October 31, 2013. No preferred stock dividends were declared for the three months ended October 31, 2014 and 2013.
XML 45 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
BASIC AND DILUTED LOSS PER SHARE
 3 Months Ended
Oct. 31, 2014
Basic and Diluted Loss Per Share [Abstract]  
BASIC AND DILUTED LOSS PER SHARE
8.                  BASIC AND DILUTED LOSS PER SHARE
 
Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock. In computing diluted net loss per share for the three months ended October 31, 2014 and 2013, no dilution adjustment has been made to the weighted average outstanding common shares because the assumed exercise of outstanding options and warrants and the conversion of preferred stock would be anti-dilutive.
 
Potential common shares not included in calculating diluted net loss per share are as follows:
 
 
 
October 31, 2014
 
October 31, 2013
 
Stock options
 
 
378,750
 
 
538,750
 
Series C Preferred Stock
 
 
1,551,200
 
 
1,551,200
 
Series D Preferred Stock
 
 
13,910,000
 
 
13,975,000
 
Total
 
 
15,839,950
 
 
16,064,950
 
XML 46 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
COMMITMENTS
 3 Months Ended
Oct. 31, 2014
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS
10.                  COMMITMENTS
 
Leases.
 
The Company is under an operating lease agreement for office space that expired in 2012 and continues on a month to month basis. The Company is also under an operating lease agreement for warehouse space that runs through September 2015 and requires for the payment of taxes, insurance and utilities.
 
Generally, the lease agreements require the payment of base rent plus escalations for increases in building operating costs and real estate taxes. Rental expense for operating leases amounted to $17,000 and $15,000 for the three months ended October 31, 2014 and 2013, respectively.
 
Product Development and Supply Agreement.
 
On September 4, 2007, the Company entered into a Product Development and Supply Agreement (the “Agreement”) with Sing Lin Technologies Co. Ltd., a company based in Taichung, Taiwan ("Sing Lin"). Pursuant to the Agreement, the Company consigned to Sing Lin the development and design of the next generation Exer-Rest and related devices. The Agreement commenced as of September 3, 2007 and had a term that extended three years from the acceptance by NIMS of the first run of production units. Thereafter, the Agreement automatically renewed for successive one year terms unless either party sent the other a notice of non-renewal. Either party was permitted to terminate the Agreement with ninety days prior written notice. Upon termination, each party’s obligations under the Agreement were to be limited to obligations related to confirmed orders placed prior to the termination date.
 
Pursuant to the Agreement, Sing Lin designed, developed and manufactured the tooling required to manufacture the acceleration therapeutic platforms for a total cost to the Company of $471,000. Sing Lin utilized the tooling in the performance of its production obligations under the Agreement. The Company paid Sing Lin $150,000 of the tooling cost upon execution of the Agreement and $150,000 upon the Company’s approval of the product prototype concepts and designs. The balance of the final tooling cost became due and payable in September 2008 upon acceptance of the first units produced using the tooling, and was paid in full during the year ended July 31, 2009.
 
Under the now-terminated Agreement, the Company also granted Sing Lin the exclusive distribution rights for the products in certain countries in the Far East, including Taiwan, China, Japan, South Korea, Malaysia, Indonesia and certain other countries. Sing Lin agreed not to sell the Products outside its geographic areas in the Far East.
 
The Agreement provided for the Company to purchase approximately $2.6 million of Exer-Rest units within one year of the September 2008 acceptance of the final product. The Agreement further provided for the Company to purchase $4.1 million and $8.8 million of Exer-Rest products in the second and third years following such acceptance, respectively. These minimum purchase amounts were based upon 2007 product costs multiplied by volume commitments. Through October 31, 2014, the Company had paid Sing Lin $1.7 million in connection with orders placed through that date. As of October 31, 2014, the Company has approximately $41,000 of payables due to Sing Lin. As of October 31, 2014, aggregate minimum future purchases under the Agreement totaled approximately $13.9 million.
 
As of October 31, 2014, the Company had not placed orders sufficient to meet the first-year or second-year minimum purchase obligations under the Agreement. The Company notified Sing Lin in June 2010 that it was terminating the Agreement effective September 2010, and Sing Lin in July 2010 demanded that the Company place orders sufficient to fulfill the three year minimum purchase obligations in the Agreement. As of the date of the issuance of these financial statements Sing Lin has not followed up on its July 2010 demand. There can be no assurance that Sing Lin will not attempt to enforce its remedies under the Agreement, or pursue other potential remedies.
XML 47 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9
RELATED PARTY TRANSACTIONS (Details Textual) (USD $)
 3 Months Ended 1 Months Ended
Oct. 31, 2014
Oct. 31, 2013
Jan. 31, 2008
Jul. 31, 2014
Sep. 12, 2011
May 30, 2012
Feb. 22, 2013
Sep. 24, 2014
Mar. 31, 2010
Related Party Transaction [Line Items]                  
Operating Leases, Rent Expense $ 17,000us-gaap_LeaseAndRentalExpense $ 15,000us-gaap_LeaseAndRentalExpense              
Line of Credit Facility, Amount Outstanding 1,000,000us-gaap_LineOfCredit     1,000,000us-gaap_LineOfCredit          
Interest Payable 532,000us-gaap_InterestPayableCurrentAndNoncurrent     498,000us-gaap_InterestPayableCurrentAndNoncurrent          
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party 7,800us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty 9,000us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty              
2011 Promissory Notes [Member]                  
Related Party Transaction [Line Items]                  
Debt Instrument, Face Amount         100,000us-gaap_DebtInstrumentFaceAmount
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndElevenPromissoryNotesMember		        
2011 Promissory Notes [Member] | Frost Gamma Investment Trust [Member]                  
Related Party Transaction [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage         11.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndElevenPromissoryNotesMember		        
Debt Instrument, Face Amount         50,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndElevenPromissoryNotesMember		        
Beneficial Ownership Percentage         10.00%nimu_BeneficialOwnershipPercentage
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndElevenPromissoryNotesMember		        
2012 Promissory Notes [Member]                  
Related Party Transaction [Line Items]                  
Debt Instrument, Face Amount           50,000us-gaap_DebtInstrumentFaceAmount
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndTwelvePromissoryNoteMember		      
2012 Promissory Notes [Member] | Hsu Gamma Investments, L.P [Member]                  
Related Party Transaction [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage           11.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= nimu_HsuGammaInvestmentsLPMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndTwelvePromissoryNoteMember		      
Debt Instrument, Face Amount           50,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= nimu_HsuGammaInvestmentsLPMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndTwelvePromissoryNoteMember		      
2013 Promissory Notes [Member]                  
Related Party Transaction [Line Items]                  
Debt Instrument, Face Amount             50,000us-gaap_DebtInstrumentFaceAmount
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndThirteenPromissoryNoteMember		    
2013 Promissory Notes [Member] | Jane Hsiao [Member]                  
Related Party Transaction [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage             11.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= nimu_JaneHsiaoMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndThirteenPromissoryNoteMember		    
Debt Instrument, Face Amount             50,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= nimu_JaneHsiaoMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_TwoThousandAndThirteenPromissoryNoteMember		    
Promissory Notes [Member]                  
Related Party Transaction [Line Items]                  
Debt Instrument, Face Amount               50,000us-gaap_DebtInstrumentFaceAmount
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_PromissoryNotesMember		  
Interest Payable 6,000us-gaap_InterestPayableCurrentAndNoncurrent
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_PromissoryNotesMember		 5,000us-gaap_InterestPayableCurrentAndNoncurrent
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_PromissoryNotesMember		              
Promissory Notes [Member] | Jane Hsiao [Member]                  
Related Party Transaction [Line Items]                  
Debt Instrument, Interest Rate, Stated Percentage               11.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= nimu_JaneHsiaoMember
/ us-gaap_TroubledDebtRestructuringDebtorCurrentPeriodAxis
= nimu_PromissoryNotesMember		  
Miami Lease [Member]                  
Related Party Transaction [Line Items]                  
Payments for Rent 4,000us-gaap_PaymentsForRent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_MiamiLeaseMember		 4,000us-gaap_PaymentsForRent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_MiamiLeaseMember		 1,250us-gaap_PaymentsForRent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_MiamiLeaseMember		            
Hialeah Lease [Member]                  
Related Party Transaction [Line Items]                  
Operating Leases, Rent Expense 6,000us-gaap_LeaseAndRentalExpense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_HialeahLeaseMember		 11,000us-gaap_LeaseAndRentalExpense
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_HialeahLeaseMember		              
Dr Phillip Frost [Member]                  
Related Party Transaction [Line Items]                  
Beneficial Ownership Percentage 10.00%nimu_BeneficialOwnershipPercentage
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_DrPhillipFrostMember		                
TransEnterix [Member]                  
Related Party Transaction [Line Items]                  
Accounts Payable, Related Parties 5,000us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_TransenterixMember		     3,000us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= nimu_TransenterixMember		          
2010 Credit Facility [Member]                  
Related Party Transaction [Line Items]                  
Line of Credit Facility, Amount Outstanding 1,000,000us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember		                
2010 Credit Facility [Member] | Frost Gamma Investment Trust [Member]                  
Related Party Transaction [Line Items]                  
Beneficial Ownership Percentage         10.00%nimu_BeneficialOwnershipPercentage
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember		       10.00%nimu_BeneficialOwnershipPercentage
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember
Line of Credit Facility, Amount Outstanding                 1,000,000us-gaap_LineOfCredit
/ us-gaap_DebtInstrumentAxis
= nimu_TwoThousandAndTenCreditFacilityMember
/ dei_LegalEntityAxis
= nimu_FrostGammaInvestmentTrustMember
Credit Facility [Member]                  
Related Party Transaction [Line Items]                  
Interest Payable $ 28,000us-gaap_InterestPayableCurrentAndNoncurrent
/ us-gaap_DebtInstrumentAxis
= nimu_CreditFacilityMember		 $ 28,000us-gaap_InterestPayableCurrentAndNoncurrent
/ us-gaap_DebtInstrumentAxis
= nimu_CreditFacilityMember		              
XML 48 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
NOTES PAYABLE (Tables)
 3 Months Ended
Oct. 31, 2014
Notes Payable [Abstract]  
Schedule of Line of Credit Facilities
At October 31, 2014, the Company was obligated under the above described Credit Facility and promissory notes to make future principal payments (excluding interest) as follows:
 
Year Ending October 31,
 
 
 
 
 
 
 
2015
 
 
1,250,000
 
 
 
$
1,250,000
 
XML 49 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
INVENTORIES (Details) (USD $)
In Thousands, unless otherwise specified
Oct. 31, 2014
Jul. 31, 2014
Work-in-progress, spare parts and accessories $ 9us-gaap_InventoryWorkInProcess $ 9us-gaap_InventoryWorkInProcess
Finished goods 446us-gaap_InventoryFinishedGoods 446us-gaap_InventoryFinishedGoods
Total inventories $ 455us-gaap_InventoryNet $ 455us-gaap_InventoryNet
XML 50 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT (USD $)
In Thousands, except Share data
Total
Common Stock [Member]
Additional Paid In Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Loss [Member]
Series B Preferred Stock [Member]
Series C Preferred Stock [Member]
Series D Preferred Stock [Member]
Balance at Jul. 31, 2014 $ (1,587)us-gaap_StockholdersEquity $ 789us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 $ 21,931us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 $ (24,323)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 $ (49)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember		 $ 0us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 $ 62us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 $ 3us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Balance, shares at Jul. 31, 2014   78,942,423us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		       100us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 62,048us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 2,795us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Conversion of Preferred Stock to Common Stock (in shares)   65,000us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		       0us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 0us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 (13)us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Conversion of Preferred Stock to Common Stock 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities 1us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 (1)us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Net loss (105)us-gaap_NetIncomeLoss 0us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 0us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 (105)us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 0us-gaap_NetIncomeLoss
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember		 0us-gaap_NetIncomeLoss
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 0us-gaap_NetIncomeLoss
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 0us-gaap_NetIncomeLoss
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Balance at Oct. 31, 2014 $ (1,692)us-gaap_StockholdersEquity $ 790us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		 $ 21,930us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember		 $ (24,428)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_RetainedEarningsMember		 $ (49)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AccumulatedOtherComprehensiveIncomeMember		 $ 0us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 $ 62us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 $ 3us-gaap_StockholdersEquity
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
Balance, shares at Oct. 31, 2014   79,007,423us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember		       100us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesBPreferredStockMember		 62,048us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesCPreferredStockMember		 2,782us-gaap_SharesIssued
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesDPreferredStockMember
XML 51 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
STOCK-BASED COMPENSATION
 3 Months Ended
Oct. 31, 2014
Stock-Based Compensation [Abstract]  
STOCK-BASED COMPENSATION
4.                  STOCK-BASED COMPENSATION
 
The Company measures the cost of employee, officer and director services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of the Company’s stock option awards is expensed over the vesting life of the underlying stock options using the graded vesting method, with each tranche of vesting options valued separately. The Company recorded stock-based compensation of $0 and $1,000, respectively, for the three months ended October 31, 2014 and 2013, respectively. All stock-based compensation is included in the Company’s selling, general and administrative costs and expenses.
 
The Company’s 2000 Stock Option Plan, as amended (the “2000 Plan”), provides for the issuance of up to 2,000,000 shares of the Company’s common stock. The 2000 Plan allows the issuance of incentive stock options, stock appreciation rights and restricted stock awards. The exercise price of the options is determined by the compensation committee of the Company’s Board of Directors, but incentive stock options, if any, must be granted at an exercise price not less than the fair market value of the Company’s common stock as of the grant date or an exercise price of not less than 110% of the fair value for a 10% shareholder. Options expire up to ten years from the date of the grant and are exercisable according to the terms of the individual option agreements. The 2000 Plan expired on March 1, 2012. No additional grants may be made under the 2000 Plan; however, previously granted options will remain in force pursuant to the terms of the individual grants.
 
In November 2010, the Company’s Board and Compensation Committee approved the Non-Invasive Monitoring Systems, Inc. 2011 Stock Incentive Plan (the “2011 Plan”). Awards granted under the 2011 Plan may consist of incentive stock options, stock appreciation rights (SAR), restricted stock grants, restricted stock units (RSU) performance shares, performance units or cash awards. Subject to adjustment in certain circumstances, the 2011 Plan authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2011 Plan. The 2011 Plan was approved by our shareholders in March 2012 and no awards have been granted under the 2011 Plan as of October 31, 2014.
 
The Company did not grant any stock options during the three months ended October 31, 2014 or 2013.
 
A summary of the Company’s stock option activity for the three months ended October 31, 2014 is as follows:
 
 
 
Shares
 
Weighted
Average
Exercise
Price
 
Weighted
 average
 remaining
 contractual
 term (years)
 
Aggregate
intrinsic
Value
 
Options outstanding, July 31, 2014
 
378,750
 
$
0.380
 
 
 
 
 
 
Options granted
 
-
 
 
n/a
 
 
 
 
 
 
Options exercised
 
-
 
 
n/a
 
 
 
 
 
 
Options forfeited or expired
 
-
 
 
n/a
 
 
 
 
 
 
Options outstanding, October 31, 2014
 
378,750
 
$
0.380
 
1.88
 
$
0
 
Options expected to vest, October 31, 2014
 
378,750
 
$
0.380
 
1.88
 
$
0
 
Options exercisable, October 31, 2014
 
378,750
 
$
0.380
 
1.88
 
$
0
 
 
Of the 378,750 options outstanding at October 31, 2014, 378,750 were issued under the 2000 Plan and none were issued outside of shareholder approved plans. There were no options exercised during the three month periods ended October 31, 2014 and 2013. There were no options forfeited or expired during the three month periods ending October 31, 2014 and there were 75,000 options forfeited or expired during the three month periods ending October 31, 2013.
 
As of October 31, 2014, there was no unrecognized costs related to outstanding stock options.
XML 52 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9
STOCK-BASED COMPENSATION (Details) (USD $)
 3 Months Ended
Oct. 31, 2014
Options outstanding Shares, Beginning balance 378,750us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
Options granted Shares 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
Options exercised Shares 0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
Options forfeited or expired Shares 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
Options outstanding Shares, Ending balance 378,750us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
Options expected to vest, Shares 378,750us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
Options exercisable, Shares 378,750us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
Options outstanding Weighted Average Exercise Price, Beginning balance $ 0.380us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
Options outstanding Weighted Average Exercise Price, Ending balance $ 0.380us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
Options expected to vest, Weighted Average Exercise Price $ 0.380us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
Options exercisable, Weighted Average Exercise Price $ 0.380us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
Options outstanding, Weighted average remaining contractual term (years) 1 year 10 months 17 days
Options expected to vest, Weighted average remaining contractual term (years) 1 year 10 months 17 days
Options exercisable, Weighted average remaining contractual term (years) 1 year 10 months 17 days
Options outstanding, Aggregate intrinsic Value $ 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
Options expected to vest, Aggregate intrinsic Value 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
Options exercisable, Aggregate intrinsic Value $ 0us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 83 165 1 false 36 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.nims-inc.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.nims-inc.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.nims-inc.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.nims-inc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT Sheet http://www.nims-inc.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersDeficit CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT false false R6.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.nims-inc.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 107 - Disclosure - ORGANIZATION AND BUSINESS Sheet http://www.nims-inc.com/role/OrganizationAndBusiness ORGANIZATION AND BUSINESS false false R8.htm 108 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.nims-inc.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R9.htm 109 - Disclosure - INVENTORIES Sheet http://www.nims-inc.com/role/Inventories INVENTORIES false false R10.htm 110 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.nims-inc.com/role/StockbasedCompensation STOCK-BASED COMPENSATION false false R11.htm 111 - Disclosure - ROYALTIES Sheet http://www.nims-inc.com/role/Royalties ROYALTIES false false R12.htm 112 - Disclosure - NOTES PAYABLE Notes http://www.nims-inc.com/role/NotesPayable NOTES PAYABLE false false R13.htm 113 - Disclosure - SHAREHOLDERS' EQUITY Sheet http://www.nims-inc.com/role/ShareholdersEquity SHAREHOLDERS' EQUITY false false R14.htm 114 - Disclosure - BASIC AND DILUTED LOSS PER SHARE Sheet http://www.nims-inc.com/role/BasicAndDilutedLossPerShare BASIC AND DILUTED LOSS PER SHARE false false R15.htm 115 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.nims-inc.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS false false R16.htm 116 - Disclosure - COMMITMENTS Sheet http://www.nims-inc.com/role/Commitments COMMITMENTS false false R17.htm 117 - Disclosure - LONG-LIVED ASSETS Sheet http://www.nims-inc.com/role/LonglivedAssets LONG-LIVED ASSETS false false R18.htm 118 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.nims-inc.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) false false R19.htm 119 - Disclosure - INVENTORIES (Tables) Sheet http://www.nims-inc.com/role/InventoriesTables INVENTORIES (Tables) false false R20.htm 120 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.nims-inc.com/role/StockbasedCompensationTables STOCK-BASED COMPENSATION (Tables) false false R21.htm 121 - Disclosure - NOTES PAYABLE (Tables) Notes http://www.nims-inc.com/role/NotesPayableTables NOTES PAYABLE (Tables) false false R22.htm 122 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables) Sheet http://www.nims-inc.com/role/BasicAndDilutedLossPerShareTables BASIC AND DILUTED LOSS PER SHARE (Tables) false false R23.htm 123 - Disclosure - LONG-LIVED ASSETS (Tables) Sheet http://www.nims-inc.com/role/LonglivedAssetsTables LONG-LIVED ASSETS (Tables) false false R24.htm 124 - Disclosure - ORGANIZATION AND BUSINESS (Details Textual) Sheet http://www.nims-inc.com/role/OrganizationAndBusinessDetailsTextual ORGANIZATION AND BUSINESS (Details Textual) false false R25.htm 125 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) Sheet http://www.nims-inc.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) false false R26.htm 126 - Disclosure - INVENTORIES (Details) Sheet http://www.nims-inc.com/role/InventoriesDetails INVENTORIES (Details) false false R27.htm 127 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.nims-inc.com/role/StockbasedCompensationDetails STOCK-BASED COMPENSATION (Details) false false R28.htm 128 - Disclosure - STOCK-BASED COMPENSATION (Details Textual) Sheet http://www.nims-inc.com/role/StockbasedCompensationDetailsTextual STOCK-BASED COMPENSATION (Details Textual) false false R29.htm 129 - Disclosure - ROYALTIES (Details Textual) Sheet http://www.nims-inc.com/role/RoyaltiesDetailsTextual ROYALTIES (Details Textual) false false R30.htm 130 - Disclosure - NOTES PAYABLE (Details) Notes http://www.nims-inc.com/role/NotesPayableDetails NOTES PAYABLE (Details) false false R31.htm 131 - Disclosure - NOTES PAYABLE (Details Textual) Notes http://www.nims-inc.com/role/NotesPayableDetailsTextual NOTES PAYABLE (Details Textual) false false R32.htm 132 - Disclosure - SHAREHOLDERS' EQUITY (Details Textual) Sheet http://www.nims-inc.com/role/ShareholdersEquityDetailsTextual SHAREHOLDERS' EQUITY (Details Textual) false false R33.htm 133 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Details) Sheet http://www.nims-inc.com/role/BasicAndDilutedLossPerShareDetails BASIC AND DILUTED LOSS PER SHARE (Details) false false R34.htm 134 - Disclosure - RELATED PARTY TRANSACTIONS (Details Textual) Sheet http://www.nims-inc.com/role/RelatedPartyTransactionsDetailsTextual RELATED PARTY TRANSACTIONS (Details Textual) false false R35.htm 135 - Disclosure - COMMITMENTS (Details Textual) Sheet http://www.nims-inc.com/role/CommitmentsDetailsTextual COMMITMENTS (Details Textual) false false R36.htm 136 - Disclosure - LONG-LIVED ASSETS (Details) Sheet http://www.nims-inc.com/role/LonglivedAssetsDetails LONG-LIVED ASSETS (Details) false false R37.htm 137 - Disclosure - LONG-LIVED ASSETS (Details Textual) Sheet http://www.nims-inc.com/role/LonglivedAssetsDetailsTextual LONG-LIVED ASSETS (Details Textual) false false All Reports Book All Reports Element us-gaap_DividendsPayableAmountPerShare had a mix of decimals attribute values: 0 2. Element us-gaap_LineOfCredit had a mix of decimals attribute values: -5 0. Element us-gaap_PreferredStockLiquidationPreference had a mix of decimals attribute values: 0 2. Element us-gaap_StockIssuedDuringPeriodSharesNewIssues had a mix of decimals attribute values: -5 0. 'Monetary' elements on report '124 - Disclosure - ORGANIZATION AND BUSINESS (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Process Flow-Through: 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS nimu-20141031.xml nimu-20141031.xsd nimu-20141031_cal.xml nimu-20141031_def.xml nimu-20141031_lab.xml nimu-20141031_pre.xml true true XML 54 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
STOCK-BASED COMPENSATION (Tables)
 3 Months Ended
Oct. 31, 2014
Stock-Based Compensation [Abstract]  
Schedule of Share-based Compensation, Stock Options, Activity
A summary of the Company’s stock option activity for the three months ended October 31, 2014 is as follows:
 
 
 
Shares
 
Weighted
Average
Exercise
Price
 
Weighted
 average
 remaining
 contractual
 term (years)
 
Aggregate
intrinsic
Value
 
Options outstanding, July 31, 2014
 
378,750
 
$
0.380
 
 
 
 
 
 
Options granted
 
-
 
 
n/a
 
 
 
 
 
 
Options exercised
 
-
 
 
n/a
 
 
 
 
 
 
Options forfeited or expired
 
-
 
 
n/a
 
 
 
 
 
 
Options outstanding, October 31, 2014
 
378,750
 
$
0.380
 
1.88
 
$
0
 
Options expected to vest, October 31, 2014
 
378,750
 
$
0.380
 
1.88
 
$
0
 
Options exercisable, October 31, 2014
 
378,750
 
$
0.380
 
1.88
 
$
0